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1.1	 Kidney	overview			The	 kidney	 is	 the	 main	 organ	 that	 integrates	 the	 human	 urinary	 system	 with	 its	purpose	to	eliminate	waste,	regulate	blood	volume	and	pressure,	balance	electrolytes	and	metabolites,	and	regulate	blood	pH.		The	highly	specialised	function	of	the	kidney	is	reflected	in	its	elaborate	and	diverse	structure.	Each	kidney	is	comprised	of	over	15	main	structures,	each	with	their	own	specific	function	and	regulatory	mechanism;	the	primary	structures	can	be	grouped	into	four	main	assemblies	which	include;	the	renal	cortex,	renal	pyramids,	renal	medulla	and	renal	pelvis,	figure	1.1.		
	



















































1.1.2	 Vasculature	compartment		Blood	that	enters	the	kidney	does	so	at	the	renal	hilum	via	the	renal	artery.	The	renal	artery	then	branches	to	form	3	segmental	arteries,	which	immediately	branch	into	5	interlobar	 arteries.	 At	 the	 junction	 of	 the	 renal	 medulla	 and	 cortex,	 the	 interlobar	arteries	give	rise	to	arcuate	arteries	and	pass	along	this	boundary	(Pallone,	Z.	Zhang,	
et	 al.	 2003).	 Branches	 from	 arcuate	 arteries	 travel	 out	 at	 90	 degrees	 through	 the	cortex	 and	 towards	 the	 capsule	 and	 are	 known	 as	 cortical	 radial	 arteries.	 Afferent	arterioles	also	arise	 from	these	 interlobular	arteries	and	divide	within	the	cortex	to	the	glomerular	capillary	network.	The	glomerular	capillaries	do	not	drain	into	a	vein	but	instead	reunite	to	form	efferent	arterioles	(Pallone	et	al.	2012).		The	 efferent	 arterioles	 then	branch	 to	 various	 regions	 depending	 on	 their	 location.	Superficallialy	situated	cortical	efferent	arterioles	found	in	the	outer	two	thirds	of	the	cortex	 feed	 a	 plexus	 of	 peritubular	 capillaries.	 These	 vessels	 supply	 blood	 to	 the	proximal	and	distal	tubules	and	portions	of	the	loops	of	Henle	and	the	collecting	ducts	before	joining	the	interlobular	veins	and	returning	to	the	inferior	vena	cava	through	the	arcuate,	interlobar,	and	renal	veins	(see	Figure	1.3).	The	efferent	arterioles	in	the	inner	 third	 of	 the	 cortex,	 juxtamedullary	 efferent	 arterioles,	 give	 rise	 to	 some	peritubular	capillaries	but	also	give	rise	to	the	vasa	recta,	small-diameter	vessels	that	penetrate	deep	into	the	medulla	after	branching	off	from	vascular	bundles	(Pallone	et	



























loop	 of	 Henle’s	 function	 is	 primarily	 to	 concentrate	 urine,	 through	 increasing	 salt	concentration	 in	 the	 filtrate.	 This	 is	 achieved	 via	 the	 countercurrent	 multiplier	system;	 countercurrent	 flow	 between	 tubular	 filtrate	 and	 blood	 flow,	 within	 the	descending	and	ascending	 limbs	and	vasa	 recta,	 respectively,	 increases	 the	osmotic	gradient	between	tubular	fluid	and	interstitial	space	(Koeppen	&	Stanton	2013d).	The	 distal	 convoluted	 tubule	 is	 the	 nephrons	 penultimate	 segment,	 where	 ion	exchange	 occurs	 across	 the	 epithelial	 cell	 apical	 and	 basolateral	 membranes	 to	regulate	potassium,	sodium,	calcium	and	pH	of	the	filtrate.	Once	filtrate	has	exited	the	distal	 tubule,	 it	 enters	 the	 collecting	ducts	where	principal	 cells	 are	 responsible	 for	sodium	reabsorption,	and	ultimately	reaching	the	bladder	for	excretion	(Koeppen	&	Stanton	2013e).			
1.2	 Renal	blood	flow	and	microcirculation			It	is	clear	from	the	complexity	of	renal	blood	flow,	the	microvascular	structures	vary	in	the	cortex	and	outer	and	inner	medulla	to	accommodate	the	specialised	functions	and	metabolic	demands	within	each	kidney	region.	In	the	cortex,	afferent	and	efferent	arterioles	 are	 the	 driving	 forces	 that	 regulate	 glomerular	 filtration.	 A	 dense	peritubular	 capillary	 plexus	 that	 arise	 from	 efferent	 arterioles	 surrounds	 the	proximal	and	distal	convoluted	tubules	and	function	to	reabsorb	substantial	volumes	of	 glomerular	 filtrate	 and	 transport	water	 and	 solutes	 back	 to	 the	 venus	 blood.	 In	contrast,	the	medullary	vasa	recta	capillary	network	serve	needs	that	are	specific	to	the	renal	medulla	alone	(Eaton	&	Pooler	2009).		The	 medulla	 is	 served	 via	 outer	 stripe	 juxtameduallary	 efferent	 arterioles	 which	further	 branch	 to	 form	 descending	 vasa	 recta	 (DVR).	 The	 renal	 medulla	 has	 two	distinct	 regions,	outer	and	 inner,	each	with	 their	own	 inner	and	outer	stripes.	Each	region	 serves	 distinct	 functions	 and	 has	 distinct	 vessel	 arraignments.	 Figure	 1.4	highlights	the	complexity	of	the	medullary	microvasculature.		Microcirculation	in	the	outer	 region	 is	 characterized	by	a	 separation	of	 capillaries	 into	vascular	bundles	 in	which	 vessels	 run	 in	 parallel	 and	 into	 dense	 capillary	 plexus’	 of	 the	 interbundle	region	capillary	networks	 that	serve	the	 inner	stripe	(Bankir	&	Derouffignac	1985).	Outer	 medulla	 DVR	 have	 been	 well	 characterized	 and	 have	 been	 proven	 to	 be	
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experimentally	valid	for	investigating	outer	medullary	endothelial	transport,	pericyte	contractility	 and	 tubule-vascular	 crosstalk	 (K.	 K.	 Evans	 et	 al.	 2015).	 Inner	medulla	DVR	 however	 are	 less	 well	 understood.	 Although	 morphologically	 similar,	 limited	studies	have	actually	investigated	their	contribution	to	renal	blood	flow	(K.	K.	Evans	
et	al.	2015).	Parallel	vascular	bundles	and	a	capillary	plexus	at	the	interbundle	region	also	 serve	 the	 inner	 stripe	 of	 the	 outer	medulla.	 The	 inner	 stripe	 vascular	 bundles	include	 long	 DVR	 that	 serve	 the	 interbundle	 region	 and	 DVR	 that	 will	 penetrate	beyond	the	inner-outer-medullary	junction	to	the	inner	medulla	(Pallone,	Turner,	et	
al.	2003).	DVR	that	supply	blood	flow	to	the	interbundle	capillary	plexus	peel	off	from	the	 periphery	 of	 the	 vascular	 bundles	 as	 they	 pass	 into	 the	 inner	 stripe.	 	 DVR	 that	reside	within	 the	 center	 of	 the	 vascular	 bundle	 cross	 the	 inner	 stripe	 of	 the	 outer	medulla	to	reach	and	perfuse	the	inner	medulla,	see	figure	1.4	(Pallone,	Z.	Z.	Zhang,	et	




































regional	blood	flow	distribution	throughout	the	medulla.	For	example,	constriction	of	DVR	within	 the	 bundle	 center	 should	 enhance	 perfusion	 of	 the	 interbundle	 region	while	constriction	of	DVR	on	the	vascular	bundle	periphery	should	enhance	perfusion	of	the	inner	medulla	(Navar	et	al.	2011).	
1.3	 Medullary	blood	flow	The	notion	that	medullary	blood	flow	(MBF)	may	be	locally	regulated	at	the	level	of	the	DVR	and	AVR	is	not	a	new	concept	per	se,	 indeed	this	was	first	suggested	in	the	1960’s	(Thurau	&	Deetjen	1962),	however	this	still	remains	a	controversial	 topic	 in	the	 renal	 field.	 The	main	 reason	 for	 this	 being	 that	 experimentally	 it	 is	 difficult	 to	access	the	renal	medulla	in	vivo,	thus	investigating	how	blood	flow	is	regulated	in	this	region	remains	an	on	going	technical	challenge.		MBF	is	served	predominately	via	the	DVR	and	AVR.	DVR	are	responsible	for	delivery	of	blood	from	the	outer	stripe	of	the	outer	medulla,	traversing	vascular	bundles	in	the	inner	 stripe	 of	 the	 outer	 medulla,	 then	 ultimately	 to	 the	 inner	 medulla,	 figure	 1.4	(Pannabecker	 &	 Dantzler	 2004).	 DVR	 are	 approximately	 half	 the	 diameter	 of	juxtamedullary	 efferent	 arterioles	 and	 range	 between	 12-18	 μM	 (Jamison	 &	 Kriz	1982).	The	DVR	wall	is	characterised	by	a	gradual	replacement	of	the	smooth	muscle	of	the	efferent	arteriole	by	contractile	pericyte	cells.	Pericyte	cells	are	smooth	muscle-	like	 cells	 that	 surround	 DVR	 and	 continuous	 capillaries	 of	 other	 tissues	 (Shepro	 &	Morel	 1993).	 Pericyte	 density	 in	 the	medulla	 becomes	 progressively	 irregular	with	increasing	medullary	depth	but	is	well	retained	into	the	inner	medulla	(F.	Park	et	al.	1997).	DVR	 have	 a	 continuous	 endothelium	 with	 tight	 junctions	 while	 AVR	 have	endothelium	 that	 is	 highly	 fenestrated	 (Mink	 et	 al.	 1984).	 The	 enclosing	 nature	 of	pericytes	 around	 DVR	 and	 presence	 of	 smooth	 muscle-like	 properties,	 myofibrils	similar	 to	 that	 of	 smooth	 muscle	 cells,	 suggest	 vasoconstrictor	 and	 vasorelaxant	properties	(Kriz	1981;	Pallone	&	C.	Cao	2007).	Efferent	 arterioles	 and	 DVR	 are	 the	 main	 medullary	 structures	 with	 sympathetic	innervation,	 which	 continues	 when	 smooth	 muscle	 cells	 are	 supplemented	 for	pericytes	 (Crawford	 et	 al.	 2013),	 therefore	 it	 is	 suggestive	 that	 vascular	 smooth	muscle	cells	of	juxtameduallry	arterioles	and	medullary	DVR	are	largely	accountable	for	the	differential	regulation	and	distribution	of	medullary	circulation	(Lemley	et	al.	1986;	R.	G.	R.	Evans	et	al.	2004;	Zimerhackl	et	al.	1987).		
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1.3.1	 Medullary	countercurrent	exchange	The	 medullary	 vasculature	 plays	 an	 important	 role	 in	 the	 generation	 of	 the	countercurrent	exchange	mechanism,	which	is	responsible	for	the	gradual	increase	of	concentrated	urine	whilst	minimising	water	loss.		Through	their	parallel	counter	flow	arrangement,	DVR	and	AVR	trap	sodium	chloride	and	urea	deposited	in	the	interstitium	by	collecting	ducts	and	loops	of	Henle.	Blood	entering	the	DVR	from	juxtaglomerular	efferent	arterioles	contains	sodium	chloride	and	 urea	 at	 concentrations	 similar	 to	 that	 of	 the	 systemic	 circulation	 (Pallone,	 Z.	Zhang,	 et	 al.	 2003).	 As	 the	 blood	 flows	 down	 the	 DVR,	 an	 increasingly	 hypertonic	medullary	 interstitium	 is	 encountered	 through	 an	 inward	 diffusion	 of	 solutes	 and	volume	efflux.	On	 its	return,	blood	flowing	through	the	AVR	is	subsequently	diluted	
via	solute	efflux	and	water	volume	influx	(Sanjana	et	al.	1975;	Sanjana	et	al.	1976).	
	
1.3.2	 Medullary	gas	exchange			The	 medullary	 microvasculature	 is	 also	 responsible	 for	 supplying	 oxygen	 and	nutrients	to	its	metabolically	active	surrounding	tissue.	However,	within	the	medulla,	the	competing	requirement	to	preserve	corticomedullary	osmotic	gradients	conflicts	with	this	requirement.	Consequently,	partial	pressure	of	oxygen	in	the	medulla	is	low,	between	10	and	25	mmHg,	which	is	due	to	oxygen	in	DVR	diffusing	across	to	adjacent	AVR	after	which	blood	 is	 shunted	back	 to	 the	 cortex,	 figure	1.5	 (Brezis	et	al.	 1991;	Brezis	&	Rosen	1995).	In	contrast,	the	partial	pressure	of	oxygen	in	the	renal	cortex	is	~55	mmHg	(Brezis	&	Rosen	1995).	To	balance	the	possible	insult	of	ischemia,	the	renal	medulla	has	evolved	and	is	able	to	continually	adapt	regional	perfusion	of	both	the	outer	and	inner	medulla	through	local	 vasodilator	 paracrine	 signalling.	 All	 paracrine	 signalling	 molecules	 share	 the	ability	to	augment	medullary	blood	flow	therefore	increase	the	local	supply	of	oxygen	(Pallone,	 Turner,	 et	 al.	 2003).	 Interestingly,	 most	 vasodilators	 also	 inhibit	 salt	reabsorption,	 therefore	 protection	 of	 potential	 hypoxic	 insult	 most	 likely	 involves	vasodilation	of	the	vasculature	to	enhance	perfusion	and	inhibiting	salt	reabsorption,	reducing	oxygen	consumption	and	demand	(Navar	et	al.	2011).	
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Figure	1.5	 Oxygen	delivery	to	 the	renal	medulla.	Oxygen	is	delivered	by	blood	cells	 in	 the	 artery.	 Red	 blood	 cells	 release	 oxygen	 in	 the	 capillaries,	which	 diffuses	into	the	interstitium	to	reach	target	cells.	Blood	with	low	oxygen	tension	passes	into	the	vein.	An	AV	oxygen	shunt	present	in	the	kidney	enables	oxygen	to	move	directly	from	the	artery	to	the	vein.	Oxygen	tensions	in	the	capillary	are	relatively	low	when	blood	cells	reach	the	peritubular	capillary	plexus,	which	indicates	that	the	kidney	is	ineffective	in	separating	oxygen.	The	relative	oxygen	tensions	are	represented	by	the	size	of	the	circles	surrounding	the	term	'O2'.	AV,	arterial-to-venous	Adapted	from	(Fry	
et	al.	2014).		













are	able	 to	measure	 the	 relative	 changes	of	blood	 flow	within	 the	medulla	 (Hansell	1992;	Mattson	et	al.	1993).	Laser-Doppler	appears	to	be	the	most	widely	used	and	accepted	method	(Cowley	et	
al.	 1995;	 Hansell	 1992).	 It	 relies	 on	 the	 Doppler	 shift	 imparted	 to	monochromatic	light	by	backscatter	from	moving	red	blood	cells	within	a	vessel	(Pallone,	Turner,	et	
al.	 2003).	 Initial	 experiments	 by	 Roman	 et	 al	 generated	 a	 new	 understanding	 to	medullary	blood	flow	with	findings	indicating	papillary	blood	flow	increased	after	an	increase	 of	 renal	 perfusion	 pressure	 but	 interestingly	 the	 inner	 medulla	 failed	 to	autoregulate	(Roman	et	al.	1988).		This	 phenomenon	 has	 been	 heavily	 investigated	 in	 the	 past	 decade	 with	 several	groups	 conforming	 the	 initial	 findings	 of	 impaired	medullary	 autoregulation,	while	others	have	produced	conflicting	results	(Cowley	1997;	Navar	et	al.	1996;	Majid	et	al.	1997).	 However	 in	 more	 recent	 years,	 it	 has	 become	 apparent,	 through	 advanced	imaging	 techniques	 and	 our	 understanding	 of	 renal	 blood	 flow,	 that	 changes	 in	medullary	circulation	can	have	a	 important	effect	on	the	pressure-natriuresis	of	 the	medulla	 and	 therefore	 effect	 long-term	 arterial	 pressure	 (Pallone	 et	 al.	 2012;	 Q.	Zhang	et	al.	2006).		
1.4	 Renal	pericytes	One	 of	 the	 main	 reasons	 that	 MBF	 is	 becoming	 an	 evermore-interesting	 research	topic	 is	 that	 of	 developing	 evidence	 favouring	 an	 intrinsic	 autoregulation	 of	medullary	blood	 flow.	As	mentioned,	MBF	 regulation	 is	 still	 poorly	understood	and	highly	 controversial,	 partly	 down	 to	 medulla	 inaccessibility	 but	 also	 due	 to	 the	relatively	uncharacterised	contractile	function	of	renal	pericytes.			Pericytes	where	first	 identified	by	Rouget	 in	the	late	1800’s	found	on	the	abluminal	side	 of	 endothelium	 walls	 and	 at	 the	 time	 thought	 to	 be	 precursors	 of	 vascular	smooth	muscle	cells	(Dore-Duffy	&	Cleary	2011).	Renal	pericytes	reside	on	DVR	when	smooth	muscle	cells	of	efferent	arterioles	become	scarce.	Pericyte	density	decreases	with	increasing	depth	of	DVR	into	the	medulla	but	remain	present	even	in	the	inner	stripe	of	the	inner	medulla	(F.	Park	et	al.	1997).	Pericytes	are	often	referred	to	as	“smooth	muscle-like”	cells	due	their	expression	of	contractile	machinery.	 Alpha-smooth	muscle	 actin,	myosin	 and	 fibronectin	 have	 all	been	shown	to	be	expressed	by	pericytes	and	to	have	functional	properties	(Skalli	et	
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1.4.1	 Pericyte	function	–	regulation	of	blood	Flow	The	 function	of	 renal	pericytes	 is	 still	 debatable	however	 given	 that	 their	 claw-like	processes	 envelop	 microvessels,	 together	 with	 expression	 of	 contractile	 and	intermediate	filaments,	its	is	thought	that	they	play	a	role	in	regulating	microvascular	tone	and	blood	 flow.	This	 therefore	 implies	 that	 renal	pericytes	may	have	a	 role	 in	regulation	of	renal	MBF,	or	at	least	to	the	extent	of	DVR	flow	regulation.		Pallone	and	colleagues	have	 carried	out	much	of	 the	early	work	 investigating	 renal	pericytes	 and	 their	 role	 within	 the	 renal	 medulla	 using	 the	 isolated	 perfused	 DVR	technique	(Pallone	1994;	Pallone	et	al.	1994;	Silldorff	&	Pallone	2001;	Edwards	et	al.	2011).	 Their	 in	 vitro	 technique	 is	 technically	 challenging,	 however	 provided	 clear	evidence	suggesting	pericyte-mediated	manipulation	of	DVR	diameter.	In	response	to	various	stimuli,	e.g.	endogenous	and	exogenous	vasoconstrictors,	angiotensin	II	(ANG	II)	and	vasodilators,	prostaglandin	E2	(PGE2)	and	nitric	oxide	(NO),	they	were	able	to	show	 that	 isolated	 perfused	DVR	 could	 constrict	 or	 dilate,	 theoretically	 at	 pericyte	locations	 along	 the	 vessel,	 therefore	 offering	 a	 local	 mechanism	 for	 the	 control	 of	vessel	tone	and	diameter	of	DVR	(Pallone	1994;	Silldorff	&	Pallone	2001).	Various	studies	have	suggested	that	pericyte	density	 is	dependent	on	the	functional	demands	of	tissue,	higher	metabolic	tissue	usually	requiring	increased	oxygen	supply	and	 nutrients,	 supported	 by	 studies	 in	 which	 differences	 in	 pericyte	 coverage	throughout	 various	 vascular	 beds	has	 been	observed	 (Diaz-Flores	et	al.	 2009;	 Sims	2000;	Crawford	et	al.	2012).	With	respect	to	the	renal	medulla	and	DVR,	its	functional	demand	is	high;	therefore,	tight	regulation	of	medullary	blood	flow	is	fundamental	for	preservation	of	medullary	 function,	 in	an	already	almost	hypoxic	environment.	This	suggests	 that	 DVR	 may	 be	 densely	 populated	 by	 pericytes	 to	 allow	 intricate	alternations	 of	 blood	 flow	 and	 preserved	 function,	 which	 has	 been	 confirmed	 in	 a	recent	study	undertaken	by	Crawford	et	al	who	were	able	to	quantify	pericytes	within	the	 different	 medullary	 sections	 (Crawford	 et	 al.	 2012),	 which	 confirmed	 earlier	reports	of	decreasing	numbers	of	pericytes	further	into	the	inner	medulla	(Pallone	et	
al.	1990;	Armulik	et	al.	2005).	This	also	relates	to	particular	regional	energy	demands	of	 the	 kidney,	with	 the	 inner	medulla	 requiring	much	 less	 compared	 to	 that	 of	 the	inner	 stripe	of	 the	outer	medulla	 (Pallone	et	al.	 2012).	 Interestingly,	Crawford	et	al	also	highlighted	the	density	of	pericyte	processes	and	suggest	the	network	of	pericyte	processes	 facilitate	 communication	 with	 each	 other	 in	 order	 to	 tightly	 regulate	
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changes	of	 blood	 flow	 in	 single	DVR	but	 also	 through	 adjacent	DVR	 to	 significantly	alter	total	MBF	(Crawford	et	al.	2012).	These	new	findings	suggested	that	in	contrast	with	what	was	originally	thought	about	medullary	blood	flow,	passive	and	driven	upstream	via	arteriolar	perfusion	pressure,	these	vasoactive	segments	of	DVR	could	play	a	key	role	in	the	regulation	of	total	and	more	importantly,	regional	blood	flow	to	the	renal	medulla	(Pallone	&	Silldorff	2001;	Pallone	et	al.	2012;	R.	G.	R.	Evans	et	al.	2004).	
	
1.4.2	 Pericyte	function-	vessel	stability		As	well	as	being	a	possible	fundamental	factor	in	regional	control	of	blood	flow	to	the	kidney,	renal	pericytes	have	been	suggested	to	have	other	critical	functions	including	formation,	 stabilization	 and	 remodelling	 of	 vascular	 beds	 (Suzuki	 et	 al.	 2003;	Hammes	 et	 al.	 2004;	 Caruso	 et	 al.	 2009).	 Revolutionary	 investigations	 using	 fate	tracing,	 transgenic	 mice	 and	 renal	 pericyte	 cell	 line	 studies,	 have	 collectively	suggested	pericytes	are	involved	in	the	pathology	of	various	renal	diseases	including	chronic	kidney	disease	(CKD)	via	loss	of	pericytes	on	microvessels,	their	involvement	in	 renal	 fibrosis	 via	 vessel	 detachment	 and	migration	 and	 also	 differentiation	 into	myofibroblasts	 (Y.	 Cao	 et	 al.	 2013;	 S.L.	 Lin	 et	 al.	 2011;	 Humphreys	 et	 al.	 2010).		Pericyte	differentiation	has	recently	been	further	investigated	as	a	possible	influential	mechanism	of	renal	fibrosis	(Kida	&	Duffield	2011;	S.L.	Lin	et	al.	2008).	These	findings	however	are	controversial	due	to	 the	generally	accepted	mechanism	of	epithelial	 to	mesenchymal	 transition	 (EMT).	 As	 its	 name	 suggests,	 EMT	 involves	 epithelial	 cells	losing	their	cell	polarity	and	cell	adhesions	to	gain	migratory	and	invasive	properties	of	mesenchymal	 cells	 (Y.	H.	 Liu	2004).	This	 transition	was	 thought	 to	be	 the	 initial	step	following	renal	insult	towards	the	progression	of	scaring	and	fibrosis.	However,	one	of	the	first	groups	to	challenge	the	role	of	EMT	as	the	source	of	myofibroblasts	in	the	kidney	demonstrated	the	alpha-smooth	muscle	actin	(αSMA)	stained	cells	where	located	 in	 the	 interstitium	 but	 not	 tubules	 of	 renal	 insulted	 mice	 and	 that	 αSMA	positive	cells	where	predominantly	located	within	the	perivascular	region	(Faulkner	




1.5	 Drug-induced	nephrotoxicity		As	the	kidney	receives	25%	of	resting	cardiac	output	over	a	large	endothelial	surface	area	 and	 filters	more	 than	 100	 litres	 of	 blood	 per	 day,	 it	 is	 not	 surprising	 that	 the	kidney	 is	 particularly	 susceptible	 to	 toxins	 within	 the	 blood	 stream	 (Koeppen	 &	Stanton	2013a).	Therefore,	nephrotoxicity	(damage	to	the	kidney	via	drugs	or	toxins)	is	 frequently	 seen	with	many	 common	medications	 in	 clinical	 use	 today	 and	 drug-induced	 renal	 injury	 contributes	 up	 to	 25%	of	 all	 cases	 of	 acute	 kidney	 injury	 as	 a	result	 of	 intrinsic	 renal	 disease	 (Kaufman	 et	 al.	 1991;	 Nash	 et	 al.	 2002).	 It	 is	 also	important	 to	 note	 that	 with	 such	 a	 high	 metabolic	 demand	 involving	 numerous	specific	enzymes	and	cellular	transport	processes,	glomerular,	tubular	and	interstitial	cells	may	be	susceptible	to	drugs	and	their	metabolites	at	higher	concentrations	than	that	of	other	tissues	within	the	body	(Eaton	&	Pooler	2009).	Several	 over	 the	 counter	 medicines	 and	 prescribed	 drugs	 have	 been	 found	 to	 be	nephrotoxic	by	one	or	more	common	pathogenic	mechanisms.	These	can	be	direct	or	indirect	 and	 include;	 altered	 renal	 haemodynamics,	 tubular	 cell	 toxicity,	inflammation,	 crystal	 nephropathy	 and	 thrombotic	 microangiopathy	 (Schetz	 et	 al.	2005;	Zager	1997).		Under	 normal	 homeostatic	 regulation,	 approximately	 120	 ml	 of	 plasma	 is	 filtered	under	 pressure	 through	 the	 glomerulus	 per	 minute	 and	 corresponds	 to	 the	glomerular	 filtration	 rate	 (GFR)	 (Koeppen	&	 Stanton	 2013b).	 The	 kidney	 is	 able	 to	maintain	 intraglomerular	 pressure	 through	 regulation	 of	 afferent	 and	 efferent	arterial	tone.		This	protective	mechanism	can	occur	 in	response	to	certain	stress	circumstances	to	prevent	a	fall	or	increase	in	the	GFR	and	subsequent	increased	risk	of	renal	damage.	For	 example,	 volume	 depletion	 will	 lead	 to	 systemic	 circulating	 prostaglandins,	compensating	for	ANG	II	induced	vasoconstriction,	causing	a	vasodilation	of	afferent	arterioles	to	allow	an	increases	blood	flow	through	to	the	glomerulus.	Drugs	 that	 inhibit	 prostaglandins,	 non-steroidal	 anti-inflammatory	 drugs	 (NSAIDS),	or	 impede	angiotensin	II	activity,	angiotensin-converting	enzyme	inhibitors	(ACEi’s)	
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can	therefore	interfere	with	the	kidney’s	ability	to	autoregulate	glomerular	pressure	and	GFR	(Palmer	2002;	Schoolwerth	et	al.	2001).	
1.5.1	 Tubular	toxicity		Due	 to	 the	 reabsorption	 function	 of	 the	 renal	 tubule,	 proximal	 tubule	 cells	 are	particularly	vulnerable	to	toxic	effects	of	drugs	due	to	their	role	in	concentrating	and	reabsorbing	 glomerular	 filtrate	 and	 consequentially	 exposing	 them	 to	 particularly	high	 levels	 of	 circulating	 toxins	 (Perazella	 2005).	 Tubular	 cell	 toxicity	 is	 mediated	through	 a	 variety	 of	 mechanisms	 including	 impairment	 of	 mitochondrial	 function,	distribution	 of	 tubular	 transport	 proteins	 and	 increasing	 oxidative	 stress	 and/or	formation	 of	 free	 radicals	 (Zager	 1997;	 Markowitz	 &	 Perazella	 2005).	 In	 addition,	either	direct	toxic	or	ischemic	effects	of	drugs	may	cause	renal	tubular	epithelial	cell	damage,	which	is,	observed	as	cellular	degeneration	and	sloughing	from	proximal	and	distal	tubular	basement	membranes,	clinically	known	as	acute	tubular	necrosis	(ATN)	(F.	G.	Silva	2004).	Clinically,	ATN	along	with	tubulointerstital	nephritis,	are	the	most	common	 presentations	 of	 drug-induced	 nephrotoxicity	 however,	 swelling	 and	vacuolisation	 of	 proximal	 tubular	 cells	 has	 also	 be	 noted	 in	 patients	 with	 osmotic	nephrosis	(Markowitz	&	Perazella	2005).	Drugs	can	cause	inflammatory	changes	in	the	glomerulus,	renal	tubular	cells,	and	the	surrounding	interstitium,	leading	to	fibrosis	and	renal	scarring.	Acute	 interstitial	 nephritis	 (AIN),	 which	 can	 result	 from	 an	 allergic	 response	 to	 a	suspected	drug,	develops	in	an	idiosyncratic,	non–dose-dependent	fashion.	AIN	is	the	underlying	 cause	 for	 up	 to	 3%	 of	 all	 cases	 of	 acute	 kidney	 injury	 (Rossert	 2001;	Perazella	2005).		
	
1.5.2	 Vascular	toxicity		One	of	the	main	issues	related	to	the	mechanisms	of	the	effects	of	CNI’s	is	the	putative	involvement	of	vascular	dysfunction,	which	can	include	thrombotic	microangiopathy,	thrombotic	thrombocytopenic	purpura	and	thrombotic	vasculitis.	In	 drug-induced	 thrombotic	 microangiopathy,	 organ	 damage	 is	 caused	 by	 platelet	thrombi	in	the	microcirculation,	as	is	seen	in	thrombotic	thrombocytopenic	purpura	(Pisoni	 et	 al.	 2001).	 Mechanisms	 of	 renal	 injury	 secondary	 to	 drug-induced	thrombotic	 microangiopathy	 include	 an	 immune-mediated	 reaction	 or	 direct	endothelial	 toxicity	 (Pisoni	 et	 al.	 2001)	 however	 injury	 to	 the	 endothelial	 cells	 is	
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considered	 the	 central	 and	 inciting	 factor	 in	 the	 sequence	 of	 events	 leading	 to	thrombotic	micoangiopathy	(Ruggenenti	et	al.	2001).	This	can	be	seen	in	vitro	by	the	various	 compounds	 associated	 with	 the	 disease:	 endotoxins,	 viruses	 and	immunosuppressives,	all	causing	direct	endothelial	cell	damage	(Remuzzi	1994).	Thrombotic	 microangiopathy	 is	 a	 well-recognized	 serious	 complication	 of	 renal	transplantation	with	occurrence	either	as	de	novo	or	recurrent.	The	latter	is	often	in	patients	with	previous	history	of	hemolytic	uremic	syndrome	(HUS),	while	de	novo	may	 be	 triggered	 by	 immunosuppressive	 drugs	 and	 acute	 antibody-mediated	rejection	(Noris	&	Remuzzi	2010).		The	 most	 commonly	 used	 immunosuppressive	 drugs	 for	 renal	 transplantation	 are	calcineurin	inhibitors	of	which	cyclosporine	and	tacrolimus	are	the	most	widely	used.		
			
1.6	 Calcineurin	Inhibitors			It	has	now	been	over	a	quarter	of	a	century	since	the	discovery	of	cyclosporine	(CsA)	and	its	iconic	influence	on	the	immune	system,	and	it	is	fair	to	say	it	is	still	the	main	drug	used	in	organ	transplantation	in	the	vast	majority	of	patients	transplanted	today	(Calne	et	al.	1978;	Powles	et	al.	1978).	CsA	was	the	first	immunosuppressive	drug	to	be	 discovered	 that	 allowed	 selective	 immunoregualtion	 of	 T	 cells	 without	unwarranted	 toxicity	 in	 animal	 models.	 Before	 discovery,	 a	 combination	 of	azathioprine,	 a	 less	 commonly	 used	 immunosuppressive	 in	 solid	 organ	 transplant,	and	 corticosteroids	were	 the	 norm	 for	 patients	 undergoing	 solid	 organ	 transplant.	The	combination	of	drugs,	and	azathioprines	poor	efficacy,	resulted	 in	a	plethora	of	unspecific	side	effects	and	untimely	led	to	allograft	rejection	and	cancer	development	(Armstrong	&	Oellerich	2001).	
1.6.1	 Cyclosporine	A	CsA	was	initially	developed	with	the	aim	of	treating	immune-mediated	disorders	but	by	the	mid	1970’s,	some	5	years	after	its	discovery,	the	first	experiments	in	animal	models	of	transplantation	indicated	remarkable	results.	Consequently,	in	1979,	CsA	
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was	used	for	the	first	time	as	a	front	line	immunosuppressive	in	kidney	transplantation	in	Cambridge,	UK	(D.	Colombo	&	Ammirati	2011).	CsA	 is	 a	 lipophilic	 peptide	 that	 can	 easily	 cross	 membranes	 of	 cells	 such	 as	 T	lymphocytes	 (Fahr	 1993b).	 CsA	 forms	 a	 complex	 with	 a	 cytosolic	 protein	 called	cyclophillin	and	ultimately	inhibits	calcineurin’s	enzymatic	activity	once	bound	with	the	CsA-cyclophillin	 complex.	Calcineurin	 is	a	 crucial	enzyme	 in	 the	 transduction	of	signals	 from	T-cell	receptors	triggering	the	promoters	of	cytokine	genes	(Takahashi	
et	 al.	 1989).	 It	 is	 a	 calcium-dependent	 serin-threonin	 phosphatase,	 also	 know	 as	protein	 phosphatates	 3	 (PP3C),	 that	 under	 normal	 active	 conditions	dephosphorylates	 the	 nuclear	 factor	 of	 activated	 T	 cells	 (NFAT)	 and	 triggers	 T-cell	promotion	 through	NFAT	 entering	 the	 nuclease,	 the	 crucial	 step	 for	 activation	 and	transcription	of	target	genes	(Takahashi	et	al.	1989;	Fischer	et	al.	1989;	Flanagan	et	
al.	1991).	These	target	genes	include	T-cell	dependent	lymphokines,	primarily	interleukin	2,	its	receptor	 (IL-2R),	 tumour	 necrosis	 factor-α	 and	 granulocyte	 macrophage	 colony-stimulating	 factor,	 which	 are	 also	 regulated	 through	 calcineurin-dependent	dephosphorylation	of	NFAT	 (Rusnak	&	Mertz	2000;	Naesens	et	al.	 2009).	However,	the	selective	immunosuppressive	property	of	CsA	is	through	the	localization	of	NFAT	primarily	in	T	cells	(Barbarino	et	al.	2013).	Although	CsA	is	predominately	 localised	to	T	 lymphocyte	NFAT,	 its	highly	 lipophilic	structure	 coupled	 to	 its	 highly	 variable	 pharmacokinetic	 profile,	 undoubtedly	translates	 to	 dephosphorylation	 of	 substrates	 other	 than	 NFAT	 in	 other	 cells	 and	tissues,	 resulting	 in	 altered	 transcription	 of	 genes	 (Rao	 et	 al.	 1997).	 NFAT	 has	 5	different	 isoforms,	 NFAT1	 –	 NFAT5,	 of	 which	 NFAT5	 is	 the	 only	 non-calcineurin	dependent,	adding	to	the	susceptibility	of	altered	NFAT	other	than	in	T	lymphocytes	(Su	et	al.	1995;	Kung	et	al.	2001;	Rao	et	al.	1997).	Some	of	 these	unwanted	altered	genes	are	thought	 to	 include:	nitric	oxide	synthase	(NOS),	 transforming	 growth	 factor	 β	 (TGF-β),	 endothelin-1,	 collagen	 I	 and	 IV	 and	BCL-2	 (Olyaei	 et	 al.	 2001;	 Bobadilla	 &	 Gamba	 2007;	 Burdmann	 et	 al.	 2003)	 all	 of	which	 add	 their	 own	 unique	 dynamic	 into	 the	 foremost	 side	 effect	 known	 of	 CsA;	nephrotoxicity.	 This	 can	 be	 clearly	 seen	 in	 he	 classic	 study	 by	 Calne	 et	 al	 who	demonstrated	 CsA	 was	 capable	 of	 nephrotoxicity	 in	 100%	 of	 patients	 treated	 for	immunosuppression	in	solid	organ	transplant	(Calne	et	al.	1978).		
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After	 initial	 high	 hopes	 for	 a	 single	 drug	 immunosuppressive	 regime	 for	 renal	transplantation,	 the	 first	 report	 of	 34	 renal	 transplant	 patients	 in	 1979	were	more	than	 underwhelming	 with	 high	 incidences	 of	 lymphomas,	 graft	 dysfunction	 and	patient	 mortality	 (D.	 Colombo	 &	 Ammirati	 2011).	 After	 the	 realisation	 that	 CsA	required	meticulous	dosing,	the	first	trial	to	demonstrate	the	unequivocal	benefit	of	CsA	in	transplant	immunosuppression	was	in	1982.	1	year	follow	up	of	the	European	Multicentre	 Trial	 Group	 involving	 232	 renal	 transplant	 patients,	 graft	 survival	was	72%	 in	 the	 CsA	 group	 compared	 to	 52%	 of	 the	 control	 group	 treated	 with	azathioprine	 and	 steroids	 (Group	 1983).	 For	 the	 10	 years	 that	 followed,	 CsA	 was	fundamental	 for	 preservation	 of	 renal	 transplantation	 until	 the	 discovery	 of	tacrolimus	led	to	a	newer	improved	immunosuppression.			
1.6.2	 Tacrolimus		Tacrolimus		(FK506)	is	a	newer	generation	calcineurin	inhibitor	that	was	discovered	in	the	early	1980’s	and	was	hoped	to	revolutionise	immunosuppression	with	its	high	efficacy	and	reduced	side	effects	compared	 to	CsA,	however	 tacrolimus	still	has	 the	common	side	effects	including	cancer,	nephrotoxicity	and	infection	(Starzl	et	al.	1989;	J.	J.	Fung	et	al.	1990).	First	approved	for	transplantation	in	1994	(Klintmalm	et	al.	1993),	FK506	belongs	to	the	macrolide	drug	family	and	has	no	structural	similarity	to	CsA.	Despite	this,	FK506	has	a	very	similar	mechanism	of	action	 to	CsA	 through	which	 it	exerts	 its	effects,	 it	crosses	 the	 cell	 membrane	 and	 inhibits	 calcineurin	 from	 dephosphorylating	 NFAT,	ultimately	preventing	T	cell	production	similar	to	CsA	(Harding	et	al.	1989;	Siekierka	
et	 al.	 1989).	 Similarly	 to	 CsA,	 FK506	 binds	 to	 a	 cytosolic	 protein.	 FK506	 binds	 to	FKBP12	and	not	cyclophylin,	and	it	is	this	complex,	not	the	drug	itself	that	is	able	to	inhibit	calcineurin	(Sabatini	et	al.	1994).	From	this	point,	both	calcineurin	inhibitors	(CNI’s)	 have	 the	 same	pharmalogical	 effect,	 albeit	 from	a	 slightly	 altered	 inhibitory	complex.		Upon	 its	discovery,	FK506	received	a	 significant	volume	of	 clinical	 interest	 through	its	increased	potency,	rapid	absorption,	quick	blood	peak	levels	and	almost	complete	metabolisation,	less	than	0.5%	of	parent	drug	excreted	in	the	urine	or	faeces	(Staatz	&	Tett	2004).	 It	 took	 less	 than	5	years	after	discovery	 to	enter	 its	 first	clinical	 trial	 in	1990	 (J.	 J.	 Fung	et	al.	 1990).	FK506	 received	 clearance	 from	 the	Unites	States	Food	and	Drug	Administration	 (FDA)	 in	1994	and	 shortly	after	by	 the	Medicines	Control	
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Agency	 in	 the	 UK	 (Randhawa	 et	 al.	 1997;	 Hooks	 1994).	 It	 was	 clear	 that	immunopharmacology	had	a	new	key	immunosuppressant.		Nevertheless,	FK506	was	not	the	perfect	immunosuppressant	that	everyone	hoped	it	to	 be.	 As	 with	 CsA,	 FK506	 did	 not	 show	 any	 overwhelming	 side	 effects	 in	 animal	studies.	There	was	evidence	of	mild	weight	loss,	increasing	blood	glucose	levels	and	lethargy	reported	in	rats	through	to	primates	(Ochiai	et	al.	1987;	Ericzon	et	al.	1992).	From	these	results,	clinical	trials	looked	promising	and	the	first	series	of	trials	began	with	 liver	 transplant	 patients.	 However,	 it	was	 a	 difficult	 decision	 regarding	which	clinical	setting	to	introduce	this	revolutionary	drug.	After	all,	the	introduction	of	CsA	had	 a	 similar	 dilemma.	 The	 initial	 results	 suggested	 FK506	 was	 appropriate	 for	“rescue	 therapy”,	 patients	 currently	 on	 immunosuppressive	 drugs	 but	 facing	 re-transplantation	due	to	organ	rejection	or	drug	toxicities	(high-risk	patients)	(Mejia	et	
al.	2014).	FK506	could	reverse	acute	rejection	of	grafts	in	almost	fifty	percent	of	CsA	treated	 patients	 (Jonas	 et	 al.	 1996).	 	 After	 its	 initial	 success,	 FK506	 for	 first-line	immunosuppressive	 therapy	 began	 in	 1996	 for	 liver,	 kidney	 and	 pancreas	transplantation	with	the	hope	of	both	high	success	and	low	rejection	rate	(Webster	et	
al.	2005).	Early	 reports	 were	 encouraging	 with	 very	 few	 major	 side	 effects	 and	 FK506	 was	extremely	well	tolerated	by	most	patient	types.	After	kidney	transplantation,	reports	highlighted	 FK506’s	 ability	 to	 significantly	 reduce	 or	 completely	 stop	 steroid	administration	 (prednisone)	 in	over	50%	of	patients,	while	all	CsA	 treated	patients	still	required	steroid	treatment	within	the	study	(Wallemacq	&	Reding	1993).	1-year	survival	rates	also	looked	promising	with	patient	and	graft	survival	rates	of	94%	and	77%	versus	90%	and	70%	of	CsA	treated	patient’s,	respectively.	Rejection	rates	were	similar	to	CsA	also,	59%	and	57%,	respectively,	indicating	a	similar	graft	versus	host	(GVH)	rejection	rate	(Shapiro	et	al.	1991).	However	 after	 the	 initial	 trials	 and	 testing	 success,	 it	 was	 becoming	 apparent	 that	FK506	was	also	stimulating	side	effects	similar	to	CsA.	Given	that	both	drugs	inhibit	the	 same	molecular	 target,	 it	 would	 be	 reasonable	 to	 expect	 such	 side	 effects	 and	ranged	 from	mild	 nausea	 to	 extreme	nephrotoxicity	 (Marti	&	 Frey	 2005).	 The	 vast	array	of	side	effects	started	to	imply	FK506	was	able	to	modify	numerous	pathways	
via	 inhibition	of	systemic	calcineurin.	In	addition,	tacrolimus	also	had	the	additional	side	 effect	 of	 new	 onset	 post	 transplant	 diabetes	 (NODAT)	 and	 worsening	 sugar	control	in	known	diabetics	(Ericzon	et	al.	1992;	Staatz	&	Tett	2004).	
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1.7	 CNI	Nephrotoxicity		CsA	 nephrotoxicity	 was	 first	 reported	 in	 the	 late	 1970’s,	 almost	 straight	 after	 its	introduction	 into	 immunosuppressive	 regimes.	 Nephrotoxicity	 was	 reported	 in	 all	three	main	compartments	of	the	kidney:	glomeruli,	arterioles	and	tubulo-intersitium	(Calne	et	al.	 1978).	 Importantly,	 this	 side	 effect	were	not	 reported	 in	 initial	 animal	experiments	(Gaston	2009)	and	would	be	undeniably	instrumental	in	future	research	with	 the	 development	 of	 new	 low-salt	 animal	 model	 to	 recreate	 a	 more	representative	human	physiological	setting.		The	 initial	 findings	 of	 nephrotoxicity	 were	 first	 labelled	 as	 an	 ambiguous	phenomenon	 due	 to	 their	 absence	 in	 animal	 studies	 and	 the	 specific	 cause	 of	nephrotoxicity	was	unclear.	However,	the	nephrotoxicity	observed	was	attributed	to	acute	 functional	 changes	 rather	 than	 physical	 changes	 in	 structure	 and	 were	therefore	reversible	(Bennett	&	Pulliam	1983;	Klintmalm	et	al.	1981).	The	functional	changes	later	became	known	as	acute	CNI	nephrotoxicity.		
1.7.1	 Acute	CNI	nephrotoxicity		
1.7.1.1	Vascular,	tubular	&	interstitial	Nephrotoxicity		Acute	 nephrotoxicity	 is	 associated	 with	 a	 reversible,	 dose-dependent	 reduction	 of	glomerular	 filtration	rate	(GFR)	and	plasma	 flow	attributed	by	both	 the	direct	 toxic	effect	 on	 renal	 vasculature	 and	 overall	 systemic	 vasoconstrictive	 effects	 of	 CNI’s	(Dieperink	et	al.	1985).	Calne	and	colleagues	who	were	the	early	investigators	of	CsA	nephrotoxicity,	 first	 noted	 nephrotoxicity	 with	 patients	 treated	 at	 what	 currently	would	be	considered	a	high	clinical	dose	of	CsA,	25	mg/kg	(Calne	et	al.	1978).	Follow	up	 studies	 using	 a	 slightly	 lower	 dosing	 regime,	 17	 mg/kg,	 revealed	 not	 only	 an	improved	GFR	 and	 blood	 pressure	 (BP)	 but	 a	much	 higher	 percentage	 of	 one	 year	predicated	 graft	 survival	 rate,	 over	 90%	 compared	 to	 60%	previously	 (Calne	 et	al.	1978).	These	reversible	functional	changes	were	first	hypothesised	to	originate	from	direct	vasoconstriction	 of	 afferent	 arterioles	 and	 nonspecific	 vasoconstriction	 of	 efferent	arterioles,	 resulting	 in	 a	 decrease	 of	 GFR	 and	 prolonged	 systemic	 exposure	 to	 CsA.	Murray	 et	 al	 first	 observed	 this	 hypothesis	 and	 confirmed	 CsA	was	 able	 to	 induce	strong	vasoconstriction	of	afferent	arterioles,	resulting	in	a	rise	of	serum	creatine	and	induced	 arterial	 hypertension	 in	 a	 conscious	 rat	model	 (Murray	 et	al.	 1985).	 Renal	vascular	resistance	and	blood	flow	in	both	arterioles	were	then	further	investigated	
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by	 others	 including	 English	 et	 al	 who	 were	 able	 to	 directly	 measure	 the	 luminal	diameter	of	afferent	arterioles	of	rats	treated	with	CsA	to	unequivocally	highlight	the	importance	 of	 these	 vascular	 parameters	 in	 the	 acute	 functional	 impairment	associated	 with	 CsA	 use	 (English	 et	 al.	 1987).	 The	 degree	 of	 CNI	 induced	vasoconstriction	can	be	seen	in	figure	1.7.	From	this	initial	study	and	the	numerous	that	followed	(Diederich	et	al.	1994;	Kon	et	
al.	1990;	Morris	et	al.	2000),	 it	was	becoming	clear	 that	vascular	dysfunction	was	a	predominate	 factor	 in	CsA	nephrotoxicity,	but	 the	key	question	still	 to	be	answered	was	how	CsA	was	able	to	induce	vascular	dysfunction	and	associated	nephrotoxicity.	It	was	postulated	that	this	may	be	due	to	the	fact	that	CsA	is	not	T	lymphocyte	specific	as	had	been	previously	suggested	and	the	resulting	alteration	 in	gene	expression	of	NOS	and	TGF-β	 for	example	contributed	 to	 the	vascular	dysfunction	 (Naesens	et	al.	2009),	see	sections	1.7.2	and	1.9.3.2	for	further	discussion.													
Figure	1.7	 CNI	 induced	 vasoconstriction	 and	 glomerular	 collapse.	 Scanning	electron	micrograph	 of	 afferent	 arteriole	 (AA)	 and	 glomerular	 tuft	 from	 control	 is	shown	on	the	left	panel.	Right	panel	is	a	similar	micrograph	from	CsA	treated	animal.	Arrowhead	highlights	degree	of	vasoconstriction	of	AA	on	right	panel	and	glomerular	collapse.	Adapted	from	(English	et	al.	1987).		
1.7.2	 Nitric	oxide		Initial	investigations	for	identifying	specific	CNI	nephrotoxicity	pathways	focused	on	nitric	 oxide	 (NO)	 as	 it	 is	 one	 of	 the	most	 potent	 agents	 able	 to	 induce	 vasodilation	within	the	vascular	bed	(Bryan	et	al.	2009).	Several	groups	have	shown	CNIs	are	able	
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to	 impair	 endothelium-dependent	 vasodilation	mediated	 through	 NO	 in	 a	 range	 of	experimental	protocols.	These	range	from	single	cell	 lines	through	to	human	 in	vivo	studies	investigating	aorta,	arteries,	and	afferent	and	efferent	arterioles	(Hortelano	et	
al.	2000;	Diederich	et	al.	1994;	Navarro-Antolin	et	al.	2000).		Since	CsA	has	 also	been	 shown	 to	 inhibit	 acetylcholine-induced	NO	production	and	subsequent	vasodilation	(Roullet	et	al.	1994),	it	would	therefore	seem	logical	that	an	increase	 of	 NO	 during	 CsA	 treatment	 would	 rectify	 the	 vascular	 dysfunction.	 Both	animal	 and	 human	 studies	 have	 investigated	 L-arginine	 supplementation	 for	preventing	 a	 decrease	 in	 systemic	 NO	 bioavailability.	 L-arginine	 is	 the	 immediate	precursor	to	NO	however	investigative	studies	have	had	varying	degrees	of	success.	In	 rats,	 L-arginine	was	 able	 to	 completely	 ameliorate	 renal	 dysfunction	 induced	 by	CsA	 (Amore	 et	 al.	 1995),	 	 however	 in	 human	 studies,	 no	 beneficial	 effect	 was	observed	 with	 a	 similar	 supplementation	 protocol	 (X.	 Z.	 Zhang	 et	 al.	 2001).	Histopathological	 lesions	 of	 the	 renal	 vasculature	 and	 tubulointerstitium	 have	 also	been	reported	to	be	ameliorated	by	L-arginine	supplementation	(Chander	&	Chopra	2005).	However,	 contradictory	 studies	 have	 found	 elevated	 expression	 of	 RNA	 and	protein	 levels	 of	 endothelial	 NOS	 (eNOS)	 in	 the	 renal	 cortex	 of	 rats	 after	administration	 of	 CsA	 but	 with	 no	 increased	 levels	 of	 circulating	 or	 renal	 NO	(Navarro-Antolin	et	al.	2000;	Stroes	et	al.	1997).		Increased	 levels	 of	 NO	 metabolites	 in	 urine	 have	 been	 observed	 as	 well	 as	 an	increased	 binding	 capacity	 of	 transcription	 factor	 AP-1	 to	 the	 eNOS	 promoter,	ultimately	increasing	NO	production,	after	CNI	administration	(Stroes	et	al.	1997;	Su	
et	al.	1995).	Interestingly,	studies	have	shown	CsA	is	able	to	increase	NOS	production	in	 healthy	 non-transplant	 volunteers,	 but	 impairs	 basal	 and	 stimulated	 NO	production	in	renal	transplant	patients	(Morris	et	al.	2000).	Endothelial	NOS	is	not	the	only	NOS	isoform	that	CNI’s	are	able	to	alter.	Hamalainen	
et	 al	 demonstrated	 inducible	 NOS	 (iNOS)	 was	 down-regulated	 by	 CsA	 in	 both	epithelial	and	macrophage	cell	lines,	in	a	NF-Kβ	independent	manner,	while	Dusting	et	
al	 reported	 similar	 findings	 with	 a	 macrophage	 cell	 line	 but	 interestingly,	 also	 in	vascular	 smooth	 muscle	 cells	 (Hamalainen	 et	 al.	 2002;	 Dusting	 et	 al.	 1999).	 This	highlights	 the	 role	 of	 NO	 production	 in	 CNI	 therapy	 and	 direct	 effects	 on	 vascular	smooth	muscle,	propagating	into	hypertension	and	nephrotoxicity.	CNIs	 are	 also	 known	 to	 increase	 free	 radical	 formation	 and	 superoxide	production,	thought	to	originate	from	vasoconstriction-associated	hypoxia	(Diederich	et	al.	1994).	
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Vasoconstriction-associated	 hypoxia	 stems	 from	 vasoconstriction	 increasing	peroxynitrite	while	superoxide	decrease	NO	production	and	bioavailability,	resulting	in	 decreased	 vasodilation	 and	 continuous	 vasoconstriction	 (Diederich	 et	 al.	 1994).	CsA	 also	 reduces	 eNOS-mediated	 NO	 production	 through	 various	 other	 pathways	including	protein	kinase	C	and	vascular	endothelial	growth	factor	(VEGF)	(Kou,	Greif	&	Michel	2002b;	Lungu	et	al.	2004).		An	 interesting	animal	study	by	Zhong	et	al	 clearly	highlighted	CsA	 is	able	 to	 induce	hypoxia	and	produce	new	free	radical	classes	exclusively	within	the	kidney	(Luntz	et	
al.	2005).	Interestingly,	this	was	prevented	with	the	addition	of	dietary	glycine.	How	glycine	 is	 able	 to	 prevent	 CsA	 nephrotoxicity	 is	 still	 unclear,	 but	 the	 majority	 of	hypothesis	 suggest	 minimisation	 of	 hypoxia-reoxygenation	 through	 a	 variety	 of	pathways	 (Zhong	 et	 al.	 1999;	 Luntz	 et	 al.	 2005;	 Zhong	 et	 al.	 1998).	 Suggested	mechanisms	include	a	decrease	in	renal	sympathetic	nerve	firing	and	direct	inhibition	of	vascular	smooth	muscle	cell	contraction	(Zhong	et	al.	1999).	The	HEGPOL	study	is	further	investigating	the	beneficial	effects	of	dietary	glycine,	albeit	in	liver	transplant	patients	 treated	 with	 CsA,	 and	 may	 provide	 a	 novel,	 cost	 effective,	 therapeutic	strategy	for	prevention	of	CNI	nephrotoxicity	(Luntz	et	al.	2005).		Taken	together,	 it	 is	apparent	that	NO	plays	a	vital	role	 in	vascular	dysfunction	and	that	 unobstructed	 vasoconstriction,	 possibly	 through	 decreased	 NO	 bioavailability	and	increased	free	radical	production,	could	be	a	foremost	mechanism	in	CNI-induced	nephrotoxicity.						
	
1.7.3	 Effect	of	CNIs	on	the	production	of	endothelin			There	is	increasing	evidence	that	CNI	nephrotoxicity	not	only	stems	from	decreased	production	 of	 vasodilators	 but	 also	 from	 increased	 production	 and	 secretion	 of	vasoconstrictor	substances,	predominately	endothelin	(ET)	(Perico	et	al.	1990).	ET	 is	 a	 potent	 vasoconstrictor,	with	 3	 isoforms,	 ET-1,	 2	 and	 3,	 and	 is	 ubiquitously	released	within	the	kidney	and	vascular	beds	(Ramirez	et	al.	2000).	It	acts	by	binding	to	 either	 of	 its	 receptors,	 ETA	 or	 ETB,	 and	 ultimately	 increases	 vasoconstriction	through	their	coupling	of	corresponding	G	proteins,	Gq	and	Gi,	respectively	(Yoshida	et	
al.	1994).	The	 association	 of	 increased	 ET	 production	 and	 CsA	 nephrotoxicity	 was	 first	identified	by	Nakahama	and	colleagues,	who	were	able	to	display	CsA	stimulated	ET	
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release	 from	 a	 renal	 epithelial	 cell	 line	 (Nakahama	 1990).	 Animal	 studies	 that	followed	 confirmed	 ET’s	 role	 in	 CsA-induced	 vasoconstriction	 and	 was	 further	highlighted	 in	 liver	 and	 other	 solid	 organ	 transplant	 patients	 with	 CsA	immunosuppressive	regimes,	all	resulting	in	an	increased	circulation	of	ET	(Kon	et	al.	1990).	ET’s	role	has	been	studied	extensively	with	respect	to	CNI	nephrotoxicity	and	much	of	the	current	research	focuses	on	the	use	of	anti-endothelial	antibodies	and	ETA	and	ETB	receptor	antagonists.			Antibodies	targeting	ET	have	shown	to	partially	reduce	CNI-induced	vasoconstriction	and	 the	 associated	 decline	 in	 GFR,	 albeit	 in	 rat	 models	 (Perico	 et	 al.	 1990).	Contradictory	to	the	findings	of	Perico	et	al	with	ET	antibodies,	Fogo	and	colleagues	demonstrated	 that	 ETA	 receptor	 antagonists	 where	 able	 to	 attenuate	 CsA-induced	reduction	 in	 GFR	 and	 renal	 blood	 flow	 (RBF),	 but	 only	 when	 infused	 prior	 to	 CsA	administration	and	not	when	used	simultaneously	or	following	CsA	therapy	(Fogo	et	
al.	1990).	However,	Davis	et	al	failed	to	highlight	any	improvement	in	renal	function	after	 using	 selective	 ETA	 receptor	 antagonists	 or	 with	 an	 ETA	 and	 ETB	 receptor	antagonist	combination	(Davis	et	al.	1994).	Taken	collectively,	it	is	clear	that	ET	does	have	a	 functioning	role	 in	CsA	nephrotoxicity	and	possibly	 results	 in	overwhelming	vasoconstriction,	development	of	hypertension	and	ultimately,	 significant	 reduction	of	 renal	 function.	 Interestingly,	 the	 exact	mechanism	 or	 pathway	 for	 CNI-mediated	increase	in	ET	is	still	not	clear,	as	is	similar	to	CNI	nephrotoxicity	in	general.		
1.7.4	 Effect	of	CNIs	on	the	production	of	thromboxane		Thromboxane	 is	 an	 additional	 vasoconstrictor	 that	 is	 associated	 with	 CNI	nephrotoxicity.	 It	 acts	 similarly	 to	ET,	by	binding	 to	 its	G	protein-coupled	 receptor,	Gq,	 and	 stimulating	 vascular	 smooth	muscle	 contraction	 through	 the	 PIP2	 pathway	(Dorn	&	Becker	1993).	Spurney	et	al	clearly	demonstrated	the	role	for	thromboxane	in	 CNI	 nephrotoxicity	 with	 their	 results	 highlighting	 the	 improvement	 of	 GFR	 and	overall	 vascular	 resistance	 in	 rats	 treated	with	a	 specific	 thromboxane	A2	 inhibitor	while	receiving	CsA	treatment	(Spurney	et	al.	1990).	The	increased	production	of	thromboxane	via	CNI	administration	is	thought	to	derive	from	 activated	 platelets	 and	 macrophages	 within	 the	 kidney,	 increased	 lipid	peroxidation,	 increased	 reactive	 oxygen	 species	 (ROS)	 production	 and	 endothelial	injury	 (Kopp	&	Klotman	1990;	Randhawa	et	al.	 1997;	Krejci	et	al.	 2010).	However,	
	 43	
clinical	 trials	 hoping	 to	 target	 these	 specific	 side	 effects	 have	 had	 mixed	 success	(Grace	 et	 al.	 1987;	 Perez	 de	 Hornedo	 et	 al.	 2007).	 Weir	 et	 al	 piloted	 the	 use	 of	 a	selective	 thromboxane	 synthase	 inhibitor	 in	 a	 cohort	 of	 renal	 transplant	 patients,	which	 ultimately	 failed	 to	 protect	 against	 CsA	 nephrotoxicity,	 despite	 reducing	urinary	and	systemic	thromboxane	metabolites	(Weir	et	al.	1992).	However,	Smith	et	
al	demonstrated	an	improvement	in	renal	function	along	with	a	decrease	in	urinary	thromboxane	A2	after	treatment	with	an	alternative	selective	thromboxane	synthase	inhibitor	 (Smith	 et	 al.	 1993).	 Therefore	 it	 remains	 unclear	 to	 what	 extent	thromboxane	 is	 a	prerequisite	 in	 the	development	of	CNI	nephrotoxicity,	 especially	with	 its	 origin	 in	 the	 arachidonic	 acid	 pathway	 and	 interrelationship	 with	prostacyclin	and	prostaglandins	(Parra	et	al.	1998).	
1.7.5	 Effect	of	CNIs	on	the	production	of	prostaglandin	&	prostacyclin		Both	 prostaglandin	 and	 prostacyclin	 are	 vasodilatory	 prostanoids	 that	 are	 able	 to	increase	 GFR	 and	 maintain	 the	 normal	 homeostatic	 gradient	 under	 hemodynamic	stress	conditions	(Pugliese	&	Ciabattoni	1984).	They	are	derived	from	the	conversion	of	 arachidonic	 acid	 (A.A)	 via	 cyclooxygenase	 enzymes	 (COX),	 of	which	 three	 forms	exist,	COX-1,	COX-2	and	COX-3	(Berti	2013).		The	 foremost	 prostaglandin	 that	 has	 a	 role	 in	 regulating	 normal	 renal	 function	 is	prostaglandin	E2	(PGE2)	(Ryffel	et	al.	1986).	Along	with	vasodilation	of	blood	vessels,	PGE2	 also	 potentiates	 platelet	 aggregation	 and	 is	 involved	 in	 inflammation	 and	 cell	growth	(Vezza	et	al.	1993).	Höcherl	et	al	were	able	to	demonstrate	not	only	a	reduced	production	of	PGE2	after	CNI	 administration	 in	 the	 rat	 kidney,	 but	 also	 a	 reduced	 expression	 of	 COX-2,	suggesting	a	 role	 for	COX-2	expression	and	PGE2	production	 in	 the	development	of	CNI	 nephrotoxicity	 (Hocherl	 et	 al.	 2002).	 Several	 studies	 have	 further	 investigated	this	pathway,	using	PGE2	administration	to	overcome	CNI-mediated	vasoconstriction.	However,	only	a	small	number	of	studies	have	demonstrated,	the	“protective”	effect	of	 PGE2	 administration	 and	 conversely,	 the	 protective	 mechanism	 is	 thought	 to	originate	 from	 a	 decreased	 intestinal	 absorption	 of	 CsA	 rather	 than	 PGE2’s	vasodilatory	properties	(Ryffel	et	al.	1986).	Interestingly,	misoprostol	is	a	PGE1	analogue	that	has	shown	to	have	renal	protective	effects.	 PGE1	 is	 a	 vasodilatory	 prostaglandin	 with	 potent	 inhibitory	 platelet	aggregation	properties	 (Moran	et	al.	 1990).	When	used	 in	 a	 rat	model,	misoprostol	was	shown	 to	attenuate	CsA	nephrotoxicity	 in	vivo	 (Paller	1988).	 In	addition,	when	
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used	 in	 humans,	 misoprostol	 was	 also	 shown	 to	 improve	 renal	 function	 after	 CsA	administration,	but	the	protective	effect	was	attributed	to	a	lower	incidence	of	acute	rejection	rather	than	a	protective	vasodilatory	effect	derived	from	misoprostol	itself	(Moran	et	al.	1990).	This	was	further	confirmed	by	Boers	et	al	who	did	not	observe	any	 beneficial	 effects	 of	misoprostol	 on	 renal	 function	when	 treating	 patients	with	CsA	for	rheumatoid	arthritis	(Boers	et	al.	1992).	Prostacyclin	 (PGI)	 is	 a	 well-known	 potent	 vasodilator	 that	 is	 implicated	 in	 the	regulation	 of	 vessel	 tone	 along	 with	 having	 antiproliferative	 and	 antithrombotic	properties	(Berti	2013).	CNIs	are	known	to	decrease	PGI	production	and	studies	with	PGI	 analogues	 have	 shown	 a	 renoprotective	 role	 against	 the	 functional	 changes	induced	by	CNIs	 in	animal	models.	However,	clinical	studies	have	shown	conflicting	results	 with	 a	 prostacyclin	 analogue,	 iloprost,	 having	 no	 effect	 on	 CsA-induced	reduction	of	GFR	in	renal	transplant	patients	(Voss	et	al.	1988;	Hansen	et	al.	1996).		It	is	clear	that	CNIs	have	the	ability	to	disrupt	a	fine	balance	between	vasoconstriction	and	 vasodilation,	 however	 CNIs	 are	 also	 involved	 in	 the	 generation	 of	 local	vasodilatory	molecules	 (Stroes	 et	 al.	 1997),	 further	 adding	 to	 the	 already	 complex	story.	The	disruption	between	the	dynamic	array	of	vasodilators	and	vasoconstrictors	predominately	 leads	 to	 vasoconstriction,	 however	 it	 is	 still	 unknown	 which	vasoconstrictor	 or	 vasodilator,	 if	 any,	 plays	 the	 key	 role	 in	 the	 development	 of	nephrotoxicity.	 This	 is	 further	 complicated	 by	 the	 fact	 each	 vasoactive	 substance	appears	to	be	activated	by	a	different	independent	pathway	(Naesens	et	al.	2009).	
	
1.7.6	 Effect	of	CNIs	on	the	renin-angiotensin-aldosterone	system	As	well	 as	 the	 significant	disruption	of	vasoactive	 substances,	CNI	nephrotoxicity	 is	thought	 to	 be,	 in	 part,	 due	 to	 the	 activation	 and	 overstimulation	 of	 the	 renin-angiotensin-	aldosterone	system	(Naesens	et	al.	2009).	The	 renin-angiotensin-aldosterone	 system	 (RAAS)	 is	 a	 major	 hormonal	 signalling	pathway	that	regulates	BP	and	fluid	balance	within	the	human	body.	The	 RAAS	 can	 be	 initially	 stimulated	 through	 a	 decrease	 in	 blood	 pressure	 and/or	blood	 volume	 or	 electrical	 stimulation,	 for	 example,	 “Fight	 or	 Flight”	 situations	(Koeppen	&	 Stanton	 2013b).	 Juxtaglomerular	 cells	within	 the	 kidney	 secrete	 renin	directly	 into	 the	 systemic	 circulation	 in	 response	 to	 a	 drop	 of	 pressure	 or	 when	stimulated	by	macula	densa	cells,	through	activation	of	their	prorenin.	Plasma	renin	
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then	converts	angiotensinogen,	released	by	the	liver,	to	angiotensin	I	(Ruester	&	Wolf	2006).	Angiotensin	I	is	unstable	and	is	subsequently	converted	to	angiotensin	II	(ANG	II)	by	the	angiotensin-converting	enzyme	(ACE),	produced	by	endothelial	cells	within	the	 lung	 (Remuzzi	et	al.	 2005).	The	main	 functions	of	ANG	 II	 are	 to	 increase	blood	pressure	 and/or	 blood	 volume,	 although	 through	 vasopressin	 release.	 ANG	 II	stimulates	the	secretion	of	the	water	retaining	hormone	vasopressin	(AVP)	from	the	pituitary	 gland	 and	 the	 release	 of	 adrenaline	 and	 noradrenaline	 (NA)	 as	 well	 as	aldosterone	from	the	adrenal	cortex	(Rüster	&	Wolf	2006),	all	aiding	in	its	function	to	increase	blood	volume	and/or	pressure.		The	 release	 of	 adrenaline	 and	 NA	 augments	 the	 vasoconstrictive	 effect	 of	 ANG	 II,	further	 increasing	 pressure,	 whereas	 release	 of	 aldosterone	 increases	 water	reabsorption	to	increase	blood	volume.		Aldosterone	 acts	 on	mineralocorticoid	 receptors	within	 principal	 cells	 of	 the	 distal	convoluted	tubule	(DCT)	and	the	collecting	duct	of	the	nephron,	where	it	up-regulates	and	 activates	 the	 epithelial	 sodium	 channel	 (ENaC)	 and	 sodium/potassium	ATPase	pump	 (Na+/K+-ATPase)	 to	 create	 a	 concentration	 gradient,	 resulting	 in	 increased	reabsorption	 of	 Na+,	 along	 with	 water	 through	 aquaporin’s	 (AQPs),	 into	 the	 blood	(Harrison-Bernard	2009).	AVP	helps	regulate	this	water	retention	by	 increasing	the	water	permeability	of	the	principal	cells.	AVP	induces	the	translocation	of	AQP’s	into	the	apical	membrane	of	the	DCT	and	collecting	duct	epithelial	cells,	allowing	water	to	move	down	its	osmotic	gradient,	increasing	water	reabsorption	from	the	filtrate	and	increasing	blood	volume	(Koeppen	&	Stanton	2013c;	Koeppen	&	Stanton	2013d).	AVP	also	helps	regulate	the	balance	of	Na+	and	K+	electrolytes,	 through	regulation	of	 the	sodium-potassium-chloride	 cotransporter	 (NKCC2)	 the	 thiazide-sensitive	 sodium-chloride	 cotransporter	 (NCC)	 and	 ENaC,	 while	 increasing	water	 volume	 (Harrison-Bernard	2009).	CNIs	 directly	 and	 indirectly	 lead	 to	 the	 activation	 of	 the	 RAAS.	 Direct	 activation	 is	through	the	release	of	renin	from	juxtaglomerular	cells,	first	demonstrated	by	Kurtz	
et	al,	who	found	a	three-fold	increase	of	renin	release	after	CsA	administration	(Kurtz	
et	al.	1988).	This	is	followed	by	a	secondary	indirect	activation	of	RAAS	instigated	by	renal	 vasculature	 haemodynamic	 changes,	 increased	 arterial	 vasoconstriction,	 and	also	decreased	production	of	vasodilators	and	increased	endothelin	secretion	(Kurtz	
et	al.	1988).	As	RAAS	activation	leads	to	ANG	II	induced	reduction	of	blood	flow	and	vasoconstriction,	the	addition	of	systemic	CNIs	further	enhances	the	haemodynamic	
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changes	 associated	 with	 CNI’s,	 representing	 a	 continuous	 loop	 of	 damage	 and	nephrotoxicity,	this	can	be	seen	in	figure	1.8.	Sodium	reduction,	which	also	stimulates	renin	 release	 and	 thus	 RAAS	 activation,	 enhances	 CNI	 nephrotoxicity,	 which	coincidently	is	the	basis	for	modern	animal	studies	investigating	CsA	nephrotoxicity	(Bennett	et	al.	1996;	Bennett	1997).		Recruitment	of	renin	containing	cells	in	afferent	arterioles	is	also	observed	with	the	use	of	CsA,	further	increasing	renin	secretion	and	RAAS	 activation	 (D.	 B.	 Lee	 1997;	 Lassila	 2002).	 This	 dramatic	 increase	 of	 renin	production	 can	 be	 seen	 clinically	 as	 hyperplasia	 of	 the	 juxtaglomerular	 apparatus	(JGA),	 potent	 vasoconstriction	 of	 afferent	 arterioles	 and	proliferation	 of	 VSMC’s,	 all	further	 contributing	 to	 the	 continuous	onslaught	of	CNI	 therapy	 (Iijima	et	al.	 2000;	Bohle	et	al.	1982).	Activation	of	RAAS,	 the	recruitment	of	renin	containing	cells	and	mobilization	 of	 VSMC’s	 is	 similar	 to	 other	 contributing	 side	 effects	 of	 CNI	nephrotoxicity	 with	 the	 underlying	 mechanisms	 remaining	 ambiguous	 and	 further	complicates	the	understanding	of	the	pathogenesis	of	renal	damage	due	to	CNIs.														






A	general	consensus	was	that	inhibition	of	RAAS	would	potentially	help	alleviate	the	sustained	vasoconstriction	and	reduce	overall	renin	secretion	(D.	B.	Lee	1997;	Lassila	2002;	Hiremath	et	al.	2007).	This	was	 investigated	 from	two	different	perspectives:	ANG	II	receptor	inhibition	and	ACE	inhibition.		ANG	 II	 receptor	 blockers	 (ARBs)	 are	 specific	 inhibitors	 to	 ANG	 II	 type	 I	 receptors	(AT1)	 and	 thus	 prevent	 ANG	 II	 from	 binding.	 Their	 use	 for	 CNI	 nephrotoxicity	 has	been	extensively	investigated,	both	in	animal	studies	and	human	trials,	however	the	results	are	contradictory	and	vary	extensively	(B.	K.	Sun	et	al.	2005;	Hannedouche	et	
al.	1996).	Losartan	is	the	most	common	ARB	to	be	investigated	with	Inigo	et	al	finding	RBF	 and	 vascular	 resistance	 improved	 with	 losartan	 treatment	 in	 patients	undergoing	 CsA	 therapy	 but	 observed	 no	 improvement	 in	 GFR	 (Iñigo	 et	 al.	 2001).	However,	Burdmann	et	al	demonstrated	overall	renal	improvement	and	reduction	of	interstitial	fibrosis	with	losartan	and	CsA	(Burdmann	et	al.	1995).	Interestingly,	out	of	the	 various	 studies	 that	 did	 show	 improvement	 with	 ARBs,	 one	 of	 the	 main	observations	 that	 repeatedly	 occurred	 was	 a	 reduction	 of	 transforming	 growth	factor-β	(TGF-β)	(Iñigo	et	al.	2001;	Lassila	et	al.	2000).	The	influence	of	TGF-	β	is	and	CNI’s	is	discussed	later	in	this	chapter.			ACE	 inhibitors	 (ACEi)	 are	 able	 to	 reduce	 or	 prevent	 RAAS	 activation	 through	inhibited	 conversion	 of	 angiotensin	 I	 to	 ANG	 II,	 thereby	 preventing	 full	 ANG	 II	conversion	and	activation	of	RAAS.	Along	with	ARBs,	ACEi	have	also	been	extensively	studied	in	both	animal	and	human	trials	 of	 for	 prevention	 of	 CNI	 nephrotoxicity.	 ACEi	 are	 particularly	 useful	 for	ameliorating	CsA	associated	hypertension,	and	in	combination	with	ARBs,	have	been	found	 to	 almost	 completely	 inhibit	 CsA	 nephrotoxicity	 and	 any	 of	 its	 markers	 in	animal	models	 (Pichler	 et	 al.	 1995;	Mervaala	 et	 al.	 1999).	 However,	 taking	 human	trials	 into	 consideration,	 the	 evidence	 is	 less	 convincing.	 Sennesael	 and	 colleagues	compared	the	effects	of	perindopril	(an	ACEi)	to	amlodipine	(a	Ca2+	channel	blocker)	when	both	used	in	CsA	treatment	(Sennesael	et	al.	1995).	Their	results	indicated	both	drugs	 were	 equally	 effective	 in	 lowering	 BP	 and	 inhibiting	 the	 functional	haemodynamic	changes	associated	with	CsA.	However,	with	such	a	small	sample	size	of	 10	 patients,	 their	 results	 cannot	 be	 fully	 extrapolated	 as	 a	 concrete	method	 for	reducing	CsA	nephrotoxicity	or	 associated	blood	pressure	 changes	 (Sennesael	et	al.	1995).	 Burdmann	 et	 al	 also	 investigated	 enalapril,	 an	 ACEi,	 along	 with	 losartan.	Similar	 to	 the	 results	 with	 losartan	 by	 Sennesael	 et	 al,	 enalapril	 reduced	 the	
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production	 of	 interstitial	 fibrosis	 and	 improved	 overall	 renal	 function	 originating	from	reduced	TGF-B	production	(Burdmann	et	al.	1995).	Furthermore,	most,	if	not	all,	studies	 were	 shown	 to	 have	 a	 reduced	 creatinine	 clearance,	 possibly	 through	haemodynamic	changes.	Given	that	creatinine	clearance	 is	possibly	the	most	widely	used,	 and	 respected	 measure	 of	 renal	 function,	 especially	 nephrotoxicity	 (Bach	 &	Lock	1987),	 the	studies	do	not	 fair	well	 in	 translation	 from	“Bench	 to	Bedside”	and	prevention	of	CsA	nephrotoxicity.		Taken	 together,	 inhibition	of	RAAS,	either	by	ARBs,	ACEis	or	a	combination	of	both	still	does	not	elucidate	the	origins	of	CsA	nephrotoxicity,	nor	show	whether	either	of	these	drug	types	can	slow	the	progression	of	renal	damage	in	a	clinical	setting.		
	
1.8	 Tacrolimus	nephrotoxicity		The	majority	of	early	CNI	nephrotoxicity	research	focused	on	CsA	as	 it	was	the	first	available	CNI	but	also	the	most	widely	used.	However,	nephrotoxicity	with	FK506	use	was	soon	becoming	just	as	routine.	Similar	to	CsA,	nephrotoxicity	was	present	in	two	forms:	functional	and	structural,	with	the	cause	of	nephrotoxicity	still	unclear	even	to	the	present	day.	Animal	 and	human	 studies	have	 shown	FK506	decreases	GFR	and	increases	 renal	 vasculature	 resistance,	 increases	 the	production	of	 vasoconstrictors	along	 with	 associated	 decrease	 of	 vasodilators,	 activates	 RAAS	 and	 increases	stimulation	 of	 sympathetic	 nerve	 activity,	 which	 all	 indicate	 a	 similar	 nephrotoxic	profile	to	CsA	(Randhawa	et	al.	1997;	Naesens	et	al.	2009).	An	 important	 study	 by	 Sigal	 and	 colleagues	 demonstrated	 the	 mechanisms	 of	immunosuppression	by	CNI’s,	 inhibition	of	 calcineurin,	 correlated	 to	 their	ability	 to	induce	nephrotoxicity	 (Sigal	et	al.	 1991).	The	 study	 involved	61	CNI	 analogues	 and	highlighted	an	interesting	point	with	regards	to	the	degree	of	calcineurin	inhibition	in	specific	tissues,	greatest	in	the	kidney,	and	the	specific	side	effects	of	CNI’s	in	certain	tissue,	emphasizing	the	direct	impact	calcineurin	inhibition	has	in	the	development	of	CNI	nephrotoxicity.	Furthermore,	 it	 is	becoming	apparent	that	the	calcineurin-NFAT	pathway	may	 be	 fundamental	 in	 the	 pathogenesis	 of	 CNI	 nephrotoxicity	 especially	given	the	pathways	role	in	COX-2	regulation	(Abraham	et	al.	2012).		The	COX-2	gene	promoter	contains	binding	sites	for	NFAT	and	has	been	suggested	to	be	 important	 for	 COX-2	 gene	 expression	 in	vitro	 (Rao	 et	al.	 1997)	 and	 therefore,	 it	could	 be	 postulated	 that	 inhibition	 of	 calcineurin	 simultaneously	 attenuates	 COX-2	expression	 and	 associated	 decrease	 of	 PGE2	 production,	 resulting	 in	 a	 influential	
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mechanism	for	CNI-induced	renal	vasoconstriction	and	decreased	GFR	(Sugimoto	et	
al.	 2001).	 Interestingly,	 a	 new	 CNI	 still	 in	 development	 (voclosporin)	 only	 induced	renal	dysfunction	in	a	very	small	number	of	patients	during	a	clinical	trial,	which	was	not	 associated	 with	 a	 decrease	 in	 PGE2	 (Papp	 et	 al.	 2008).	 With	 regards	 to	 renal	transplantation,	voclosporin	 is	 just	as	potent	to	FK506	 in	respect	 to	acute	rejection,	safety	profile	and	triglyceride	or	magnesium	levels	(Ling	et	al.	2013).	However,	short-term	 results	 have	 not	 shown	 voclosporin	 to	 be	 of	 greater	 benefit	 over	 FK506	 in	respect	to	overall	kidney	function	and	only	long-term	results	will	truly	indicate	if	it	is	of	superior	quality	for	transplantation	(Ling	et	al.	2013).	Although	FK506	is	up	to	100	times	more	potent	than	CsA	(Assmann	et	al.	2001)	there	is	extensive	evidence	demonstrating	that	it	has	a	lower	nephrotoxicity	potential	than	CsA.	Animal	and	human	studies	have	shown	that	the	vasoconstrictive	effect	of	FK506	is	 weaker	 than	 CsA	 (Klein	 et	 al.	 2002;	 Nankivell,	 Chapman,	 et	 al.	 2004;	 Nankivell,	Borrows	 et	 al.	 2004),	 it	 also	 has	 a	 lower	 fibrogenic	 potential	 (Jain	 et	 al.	 2000).	However	 as	 with	 CsA,	 results	 vary	 considerably	 and	 conflict	 depending	 on	 the	experimental	protocol.			The	group	of	van	Groningen	were	unable	to	show	FK506’s	lower	fibrogenic	potential	and	 in	 fact,	 demonstrated	 a	 contradictory	 result	 with	 increased	 development	 of	fibrosis	 with	 FK506	 use	 in	 renal	 transplant	 patients	 (Groningen	 et	 al.	 2006).	Furthermore,	single	and	multicentre	studies	have	indicated	the	benefit	of	FK506	over	CsA	 with	 regards	 to	 overall	 renal	 function,	 however,	 identical	 studies,	 single	 and	multicentre,	 show	conflicted	 results	with	no	benefit	whatsoever	 (Israni	et	al.	 2002;	Kobashigawa	 et	 al.	 2006;	 Lucey	 et	 al.	 2005).	 Importantly,	 these	 studies	 where	 all	conducted	 in	 a	 non-renal	 transplant	 setting.	 Analysis	 of	 renal	 transplantation	nephrotoxicity	 is	much	more	 difficult	 to	 extrapolate	 due	 to	 interference	with	 renal	allograft	 rejection	 phenomena.	 This	 being	 said,	 when	 FK506	 and	 CsA	 had	 similar	levels	of	acute	rejection,	equal	efficacy	and	in	the	renal	transplantation	setting,	FK506	was	associated	with	 considerably	 lower	 serum	creatinine	 levels	 and/or	higher	GFR	compared	 to	 CsA	 therapy	 and	 also	 improved	 graft	 survival	 (Vincenti	 et	 al.	 2007;	Webster	et	al.	2005).	Studies	have	also	highlighted	conversion	from	CsA	to	FK506	for	allograft	 dysfunction	 results	 in	 a	 significant	 improvement	 in	 renal	 function,	highlighting	 the	 original	 role	 of	 FK506	 for	 “rescue	 therapy”	 in	 high-risk	 patients	(Garlicki	et	al.	2006).	This	is	further	demonstrated	by	the	SYMPHONY	study,	a	 large	randomized	 multicentre	 trial	 investigating	 various	 immunosuppressive	 regimens,	
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1.9.1	 Chronic	vascular	nephrotoxicity		More	 importantly	 than	 the	 acute	 functional	 changes	 of	 CNI	 nephrotoxicity,	 chronic	nephrotoxicity	 is	 quintessentially	 the	 Achilles	 heal	 of	 modern	 day	immunosuppression.	Unlike	 acute	CNI	nephrotoxicity,	which	 can	be	overcome	with	dosing	 alterations	 and	 withdrawal	 regimes,	 chronic	 CNI	 nephrotoxicity	 leads	 to	 a	complete	 deterioration	 of	 the	 renal	 architecture	 with	 the	 almost	 inevitable	progression	to	chronic	kidney	disease	(CKD)	and	renal	failure	(Naesens	et	al.	2009).		An	 early	 study	 by	Myers	 et	al	 was	 the	 first	 to	 demonstrate	 CsA	 is	 capable	 of	 both	acute	functional	changes	but	also	irreversible	alterations	in	renal	architecture	(Myers	
et	al.	1984).	The	study	highlighted	early	development	of	 interstitial	 fibrosis,	 tubular	atrophy	 and	 focal	 glomerular	 sclerosis	 after	 just	 12	months	 of	 CNI	 therapy.	 It	was	then	 later	 discovered	 that	 vessels,	 tubulointerstitium	 and	 glomeruli	 could	 be	irreversibly	 altered	 with	 CNI	 use	 and	 progressed	 with	 time	 after	 transplantation.	Remarkably,	10	years	post-transplantation,	biopsy	lesions	suggestive	of	chronic	CNI	nephrotoxicity	 were	 seen	 in	 virtually	 all	 patients	 (Bennett	 et	 al.	 1996)	 however	 it	must	 be	 made	 clear	 that	 CNI	 nephrotoxicity	 has	 no	 specific	 lesions,	 therefore	 to	suggest	 CNI	nephrotoxicity	 alone	 as	 the	 only	 contributing	 factor,	 and	 that	 no	other	underlying	aspects	 like	hypertension	or	hyperlipidaemia	may	have	played	a	 role	 in	the	development	of	 renal	decline	 is	 somewhat	naïve,	 especially	as	even	 to	 this	day,	
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there	 is	 very	 little	 evidence	 for	 specific	 markers	 in	 CNI	 pathology	 (Nankivell,	Borrows,	C.	L.	Fung,	et	al.	2004).																	As	already	stated,	chronic	use	with	CNIs	effects	all	three	major	compartments	of	the	kidney	 but	 importantly,	 all	 subdivisions	 have	 individual	 mechanisms	 for	 the	development	of	nephrotoxicity	and	distinct	pathologies.	This	is	important	for	clinical	identification	 of	 the	 term	 chronic	 CNI	 nephrotoxicity,	 which	 ironically,	 the	 term	“chronic”	 has	 often	 been	 used	haphazardly	with	 no	 convincing	 evidence	 to	 suggest	otherwise	and	only	due	to	allograft	dysfunction	(Fioretto	et	al.	2011).	Therefore,	the	term	 chronic	 CNI	 nephrotoxicity	 must	 be	 used	 to	 describe	 CNI-induced	 structural	damage,	often	in	the	form	of	intestinal	fibrosis	visualized	through	biopsy	staining	(S.	H.	Lee	et	al.	2005;	Gaston	2009;	Bennett	et	al.	1996).	Chronic	nephrotoxicity	is	often	associated	 with	 deteriorating	 hyaline	 changes	 in	 afferent	 arterioles	 consisting	 of	endothelial	 cell	 swelling,	 hyaline	 deposition	 and	 smooth	 muscle	 lesions	 and	 cell	necrosis	 (Naesens	 et	 al.	 2009).	 Although	 very	 few	 histological	 markers	 for	 CNI	nephrotoxicity	are	thought	to	exist,	due	in	part	to	allograft	rejection	phenomena,	key	markers	help	distinguish	between	nephrotoxicity	and	other	underlying	 risk	 factors.	In	renal	transplantation,	the	arteriolar	lesions	are	thought	to	be	markers	for	chronic	nephrotoxicity	 rather	 than	 graft	 rejection	 (Bakker	 et	al.	 2004).	 Arteriole	 segmental	thickening	 resulting	 in	 a	 “pearl	 necklace”	 type	 appearance	 on	 the	 outer	 region	 is	typical	 for	 chronic	 CNI	 use,	 and	 helps	 characterise	 against	 normal	 arteriosclerosis,	which	is	typically	characterised	by	hyaline	deposits	localised	under	the	endothelium	(Liptak	&	Ivanyi	2006).	
	Acutely,	 CNI	 nephrotoxic	 vascular	 effects	 are	 the	 most	 predominant	 and	 clinically	relevant	 for	 treatment.	 Commonly	 known	 as	 acute	 arteriolopathy	 (Mittal	 &	 Kohli	2014;	Naesens	et	al.	2009),	these	functional	changes	have	already	been	discussed,	but	a	 combination	of	 increased	vasoconstrictors	and	reduced	vasodilators,	 activation	of	RAAS,	production	of	free	radicals	and	sympathetic	nerve	activation	ultimately	lead	to	renal	 vasculature	 dysfunction	 and	 the	 gradual	 decline	 of	 GFR	 and	 overall	 kidney	function.		Chronic	vascular	effects	are	dissimilar	by	the	fact	they	cannot	be	overcome	through	medical	intervention.	i.e.	removal	of	insult	or	dosing	alterations.		Nodular	hyaline	deposits	in	afferent	arterioles,	arteriolar	hyalinosis,	is	characterised	by	replacement	of	smooth	muscle	cells	by	protein	deposits,	hyaline,	at	the	boundary	
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wall	of	afferent	arterioles	(Nolin	&	Himmelfarb	2010)	and	is	commonly	regarded	as	a	hallmark	 for	 CNI	 nephrotoxicity	 (Mihatsch	 et	 al.	 1998).	 Inevitably	 these	 deposits	become	 larger	 and	 subsequently	 narrow	 the	 vascular	 lumen,	 reducing	 blood	circulation	 and	 decrease	 GFR.	 Although	 regarded	 as	 irreversible,	 experimental	 and	clinical	 studies	 have	 produced	 very	 interesting	 data	 with	 regards	 to	 fibrosis	regression.	 Collins	 et	 al	 reported	 that	 complete	 regression	 of	 severe	 CsA-induced	artriolopathy	and	remodelling	of	arterioles	could	be	achieved	with	complete	removal	of	CsA	 therapy	or	a	 severe	 reduction	 in	dosage	 (Collins	et	al.	 1992).	These	 findings	are	 similar	 to	 Morozumi	 et	 al	 who	 observed	 the	 complete	 regression	 of	 CsA-associated	artriolopathy	and	remodelling	of	arterioles	with	preserved	renal	function	after	complete	removal	of	CsA	therapy	or	severely	reduced	dosage	(Morozumi	et	al.	1992).	The	 pathogenesis	 of	 chronic	 CNI	 nephrotoxicity,	 specifically	 vascular	 toxicity,	 has	been	 comprehensively	 studied	 over	 the	 past	 twenty	 years,	 however,	 the	 origins	 of	these	lesions	have	been	difficult	to	extrapolate	due	to	the	lack	of	viable	reproducible	animal	models.	 It	wasn’t	 until	 the	 laboratory	 of	 Elzinga	 and	Rosen	 discovered	 that	sodium	depletion	was	able	to	exacerbate	CsA	nephrotoxicity	and	produced	a	quicker	chronic	 model	 compared	 to	 previous	 methods	 but	 more	 importantly,	 sodium	depletion	 produced	 histological	 changes	 that	 where	 clinically	 relevant	 with	 the	human	setting	(Elizanga	et	al.	1993).			
1.9.2	 Calcineurin	and	NFAT	Mechanisms	 for	 chronic	 CNI	 nephrotoxicity	 are	 still	 poorly	 defined	 but	 are	understood	 to	 be	 similar	 to	 acute	 nephrotoxicity,	 with	 a	 combination	 of	 factors	contributing	to	the	overall	smooth	muscle	changes	and	deposition	of	granular	protein	(Chapman	2011).	Interestingly,	there	have	been	studies	indicating	the	importance	of	the	calcineurin/NFAT	pathway	 in	smooth	muscle	cell	regulation	and	differentiation.	Graef	et	al	were	able	 to	 show	early	 calcineurin/NFAT	signalling	 initiates	 the	 future	cross	 talk	 and	 stability	 between	 vessels	 and	 surrounding	 tissues	 that	 develop	 the	vasculature	 network	 (Graef	 et	 al.	 2001).	 It	 is	 therefore	 possible	 CNIs	 may	 be	responsible	 for	 vasculature	 remodelling	 through	 direct	 inhibition	 of	 calcineurin	 as	well	 as	 an	 onslaught	 of	 other	 contributing	 factors	 i.e.	 sustained	 vasoconstriction	(Sieber	&	Baumgraass	2009).	
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1.9.3	 Chronic	interstitial	nephrotoxicity		
1.9.3.1	Reactive	oxygen	species			Histopathology,	 chronic	 tubulointerstitium	 CNI-induced	 nephrotoxicity	 will	 lead	 to	one	 very	 apparent	 feature,	 striped	 interstitial	 fibrosis	 (Wang	 &	 Salahudeen	 1995;	Liptak	 &	 Ivanyi	 2006).	 This	 often	 occurs	 in	 parallel	 with	 the	 persistent	vasoconstrictive	effects	of	CNIs	and	arterial	narrowing,	 leading	 to	subsequent	 renal	ischemia	 and	 possible	 ischemic	 reperfusion	 injury	 and	 generation	 of	 free	 radical	production	 and	 cell	 apoptosis	 (Djamali	 2007;	 LopezOngil	 et	 al.	 1996).	 Zhong	 et	 al	have	demonstrated	this	pathway	with	local	ischemia	of	the	tubular-interstitial	region	from	 CNI	 induced	 vasoconstriction,	 leading	 to	 the	 formation	 of	 ROS	 production	(Zhong	 et	 al.	 1998).	 ROS	 production	 in	 the	 development	 of	 chronic	 nephrotoxicity	was	 first	highlighted	by	Wang	et	al	who	observed	 the	beneficial	 effect	 of	 vitamin	E	ROS	 scavenging	 in	 CsA-induced	 nephrotoxicity	 via	 lipid	 peroxidation	 (Wang	 &	Salahudeen	1995).	However,	clinical	trials	using	vitamin	E	as	an	antioxidant	have	had	poor	 outcomes	 and	 furthermore,	 it	 soon	 became	 apparent	 that	 vitamin	 E	 reduces	trough-levels	 of	 CsA,	 rather	 than	 counteracting	 ROS	 production,	 leaving	 transplant	patients	at	substantial	risk	of	infection	or	graft	loss	(Barany	et	al.	2001;	de	Vries	et	al.	2006;	Wang	&	Salahudeen	1995).	Ischemic	 conditions	 in	 renal	 tissue	 is	 similar	 to	 other	 organs;	 vascular	vasoconstriction	resulting	in	subsequent	re-oxygenation	injury	and	formation	of	ROS	and	free	radicals	leading	to	cell	injury	and	death	via	apoptosis	(Longoni	et	al.	2001).	Scavengers	 of	 ROS	 therefore	 seem	 a	 plausible	 target	 for	 prevention	 of	 chronic	nephrotoxicity.	 Catalase,	 an	 enzyme	 capable	 of	 breaking	 down	 hydrogen	 peroxide	(immediate	 precursor	 of	 the	 hydroxyl	 radical)	 has	 been	 indicated	 to	 reduce	 CsA	associated	cellular	apoptosis	(Jennings	et	al.	2007)	however,	CsA	is	capable	of	direct	production	of	ROS	which	was	exhibited	via	proximal	tubular	epithelial	cells	gathering	intracellular	ROS	and	lipid	peroxidation	products	(Galletti	et	al.	2005).	Furthermore,	activation	of	the	RAAS	has	also	been	identified	as	a	pathway	in	the	direct	production	of	ROS	through	CNI	therapy	(Parra	et	al.	1998;	Nishiyama	et	al.	2003).			
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1.9.3.2	TGF-β	Although	 it	 is	 unanimously	understood	 there	 is	no	 single	 contributing	 factor	 to	 the	pathogenesis	of	chronic	CNI	nephrotoxicity,	TGF-β	appears	to	be	a	dominant	cytokine	that	 continuously	 presents	 itself	 through	 CNI-induced	 upregulation.	 TGF-β	 plays	 a	major	 role	 in	 the	 generation	 of	 renal	 fibrosis	 through	 direct	 stimulation	 of	extracellular	matrix	(ECM)	proteins	but	also	reducing	collagenase	production	which	limits	 the	 degradation	 of	 ECM	 (Wolf	 2006).	 Renal	 TGF-β	 production	 has	 been	confirmed	 in	 interstitial	 macrophages,	 fibroblasts	 and	 tubular	 epithelial	 cells,	 with	studies	 suggesting	 the	 majority	 of	 TGF-β	 is	 confined	 to	 interstitial	 fibroblasts	(Feldman	et	al.	2007;	Y.	H.	Liu	2004).	CsA	also	stimulates	systemic	production	of	TGF-	β	via	autocrine	mechanisms	and	upregulation	of	its	receptors	(Border	&	Noble	1994).	Interestingly,	TGF-β	is	upregualted	by	CNIs	in	proximal	tubular	cells	independent	of	acute	functional	alterations	and	induces	epithelial	to	mesenchymal	transition	(EMT)	(Slattery	et	al.	2005).	
	
1.9.3.3	Epithelial	to	mesenchymal	transition	(EMT)		EMT	 is	 currently	 a	 controversial	 subject	 with	 regard	 to	 chronic	 fibrosis;	 some	investigators	hypothesise	it	is	the	major	pathway	of	scar	forming	tissue,	while	others	have	 investigated	 exclusively	 to	 invalidate	 this	 hypothesis	 and	 believe	 it	 only	 as	 a	phenomena	(Slattery	et	al.	2005;	Faulkner	et	al.	2005;	Y.	H.	Liu	2004).		EMT	 is	 a	multistep	 process	 in	which	 epithelial	 cells	 lose	 their	 epithelial	 phenotype	and	 acquire	 new	 characteristics	 features	 of	 mesenchyme	 including	 disruption	 of	polarised	epithelial	cell	morphology,	de	novo	α-smooth	muscle	actin	expression	and	reorganization,	 down	 regulation	 of	 E-cadherin	 resulting	 in	 the	 loss	 of	 cell	 to	 cell	adhesion,	 destruction	 of	 basement	 membranes	 and	 increased	 cell	 migration	 and	invasion	(Thiery	&	Sleeman	2006).	Remarkably,	the	exact	opposite	of	these	processes	can	 also	 occur	 in	 mesenchymal-epithelial	 transition	 (MET).	 The	 complex	 balance	between	EMT	and	MET	can	be	seen	in	figure	1.9.	Vieira	and	colleagues	demonstrated	a	progressive	increase	in	renal	TGF-β	production	with	CsA	treatment	resulting	in	development	of	tubulointerstitial	fibrosis	and	Cuhaci	
et	al	 found	>70%	of	 renal	biopsies	 from	 renal	 transplant	patients	 treated	with	CsA	had	extremely	high	 levels	 of	TGF-β	 staining	 (Vieira	et	al.	 1999;	Cuhaci	et	al.	 1999).	
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Interestingly,	the	patients	with	high	TGF-β	had	a	3	times	higher	rate	of	renal	decline	compared	to	patients	with	no	or	little	TGF-β	(Vieira	et	al.	1999;	Cuhaci	et	al.	1999).	CsA	 has	 also	 been	 shown	 to	 upregulate	 TGF-β	 expression	 in	 juxtaglomerular	 cells	(Wolf	et	al.	1990),	which	could	be	important	in	chronic	activation	of	RAAS	since	TGF-β	 expression	 is	 thought	 to	 be	 mediated	 via	 both	 an	 ANG	 II	 dependent	 and	independent	mechanism	(Campistol	et	al.	1999;	Wolf	2006;	Iñigo	et	al.	2001;	B.	K.	Sun	
et	al.	2005).	Animal	studies	have	exhibited	a	significantly	lower	expression	of	TGF-β	and	interstitial	fibrosis	after	administration	of	losartan,	an	AT1	antagonist	(Campistol	
et	al.	 1999).	Furosemide	and	hydralazine	have	also	 shown	 to	 reduce	TGF-β	but	not	associated	 CNI-induced	 arteriolopathy	 (Pichler	 et	 al.	 1995),	 suggesting	 ANG	 II	 and	AT1	partnership	play	a	major	role	in	the	pathogenesis	of	CNI-induced	arteriolopathy.				
	







1.9.4	 Glomerular	nephrotoxicity		Chronic	glomerular	nephrotoxicity	is	probably	the	most	fundamental	aspect	of	renal	decline	via	nephrotoxicity.	Once	the	glomeruli	have	been	subject	to	chronic	onslaught	of	 vasoconstriction	 and	 hyaline	 deposition,	 they	 are	 unable	 to	 filter	 blood,	 process	metabolites	and	excrete	toxins	(Sánchez-Lozada	et	al.	2005).	The	 most	 common	 form	 of	 glomerular	 injury	 is	 global	 glomerulosclerosis,	 and	 is	result	 of	 CNI-induced	 arteriolar	 hyalinosis,	 arteriolopathy	 and	 glomerular	 ischemia	(Perico	et	al.	1996).	However,	global	glomerulosclerosis	is	not	specific	to	chronic	CNI	use	 and	 its	 development	 can	 be	 associated	 with	 various	 underlying	 factors.	 The	extent	of	glomerular	vasoconstriction	 induced	via	CNIs	can	be	seen	 in	 figure	1.7.	 In	addition,	 focal	 segmental	 glomerulosclerosis	 is	 also	 associated	 with	 CNIs,	 deriving	from	 hyperfilatraion	 injury	 connected	 to	 arteriolar	 hyalinosis	 or	 global	glomerulosclerosis	(Nankivell,	Borrows,	C.	Fung,	et	al.	2004;	Nankivell	et	al.	2004).	Arguably	 the	 most	 influential	 and	 well-known	 study	 investigating	 chronic	 CNI	nephrotoxicity	was	by	Nankivell	et	al	(Nankivell	et	al.	2004).	The	authors	intended	to	look	 for	 the	 progression	 of	 CsA	 nephrotoxicity	 via	 biopsy	 examination	 which	 was	took	at	routine	intervals;	before	implantation;	1,	2	and	4	weeks;	after	months	3,	6	and	12	then	finally	yearly	biopsies	for	10	years	post	transplantation.	Their	results	proved	the	unequivocal	progression	of	renal	decline	with	100%	of	patients	showing	lesions	considered	 reliable	 of	 chronic	 CsA	 nephrotoxicity	 (Nankivell	 et	 al.	 2004).	 An	important	 note	 to	 add	 is	 that	 other	 causes	 of	 hyalinosis	 including	 hypertension,	ischemic	injury,	dyslipidaemias,	hyperglycaemia	and	donor	hyalinosis	were	ruled	out,	therefore	 concluding	 that	 long-term	 CNI	 therapy	 was	 inappropriate	 for	 renal	transplantation	 (Nankivell	 et	 al.	 2003).	 Interestingly,	 studies	 were	 on-going	 at	 the	time	 looking	 for	 minimal	 exposure	 to	 CNIs	 and	 alternative	 immunosuppression	throughout	 the	 Nankivell	 et	 al	 study	 (Baboolal	 2003;	 Chapman	 2011;	 Olyaei	 et	 al.	2001).	
	
1.9.5	 Chronic	tubular	nephrotoxicity		Lastly,	 chronic	 tubular	 toxicity,	 toxic	 tubulopathy,	 plays	 a	 major	 role	 in	 the	development	of	CNI	nephrotoxicity	and	renal	decline	(Krejci	et	al.	2010).	The	 SEMINAL	 study	 by	 English	 and	 colleagues	 was	 one	 of	 the	 distinguished	investigations	to	demonstrate	proximal	tubule	necrosis	is	not	a	feature	of	acute	CNI	
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nephrotoxicity	 in	animal	models	but	 rather	a	 consequence	of	 chronic	CNI	exposure	(English	 et	 al.	 1987).	 However,	 in	 vitro	 studies	 and	 clinical	 trials	 suggested	 CNI-induced	 tubular	 injury	 was	 a	 subtler	 affair.	 There	 has	 been	 numerous	 studies	showing	increased	urinary	excretion	of	proximal	tubule	derived	enzymes,	 increased	excretion	 of	 magnesium,	 impaired	 urinary	 concentrating	 ability	 and	 hyperkalemia	after	CNI	therapy	(Deppe	et	al.	1997;	Holzmacher	et	al.	2005;	Yamauchi	et	al.	1998),	suggesting	 a	 form	 of	 CNI	 related	 tubule	 dysfunction.	 In	 vitro	 studies	 have	 also	highlighted	direct	dose-dependent	toxic	effects	of	CNIs	on	renal	tubular	cell	lines	with	a	 variety	 of	 pathways	 contributing	 to	 their	 damage	 (Wilson	 &	 Hartz	 1991).	 These	include	lipid	peroxidation,	tumour	suppressor	p53	expression,	dysfunctional	calcium	signalling	and	reduced	NO	production,	all	recognised	as	tubular	toxicity	mechanisms	(Galletti	et	al.	2005;	Healy	et	al.	1998;	Gordjani	et	al.	2000).	Heat	 shock	 proteins,	 a	 form	 of	 cell	 stress	 protein,	 have	 also	 been	 suggested	 in	 the	development	of	tubular	toxicity,	although	indirectly	(Paslaru	et	al.	2000).	Cavalho	et	
al	demonstrated	only	extremely	high	 levels	of	CsA,	100ug/ml,	caused	direct	 tubular	injury	via	heat	 shock	protein	expression	but	could	be	prevented	with	alterations	of	calcium	or	magnesium	in	the	cell	culture	media	(Carvalho	da	Costa	et	al.	2003).	Interestingly,	chronic	tubular	damage	leads	to	the	development	of	atubular	glomeruli,	perfused	 glomeruli	 that	 are	 disconnected	 from	 their	 associated	 proximal	 tubule	(Krejci	et	al.	2010).	Histologically,	they	appear	smaller	and	have	capsular	fibrosis	or	severely	contracted	within	an	enlarged	glomerular	cyst	(Koesters	et	al.	2010;	Krejci	
et	al.	2010).	Together,	 these	 studies	 suggest	 that	 although	 acute	 tubular	 toxicity	 is	 not	 as	widespread	as	vascular	dysfunction,	these	small	but	important	changes	in	tubular	cell	function	may	be	relevant	to	cell	survival	and	ultimately	graft	survival	after	long-term	exposure	to	CNI’s.			
1.9.6	 Isometric	vacuolisation			Histologically,	 tubulopathy	 manifests	 after	 arteriolopathy	 (d'Ardenne	 et	 al.	 1986;	Mescher	2013).	However	it	is	thought	to	be	just	as	significant	in	the	development	of	CNI	nephrotoxicity.	Importantly,	most	tubular	lesions	accompanying	CNI	therapy	are	non-specific	and	seen	in	a	variety	of	conditions	and	various	therapies	i.e.	steroid	and	azathioprine	administration	and	therefore	to	clinically	identify	CNI	tubulopathy	extra	care	must	be	taken	(Russell	et	al.	2008).	
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et	al.	1986).	However,	these	lesions	are	also	nonspecific	and	often	occur	in	ischemic	injury	without	CNI	treatment.	In	addition,	inclusion	bodies	have	been	found	in	donor	kidneys	 pre-transplantation	 therefore,	 pre-CNI	 administration	 and	 limit	 their	usefulness	in	diagnostics	of	CNI	nephrotoxicity	(Morozumi	et	al.	1992).	
	
1.9.8	 CNI-induced	apoptosis		CNI’s	 have	 been	 shown	 to	 activate	 apoptosis	 genes	 and	 subsequently	 increase	apoptosis	in	tubular	cells,	correlating	with	CNI	tubular	atrophy	and	tubulointerstitial	fibrosis	(Servais	et	al.	2008).	P-glycoprotein	 is	 completely	 inhibited	 by	 CsA	 and	 may	 additionally	 contribute	 to	structural	 lesions	 of	 chronic	 nephrotoxicity	 by	 preventing	 P-glycoprotein	 from	removing	 CsA	 within	 the	 cell	 therefore	 increasing	 local	 concentration	 and	 toxicity	(Chaurk	et	al.	1995;	Saeki	et	al.	1993).	P-glycoprotein	is	a	drug	transporter	expressed	on	 the	 apical	membrane	of	 tubular	 epithelial	 cells	 (Saeki	et	al.	 1993).	 Losartan	has	been	 shown	 to	 reduce	 the	 level	 of	 CNI-induced	 apoptosis	 in	 proximal	 tubule	 cells	suggesting	a	role	for	ANG	II	in	this	pathway,	further	confirmed	by	other	groups	(Xiao	
et	al.	2013)	highlighting	the	role	ANG	II	may	have	in	the	pathogenesis	of	chronic	CNI	nephrotoxicity	(Thomas	et	al.	1998).		
1.9.9	 Electrolyte	disturbances	Probably	 one	 of	 the	 most	 obvious	 markers	 with	 regards	 to	 tubular	 toxicity	 is	 the	identification	of	electrolyte	alterations	through	tubular	dysfunction	and	identification	of	tubule	sections	most	susceptible	to	CNI	damage.	Typically,	CNI	treatment	leads	to	a	variety	 of	 electrolyte	 disturbances	 including	 hyperkalemia,	 hypomagnesemia,	hyperchloremic	metabolic	 acidosis	 and	 hyperuricema	 (Heering	 &	 Grabensee	 1991;	Heering	et	al.	1998;	Lin	et	al.	1989).	Interestingly,	there	is	a	clinical	condition	that	has	remarkable	similarities	to	chronic	CNI	 nephrotoxicity	 with	 regards	 to	 electrolyte	 disturbances.	 Type	 I	 Barter’s	syndrome	patients	have	mutations	of	the	Na+-K+-2Cl-cotransporter	(NKCC2)	situated	in	 the	apical	membrane	of	 tubular	epithelial	 cells	 (Naesens	et	al.	2004).	Commonly,	
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both	 conditions	 show	 symptoms	 of	 magnesium	 wasting,	 hyperaldosteronism,	nephrocalcinosis	 and	 juxtaglomerular	 hyperplasia.	 This	 was	 further	 highlighted	 in	patients	receiving	CSA	treated	with	 furosemide,	an	NKCC2	 inhibitor	and	resulted	 in	normalization	of	electrolyte	regulation	(Naesens	et	al.	2004).		However,	 not	 all	 symptoms	 correlate	 with	 each	 condition.	 Hyperkalemia	 and	metabolic	 acidosis	 are	not	 seen	 in	Barter’s	 syndrome	but	are	 in	CNI	nephrotoxicity	(Stahl	et	al.	1986;	Tumlin	&	Sands	1993).	
	
1.9.10	 CNI-Induced	hyperkalaemia	It	has	been	suggested	CNI	associated	hyperkalaemia	is	multifactorial	and	observed	in	up	to	40%	of	patients	treated	with	CNIs	(Naesens	et	al.	2009).	CsA	has	been	shown	to	alter	 the	 function	 of	 several	 transporters,	 increase	 activity	 of	 RAAS	 and	 impair	tubular	 sensitivity	 to	 aldosterone	 (Fervenza	 et	 al.	 2004;	 C.	 H.	 Lee	 &	 Kim	 2007).	Studies	suggest	CsA	directly	 impairs	the	function	of	potassium	secreting	cells	 in	the	cortical	 collecting	 tubule	 via	 reduced	 activity	 of	 the	 Na+,K+-ATPase	 and	 associated	increased	chloride	reabsorption	(C.T.	Lee	et	al.	2002).	CNIs	inhibit	luminal	potassium	channels	and	increase	chloride	reabsorption	via	alterations	of	WNK	kinases	(Hoorn	et	
al.	 2011).	 There	 is	 also	 evidence	 of	 decreased	 expression	 of	 mineralorticoid	receptors,	 seen	 in	>75%	of	patents	 treated	with	CNIs,	 leading	 to	hyperkalemia	 and	metabolic	acidosis	via	aldosterone	resistance	(Heering	et	al.	2004).	CNI-associated	 magnesium	 wasting	 is	 associated	 with	 chronic	 interstitial	 fibrosis,	increased	renal	decline	and	increased	rate	of	renal	graft	loss	(Naesens	et	al.	2009).	As	well	as	suppressing	reabsorption	of	magnesium	from	tubules,	studies	have	insinuated	CNIs	 reduce	 paracellin-1	 expression	 in	 the	 thick	 ascending	 limb,	 reducing	paracellular	magnesium	reabsorption	and	also	 indirectly	openning	ATP-sensitive	K+	channels,	both	of	which	could	contribute	to	CNI-associated	hyperkalemia	(C.	H.	Lee	&	Kim	2007).	
	
1.9.11	 Metabolic	acidosis		Metabolic	 acidosis	 is	 another	 common	 electrolyte	 disorder	 observed	 in	 patients	treated	with	 CNIs.	 Tubular	 acidosis	 is	 generally	 a	mild	 and	 symptomatic	 condition	seen	 in	renal	 transplant	recipients	however	can	be	classified	as	proximal	and	distal	
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tubular	 acidosis	 (Heering	 et	 al.	 1998;	 Healy	 et	 al.	 1998).	 Proximal	 acidosis	 is	characterised	by	bicarbonate	wasting	due	to	direct	 toxic	effects	of	CNIs	while	distal	acidosis	 is	 characterised	 by	 inhibition	 of	 hydrogen	 ion	 excretion	 (C.	 H.	 Lee	 &	 Kim	2007).		Specific	 use	 of	 CsA	 has	 a	 predisposition	 to	 instigate	 distal	 acidosis	 and	 associated	increased	potassium	excretion,	with	several	studies	suggesting	diet	as	susceptibility.		Collecting	ducts	have	two	types	of	intercalated	cells,	the	hydrogen	ion	alpha	secreting	or	bicarbonate	beta	 secreting	 intercalated	cell	 (C.	H.	Lee	&	Kim	2007).	An	acid	 rich	diet	 produces	 more	 alpha-intercalated	 cells	 were	 alkane	 rich	 diets	 express	 an	increased	 number	 of	 beta-intercalated	 cells	 (C.	 H.	 Lee	 &	 Kim	 2007).	 The	 protein	hensin	 is	 crucial	 in	 mediating	 transformation	 between	 beta	 and	 alpha	 intercallted	cells	 and	 it	 has	 been	 shown	 that	metabolic	 acidosis	 induces	 the	 polymerization	 of	extracellular	hensin	(Schwartz	&	Al-Awqati	2005).	Generation	of	hensin	leads	to	the	differentiation	 of	 bicarbonate	 secreting	 beta	 cells	 into	 acid	 secreting	 alpha	 cells	(Schwartz	&	Al-Awqati	2005).	CNIs	inhibit	polymerization	of	hensin	in	protein	and	the	resulting	acid	secreting	alpha	cells	will	be	less	abundant,	therefore	increase	the	risk	of	metabolic	acidosis	(C.	H.	Lee	&	Kim	2007).			
1.10	 CNI	Pharmacokinetics	and	Pharmacogenetics	
1.10.1	Multidrug	resistance	protein		Due	to	CNIs	having	such	a	small	therapeutic	window,	their	pharmacokinetics	plays	a	considerable	 role	 in	 their	 immunosuppressive	 viability	 and	 variability.	 The	pharmacokinetics	 of	 CNIs	 are	 characterised	 by	 high	 inter-patient	 variability,	 with	variability	 linked	 to	 genetic	 variation	 of	 transporters	 associated	 with	 CNI	pharmacokinetics	 (Armstrong	&	Oellerich	 2001;	 Barbarino	 et	al.	 2013).	 Because	 of	this	 genetic	 predisposition,	 maintaining	 target	 concentrations	 CNI’s	 is	 complicated	and	 often	 results	 in	 varying	 dose	 concentration	 correlations,	 the	 lowest	 drug	concentration	 is	 easier	 to	 measure	 rather	 than	 maximal	 for	 each	 individual	 (Fahr	1993b).		Taken	 orally,	 CNI’s	 are	 absorbed	 from	 the	 intestine	 with	 peak	 concentrations	typically	 reached	within	 2	 hours,	 although	 intestinal	 absorption	 of	 CNIs	 is	 low	 and	variable	depending	on	several	factors	including	digestion	of	food	and	diabetes	(Fahr	
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1993a).	 CNIs	 are	 inhibitory	 substrates	 for	 the	 metabolizing	 cytochrome	 P450	 3A	isoenzymes,	namely	CYP3A4	and	CYP3A5,	and	of	the	multidrug	efflux	transporter	P-glycoprotein	(MDR1	(Naesens	et	al.	2009).	The	variability	in	expression	and	function	of	these	enzymes	and	transporter	is	likely	to	explain	the	variability	in	CNI	absorption.		MDR1	is	an	ATP-dependent	drug	transporter	responsible	for	transporting	drugs	from	the	 cytoplasm	 to	 the	 cell	 surface	 and	 ultimately	 into	 the	 extracellular	 space	 for	secretion	 (Cascorbi	 2013).	 Within	 the	 kidney,	 MDR1	 is	 found	 prominently	 in	 the	brush	 border	 of	 proximal	 tubular	 epithelial	 cells	 (Robert	 J	 Alpern	 2008).	 Not	surprisingly,	 MDR1	 has	 been	 shown	 to	 be	 upregulated	 with	 exposure	 to	 CsA	 and	lower	expression	is	thought	to	be	a	predisposing	risk	factor	for	development	of	CNI	nephrotoxicity	(Jette	et	al.	1996;	Hauser	et	al.	2005).	CNIs	distribute	extensively	into	tissue	and	the	cellular	fraction	of	blood	(Fahr	1993a).	Erythrocytes	 have	 a	 high	 concentration	 of	 FKB12,	 FK506’s	 intracellular	 binding	protein,	and	explains	why	whole	blood	concentrations	of	FK506	are	~5	times	higher	than	 in	 plasma,	 where	 it	 is	 bound	 to	 albumin	 and	 lipoproteins	 (M.	 Winkler	 et	 al.	1994).	CNIs	 are	mainly	 eliminated	 in	 bile,	 >90%,	 and	have	been	 shown	 to	be	metabolized	into	 at	 least	 15	 metabolites	 (Uetrecht	 2009).	 Interestingly,	 CYP3A4	 is	 primarily	involved	 in	 the	 metabolism	 of	 CsA	 whereas	 CYP3A5	 is	 predominant	 in	 the	metabolism	of	FK506	(Hesselink	et	al.	2003).	Metabolism	of	CNI’s	mainly	occur	in	the	liver	and	GI	tract	and	is	effectively	complete	with	<1%	of	each	parent	drug	appearing	in	urine	or	faeces	(Watkins	1990).		Of	recent	interest,	pharmacogenomics	has	become	an	area	of	research	with	regards	to	individual	variability	and	identification	of	individual	susceptibility	to	CNI	side	effects.	Genetic	 polymorphisms	 in	 the	 CYP3A	 gene	 has	 been	 shown	 to	 influence	 CNI	pharmacokinetics	and	the	possibility	of	identifying	those	most	at	risk	of	toxicity	from	recessive	alleles	is	becoming	an	intriguing	possibility	(Utecht	et	al.	2006).			
	
1.10.2	 Pharmacogentic	mutations		There	have	been	over	40	single	nucleotide	polymorphisms	(SNPs)	identified	with	the	CYP3A4	 gene,	 with	 the	 SNP	 CYP3A4*1B	 being	 most	 studied,	 an	 A>G	 transition	 at	position	392	in	the	5’	regulatory	region	(S.-F.	Zhou	et	al.	2009).	Clinically,	it	has	been	suggested	 this	 allele	 results	 in	 reduced	 enzymatic	 activity	 however	 microsomal	
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studies	have	not	been	able	to	confirm	this	therefore	to	what	extent	this	mutation	has	in	 predisposition	 of	 CNI	 nephrotoxicity	 remains	 unclear	 (Utecht	 et	 al.	 2006;	Barbarino	 et	 al.	 2013).	 Furthermore,	 increased	 transcription	 of	 CYP3A4	 has	 been	demonstrated	 in	 vivo	 after	 CNI	 administration,	 suggesting	 a	 theoretical	 higher	expression	and	activity	(Utecht	et	al.	2006).	The	 role	of	 SNP’s	on	MDR1	 function	 is	 less	well-defined,	with	 studies	 indicating	no	association	of	MDR1	SNP’s	on	CsA	pharmacokinetics	while	FK506	interaction	studies	are	not	as	consistent	(Qiu	et	al.	2008).	However,	a	recent	study	investigating	a	SNP	at	position	3435-T,	the	TT	genotype,	of	kidney	donors	was	associated	with	chronic	CNI	nephrotoxicity	(Hauser	et	al.	2005).	This	SNP	has	been	associated	with	an	altered	 function	of	MDR1	and	resulting	 in	an	increased	risk	of	nephrotoxicity	of	over	40%	(Hauser	et	al.	2005).	The	same	genotype	was	also	studied	in	liver	transplant	patients	but	found	contradictory	results,	with	the	TT	 genotype	 group	having	 a	 reduced	 risk	 of	 renal	 dysfunction	 and	development	 of	nephrotoxicity	(Hebert	et	al.	2003).	Therefore,	to	suggest	identification	of	SNPs	may	help	combat	CNI	toxicity	is	not	only	a	touch	naïve	but	also	dangerous	with	risking	a	single	SNP	identification	for	predisposition.	This	being	said,	discovery	of	individuals	who	 could	 be	 at	 risk	 through	 SNP’s	 may	 help	 clinicians	 in	 choosing	 suitable	immunosuppressive	regimes	with	maximum	efficacy	and	reduced	chances	of	adverse	effects.			
1.11	 Mammalian	Target	of	Rapamycin	Inhibitors	(mTOR-i)	
	Although	 CNI	 minimisation	 protocols	 rely	 heavily	 on	 a	 concoction	 of	 steroids	 and	other	immunosuppressive	drugs,	azathioprine	and	mycophenolate	mofetil	(MMF)	for	example,	there	has	been	increasing	interest	in	the	use	of	rapamycin	to	fill	the	gap	of	insufficient	drug	combinations.		Rapamycin,	 clinically	known	as	sirolimus,	 is	a	macrolide	antibiotic	produced	by	 the	bacterium	 Streptomyces	 hygroscopicus	 first	 discovered	 in	 the	 mid	 1970’s	 (Sehgal	2003).	Although	initially	investigated	as	an	antifungal,	it	soon	became	clear	that	it	had	potent	antitumor	and	immunosuppressive	properties	(Selzner	et	al.	2010).			Its	 structural	 similarity	 to	 FK506	 was	 suggestive	 to	 the	 discovery	 of	 another	 CNI,	similar	 to	 FK506.	 However,	 unlike	 CsA	 and	 FK506,	 rapamycin	 does	 not	 inhibit	 the	secretion	of	IL-2	through	calcineurin	inhibition.		
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Rapamycin	 binds	 to	 the	 same	 intracellular	 cytosolic	 protein	 as	 FK506,	 FKBP12,	however	the	rapamycin-FKB12	complex	does	not	interact	with	calcineurin,	instead	it	inhibits	 the	 mammalian	 Target	 Of	 Rapamycin	 (mTOR)	 pathway	 through	 direct	binding	to	mTOR	complex	1	(Ballou	&	R.	Z.	Lin	2008).	mTOR	 is	 a	 serine/threonine	 protein	 kinase	 that	 is	 responsible	 for	 cell	 regulation,	growth,	proliferation	and	survival.	 It	 comprises	of	 two	distinct	complexes,	MTORC1	and	MTORC2,	 both	 of	which	 are	 structurally	 unrelated	 (Bracho-Valdes	et	al.	 2011).	Each	 complex	 has	 been	 shown	 to	 be	 localised	 to	 different	 cellular	 organelles	 and	ultimately	 effects	 their	 function	 and	 activation.	 Essentially,	MTORC1	 is	 responsible	for	protein	synthesis	and	monitoring	of	energy	production	and	consummation	while	MTORC2	is	responsible	for	regulation	of	cellular	structure	and	metabolism	(Bracho-Valdes	et	al.	2011).	Rapamycin	has	a	large	affinity	for	MTORC1	which	is	relevant	for	immunosuppressive	 properties	 (Toschi	 et	 al.	 2009).	 MTORC2	 and	 rapamycin	interaction	 is	 significantly	 more	 complex	 with	 the	 pathway	 and	 molecular	interactions	still	remaining	unclear	(Toschi	et	al.	2009).		Once	 the	 rapamycin-FKB12	 complex	 has	 bound	 to	 mTOR,	 there	 is	 subsequent	inhibition	of	both	DNA	and	protein	synthesis	which	ultimately	results	in	cell	arrest	in	late	G1	from	progression	to	the	S	phase	(Ballou	&	R.	Z.	Lin	2008).	In	IL-2	stimulated	T	cells,	this	results	in	inhibition	of	lymphocyte	growth	and	differentiation,	therefore	an	immunosuppressive	 effect	 (Sehgal	 2003).	 One	 of	 the	 key	 differences	 between	rapamycin	 and	 CNIs	 is	 their	 immunosuppressive	 properties.	 CNIs	 inhibit	 the	transcription	of	IL-2	through	calcineurin	blockade	therefore	 limited	IL-2	production	(Barbarino	 et	 al.	 2013)	 whereas	 rapamycin	 inhibits	 the	 transduction	 pathway	required	 for	 progression	 of	 cytokine	 stimulated	 T	 cells	 from	 G1	 to	 S	 phase,	consequently	suppressing	interleukin-driven	T	cell	proliferation	(Sehgal	2003).	Calne	 and	 colleagues	 conducted	 the	 first	 in	 vivo	 study	 using	 rapamycin	 for	immunosuppression,	 which	 highlighted	 improved	 animal/allograft	 survival	 and	function	 compared	 to	 non-immunosuppressed	 controls	 (Calne	 et	 al.	 1989).	 Their	initial	immunosuppressive	findings	were	further	highlighted	in	studies	using	a	range	of	 animal	 models	 and	 eventually	 human	 trials	 (Sehgal	 2003;	 Morelon	 et	 al.	 2001;	MacDonald	 &	 Grop	 2001).	 Importantly,	 rapamycin	 does	 not	 present	 any	 acute	 or	chronic	alterations	in	renal	blood	flow	or	GFR	(V.	W.	V.	Lee	&	Chapman	2005).	Kreis	and	colleagues,	using	a	randomised	trial,	were	able	to	demonstrate	rapamycin	treated	patients	 had	 lower	 serum	 creatinine	 levels	 compared	 to	 those	 on	 CsA	
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immunosuppression	 suggesting	 an	 improved	 GFR	 over	 CsA	 patients	 (Kreis	 et	 al.	2000).	The	authors	results	also	proved	pivotal	 in	the	realisation	that	rapamycin	did	not	induce	obvious	nephrotoxicity	in	the	human	transplant	setting	and	only	resulted	in	mild	adverse	effects.				The	 side	 effects	 associated	 with	 rapamycin	 use	 include	 myelosuppression,	hyperlipidemia	and	anaemia,	however	most	are	mild	and	can	typically	be	overcome	
via	dose	reductions	(Sehgal	2003;	V.	W.	V.	Lee	&	Chapman	2005).	
	
1.11.1	mTOR-i	nephrotoxicity		Nephrotoxicity	associated	with	rapamycin	is	rare	and	usually	reported	in	a	case-by-case	basis,	interestingly;	most	reported	cases	indicate	development	of	nephrotoxicity	only	in	preconditioned	disease	states.	E.g.	glomerulonephritis.	Fervenza	et	al	investigated	the	use	of	rapamycin	in	chronic	glomerulonephritis	(GN)	and	 moderate	 kidney	 failure.	 Within	 6	 weeks	 of	 transplantation	 and	 rapamycin	therapy,	over	50%	of	patients	had	developed	actuate	kidney	failure	however	kidney	function	improved	after	cessation	of	rapamycin	(Fervenza	et	al.	2004).	This	is	not	too	dissimilar	to	Dittrich	et	al	who	reported	patients	with	chronic	allograft	dysfunction	 developed	 biopsy-confirmed	 post	 transplantation	 GN,	 9	 months	 after	conversion	 to	 rapamycin	 from	 a	 CNI	 based	 regime.	 Intriguingly,	 kidney	 function	stabilized	in	all	patients	after	reintroduction	of	CNI	therapy	(Dittrich	et	al.	2004).	
	
1.11.2	 Acute	graft	rejection		Although	 direct	 rapamycin	 nephrotoxicity	 is	 still	 rare	 when	 used	 for	immunosuppression,	 there	 has	 been	 evidence	 to	 suggest	 it	 has	 a	 limited	 ability	 to	prevent	acute	graft	rejections	compared	to	CNI’s.		The	 SYMPHONY	 study	 set	 out	 to	 investigate	 rejection	 rates	 of	 rapamycin	 &	 MMF	combinations	against	low	dose	CNI	&	MMF	treatment	(Ekberg	et	al.	2007).	The	study	suggested	 a	 cohort	 of	 patients	 on	 rapamycin	 &	 MMF	 had	 higher	 rejection	 rates	without	any	 improvement	 in	 renal	 function	compared	 to	 those	 treated	with	CNIs	&	MMF.	These	initial	findings	have	also	been	confirmed	(Ekberg	et	al.	2010)	suggesting	that	specific	immunosuppressive	regimes	must	be	considered	carefully	to	obtain	the	best	outcome	of	each	individual	patient.		
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1.11.3	mTOR-i	interactions		
1.11.3.1	 CsA	&	mTOR-I’s	An	 important	point	 to	note	about	 rapamycin	 therapy	 is	 its	 combined	use	with	CsA.	This	topic	remains	controversial	with	studies	indicating	contradictory	results	and	no	clear	option	on	drug	combinations.		
In	 vitro	 and	 animal	 studies	 have	 shown	 application	 of	 CsA	 in	 combination	 with	rapamycin	 has	 a	 synergistic	 and	 unprecedented	 immunosuppressive	 effect	(MacDonald	2003;	Brook	et	al.	2005;	Andoh	et	al.	1996;	Podder	et	al.	2001).	This	extraordinary	discovery	led	to	the	possibility	of	a	using	a	reduced	dosage	of	each	compound,	 CsA	 and	 rapamycin,	 while	 still	 able	 to	 maintain	 a	 safe	 and	 suitable	immunosuppression	condition	(Brook	et	al.	2005).	Two	 large	 phase	 III	 and	 randomized	 trials	 investigated	 the	 use	 of	 CsA-rapamycin	combination	against	placebo	or	CsA-azathioprine	combination	(Baboolal	2003;	Kahan	2003).	The	results	 suggested	 that	CsA-rapamycin	combination	significantly	 reduced	the	 number	 of	 acute	 rejections	 compared	 to	 other	 immunosuppressive	 therapies.	However,	similar	trough	levels	of	CsA	throughout	the	groups,	along	with	rapamycin	treated	 patients	 having	 the	 worst	 renal	 function	 at	 1-year	 post	 transplantation,	suggests	 that	 rapamycin	may	 possibly	 increase	 the	 renal	 toxicity	 of	 CsA	 (Baboolal	2003;	Kahan	2003).		It	is	now	therefore	generally	accepted	that	long-term	use	of	CsA	in	 combination	with	 rapamycin	 is	 avoided	 to	 elude	 further	 nephrotoxicity	 or	 renal	dysfunction	(MacDonald	2003;	Jeanmart	et	al.	2002;	Cheng	et	al.	2008).		Instead,	 combination	 of	 both	 drugs	 for	 induction	 therapy,	 initial	 synergistic	immunosuppression,	then	discontinuation	of	CsA	after	several	months	is	conceivably	a	better	option	to	utilize	this	powerful	immunosuppressive	combination	(Lebranchu	
et	al.	2009).	Lebranchu	and	colleagues	 investigated	this	hypothesis	 in	an	open	 label	trial	 with	 results	 proving	 positive,	 allowing	 CsA	 to	 be	 discontinued	 3	months	 post	transplant,	an	improved	overall	renal	function	and	lower	blood	pressure	compared	to	a	continued	CsA-rapamycin	dosing	treatment	(Lebranchu	et	al.	2009).			The	 increased	 toxicity	 observed	 with	 combination	 of	 rapamycin	 and	 CsA	 is	exclusively	 attributed	 to	 the	 metabolization	 of	 these	 compounds.	 Both	 are	metabolised	 by	 cytochrome	 P450	 CYP3A4	 and	 MDR1	 enzymes	 and	 therefore	 it	 is	logical	 to	 assume	 some	 form	 of	 pharmacokinetic	 interaction	 (Naesens	 et	al.	 2009).	Podder	 and	 colleagues	were	 able	 to	 investigate	 this	 in	 great	 detail	 using	 a	 low-salt	
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animal	model	(Podder	et	al.	2001).	The	results	 implied	rapamycin	has	the	ability	 to	potentiate	CsA	nephrotoxicity	via	increasing	systemic	and	local	renal	concentrations	of	CsA	via	reduced	metabolism	(Podder	et	al.	2001).	Importantly,	the	study	suggested	that	whole	blood	concentrations	do	not	correlate	with	local	renal	concentrations	and	care	 must	 be	 taken	 when	 extrapolating	 renal	 exposure	 to	 a	 combination	 of	 these	drugs.		
1.11.3.2	 FK506	&	mTOR-I’s	Most	 research	 involving	 mTOR-i’s	 and	 their	 associated	 interactions	 in	immunosuppression	 has	 been	 done	 with	 CsA.	 This	 is	 most	 likely	 due	 to	 our	knowledge	of	CsA	and	its	unprecedented	use	in	organ	transplant	since	the	1970’s.		However,	 in	 recent	 years,	 tacrolimus	 has	 become	 an	 ever-increasing	 choice	 for	immunosuppression	 due	 to	 its	 increased	 potency	 and	 reduced,	 although	 still	prominent,	 nephrotoxicity.	 Post	 transplant,	 tacrolimus	 immunosuppression	 now	accounts	 for	over	80%	of	 living	donors	(Matas	et	al.	2015).	 It	 is	 therefore	 logical	 to	investigate	the	potential	side	effects	of	mTOR-I’s	and	a	tacrolimus	combination.		As	with	most	studies	involving	CNI’s,	reports	are	conflicting	with	no	clear	evidence	of	a	completely	safe	or	detrimental	combination	drug	regime.		Piao	 et	 al	 have	 reported	 a	 unfavourable	 effect	 with	 a	 combination	 of	 FK506	 and	rapamycin	 (Piao	 et	 al.	 2014).	 The	 authors	 underlined	 the	 significant	 difference	 of	renal	 injury	 in	treatment	groups	of	FK506	alone	or	 in	combination	with	rapamycin,	with	the	latter	producing	increased	renal	and	pancreatic	cell	injury.	Interestingly,	the	authors	 also	 emphasised	 an	 increase	 in	 8-hydroxy-2'-deoxyguanosine,	 an	 oxidative	stress	marker	in	the	combined	treatment	group,	indicating	the	role	of	ROS	production	in	nephrotoxicity,	similar	to	reports	seen	with	CsA	and	rapamycin	combination	(Lisik	
et	al.	2007).		On	the	other	hand,	Vu	et	al	demonstrated	a	beneficial	effect	of	combined	FK506	and	rapamycin	 in	 a	 heart	 allograft	 model	 (Vu	 et	 al.	 1997).	 The	 authors	 reported	 a	combination	 did	 not	 produce	 an	 antagonistic	 effect	 compared	 to	 either	 drug	 alone	and	in	addition,	the	study	also	highlighted	prolonged	graft	survival	with	a	combined	regime	compared	to	either	immunosuppressive	alone	(Vu	et	al.	1997).		Taken	 together,	 these	 early	 experimental	 studies	 suggest	 that	 immunosuppressive	combinations	run	the	risk	of	adverse	effects,	even	if	previous	reports	have	suggested	safe	use.		
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A	possible	reason	for	such	variance	in	side	effects	between	groups	is	due	to	the	large	Interpatient	and	 intrapatient	variability	of	 immunosuppressant’s.	Therefore,	 careful	consideration	 must	 be	 taken	 to	 ensure	 each	 patient	 receives	 sufficient	immunosuppression	while	having	minimal	a	minimal	exposure	to	the	risk	of	adverse	side	effects.																														
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1.12	 Aims	of	the	investigation		It	 is	well	 known	 that	 CNIs	 affect	 the	 larger	 arterioles	 of	 the	 kidney	 and	 ultimately	instigate	 nephrotoxicity	 through	 a	 variety	 of	 pathways,	 however	 their	 influence	 on	the	renal	medullary	microcirculation	is	still	poorly	investigated.	The	 initial	 aim	 of	 this	 study	 is	 to	 investigate	 the	 effect(s)	 of	 CNIs	 on	 medullary	microcirculation,	 with	 particular	 focus	 on	 vasa	 recta	 diameter	 and	 pericyte	contractility,	 with	 a	 view	 to	 inferring	 their	 effect(s)	on	medullary	microcirculation.	This	is	addressed	in	Chapter	3	using	the	already	established	live	kidney	slice	model.		A	 major	 compilation	 of	 renal	 transplantation	 is	 the	 development	 of	 hypertension,	with	 over	 90%	 of	 recipients	 developing	 some	 form	 of	 systemic	 hypertension	following	 surgery	 (Textor	et	al.	 1994;	Midtvedt	&	Hartmann	2002a).	This	has	been	historically	 combated	 with	 use	 of	 antihypertensives	 and	 careful	 monitoring	 of	immunosuppressive	 drug	 levels.	 However,	 anecdotally	 it	 has	 been	 suggested	 that	antihypertensives	may	 reduce	 CNI-induced	 nephrotoxicity.	 	The	 second	 aim	 of	 this	study	 is	 to	 investigate	 the	 effect	 of	 combined	 application	 of	 antihypertensives	 and	CNIs	on	vasa	recta	diameter	and	pericyte	contractility,	with	a	view	to	inferring	their	effect(s)	on	medullary	microcirculation.		This	is	addressed	in	Chapter	4.				Chapter	5	of	this	thesis	sets	out	to	investigate	the	feasibility	of	single	vessel	perfusion	of	in	 situ	vasa	 recta	 for	 studying	 the	 molecular	 and	 cellular	 events	 when	 CNIs	 are	luminally	 perfused,	 creating	 a	 more	physiological	 setting	 for	 future	 studies	 (i.e.	perfused	 vasa	 recta	 in	 live	 kidney	 slices).	 This	 data	 will	 aid	 our	 understanding	of	medulla	microcirculation	after	CNI	treatment	and	may	identify	a	novel	role	for	renal	pericytes	in	the	initiation	or	augmentation	of	CNI-induced	nephrotoxicity.	Lastly,	in	Chapter	6,	using	multiphoton	microscopy,	the	live	kidney	slice	model	is	used	to	identify	molecular	signaling	pathways	after	the	tissue	is	treated	with	CNIs	to	help	identify	 preliminary	 pathways	 for	 the	 prevention	 of	 nephrotoxicity.	 The	 chapter	focuses	on	mitochondrial	dysfunction	and	ROS	production.					 	
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2.	 General	Methodology		
2.1	 Animals			Animal	 experiments	 were	 conducted	 in	 accordance	 with	 United	 Kingdom	 Home	Office	Scientific	Procedures	Act	(1986).	Adult	male	Sprague-Dawley	rats	(250–300	g)	were	 obtained	 from	 Charles	 River	 UK	 Ltd,	 Kent,	 UK.	 Animals	 were	 fed	 standard	animal	 chow	 and	 housed	 in	 standard	 12-hour	 lighting	 conditions.	 Prior	 to	experimentation,	animals	were	killed	by	cervical	dislocation.			
2.2	 Live	kidney	slice	model		
2.2.1	 Slice	preparation				Kidneys	 were	 removed	 following	 cervical	 dislocation,	 promptly	 decapsulated,	 and	placed	 in	 ice-cold	physiological	 saline	solution	 (PSS)	bubbled	with	95%	O2/5%	CO2	and	prepared	for	slicing.	Prior	to	slicing,	the	kidneys	had	any	renal	artery	remnants	removed.	A	single	kidney	was	secured	on	the	slicing	block	of	a	vibratome	tissue	slicer	(Leica	model	VT1200S;	Leica	Microsystems	(UK)	Ltd,	Milton	Keynes,	Bucks,	UK),	and	submerged	 in	a	bath	of	 ice-cold	PSS	bubbled	with	95%	O2/5%	CO2.	PSS	 contained	(mM)	 100	 NaCl,	 5	 KCl,	 0.24	 NaH2PO4,	 0.96	 Na2HPO4,	 10	 Na	 acetate,	 1	 CaCl2,	 1.2	MgSO4,	5	glucose,	25	NaHCO3,	5	Na	pyruvate	(Sigma-Aldrich	Ltd,	Poole,	Dorset,	UK).	The	pH	was	adjusted	to	7.4	using	1	M	NaOH.	The	outer	cortical	dome	region	(∼3	mm	tissue)	of	the	kidney	was	removed	to	expose	the	top	of	the	renal	medulla	and	serial	200	μm-thick	coronal	kidney	slices	(intact	cortex	and	medulla)	were	cut.	Slices	were	collected	and	maintained	at	room	temperature	in	a	holding	chamber	containing	PSS,	and	bubbled	with	95%	O2/5%	CO2	 to	maintain	 tissue	viability.	Kidney	 slices	 to	be	used	 in	 ‘live’	 functional	 experiments	were	maintained	 for	 up	 to	 3	 h	 in	 the	 holding	chamber.	The	process	can	be	visually	understood	in	figure	2.0.	
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Figure	2.0	 The	live	kidney	slice	model.		a)	250-300	g	male	Sprague-Dawley	(SD)	rats	were	killed	by	cervical	dislocation	and	whole	kidneys	were	rapidly	removed	(b)	and	secured	on	to	the	block	of	a	vibrotome	slicer,	 as	 shown	 in	 (c).	 Once	 the	 outer	 cortical	 dome	 region	 had	 been	 removed	 to	expose	 the	medulla,	 serial	 200	 μm	 thick	 slices	were	 cut.	 A	 single	 kidney	 slice	was	secured	 in	 an	 open	bath	 chamber	using	 a	 platinum	anchor,	 as	 shown	 in	 (d),	which	was	 transferred	 to	 the	 stage	 of	 an	 upright	 Olympus	 microscope	 (e).	 Kidney	 slices	were	continuously	superfused	with	oxygenated	PSS	via	 inlet	(red	arrow)	and	outlet	(yellow	arrow)	valves.		













images	 were	 captured	 as	 a	 video	 sequence	 via	 a	 Olympus	 63×	 water	 immersion	objective	 (0.9	 NA)	 coupled	 to	 a	 Rolera	 XR	 digital	 charged	 coupled	 device	 (CCD)	camera	(Qimaging,	Surrey,	Canada).	Real-time	video	images	of	changes	in	vasa	recta	diameter	were	collected	every	second	and	recorded	using	Image	Pro	Software	(Media	Cybernetics	Inc.,	Marlow,	Bucks,	UK).		Live	kidney	slices	were	superfused	with	compounds	prepared	in	PSS	All	vasoactive	compounds	were	purchased	from	Sigma-Aldrich	Ltd	and	all	working	solutions	were	prepared	in	oxygenated	PSS	on	the	day	of	experimentation.		
	





Figure	2.1	 Calculation	of	percentage	change	in	vessel	diameter.	A:	an	average	of	 the	 first	10	measurements,	50	seconds,	was	taken	to	represent	the	resting	vessel	diameter	 for	 both	 pericyte	 and	 non-pericyte	 sites.	 B:	 Succeeding	 diameter	measurements	were	expressed	as	a	percentage	of	 the	corresponding	baseline	value	for	both	pericyte	and	non-pericyte	sites.	Adapted	from	(Crawford	et	al.	2012).		
2.3	 Microperfusion	of	in	situ	vasa	recta			Live	kidney	slices	were	transferred	to	the	stage	of	an	upright	Scientifica	microscope	(model	 SliceScope	 Pro	 1000;	 Scientifica	 Ltd,	 East	 Sussex,	 UK).	 Kidney	 slices	 were	continuously	superfused	as	previously	described	with	PSS,	bubbled	with	95%	O2/5%	CO2	 and	 maintained	 at	 room	 temperature.	 DIC	 images	 were	 captured	 through	 an	Olympus	60×	water	immersion	objective	(0.9	NA).	Real-time	video	images	of	changes	in	 vasa	 recta	 diameter	were	 collected	 every	 second	 by	 an	 attached	 Rolera	 XR	 CCD	camera	 (Qimaging,	 Surrey,	Canada)	and	 recorded	using	 Image	Pro	Software	 (Media	Cybernetics	Inc.,	Marlow,	Bucks,	UK).	Before	perfusion,	 vessels	were	visually	 selected	 for	 suitability	 (~7-10	μm	wide	and	~25-50	 μm	 below	 surface)	 and	 viability	 (long	 enough	 to	 withstand	 perfusion	pressure	 and	 pipette	 puncture).	 Pericytes	 were	 identified	 on	 suitable	 vessels	 as	previously	described.				Glass	micropipettes	were	prepared	using	borosilicate	glass	(1.5	mm	OD,	1.17	mm	ID;	Harvard	 Apparatus)	 and	 a	 dual	 stage	micropipette	 puller	 (model	 PC-10:	 Narishige	
%	Δ	Vessel	Diameter	=	 	 Measured	Diameter	(D)	Mean	Baseline	Diameter	(Db)	 X	100	
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International	ltd,	London,	UK)	to	produce	pipettes	with	an	inner	diameter	of	~3	μM	and	outer	diameter	of	~4	μM	at	the	pipette	tip.		Pipettes	were	 filled	with	 PSS	 ±	 selected	 compound	 after	 filtration	 using	 a	 0.20	 μM	sterile	 syringe	 filter	 (Cole-Parmer,	 London,	 UK)	 before	 securing	 onto	 a	 manual	micromanipulator	(model	LBM-7:	Scientifica	Ltd,	East	Sussex,	UK).	Positive	pressure	was	 applied	 via	 attached	 sphingometer	 adapted	 to	 a	 connected	 reservoir	 to	 avoid	pipette	blockage.		The	pipette	was	manually	lowered	into	the	bath	(above	the	vessel	of	 interest)	 before	 diagonally	 puncturing	 the	 vessel	 wall	 and	 allowing	 minimal	pressure/flow	(<	5	mmHg)	 into	 the	vessel,	 seen	 in	 figure	2.3.	 	For	both	control	and	experimental	conditions,	the	perfused	vessel	(<5	mmHg)	was	allowed	to	stabilize	for	at	least	5	minutes	prior	to	an	increase	of	pressure/flow.						After	 the	 initial	 stabilization	 period,	 pressure	was	 gradually	 increased	 until	 chosen	pressure	was	met	(15–100	mmHg)	and	stable.	Video	images	of	vessels	were	recorded	just	before	increase	of	pressure	to	generate	a	baseline	for	measurement	later	off	line.			
	
Figure	2.2	 Perfusion	of	vasa	recta	capillary	within	the	live	slice	model.			Perfusion	 pipettes	 (arrow	 head)	 punctured	 parallel	 vasa	 recta	were	 a	 pericyte	 site	(dashed	 red	 lines)	was	 visible	 in	 conjugation	with	 corresponding	 non-pericyte	 site	(dashed	yellow	lines).			
2.4	 Multiphoton	imaging	on	the	live	kidney	slice		
2.4.1	 Imaging	system		Live	 kidney	 slices	 were	 imaged	 using	 a	 custom	 built	 2-photon	 imaging	 system	configured	 by	 Scientifica	 UK,	 East	 Sussex.	 Additional	 details	 can	 be	 found	 online:	http://www.scientifica.uk.com/products/multiphoton-imaging-system	
8"μM"""
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The	 base	 microscope	 consisted	 of	 Scientifica’s	 brightfield	 SliceScope	 Pro,	 fully	motorised	 in	X,	 Y,	 Z	directions	 and	DIC	 imaging	 capable	 through	attached	Olympus	60×	water	immersion	objective	(0.9	NA).		The	microscope	has	 an	 attached	 galvo	 scan	head	 allowing	 for	 variable	 scan	 speeds	while	reducing	the	kidney	slice	exposure	to	laser	light.	The	scan	head	consists	of	two	back	 apertures,	 small	 (<9mm)	 and	 large	 (<20mm)	 and	 galvanometers	 from	Cambridge	Technology	(8315	KL	with	3	mm	X	and	Y	mirrors).		Attached	 to	 the	 galvo	 scan	 head	 is	 the	multiphton	 detection	 unit	 consisting	 of	 two	photo-multiplier-tube	 (PMT)	 based	 detector	 modules,	 containing	 integrated	 high	voltage	supply,	active	voltage	divider,	preamplifier	and	1.25	MHz	low-pass	filter.	The	detection	unit	uses	R9880U	series	detectors	and	is	fitted	with	a	visible	665	nm	long-pass	dichroic	mirror	and	680	nm	short-pass	dichroic	laser	blocking	filter.			
2.4.2	 Laser		In	 order	 to	 excite	 samples,	 a	 300-nm	 tunable	 (690	 –	 1040	 nm)	 titanium/sapphire	femtosecond	 laser	 (Mai-Tai	 HP;	 Newport	 Co	 Spectra-Physics,	 Mountain	 View,	California)	was	used	to	excite	fluorescent	probes.	The	laser	provides	up	to	2.5	watts	of	adjustable	average	power	and	a	pulse	width	of	less	than	100	femtoseconds.	Laser	power	to	samples	rarely	increased	over	60	μW.	
	
2.5	 Statistics		All	data	are	presented	as	mean	values	±	SEM;	n	numbers	are	displayed	as	number	of	kidney	 slices	 and	 number	 of	 animals,	 individually	 indicated	 with	 brackets	 (	 ).	 All	experiments	were	 performed	 in	 at	 least	 six	 different	 animals.	 Statistical	 evaluation	was	performed	with	 Instat	 (v2.05a;	GraphPad	software,	 San	Diego,	CA,	USA).	When	two	groups	were	compared,	a	Student’s	t-test	(two-tailed,	paired	or	unpaired	where	appropriate)	was	used.	A	value	of	P	<	0.05	was	considered	statistically	significant.			 	
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3.	 The	 effect	 of	 calcineurin	 inhibitors	 on	 renal	 medullary	
vessels	and	tubules			
3.1	 Introduction		As	 previously	 mentioned,	 CNIs	 have	 a	 plethora	 of	 unwanted	 side	 effects	 to	 which	there	 is	no	 single	proven	point	of	 cause	 (Naesens	et	al.	 2009).	The	most	 influential	side	 effect	 to	have	detrimental	 consequences	 on	 graft	 function	 is	 nephrotoxicity,	 of	which	there	are	two	types,	acute	and	chronic,	as	described	in	the	general	introduction	(sections	1.7	&	1.9).	Although	 there	 have	 been	 countless	 trials	 targeting	 CNI-induced	 nephrotoxicity,	most,	 if	not	all,	have	had	very	 little	 success	 in	 its	prevention,	especially	 the	chronic	form	 which	 typically	 manifests	 as	 long-term	 structural	 alterations	 of	 vascular	 and	tubular	architecture	(Chapman	2011).		Acute	CNI	nephrotoxicity	is	the	general	term	used	for	patients	presenting	functional	haemodynamic	alterations	that	can	be	typically	overcome	with	dose	adjustments	or	CNI	 withdrawal.	 The	 classical	 trait	 of	 acute	 CNI	 nephrotoxicity	 is	 the	 reduction	 of	glomerular	 filtration	 rate	 (GFR),	 attributed	 to	 the	 vasoconstriction	 of	 afferent	arterioles	 (Tsechan	 2002).	 Several	 studies	 in	 the	 1980’s	were	 able	 to	 convincingly	show	the	significant	changes	of	vascular	flow	after	CNI	treatment	and	highlighted	the	importance	of	vascular	dysfunction	for	these	particular	changes	after	CNI	use	(Barros	
et	al.	1987;	Laskow	et	al.	1988).	The	studies	were	able	to	show	significantly	reduced	single	nephron	GFR	after	CNI	treatment	compared	to	controls,	which	corresponded	to	total	significant	GFR	reduction	after	CNI	treatment.		CNI-induced	 vascular	 dysfunction	 has	 been	 studied	 extensively	 in	 vitro	and	 in	 vivo	and	 is	 generally	 accepted	 to	 originate	 from	 an	 increase	 of	 vasoconstrictors	 and	decrease	 in	 vasodilatory	 molecules.	 These	 include	 endothelin,	 thromboxane,	prostaglandin	E2	(PGE2)	and	nitric	oxide	(NO)	(Naesens	et	al.	2009).	This	was	first	highlighted	by	Murray	et	al,	displaying	the	importance	of	afferent	and	efferent	arteriole	vasoconstriction	and	the	development	of	acute	CNI	nephrotoxicity	(Murray	et	al.	1985).	With	this	in	mind,	it	is	apparent	that	acute	CNI	nephrotoxicity	is	clearly	vascular	dependent,	and	addressing	the	CNI-induced	alterations	in	renal	blood	flow	are	the	first	port	of	call	in	prevention	of	nephrotoxicity.	Conversely,	 very	 few	 studies	 have	 looked	 at	 the	 importance	 of	 the	 renal	microcirculation	and	its	contribution	to	CNI	nephrotoxicity.	Watarai	et	el	used	laser	
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Doppler	 readings	 to	 investigate	 the	 effects	 of	 CNIs	 on	 the	 renal	microcirculation	 of	rats,	 while	 simultaneously	 investigating	 the	 altered	 production	 of	 NO	 in	 blood	samples	 (Watarai	 et	 al.	 2004).	 Their	 results	 highlighted	 the	 importance	 of	 NO	generation	within	the	microcirculation,	and	the	effect	of	attenuating	NO	production,	which	they	concluded	as	being	pivotal	in	the	development	of	CNI	nephrotoxicity.		In	addition,	endothelial	dysfunction	 is	generally	 thought	as	a	critical	 factor	 towards	the	development	of	vascular	dysfunction	in	CNI	nephrotoxicity.	Both	CNIs	inhibit	NO	production,	 though	 no	 defined	 mechanism	 has	 been	 identified,	 and	 also	 inhibit	endothelium-dependent	NO-mediated	 renal	 vasodilation,	 through	 the	 dysregulation	of	eNOS	(Naesens	et	al.	2009).	They	are	also	known	to	increase	the	production	of	free	radicals	and	superoxide	synthesis.	 Interestingly,	both	CNIs	decrease	eNOS-mediated	NO	 production	 through	 various	 pathways	 including	 increased	 thromboxane	 A2	production,	decreased	vascular	endothelial	growth	factor	and	decreasing	cholesterol	content	 in	 caveolae	 (Oriji	 &	 Schanz	 1999.;	 Kou,	 Greif	 &	Michel	 2002a;	 Lungu	 et	al.	2004).		Interestingly,	CNIs	have	also	been	shown	to	impair	the	ability	of	platelets	to	mediate	vasodilation.	 Platelets	 from	 CsA	 treated	 patients	 failed	 to	 induce	 vasorelaxation	 of	pre-constricted	 arteries	 while	 platelets	 from	 control	 patients	 induced	 a	 significant	increase	 in	 vessel	 diameter.	 Furthermore,	 control	 platelets	 exposed	 to	 CsA	 in	 vitro	lost	 their	 vasorelaxation	 ability	 in	 a	 concentration	 and	 time	 dependent	 manner	(Óskarsson	et	al.	1997).		Moreover,	 CsA	has	been	 shown	 to	 enhance	platelet	 coagulant	 activity	 through	 lipid	dysfunction	 in	 platelet	 membranes	 (Tomasiak	 et	 al.	 2007).	 This	 data,	 along	 with	inhibited	 platelet-mediated	 vasodilation,	 suggests	 that	 CNIs	 may	 have	 a	 role	 in	thrombin	generation	and	may	contribute	to	the	pathogenesis	of	the	thromboembolic	phenomena	associated	with	the	use	of	CNIs	(Grace	et	al.	1987).	
3.1.2	 Renal	microcirculation	As	already	highlighted	(chapter	1),	the	renal	microcirculation	is	regionally	specific	in	terms	of	metabolic	needs	and	demands,	 and	 therefore	 it	would	 seem	reasonable	 to	assume	 local	 regional	 mechanisms	 are	 in	 place	 for	 regulation	 of	 blood	 flow.	Regulation	of	renal	blood	flow	in	the	cortex	is	well	established	(Robert	J	Alpern	2008;	Young	 et	 al.	 1996;	 Koeppen	 &	 Stanton	 2013b;	 R.	 G.	 R.	 Evans	 et	 al.	 2004)	 and	 is	recognised	 that	 blood	 flow	 in	 the	 cortex	 is	 regulated	 upstream	 via	 pre-capillary	arteriole	 vasoconstriction	 and	 dilation.	 Conversely,	 due	 to	 the	 inaccessibility	 of	 the	
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renal	medulla	 in	vivo,	 particularly	 the	 inner	medulla,	 regulation	of	medullary	blood	flow	(MBF)	is	less	well	understood.		MBF	is	supplied	via	vasa	recta	capillaries,	arsing	from	efferent	arterioles	of	juxtamedullary	nephrons.	DVR	penetrate	the	renal	medulla	in	 vascular	 bundles	 giving	 rise	 to	 the	 capillary	 plexus,	 wrapping	 around	 collecting	ducts	and	loops	of	Henle	(Pallone	et	al.	1990).	Arising	from	this	plexus	are	the	AVR,	which	subsequently	returns	blood	to	the	cortex,	passing	through	the	outer	medullary	vascular	bundles,	see	figure	1.4.	(Pallone,	Turner,	et	al.	2003).	Given	 that	 until	 recently,	 it	 was	 assumed	 MBF	 was	 controlled	 upstream	 of	 the	glomerulus	 via	 afferent	 arterioles,	 it	 was	 assumed	 that	 blood	 flow	 via	 a	 capillary	network	 lacking	contractile	SMC’s	was	passive	(R.	G.	R.	Evans	et	al.	2004;	Kennedy-Lydon	et	al.	2012).	However	 in	 recent	 years,	 MBF	 has	 received	 a	 substantial	 increase	 in	 research,	emphasising	 the	 importance	 of	 the	 renal	 medulla	 in	 regulation	 of	 salt	 and	 water	excretion	 (Cowley	 1997).	 Recent	 advances	 in	 technology,	 including	 laser	 Doppler	probes	 and	 confocal	microscopy,	 has	 enabled	 a	 far	more	detailed	 understanding	 of	the	 regulation	of	MBF	 than	what	was	previously	 acknowledged	 (Kneen	et	al.	 1999;	Hansell	1992).	This	has	led	to	the	now	more	accepted	view	of	local	regulation	within	the	medulla,	 independent	of	total	RBF,	through	contractile	pericyte	cells	residing	on	vasa	recta	capillaries	(Pallone	&	Silldorff	2001).				
3.1.3	 Renal	pericytes		As	 previously	 discussed,	 renal	 pericytes	 are	 a	 specialised	 population	 of	 contractile	cells	known	to	reside	on	DVR	within	 the	medulla.	Although	originally	discovered	 in	1873	 by	 Charles	 Rouget,	 these	 cells	 were	 thought	 to	 function	 only	 as	 vessel	“stabilisers”	with	no	real	 function	(Dore-Duffy	&	Cleary	2011)	until	 recent	years,	 in	which	there	has	been	a	significant	rise	in	the	number	of	publications	focusing	on	the	functional	role	of	pericytes	in	the	regulation	of	blood	flow	(Tell	et	al.	2006;	Kennedy-Lydon	 et	 al.	 2012;	 Peppiatt	 et	 al.	 2006;	 Bandopadhyay	 et	 al.	 2001;	 Crawford	 et	 al.	2012).	The	 initial	 studies	 involving	pericytes	 and	 their	 role	 in	MBF	 regulation	was	 carried	out	 by	 Pallone	 and	 colleagues	 who	 used	 an	 isolated	 perfused	 DVR	 technique	 to	visualize	 the	 vasoactive	 properties	 these	 cells	 had	when	 exposed	 to	 certain	 stimuli	(Pallone	et	al.	1994;	Pallone	1994).	Although	 the	 technique	was	 fundamental	 in	 the	initial	understanding	of	pericyte	contractility,	it	involves	the	complete	removal	of	any	
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surrounding	architecture	and	loss	of	any	stabilising	remnants	and	as	such,	potential	sources	of	endogenous	vasoactive	mediators.	The	 live	 kidney	 slice	 model	 pioneered	 by	 Crawford	 et	 al	 sought	 to	 provide	 an	alternative	 model	 in	 which	 the	 surrounding	 architecture	 remained	 intact	 and	facilitated	 investigations	 in	 the	 importance	 of	 tubular-vascular	 crosstalk	within	 the	inner	medulla	for	regulation	of	blood	flow	(Crawford	et	al.	2012).	Crawford	 et	 al	 were	 able	 to	 demonstrate	 the	 viability	 of	 the	 live	 slice	 model	 by	replicating	 results	 first	published	by	Pallone	and	 colleagues	 (Crawford	et	al.	 2012),	but	 also	 highlighted	 the	 importance	 of	 tubular-vascular	 crosstalk	 via	 extracellular	nucleotides	 released	 from	 renal	 tubules	 (Crawford	 et	 al.	 2011),	 emphasising	 the	importance	of	an		in	situ	vasa	recta	model	for	enhancing	our	understanding	of	MBF.			Given	 the	 established	 vascular	 component	 of	 CNI-induced	 nephrotoxicity	 and	 the	recent	evidence	favouring	localised	regulation	of	MBF,	the	primary	aim	of	this	study	was	 to	 investigate	 the	 possible	 effects	 CNIs	 have	 on	 the	 renal	 medullary	microcirculation,	with	particular	focus	on	MBF	and	the	role	of	contractile	pericytes,	in	CNI-mediated	nephrotoxicity.				
3.2	 Methods		Intact	 live	kidney	 slices	were	obtained	as	described	 in	 chapter	2:	General	methods.	Live	kidney	slices	were	superfused	with	cyclosporine	A	(CsA),	tacrolimus	(FK506)	or	rapamycin,	 all	 purchased	 from	 Sigma-Aldrich	 (Dorset,	 UK).	 All	 working	 solutions	were	prepared	in	95%	O2	/	CO2	PSS,	however	stocks	of	CsA	and	FK506	were	made	in	dimethyl	sulfoxide	(DMSO).	Final	concentrations	of	all	working	solutions	containing	DMSO	were	less	than	1%.	A	1%	DMSO	control	experiment	was	carried	out	to	assess	DMSO	effects	on	in	situ	vasa	recta.	In	all	experiments	to	determine	the	effect	on	vasa	recta	 diameter,	 kidney	 slices	 were	 superfused	 with	 95%	 O2	 /	 CO2	 PSS	 for	 ~100	seconds	(s)	 to	establish	a	baseline	vessel	diameter	at	 the	pericyte	and	non-pericyte	sites.	 Slices	were	 then	 exposed	 to	 CsA	 or	 FK506	 for	 approximately	 700	 s	 and	 then	subjected	 to	 a	 PSS-wash	 to	 assess	 reversibility	 of	 any	 drug-induced	 alteration	 in	vessel	 diameter.	 Similar	 experiments	 were	 performed	 with	 rapamycin	 to	 rule	 out	adverse	 effects	 from	 similar	 immunosuppressant’s	 that	 do	 not	 interfere	 with	calcineurin	inhibition.	Analysis	of	video	images	of	changes	in	vasa	recta	diameter	are	as	described	previously	in	chapter	2:	general	methods,	using	the	free	public	domain	
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software	IMAGE	J	(NIH;	http://rsb.info.nih.gov).	For	each	experiment,	a	pericyte	site	and	 non-pericyte	 site	 were	 identified	 on	 a	 single	 vasa	 recta	 capillary.	 Each	 non-pericyte	site	acted	as	control	 for	subsequent	pericyte	site.	The	diameter	of	 the	vasa	recta	at	both	of	these	locations	was	measured	every	five	seconds	for	the	duration	of	the	experiment.	An	average	of	the	first	five	measurements	was	taken	to	represent	the	resting	 diameter	 value	 (i.e.	 baseline	 diameter)	 for	 the	 selected	 pericyte	 and	 non-pericyte	sites.	All	subsequent	diameter	measurements	at	both	sites	were	calculated	as	a	percentage	change	of	the	corresponding	resting	diameter	value.			
3.2.1	 Statistics		All	data	are	presented	as	mean	values	±	SEM;	n	numbers	are	displayed	as	number	of	kidney	 slices	 and	 brackets	 refer	 to	 number	 of	 animals.	 All	 experiments	 were	performed	in	at	least	six	different	animals.	Statistical	assessment	was	conducted	with	GraphPad	Prisim		(v5.0f;	GraphPad	software,	San	Diego,	CA,	USA).	When	two	groups	were	compared,	a	Student’s	t-test	(two-tailed,	paired	or	unpaired	where	appropriate)	was	used.	A	value	of	P	<	0.05	was	considered	significant.																
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3.3	 Results		
3.3	 Effect	of	CsA	on	in	situ	vasa	recta	capillaries	The	 calcineurin	 inhibitor	 cyclosporine	 A	 was	 investigated	 for	 its	 possible	 role	 in	altering	vasa	recta	diameter	via	pericyte-mediated	contraction	or	dilation.	To	test	this	hypothesis,	 live	 kidney	 slices	 were	 superfused	 with	 CsA	 and	 real	 time	 changes	 in	subsurface	vasa	recta	diameter	was	measured	at	pericyte	and	non-pericyte	sites.		Superfusion	 (~700	 s)	 of	 CsA	 (10	 μM)	 resulted	 in	 a	 reversible	 constriction	 of	 vasa	recta	 capillaries	 (Figure	 3.0).	 Vasoconstriction	was	 significantly	 greater	 at	 pericyte	sites	(12.7	±	0.88%,	n=13	(9))	compared	to	non-pericyte	sites	(2.4	±	0.62%,	n=13	(9);	P<0.001)	(Figure	3.0).	The	CsA-evoked	constriction	of	vasa	recta	was	reversed	upon	washout,	and	vessel	diameter	returned	to	at	least	90%	of	the	original	baseline	vessel	diameter	after	400	s	washout.	The	success	rate	of	experiments	was	classed	as	%	of	responders,	described	in	general	methods,	and	application	of	CsA	resulted	in	≥	75%	of	pericyte	constrictions.		Due	 to	 the	 fact	 the	surface	of	 the	kidney	slice	 is	damaged	during	slicing,	 imaging	of	vasa	recta	are	subsurface	and	~50	μm	deep	and	 therefore	higher	concentrations	of	drugs	than	normally	seen	clinically	or	in	vivo	may	be	required	to	allow	deeper	tissue	penetration.	 To	 determine	 if	 clinically	 relevant	 concentrations	 of	 CsA	 had	 a	vasoconstrictive	effect,	a	series	of	concentration	response	experiments	were	carried	out	using	 concentrations	of	CsA	 that	match	whole	blood	 concentrations	of	CsA	and	the	 area	 under	 the	 curve	 (AUC)	 total	 drug	 exposure	 (Schiff	 et	 al.	 2007).	 Clinically,	concentration	max	(Cmax)	is	the	concentration	of	CsA	in	whole	blood	after	exposure	that	is	most	likely	to	cause	CsA	toxicity	(Armstrong	&	Oellerich	2001).	Therefore,	the	range	of	concentrations	used	in	clinically	relevant	functional	experiments	should	be	equal	to	or	less	than	Cmax.			Superfusion	(~700	s)	of	CsA	(1,	3	and	5	μM,	respectively)	all	resulted	in	a	reversible	constriction	of	vasa	recta	capillaries	 (Figure	3.1).	Vasoconstriction	was	significantly	greater	at	all	pericyte	sites	(5.3	±	0.99%,	8.8	±	1.03%	and	10.2	±	0.81%,	respectively)	compared	 to	 non-pericyte	 sites	 (2.4	 ±	 0.89%,	 2.56	 ±	 0.65%	 and	 2.20	 ±	 0.60%,	respectively,	 n=13	 (9);	 P<0.05,	 P<0.001,	 P<0.001),	 (Figure	 3.1).	 The	 CsA-evoked	constriction	of	vasa	recta	was	reversed	upon	washout,	and	vessel	diameter	returned	to	 ≥	 90%	 of	 the	 original	 baseline	 vessel	 diameter	 after	 400	 s	 following	 each	concentration	of	CsA.	
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Figure	3.0	 DIC	 imaging	 of	 CsA-induced	 constriction	 of	 in	 situ	 vasa	 recta	
























































Figure	3.1	 Concentration	 dependent	 effect	 of	 cyclosporine	 A	 on	 pericyte-
mediated	constriction	of	vasa	recta.	Superfusion	of	live	kidney	tissue	with	CsA	1-10	μM	evoked	a	concentration	dependent	constriction	of	vasa	recta	at	pericyte	sites	(black	bars)	compared	to	non-pericyte	sites	(grey	bars).	Clinically	relevant	values,	1-5	μM,	 induced	 significant	 pericyte-mediated	 constriction	 of	 vasa	 recta	 capillaries	compared	 to	 non-pericyte	 sites.	 Values	 are	 mean	 ±	 SEM.,	 n=13	 (9).	 *P	 <0.05,	 ***	P<0.001.	
	
	

























P<0.001),	 (Figure	 3.2).	 The	 FK506-evoked	 constriction	 of	 vasa	 recta	 was	 reversed	upon	washout,	and	vessel	diameter	returned	to	≥	90%	of	the	original	baseline	vessel	diameter	after	400	s	 following	washout.	Application	of	FK506	resulted	 in	≥	70%	of	pericyte	constrictions.		As	 FK506	 is	 100	 times	more	 potent	 than	 CsA	with	 regards	 to	 immunosuppression	(Kino	et	al.	1987),	therapeutic	drug	monitoring	(TDM)	is	essential	to	maintain	a	safe	and	effective	 therapeutic	window.	However,	 systemic	 concentrations	do	not	always	correlate	 to	 target	 organ	 concentrations.	 Ideally,	 systemic	 concentrations	 of	 FK506	would	 correlate	 to	 single	 organ	 concentrations,	 however,	 given	 that	 the	 kidney	 is	responsible	 for	 the	 filtration	 of	 drugs,	 it	 is	 susceptible	 to	 accumulation	 of	 higher	concentrations	 of	 drugs	 than	 seen	 in	 other	 organs.	 This	 has	 been	 observed	 with	FK506	 use	 and	 concentrations	 in	 the	 kidney	 at	more	 than	 10	 times	 recommended	therapeutic	level	(NA.	2002).		Therefore,	 to	 test	 whether	 clinically	 relevant	 concentrations	 of	 FK506,	 in	 whole	blood,	had	the	potential	to	constrict	vasa	recta	via	pericytes,	concentrations	ranging	from	minimal	trough	levels,	C0,	to	just	above	Cmax	were	investigated.		
	Superfusion	(~700	s)	of	FK506	(8x10-4,	0.05,	0.1	and	1	μM)	resulted	 in	a	reversible	constriction	of	vasa	recta	capillaries.	The	lowest	concentration	of	FK506,	8x10-4	μM,	failed	to	evoke	a	vasoactive	response	(Figure	3.3).	Vasoconstriction	was	significantly	greater	at	pericyte	sites	using	concentrations	1	and	0.1	μM	(9.7	±	0.49%	and	8.73	±	1.3%,	respectively,	n=8	(8))	compared	to	non-pericyte	sites	(2.74	±	0.39%,	and	2.22	±	0.74%,	 respectively,	 n=8	 (8);	 P<0.001,P<0.01	 (Figure	 3.3).	 The	 FK506-evoked	constriction	of	vasa	recta	was	reversed	upon	washout,	and	vessel	diameter	returned	to	≥	90%	of	the	original	baseline	vessel	diameter	after	400	s	following	washout	at	all	concentrations.	Although	 the	 response	 of	 0.05	 μM	 did	 not	 produce	 a	 significant	 constriction,	 there	was	 a	 trend	 towards	 greater	 pericyte-mediated	 constriction	 (4.87	 ±	 0.98%)	 when	compared	to	non-pericyte	mediated	constriction	(2.24	±	0.45%,	figure	3.3).					
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Figure	3.2	 investigating	 the	 effect	 of	 FK506	 on	 in	 situ	 vasa	 recta	 capillary	





















































Figure	3.3	 Superfusion	 of	 live	 kidney	 slices	 with	 FK506	 induces	 a	
concentration	 dependent	 pericyte-mediated	 constriction	 of	 vasa	 recta.		Superfusion	 of	 live	 kidney	 tissue	 with	 FK506	 8x10-4-3	 μM	 evoked	 a	 concentration	dependent	constriction	of	vasa	recta	at	pericyte	sites	(black	bars)	compared	to	non-pericyte	 sites	 (grey	 bars).	 Clinically	 relevant	 value,	 0.1	 μM,	 induced	 a	 significant	pericyte-mediated	 constriction	 of	 vasa	 recta	 capillaries,	 while	 0.05	 μM	 produced	 a	trend	 towards	 greater	 pericyte-mediated	 constriction,	 though	 not	 at	 statistically	significant	values.	Values	are	mean	±	S.E.M.,	n=8	(8),	**	P	<0.01,	***	P<0.001.	
	
3.3	 Effect	of	rapamycin	on	in	situ	vasa	recta	capillaries		The	 effect	 of	 rapamycin	 was	 investigated	 in	 the	 live	 kidney	 slice	 model	 to	demonstrate	if	 it	had	a	role	 in	reducing	vasa	recta	diameter	specifically	at	pericytes	on	subsurface	vessels.		Superfusion	(~700	s)	of	rapamycin		(1	μM)	resulted	in	no	significant	constriction	of	vasa	 recta	 capillaries	 (Figure	 3.4).	 When	 vasoconstriction	 was	 noted,	 it	 was	 not	significantly	greater	at	pericyte	sites	(4.30	±	2.5%,	n=9	(9))	compared	to	non-pericyte	sites	 (1.31	 ±	 1.3%,	 n=9	 (9);	 P>0.05),	 (Figure	 3.4).	 Upon	 washout,	 vessel	 diameter	continued	to	be	stable	and	rarely	dropped	below	95%	of	the	original	baseline	vessel	diameter	after	400	s	following	washout.	
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Figure	3.4	 Superfusion	of	 live	kidney	slices	with	rapamycin	does	not	 induce	
















































3.5	 Effect	of	CsA,	FK506	and	rapamycin	on	in	situ	renal	tubules		One	 of	 the	 major	 advantages	 of	 the	 live	 kidney	 slice	 model	 is	 that	 the	 structural	architecture	 is	 intact;	 therefore	 the	 vasa	 recta	 capillaries,	 tubules,	 and	 intrarenal	innervation	are	all	preserved	(Crawford	et	al.	2012).	Taken	together,	this	allows	for	a	more	complete	understanding	of	renal	cell	communication	between	the	architecture	when	compared	to	isolated	models	(Burg	1972;	Sendeski	et	al.	2013).		CNI	 nephrotoxicity	 is	 not	 just	 vascular	 dependent.	 Tubular	 toxicity,	 necrosis	 of	tubular	epithelium	that	form	renal	tubules,	is	a	well	known	side	effect	of	CNI	therapy	and	when	left	untreated,	can	further	develop	into	additional	complications	including	tubular	atrophy,	tubulo-	interstitial	fibrosis	and	tubular	acidosis	(Carvalho	da	Costa	et	











Figure	3.5	 Superfusion	of	 CNIs	 and	 rapamycin	did	not	 evoke	morphological	

















































3.6	 Effect	of	combining	CNIs	with	rapamycin	on	in	situ	vasa	recta	diameter			With	 organ	 rejection	 being	 one	 of	 the	 biggest	 concerns	 after	 renal	 transplant,	sufficient	 immunosuppression	 is	 essential	 for	 avoiding	 graft-versus-host	 disease	(GVHD)	 and	 maintaining	 normal	 function	 of	 the	 transplanted	 kidney.	 With	 the	approval	of	rapamycin	by	the	FDA	in	1999	(Sehgal	2003),	clinicians	anticipated	that	combining	 rapamycin	 with	 CNIs	 would	 enhance	 immunosuppression	 and	 delay	 or	prevent	graft	rejection	(Ikeda	et	al.	1997;	MacDonald	2003;	McAlister	et	al.	2000).		Shortly	 after	 however,	 it	 was	 becoming	 apparent	 that	 a	 combination	 of	immunosuppressive	drugs,	especially	CsA	and	rapamycin,	not	only	increased	the	risk	of	 graft	 rejection	but	 also	nephrotoxicity,	 confirmed	by	 increased	 rates	 of	 rejection	and	positive	nephrotoxicity	biopsies	(Podder	et	al.	2001;	MacDonald	2003;	O'Connell	




Figure	3.6	 Superfusion	 of	 CNIs	 in	 combination	with	 rapamycin	 induces	 and	











































































3.7	 Discussion			The	main	 aim	 of	 this	 investigation	was	 to	 establish	 if	 CNIs	 affect	 in	 situ	vasa	 recta	capillary	 diameter	 and	 if	 so,	 specifically	 via	 their	 action	 on	 pericytes.	 The	experimental	 model	 used	 also	 enabled	 the	 effects	 of	 CNIs	 on	 renal	 tubules	 to	 be	investigated	 and	 the	 possible	 role	 of	 tubular-vascular	 crosstalk	 in	 mediating	 CNI	nephrotoxicity.		The	 main	 finding	 of	 this	 study	 is	 that	 both	 cyclosporine	 A	 and	 tacrolimus	 act	specifically	at	renal	pericytes	to	cause	a	significant,	reversible,	decrease	in	vasa	recta	diameter	 of	 in	 situ	 capillaries,	 at	 relevant	 clinical	 concentrations.	 Conversely,	 the	mTOR	inhibitor,	rapamycin,	failed	to	evoke	any	significant	constriction	of	vasa	recta	
via	pericytes.		Based	on	previous	publications	using	the	live	slice	model	(Crawford	et	al.	2012)	that	used	Poiseuilles’s	law	to	estimate	changes	in	blood	flow	(Landis	1933;	Peppiatt	et	al.	2006),	a	10%	decrease	of	vasa	recta	diameter,	via	pericyte	constriction,	would	result	in	an	approximate	1.5	increase	of	renal	blood	flow	resistance	(RBFR).	Given	that	MBF	is	crucial	for	maintenance	of	normal	kidney	function,	it	is	conceivable	that	during	CNI	treatment,	 MBF	 may	 be	 impaired	 sufficiently	 enough	 that	 this	 may	 contribute	towards	CNI-mediated	nephrotoxicity	as	a	whole.			Ever	 since	 their	 first	 use	 for	 immunosuppression,	 CNIs	 have	 been	 known	 to	 be	nephrotoxic	 in	 all	major	 compartments	of	 the	kidney,	however	 the	 exact	molecular	and	 cellular	 source	 of	 the	 insult	 has	 never	 truly	 been	 elucidated.	 One	 of	 the	 first	studies	 to	 suggest	 renal	 vascular	 vasoconstriction	 as	 a	 predominant	 factor	 for	 the	development	of	 acute	CNI	nephrotoxicity	was	 carried	out	 in	 the	80’s	 (Murray	et	al.	1985).	 They,	 along	 with	 other	 groups,	 were	 able	 to	 conclusively	 demonstrate	 the	importance	of	CNIs	in	their	ability	to	increase	renal	vascular	resistance	in	the	afferent	and	 efferent	 arterioles,	 subsequently	 leading	 to	 impairment	 of	 blood	 flow	 and	decreased	GFR	(Barros	et	al.	1987;	Laskow	et	al.	1988).		The	 mechanisms	 of	 vascular	 dysfunction	 triggered	 through	 CNIs	 is	 however	 still	unclear	with	theories	ranging	from	direct	endothelial	injury	to	increased	production	of	superoxide	(Diederich	et	al.	1994;	Voss	et	al.	1988;	J.	W.	Park	et	al.	2011;	Krejci	et	
al.	 2010)	 ,	 although	 it	 is	 generally	 accepted	 that	 an	 increase	 in	 vasoconstrictors	(endothelin,	thromboxane	and	ANG	II)	and	a	decrease	in	vasodilators	(PGE2,	NO	and	
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prostacyclin)	all	contribute	to	the	prevailing	increase	in	vascular	resistance	(Naesens	
et	al.	2009).		It	 is	 important	 to	 note	 that	 although	 this	 evidence	 is	 based	 on	 studies	 focusing	 on	larger	 pre-capillary	 arterioles,	 little	 is	 known	 about	 the	 smaller	 capillaries,	 and	 in	particular	 for	 this	 study,	 the	 effects	 of	 CNIs	 on	 vasa	 recta	 and	 their	 contractile	pericytes.		Previous	data	has	shown	that	all	of	the	vasoactive	substances	able	to	effect	the	larger	arterioles	 have	 been	 able	 to	 effect	 vasa	 recta	 diameter,	 via	 pericytes,	 either	 in	isolation	 or	 in	 situ	 experimental	 models	 (Silldorff	 &	 Pallone	 2001;	 Rhinehart	 &	Pallone	2001a;	Pallone	&	Silldorff	2001;	Crawford	et	al.	2012;	Crawford	et	al.	2013).	Therefore,	 it	 appears	 reasonable	 to	 assume	 that	 CNIs	 would	 be	 able	 to	 not	 only	decrease	 vascular	 blood	 flow	 to	 the	 larger	 arterioles	 supplying	 the	 cortex	 of	 the	kidney,	 but	 also	 decrease	 blood	 flow	 to	 the	 renal	medulla	 via	 vasa	 recta	 obtrusion	through	pericyte	 constriction.	 This	 in	 turn	not	 only	 decreases	 the	 blood	 flow	 to	 an	already	borderline	hypoxic	area	of	the	kidney	(Baumgärtl	et	al.	1972;	Brezis	&	Rosen	1995),	the	inner	renal	medulla	is	already	subject	to	a	reduced	flow	of	blood	therefore	increasing	the	risk	of	hypoxia	(R.	G.	Evans	et	al.	2008).	In	addition,	this	reduction	of	blood	 flow	 increases	 the	 risk	 of	 dysfunctional	 cortico-medullary	 osmotic	 gradients	that	are	required	to	drive	water	and	solute	reabsorption	crucial	for	accurate	function	of	the	kidney	(Pallone,	Turner,	et	al.	2003).		Taken	 together,	 the	 initial	 data	 presented	 here	 demonstrates	 for	 the	 first	 time	 the	ability	 of	 renal	 pericytes	 to	 constrict	 vasa	 recta	 capillaries	 upon	 acute	 exposure	 to	CNIs.	This	could	consequently	disrupt	both	cortical	and	medullary	blood	flow,	which	if	 left	 untreated,	 could	 develop	 into	 further	 complications	 including	 ischemia	 and	longer	 term	 complications	 of	 fibrosis	 that	 lead	 to	 complete	 renal	 failure	 and	 total	graft	loss.				Chronic	CNI	nephrotoxicity	is	unfortunately	outwith	the	realms	of	this	experimental	model.	The	live	kidney	slice	is	viable	up	to	4	hours	post	slicing	(Crawford	et	al.	2012,		unpublished	data)	however	chronic	CNI	nephrotoxicity	may	take	months	to	develop	(Bakker	et	al.	2004;	Chapman	2011).	Nonetheless,	 it	has	been	shown	that	 following	acute	 insult,	 renal	pericytes	are	able	 to	detach	 from	 their	associated	capillary	beds,	migrate	 to	 the	 interstitium	 and	 form	 the	 basis	 of	 fibrous	 scarring	 tissue	 through	 a	variety	 of	 mechanisms	 (Peppiatt-Wildman	 2013;	 Humphreys	 et	 al.	 2010;	 Fligny	 &	
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Duffield	 2013;	 Schrimpf	&	Duffield	 2011).	 In	 addition,	 it	 has	 also	 been	 shown	 that	continued	vasoconstriction	of	pericytes	“switches	off”	their	ability	to	return	to	normal	resting	tension	resulting	in	a	permanent	constricted	state	(Peppiatt	et	al.	2006;	Vates	
et	al.	2010;	Hamilton	et	al.	2010).	Together,	these	data	highlights	the	possible	role	for	pericytes	 contributing	 towards	 chronic	 CNI	 nephrotoxicity	 through	 either	 vessel	detachment	or	continued	capillary	constriction.				The	 data	 presented	 here	 for	 the	 effects	 of	 CNIs	 on	 renal	 tubules	 is	 however,	somewhat,	 underwhelming.	 It	 is	 known	 that	 CsA,	 and	more	 specifically	 FK506,	 are	prone	 to	 cause	 nephrotoxic	 effects	 through	 tubule	 dysfunction	 including	 isometric	vacuolisation	 and	 tubule	 atrophy	 in	 the	 weeks	 following	 allograft	 transplant	(Mihatsch	 et	 al.	 1985;	 Mihatsch	 et	 al.	 1986).	 However,	 with	 regards	 to	 acute	 CNI	nephrotoxicity,	 these	 “specific”	 lesions	 are	 rarely	 seen	 or	 develop	 and	 only	 truly	mature	when	 chronic	 nephrotoxicity	 has	 been	 firmly	 established	 through	 biopsies.	This	 is	somewhat	why	acute	CNI	nephrotoxicity	 is	 so	hard	 to	clinically	 identify.	For	example	 the	 “specific”	 lesions	 that	 CNIs	 induce,	 especially	 in	 terms	 of	 kidney	transplantation,	 far	 too	 often	 coincide	with	 other	 injury	 occurrences	 and	 are	 often	overlooked	(d'Ardenne	et	al.	1986).			The	data	 also	 suggests	 a	novel	mechanism	 for	 the	 reduced	nephrotoxic	 side	 effects	seen	 with	 rapamycin.	 Clinically,	 rapamycin	 is	 a	 considerably	 less	 nephrotoxic	immunosuppressant,	 however	 it	 is	 very	 rarely	 used	 alone,	 and	 often	 used	 in	combination	with	FK506	and/or	steroids.	It	must	be	noted	that	data	presented	here	indicates	 combination	 drug	 therapy	 by	 itself	 increases	 the	 chance	 of	 adverse	 drug	interactions	and	side	effects	(Andoh	et	al.	1996;	Brook	et	al.	2005;	MacDonald	2003).	Rapamycin	was	first	noted	to	have	immunosuppressive	effects	in	the	late	90’s	when	its	initial	use	of	an	antifungal	agent	was	halted	and	used	for	immunosuppression	and	graft	 survival	 (Sehgal	 2003).	 Although	 not	 a	 CNI,	 rapamycin	 has	 similar	immunosuppressive	properties.	Instead	of	inhibiting	secretion	of	interleukin	2	(IL-2)	
via	 calcineurin,	 rapmycin	 inhibits	 IL-2	 receptor-dependent	 signal	 transduction	mechanisms	via	mTOR	(V.	W.	V.	Lee	&	Chapman	2005).	The	 main	 advantage	 of	 rapamycin	 immunosuppression	 is	 the	 low	 level	 of	nephrotoxicity	 it	 produces,	 therefore	 seems	 a	 logical	 choice	 for	 the	 clinical	 setting.	However,	 it	 was	 noted	 that	 early	 graft	 rejection	 rates	 with	 rapamycin	 alone,	 or	 in	
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combination	with	steroids,	were	significantly	higher	than	that	of	patients	treated	with	CNIs	 (Marti	 &	 Frey	 2005;	 Dittrich	 et	 al.	 2004;	 Kreis	 et	 al.	 2000).	 This,	 along	 with	impaired	wound	healing	(V.	W.	Lee	&	Chapman	2005;	Sehgal	2003),	has	reduced	its	use	 in	 various	 transplant	 centres,	 though	 still	 a	 highly	 regarded	 tool	 for	 transplant	immunosuppression.	Given	that	rapamycin	is	a	macrolide,	it	differs	from	CNIs	in	its	structure	and	mode	of	action	(Sehgal	2003).	It	complexes	to	the	same	binding	protein	as	FK506,	FKB12,	but	does	not	inhibit	calcineurin,	as	is	the	case	with	FK506.	Instead,	the	rapamycin-FKB12	complex	 inhibits	 the	 mammalian	 target	 of	 rapamycin	 (mTOR)	 which	 ultimately	inhibits	 the	 response	 to	 IL-2	 and	 T/B	 cell	 activation,	 unlike	 inhibition	 of	 IL-2	 as	 is	seen	with	FK-506	in	T	lymphocytes	(Morelon	et	al.	2001).	Because	 rapamycin	 does	 not	 directly	 inhibit	 calcineurin,	 this	 has	 been	 the	 reason	suggested	 for	 its	 reduced	 nephrotoxic	 effects	 (Sehgal	 2003).	 CNI	 nephrotoxicity	 is	thought	 to	be	elicited	 from	 the	complete	or	partial	 inhibition	of	 calcineurin	activity	(Krejci	et	al.	2010).	Calcineurin	 is	 a	 calcium/calmodulin	 dependent	 phosphatase	 that	 is	 required	 for	dephosphorylation	of	the	nuclear	factor	of	activated	T	cells	(NFAT)	(Rao	et	al.	1997).	Once	dephosphorylated,	NFAT	 is	able	 to	 translocate	 to	 the	nucleus,	upregulate	 IL-2	transcription	 and	 therefore	 T	 cell	 activation	 (Naesens	 et	 al.	 2009).	 One	 important	note	 is	 that	 calcineurin	 and	 NFAT	 isoforms	 are	 not	 T	 cell	 specific	 and	 therefore	suppression	 of	 the	 pathway	 can	 lead	 to	 various	 forms	 of	 toxicity,	 not	 just	nephrotoxicity	(E.	H.	Liu	et	al.	2007)	and	is	a	mechanism	occurring	in	addition	to	the	direct	action	of	CNIs	on	pericytes.		The	 data	 presented	 here	 therefore	 indicates	 that	 rapamycin	 is	 unable	 to	 produce	significant	pericyte-mediated	vasoconstriction	of	vasa	recta	and	consequently	would	have	 a	 reduced	 detrimental	 effect	 on	 MBF	 compared	 to	 CNIs.	 Although	 the	 data	presented	 does	 not	 completely	 replicate	 in	 vivo	 settings	 it	 provides	 evidence	suggesting	that	in	the	medulla,	rapamycin	has	less	nephrotoxic	side	effects	over	CNIs.	It	is	now	well	documented	that	rapamycin	has	a	significantly	lower	toxicity	potential	than	either	CNI,	however	if	used	in	combination,	the	pharmacokinetic	profile	of	each	drug	dramatically	changes.	O’Connell	et	al	have	demonstrated	that	a	rapamycin	and	CsA	 combination	 significantly	 increases	 cytotoxicity	 in	 renal	 glomerular	 mesangial	cells	 compared	 to	 either	 drug	 alone,	 and	 thought	 to	 be	 mediated	 through	 SMAD	signalling	 (O'Connell	et	al.	 2012).	Podder	et	al	 investigated	 this	 combination	 in	vivo	
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and	 was	 able	 to	 confirm	 the	 increased	 toxicity	 of	 both	 drugs	 when	 used	 in	combination	(Podder	et	al.	2001),	however,	the	increase	of	toxicity	observed	was	not	due	to	SMAD	signalling	but	pharmacokinetic	interactions.	Both	drugs	are	extensively	metabolised	 by	 the	 CYP	 3A	 enzymes,	 therefore	 upon	 combined	 use,	 a	 coincidental	increase	 in	systolic	concentrations	of	both	drugs	 is	undoubtedly	anticipated	(Picard	
et	 al.	 2007).	 Interestingly,	 McAlister	 et	 al	 have	 demonstrated	 that	 a	 group	 of	transplant	patients	(liver,	kidney	or	pancreas)	who	underwent	rapamycin	and	FK506	combination	 therapy,	 presented	 excellent	 graft	 function	 and	 low	 rejection	 rates	without	 drug-induced	 side	 effects	 (McAlister	 et	 al.	 2000).	 Therefore	 it	 is	 hard	 to	deduce	 the	 extent	 of	 toxicity	with	 combined	 immunosuppression,	 especially	 in	 the	age	 of	 genetic	medicine	 and	 influence	 of	 polymorphisms	 on	 single	 genes	 including	CYP	3A	(Barbarino	et	al.	2013).	Like	CNIs,	 rapamycin	showed	no	significant	changes	 in	 tubule	cell	 size	or	diameter,	however	 recent	 evidence	 points	 towards	 rapamycin’s	 ability	 to	 induce	 tubule	dysfunction	 in	 the	 forms	 of	 apoptosis,	 tubule	 collapse	 and	 acute	 necrosis.	 This	suggests	 that	 even	 though	 rapamycin	 might	 have	 less	 obvious	 toxic	 effects,	 it	 too	could	 be	 an	 emerging	 immunosuppressant	 with	 the	 potential	 for	 development	 of	nephrotoxicity	(Marti	&	Frey	2005).								 	
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4.	 The	 effect	 of	 antihypertensive	 drugs	 in	 combination	 with	
CNIs	on	renal	medulla	in	situ	vasa	recta		
4.1	 Introduction		Hypertension	is	the	leading	risk	factor	for	premature	death,	stroke	and	development	of	 heart	 disease	 worldwide	 (Joffres	 et	 al.	 2013),	 therefore	 development	 of	hypertension	in	renal	transplant	patients	is	an	even	greater	risk	factor	to	consider	for	proper	 function	 of	 renal	 allografts.	 This	 chapter	 set	 out	 to	 investigate	 the	 use	 of	commonly	 prescribed	 antihypertensives	 in	 combination	 with	 CNIs	 to	 study	 their	contractile	effect	on	vasa	recta	pericytes	and	possibly	identify	a	novel	mechanism	for	the	reduced	nephrotoxicity	seen	in	patients	treated	with	CNIs	and	antihypertensives.	After	 successful	 kidney	 transplantation,	 before	 CNIs	 were	 introduced	 for	 first	 line	immunosuppression,	less	than	50%	of	patients	leaving	hospital	care	would	have	had	some	 form	 of	 hypertension	 (First	 et	al.	 1994).	 However,	 after	 CNI	 introduction	 for	maintenance	 immunosuppression	 in	 1983,	 up	 to	 90%	 of	 all	 patients	 treated	 have	systemic	hypertension	(Textor	et	al.	1994;	Midtvedt	&	Hartmann	2002a).	Although	CNIs	and	steroids	do	have	a	clear	role	in	the	development	of	pre	and	post-transplant	hypertension,	 its	development	 in	 the	transplant	population	 is	 in	contrast	to	 the	general	population,	due	 to	 the	 fact	donor	and	 recipients	have	 individual	 risk	factors	for	hypertension.		Some	of	the	major	risk	factors	associated	with	hypertension	are	highlighted	in	table	1.	
	
Table1	 Risk	 factors	 including	 pre	 and	 post-transplant	 of	 donor	 and	
recipient	contributing	to	hypertension	before	and	after	transplant.		
	





4.1.2	 Hypertension	and	graft	function		Due	to	 the	 fundamental	role	of	 the	kidney	 in	maintaining	blood	pressure,	 it	 is	clear	that	hypertension	is	a	compelling	risk	factor	for	the	survival	and	function	of	any	renal	graft	(Aparicio	et	al.	2013;	Mangray	&	Vella	2011;	Curtis	et	al.	1988;	First	et	al.	1994).	Moreover	 it	 has	 been	 known	 for	 some	 time	 that	 there	 is	 an	 intimate	 relationship	between	the	prevalence	of	hypertension	and	the	gradual	demise	of	GFR	(Cowley	et	al.	1995;	 Aparicio	 et	 al.	 2013).	 However,	 the	 underlying	 mechanisms	 linking	 these	parameters	(GFR,	hypertension	and	graft	survival)	is	still	poorly	understood	and	as	to	whether	 the	 long-term	 reduction	 in	 systemic	 BP,	 improves	 graft	 function	 similarly	remains	unknown.	Modena	et	al	identified	a	link	between	an	increase	in	BP	and	increased	rates	of	renal	decline	in	transplant	patients	(Modena	et	al.	1991).	The	data	obtained	by	Modena	et	
al	 scrutinised	 the	 link	 from	 reciprocal	 of	 serum	 creatinine	 versus	 time	 plots	 in	patients	 with	 clinical	 and	 histologic	 evidence	 of	 chronic	 renal	 transplant	 rejection	(Modena	et	al.	 1991).	 Furthermore,	Opelz	et	al	 underlined	 the	 association	between	higher	BP	and	kidney	graft	survival	1	year	post	transplant	(Opelz	et	al.	1997).	Opelz	
et	al	 identified	29,000	patients	with	higher	post-transplant	hypertension	 than	non-renal	transplant	controls,	resulting	in	an	increased	risk	for	graft	dysfunction	(Opelz	et	
al.	 1997).	 Interestingly,	 the	 data	 produced	 by	 Opelz	 et	 al	 was	 followed	 up	 to	investigate	 chronic	 graft	 dysfunction	 and	 was	 significantly	 associated	 with	 an	increase	in	BP.	The	data	produced	by	Opelz	et	al	was	able	to	undeniably	conclude	that	post-transplant	blood	pressure	 is	 a	highly	 significant	predictor	of	 long-term	kidney	allograft	function	(Opelz	et	al.	1997).		Remarkably,	both	Modena	et	al	and	Opelz	et	al	failed	 to	 take	 into	account	 the	role	of	CNIs	 in	 the	development	of	hypertension	and	graft	 survival	 in	 each	 of	 the	 authors	 respective	 studies,	 even	 though	 it	 has	 been	known	 for	 some	 time	 that	 CNIs	 are	 a	 significant	 factor	 in	 the	 development	 of	transplant	hypertension	(First	et	al.	1994;	Curtis	et	al.	1988;	Textor	et	al.	1994).		
4.1.3	 Calcineurin	inhibitors	and	development	of	hypertension		Even	 though	both	 cyclosporine	 and	 tacrolimus	have	both	been	 shown	 to	 induce	 or	augment	 hypertension	 in	 transplant	 patients	 (Hohage	 et	al.	 1996;	Mangray	&	Vella	2011;	 Curtis	 et	 al.	 1988;	 First	 et	 al.	 1994;	 Hoskova	 et	 al.	 2014),	 this	 data	 and	 the	additional	risk	factors	discussed	above,	it	is	therefore	almost	impossible	to	asses	the	contribution	of	CNIs	to	the	development	of	hypertension	after	renal	transplant.	
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However,	if	data	is	compared	to	that	collated	from	non-renal	transplant	patients,	the	extent	 to	 which	 CNI’s	 are	 capable	 of	 inducing	 hypertension	 can	 start	 to	 be	disentangled	(Hoorn,	et	al.	2012;	Moes	et	al.	2014;	Textor	et	al.	2000;	Naesens	et	al.	2009).	Evidence	suggests	 that	 the	 incidence	of	hypertension	 in	patients	undergoing	bone	 marrow	 or	 heart	 transplant	 in	 the	 absence	 of	 CNI	 therapy	 is	 relatively	uncommon,	below	10%,	prior	to	CNI	therapy,	but	rose	significantly	to	approximately	50%	 in	bone	marrow	 transplants	and	80%	 in	heart	 transplants	after	CNI	 induction	therapy	(Textor	et	al.	1994;	Shiba	et	al.	2004).		Based	 on	 the	 above	 evidence	 it	 is	 therefore	 seems	 evident	 that	 CNIs,	 to	 a	 certain	degree,	have	the	capacity	to	induce	hypertension	after	transplantation.			Data	suggests	that	the	hypertensive	effects	of	CNI’s	could	be	attributed	to	two	major	models;	i)	vascular	effects	and	ii)	sodium	retention,	both	will	be	discussed	below.		
4.1.3.1		Vascular	effects	of	CNIs	CNIs	have	been	 shown	 to	 induce	 systemic	 and	 renal	 vasoconstriction	 (Hoorn,	et	al.	2012;	 Kaye	 et	 al.	 1993),	 through	 an	 ANG	 II	 independent	 pathway	 (Murray	 et	 al.	1985).	 Renal	 vasoconstriction	 induced	 by	 CNIs	 is	 thought	 to	 originate	 from	 the	increased	production	of	endothelin	via	preglomerular	arteries	(Cavarape	et	al.	1998).	This	 has	 been	 demonstrated	 directly	 in	 studies	 performed	 in	 rat	 models	 of	 CNI	hypertension	which	utilised	in	vivo	measurements	of	mean	arterial	pressure	and	GFR	to	 show	 endothelin	 receptor	 antagonists	 significantly	 reducing	 CNI-induced	hypertension	 (Perico	 et	 al.	 1990),	 although	 it	 is	 still	 unclear	 whether	 endothelin	contributes	 towards	 CNI	 hypertension	 through	 renal	 or	 systemic	 vasoconstriction.	For	 example,	 Forslund	 et	 al	 have	 demonstrated	 that	 patients	 treated	 with	 CNIs	develop	 hypertension	 independent	 of	 circulating	 endothelin	 levels.	 The	 data	produced	by	Forslund	et	el	was	able	to	show	rheumatoid	arthritis	patients	receiving	CsA	had	 an	 increased	 systolic	 and	diastolic	BP	6	months	 after	 initial	 treatment	but	endothelin,	 as	 well	 as	 aldosterone	 and	 antidiuretic	 hormone	 levels	 remained	unchanged	(Forslund	et	al.	1995).	Furthermore,	Lanese	and	Conger	have	been	able	to	demonstrate	 the	 direct	 contractile	 effect	 of	 CsA	 via	 endothelin	 on	 rat	 afferent	 and	efferent	 arterioles	 of	 the	 renal	 microvasculature	 however	 their	 data	 suggests	 that	endothelin	 is	 only	 responsible	 for	 constriction	 of	 the	 afferent	 arteriole	 and	 not	efferent	(Lanese	&	Conger	1993).							
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As	well	as	increased	vasoconstriction,	CNI	impaired	vasodilation	has	been	associated	with	 the	 onset	 of	 hypertension.	 CsA	 has	 been	 shown	 to	 reduce	 spontaneous	relaxation	 of	 resistance	 vessels	 in	 rat	 and	 humans	 and	 inhibit	 endothelium-dependent	relaxation	(Richards	et	al.	1989;	Lassila	et	al.	2001;	Vaziri	et	al.	2002.)	via	the	reduction	of	nitric	oxide	(NO)	(Morris	et	al.	2000).	NO	has	also	been	implicated	in	the	generation	of	reactive	oxygen	species	(ROS)	via	CsA	treatment	(H.-W.	Chen	et	al.	2002;	Perez	de	Hornedo	et	al.	2007).	The	studies	of	Chen	et	al	and	Hornedo	et	al	have	been	 able	 to	 demonstrate	 CsA	 mediated	 production	 of	 ROS	 is	 via	 altered	mitochondrial	 physiology	 and	 decreased	 production	 of	 antioxidant	 compounds	including	NAD(P)H,	inducible	nitric	oxide	synthase	(iNOS),	Hsp70	and	dissipation	of	mitochondrial	membrane	potential	 (H.W.	 Chen	et	al.	 2002;	 Perez	de	Hornedo	et	al.	2007)	therefore	a	possible	link	between	the	up	regulation	of	ROS	and	decrease	of	NO	could	be	partly	responsible	for	the	vasoconstrictive	effects	seen	with	CNIs.	Data	yielded	from	cell	line	studies	has	demonstrated	that	down	regulation	of	NO	after	CsA	treatment	occurs	in	response	to	the	inhibition	of	iNOS	in	VSMC’s	(Marumo	et	al.	1995).	 Tacrolimus	 has	 not	 been	 shown	 to	 induce	 such	 effect	 on	 iNOS	 production	although	in	studies	performed	in	rats,	it	has	been	shown	to	reduce	endothelial	nitric	oxide	synthase	 in	aorta	and	also	renal	vasculature	(Eguchi	et	al.	2013;	Takeda	et	al.	1999),	therefore,	taken	together,	CNIs	can	be	clearly	demonstrated	to	effect	systemic	and	local	renal	production	of	NO	and	possibly	contribute	towards	the	progression	of	hypertension.		CNIs	have	been	shown	to	activate	the	renin-angiotensin	system	(RAAS)	both	directly,	
via	 juxtaglomerular	 cells	 secreting	 renin	 into	 the	 blood	 stream	 (Kurtz	 et	 al.	 1988;	Lassila	2002;	Friis	et	al.	2006)	and	 indirectly,	via	hemodynamic	alterations	 induced	by	 ANG	 II	 vasoconstriction	 (Ruester	 &	 Wolf	 2006)	 therefore,	 the	 mechanisms	 for	RAAS	activation	via	CNIs	still	remains	somewhat	obscure.	Studies	performed	in	rats	and	humans	investigating	circulating	plasma	renin	activity	have	shown	contradictory	results	with	Kurtz	et	al	indicating	increased	levels	of	renin	after	CsA	treatment	(Kurtz	
et	al.	 1988)	whereas	Klein	 et	al	 demonstrated	 suppressed	 levels	 of	 renin	 after	 CNI	administration	 (Klein	 et	al.	 2002).	 Rats	 treated	with	 CsA	have	 been	 shown	 to	 have	significantly	higher	levels	of	systemic	and	renal	ANG	II	concentrations	(Nishiyama	et	
al	2003),	 feasibly	 leading	 to	 the	 increased	production	of	 	 renal	ROS	which	was	also	demonstrated	by	Nishiyama	et	el	who	concluded	that	ROS	generation	induced	by	the	
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increased	 production	 of	 ANG	 II	 contributes	 to	 the	 development	 of	 CsA-induced	hypertension	(Nishiyama	et	al,	2003).	Intriguingly,	CsA	has	been	shown	to	double	the	amount	 of	 ANG	 II	 type	 1	 receptor	 in	 VSMC’s,	 that	 could	 account	 for	 the	 increased	vasoconstrictive	 effects	 in	 combination	 with	 the	 excess	 production	 of	 ANG	 II	(Avdonin	et	al.	1999).	
4.1.3.2		Sodium	retaining	effects	of	CNIs		In	recent	years,	it	has	become	increasingly	evident	that	CNI-induced	hypertension	is	not	completely	dependent	on	their	vasoconstrictive	attributes	but	also	their	sodium	retaining	properties	 (Hoorn,	et	al.	2012;	Mangray	&	Vella	2011;	Hoorn	et	al.	2012).	The	 definitive	 study	 to	 identify	 this	 effect	 was	 carried	 out	 by	 Curtis	 et	 al	 who	investigated	 15-hypertensive	 renal	 transplant	 patients,	 comparing	 data	 collected	from	 patients	 having	 received	 CsA	 treatment,	 against	 15	 control	 hypertensive	patients	 treated	with	 azathioprine	 (Curtis	 et	al.	 1988).	 Using	 a	 salt	 variable	 diet	 in	treated	patients	and	controls,	 the	authors	were	able	to	demonstrate	the	 increase	or	decrease	in	BP	levels	after	increasing	dietary	salt	intake	whereas	the	control	patients	had	no	such	change	in	BP	under	the	same	salt	conditions	(Curtis	et	al.	1988).	Whilst	 the	 precise	mechanisms	 underlying	 the	 CNI’s-induced	 sodium	 retention	 are	unknown,	 several	 studies	 have	 suggested	 that	 CNIs	 alter	 the	 expression	 of	 major	sodium	 transporters	 as	 the	 reason	 for	 this	 physiological	 effect	 and	 thus	 these	represent	a	novel	target	for	the	attenuation	of	CNI-induced	sodium-	retention.				Sodium	reabsorption	in	the	kidney	is	vital	for	correct	homeostasis	of	electrolytes	and	water	 balance.	 There	 are	 4	 major	 transporters	 expressed	 along	 the	 renal	 tubules	responsible	for	over	99%	of	total	sodium	reabsorption	(Koeppen	&	Stanton	2013d).	These	 include	 the	 sodium-hydrogen	 exchanger	 type	 3	 (NHE3)	 located	 on	 the	proximal	 tubule,	 the	 sodium-potassium-chloride	 co-transporter	 type	 2	 (NKCC2)	situated	within	 the	 loop	of	Henle,	 the	 sodium	chloride	 cotransporter	 (NCC)	 located	within	the	distal	convoluted	tubule	and	the	epithelial	sodium	channel	(ENaC)	in	the	collecting	duct	(Hoorn	et	al.	2012).	Although	 all	 of	 the	 aforementioned	 transporters	 will	 undoubtedly	 have	 some	contribution	 towards	 the	 increased	 sodium	 reabsorption,	 it	 is	 the	 NCC	 that	 has	received	 the	most	 interest	 in	 recent	years	 (Damiano	et	al.	 2010;	Hoorn	et	al.	 2011;	Blankenstein	et	al.	2014;	Hoorn	et	al.	2012).	
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Various	studies	have	focused	their	efforts	on	investigating	which	of	the	transporters	is	involved	in	the	CNI-induced	sodium	retention	and	an	interesting	study	by	Hoorn	et	
al	 investigated	 the	 possible	 role	 of	 WNK	 kinase	 mutations	 in	 the	 prevalence	 of	hypertension	 while	 under	 CNI	 therapy	 (Hoorn	 et	 al.	 2011).	 Their	 hypothesis	 was	based	 on	 the	 fact	 that	 certain	 tubular	 disorders	 caused	 by	 CNIs	 have	 a	 striking	similarity	to	Gordon	syndrome,	a	rare	from	of	hereditary	hypertension	(Hoorn	et	al.	2009).	 They	 revealed	 that	 NCC	 knock	 out	 mice	 did	 not	 develop	 salt	 sensitive	hypertension	after	CNI	 treatment	but	mice	over	expressing	NCC	had	an	augmented	hypertensive	response	to	CNIs.	This	was	extrapolated	to	renal	transplant	patents	and	using	 simple	 thiazide	diuretics,	 to	 inhibit	NCC,	 they	were	able	 to	 show	a	decreased	expression	of	phosphorylated,	activated	form,	of	NCC	(Hoorn	et	al.	2011).	In	turn,	this	inactive	 form	 of	 NCC	 was	 unable	 to	 induce	 levels	 of	 hypertension,	 via	 salt	reabsorption,	seen	in	patients	treated	with	CNIs	alone.	This	 simple,	 but	 ingenious,	 method	 for	 reducing	 the	 potential	 risk	 of	 CNI	hypertension	 is	 a	 leap	 forward	 in	 rational	 for	 therapeutic	 interventions	 seeking	 to	ameliorate	CNI-induced	hypertension	 (Hoorn	et	al.	 2011;	Hoorn	et	al.	 2012;	Hoorn,	Walsh,	McCormick,	et	al.	2012).	
4.1.4	 CNI-induced	hypertension	treatment		Following	renal	transplant,	a	complete	lifestyle	change	is	required	to	combat	the	risk	or	 progression	 of	 hypertension	 and	 graft	 function	 or	 loss	 of	 function.	 This	 usually	includes	dietary	changes,	weight	loss	and	physical	exercise	adjustments	(Midtvedt	&	Hartmann	2002b).		Even	having	implicated	many	of	the	above	significant	changes,	most	patients	require	1	or	more	antihypertensive	medications	to	consistently	control	BP	(Mangray	&	Vella	2011;	Midtvedt	&	Hartmann	2002a).	These	include	a	variety	of	target	specific	drugs	with	 the	 aim	 of	 combating	 either	 CNI-mediated	 vasoconstriction	 or	 salt	 retaining	effects	(Aparicio	et	al.	2013;	Mangray	&	Vella	2011).			Angiotensin	converting	enzyme	 inhibitors	(ACEi)	and	angiotensin	receptor	blockers	(ARBs)	 were	 one	 of	 the	 first	 medications	 used	 in	 attempt	 to	 combat	 CNI	 induced	hypertension	(Aparicio	et	al.	2013).	In	non	renal	transplant	patients,	both	drug	types	have	been	shown	to	slow	the	progression	of	chronic	renal	disease	via	a	reduction	in	glomerular	 pressure	 (Naesens	 et	 al.	 2009;	 Wolf	 2006;	 Remuzzi	 et	 al.	 2005)	 and	interestingly,	have	also	been	shown	to	inhibit	TFG-β,	a	growth	factor	upregulated	by	
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CNIs	and	responsible	for	chronic	allograft	dysfunction	(Lewis	et	al.	1993;	Maschio	et	
al.	 1996).	 However,	 when	 used	 under	 renal	 transplant	 conditions,	 their	 effect	 on	hypertension	 and	 chronic	 allograft	 dysfunction	 still	 remains	 unclear	 with	 trials	suggesting	both	beneficial	and	detrimental	effects	 thus	 these	agents	should	be	used	with	caution	(Hiremath	et	al.	2007;	Dudley	2001).			Calcium	 channel	 blockers	 (CCB)	 are	 an	 attractive	 option	 for	 clinicians	 trying	 to	attenuate	CNI-induced	hypertension	due	 to	 their	vasodilatory	properties	 (Frishman	2007;	Ladefoged	&	Andersen	1994;	Baroletti	et	al.	2003).	CNIs	predominantly	induce	vasoconstriction	 within	 the	 vasculature	 via	 their	 action	 on	 voltage	 gated	 calcium	channels	 in	 smooth	 muscle	 cells.	 Blocking	 these	 channels	 results	 in	 a	 subsequent	reduction	 in	 VSMC	 contraction	 and	 in	 some	 cases	 even	 induces	 vasodilation	 (Katz	1986).	 However	 CCBs	 fall	 into	 two	 main	 classes;	 dihydropyridines	 and	nondihydropyridines	and	although	both	classes	ultimately	 inhibit	 calcium	channels,	they	 vary	 considerably	 in	 their	molecular	 targets	 and	 pharmacokinetics	 (Frishman	2007),	which	 is	 particularly	 important	 for	 transplant	 patients	 already	 on	 a	 lifetime	“cocktail”	 of	 medications	 and	 increases	 the	 risk	 of	 adverse	 effects	 through	 drug	interactions.	 For	 example,	 a	 study	 by	 Karllova	 et	 al	 revealed	 the	 commonly	 used	herbal	medication,	St	 Johns	wort,	used	 for	 its	antidepressant	and	anti-inflammatory	properties	significantly	reduced	the	systemic	levels	of	CsA	in	transplant	patients	and	put	the	patients	at	severe	danger	of	under	immunosuppression	and	increased	risk	of	graft	rejection	(Karliova	et	al.	2000).		Diuretics,	 including	 loop	 diuretics,	 have	 had	 the	 least	 amount	 of	 attention	 with	regards	to	attenuating	CNI-induced	hypertension	over	the	past	30	years.	Nonetheless,	they	have	been	a	valuable	tool	for	reducing	salt	and	water	retention	in	hypertensive	transplant	patients	(Vergoulas	2001).	Hypertension	in	renal	transplant	patients	was	initially	thought	to	derive	from	CNI-mediated	oedema	and	vasoconstriction	(Mangray	&	Vella	2011),	however	a	new	mechanistic	proposal	has	been	put	forward	regarding	the	 activation	 of	 NCC	 and	 increased	 salt	 reabsorption	 (Hoorn	 et	 al.	 2011)	 as	previously	 described,	 and	 may	 offer	 a	 new	 pharmacokinetically	 safe	 method	 for	treating	hypertension	after	renal	transplant.		Given	 the	vast	 array	of	 risk	 factors	 for	CNI-induced	hypertension,	 coupled	with	 the	numerous	amount	of	medications	used	to	treat	the	complication,	it	is	clear	that	CNI-
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induced	 hypertension	 is	 not	 only	 inevitable	 in	 most	 cases,	 but	 its	 management	remains	 clinically	 complicated.	 The	 combination	 of	 immunosuppressant’s	 and	antihypertensives	 must	 be	 selected	 with	 caution	 due	 to	 the	 interplay	 of	 drug	interactions	and	possible	cause	for	further	complications.	The	 aim	 of	 this	 study	was	 to	 investigate	 the	 combination	 of	 antihypertensives	 and	CNIs	to	determine	their	effect,	if	any,	on	renal	medullary	vasculature	and	in	particular	focus,	the	effect	of	CNIs	on	pericytes	in	the	presence	of	antihypertensive	medications.			
4.2	 Methods		Intact	 live	kidney	slices	were	obtained	as	previously	described	 in	General	Methods.	Live	kidney	slices	were	superfused	with	cyclosporine	A	(CsA)	or	tacrolimus	(FK506)	in	 the	 presence	 of	 losartan,	 hydrochlorothiazide	 (HCT),	 diltiazem	 or	 isradipine,	 all	purchased	from	Sigma-Aldrich	(Dorset,	UK).		All	working	solutions	were	prepared	in	95%	O2	/	CO2	PSS	however	stocks	of	CsA	and	FK506	were	made	in	DMSO.	The	final	DMSO	in	all	working	solutions	was	less	than	1%.	In	all	experiments	to	determine	the	affect	on	vasa	recta	diameter,	kidney	slices	were	superfused	with	95%	O2	/	CO2	PSS	for	~100	 s	 to	 establish	 a	baseline	 vessel	 diameter	 at	 the	pericyte	 and	non-pericyte	sites.	 Slices	 were	 then	 exposed	 to	 CsA,	 or	 FK506	 and	 an	 antihypertensive	 for	approximately	700	s	and	then	subjected	to	a	PSS-wash	to	assess	reversibility	of	any	affect.	In	some	instances,	imaging	experiments	commenced	after	an	incubation	of	the	slice	 in	the	particular	antihypertensive,	all	 tissue	was	continually	perfused	with	PSS	bubbled	with	 95%	O2	/	 CO2	and	 desired	 concentration	 of	 antihypertensive.	 Control	experiments	for	the	effect	of	antihypertensive	alone	were	also	carried	out.	Analysis	of	video	recordings	of	changes	in	vasa	recta	diameter	has	been	described	previously	in	general	methodology.	 	 Briefly,	 each	 experiment	was	 analysed	 using	 the	 free	 public	domain	 software	 IMAGE	 J	 (NIH;	 http://rsb.info.nih.gov).	 For	 each	 experiment,	 a	pericyte	 site	 and	 non-pericyte	 site	 were	 identified	 on	 a	 single	 casa	 recta	 capillary	acting	as	a	paired	control.	The	diameter	of	 the	vasa	recta	at	both	of	 these	 locations	was	measured	every	five	frames	for	the	duration	of	the	experiment.	An	average	of	the	first	five	measurements	was	taken	to	represent	the	resting	diameter	value	(i.e.	100%)	for	 the	 selected	 pericyte	 and	 non-pericyte	 sites.	 All	 subsequent	 diameter	measurements	 at	 both	 sites,	 increase	 or	 decrease,	were	 calculated	 as	 a	 percentage	change	of	the	corresponding	resting	diameter	value.			
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4.2.1	 Statistics		All	data	are	presented	as	mean	values	±	SEM;	n	numbers	are	displayed	as	number	of	kidney	 slices,	 and	 were	 appropriate,	 (number	 of	 animals).	 All	 experiments	 were	performed	in	at	least	six	different	animals.	Statistical	assessment	was	performed	with	GraphPad	Prisim		(v5.0f;	GraphPad	software,	San	Diego,	CA,	USA).	When	two	groups	were	compared,	a	Student’s	t-test	(two-tailed,	paired	or	unpaired	where	appropriate)	was	used.	A	value	of	P	<	0.05	was	considered	significant.				
4.3	 Results		
4.3	 Investigating	the	effect	of	losartan	on	CsA-mediated	changes	in	vasa	recta	
diameter			To	 determine	 whether	 the	 vasoconstrictive	 effects	 of	 CsA	 on	 in	 situ	 vasa	 recta	 via	pericytes	 is	mediated	by	angiotensin,	 the	 selective	ANG	 II	 type	 I	 receptor	 inhibitor,	losartan,	 tissue	 was	 exposed	 to	 both	 losartan	 and	 CsA	 to	 explore	 any	 significant	losartan-mediated	alterations	in	CsA	evoked	constriction	of	vasa	recta.			Superfusion	(~700	s)	of	CsA	&	losartan	(5	μM	/	100	nM,	respectively)	resulted	 in	a	reversible	constriction	of	vasa	recta	capillaries	via	pericytes	(Figure	4).	CsA-mediated	an	11.80	±	0.60%	constriction	of	vasa	recta	via	pericytes	in	the	presence	of	losartan	that	was	not	significantly	different	to	the	constriction	evoked	by	CsA	alone	(12.17	±	0.88%,	 n=8	 (7),	 figure	 4).	 Changes	 in	 vessel	 diameter	 at	 non-pericytes	via	 CsA	 and	losartan	(5	μM	/	100	nM)	was	not	significantly	different	when	compared	to	CsA	alone	(5	μM)	alone	(3.4	±	1.1%	and	2.9	±	0.88%,	respectively).	The	CsA	and	losartan	evoked	constriction	of	vasa	recta	was	reversed	upon	washout,	and	vessel	diameter	returned	≥	92%	of	the	original	baseline	vessel	diameter	after	500	s	following	washout.	Superfusion	of	losartan	alone	has	previously	been	shown	to	have	no	significant	effect	on	vasa	recta	diameter	at	pericyte	and	non	pericyte	sites	(Crawford	et	al.	2012).		In	 order	 to	 investigate	 the	 possible	 concentration	 dependent	 effect	 of	 CsA	 on	 vasa	recta	pericytes,	losartan	was	used	in	combination	with	CsA	at	lower	concentrations	to	
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determine	 if	 CsA	 dependent	 vasoconstriction	 at	 clinical	 concentrations	 was	influenced	by	complete	ANG	II	type	I	receptor	inhibition.		Superfusion	(~700	s)	of	CsA	&	losartan	(1	and	3	μM	/	100	nM,	respectively)	resulted	in	 a	 reversible	 constriction	 of	 vasa	 recta	 capillaries	 via	 pericytes	 (Figure	 4).	Vasoconstriction	at	pericytes	sites	induced	by	CsA	&	losartan	(1	and	3	μM	/	100	nM)	was	not	significantly	attenuated	by	the	presence	of	losartan	(5.99	±	0.51	%	and	9.02	±	0.48%,	 respectively,	 n=8	 (7))	 compared	 to	 superfusion	 of	 CsA	 (1	&	 3	 μM)	 alone	 at	pericyte	sites	(6.8	±	0.89%	and	9.49	±	1.03%,	respectively,	n=8	(7))	(Figure	4).	Similarly,	 changes	 in	 vessel	 diameter	 at	 non-pericyte	 sites	 induced	 by	 CsA	 and	losartan	(1	&	3	μM	/	100	nM)	was	not	significantly	different	when	compared	to	CsA	(1	&	3	μM)	alone.	All	 CsA	 and	 losartan	 induced	 vasoconstrictions	 were	 reversed	 upon	 washout	 and	returned	to	≥	92%	original	baseline	diameter	after	500	s	following	washout.				
	
Figure	4.0	 CsA-induced	 constriction	 of	 vasa	 recta	 is	 not	 significantly	




















4.4	 The	 effect	 of	 losartan	 on	 the	 FK506-mediated	 changes	 in	 vasa	 recta	
diameter	As	 losartan	had	no	significant	 inhibitory	effect	on	CsA	mediated	vasoconstriction,	 it	was	 hypothesised	 that	 it	 would	 similarly	 have	 no	 inhibitory	 effect	 on	 FK506-mediated	vasoconstriction.	Superfusion	(~700	s)	of	FK506	&	losartan	(1	μM	/	100	nM,	respectively)	resulted	in	a	reversible	 constriction	 of	 vasa	 recta	 capillaries	 via	 pericytes	 (Figure	 4.1).	Vasoconstriction	 induced	by	FK506	and	 losartan	was	not	significantly	attenuated	at	pericyte	sites	compared	to	superfusion	of	FK506	alone	at	pericyte	sites	(10.99	±	0.13	and	 11.31	 ±	 0.74%,	 respectively,	 n=7	 (7),	 figure	 4.1).	 Vasoconstriction	 at	 non-pericytes	 via	 FK506	 and	 losartan	 (1	 μM	 /	 100	 nM)	 was	 not	 significantly	 different	when	 compared	 to	 FK506	 alone	 (1	 μM)	 alone	 (2.78	 ±	 1.1%	 and	 1.67	 ±	 0.78%,	respectively).	The	 FK506	 and	 losartan	 evoked	 constriction	 of	 vasa	 recta	 was	 reversed	 upon	washout,	 and	 vessel	 diameter	 returned	 to	 ≥	 95%	 of	 the	 original	 baseline	 vessel	diameter	after	500	s	following	washout.		As	with	CsA	experimentation,	FK506	was	investigated	for	concentrations	dependent	effects	in	combination	with	losartan.		Superfusion	(~700	s)	of	FK506	&	losartan	(0.05	and	0.1	μM	/	100	nM,	respectively)	resulted	in	a	reversible	constriction	of	vasa	recta	capillaries	via	pericytes	(Figure	4.1).	Vasoconstriction	induced	by	FK506	&	losartan	(0.05	and	0.1	μM	/	100	nM)	was	not	significantly	attenuated	at	pericyte	sites	(5.11	±	0.98%	and	8.00	±	0.6%,	respectively,	n=7	 (7))	 compared	 to	superfusion	of	FK506	(0.05	&	0.1	μM)	alone	at	pericyte	 sites	(5.2	±	0.59%	and	8.71	±	1.11%,	respectively,	n=7	(7),	figure	4.1).	Similarly,	vasoconstriction	at	non-pericyte	sites	induced	by	FK506	and	losartan	(0.05	&	0.1	μM	/	100	nM)	was	not	significantly	different	when	compared	to	FK506	(0.05	&	0.1	μM)	alone.	All	FK506	and	losartan	induced	vasoconstrictions	were	reversed	upon	washout	 and	 returned	 to	 ≥	 95%	 original	 baseline	 diameter	 after	 500	 s	 following	washout.	
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Figure	 4.1	 	 FK506-induced	 constriction	 of	 vasa	 recta	 is	 not	 significantly	
attenuated	by	the	AT1	receptor	antagonist	losartan.	Bar	graph	showing	the	mean	%	change	in	vasa	recta	diameter	at	pericyte	sites	when	slices	were	superfused	with	FK506	alone	at	varying	concentrations	(0.05,	0.1	and	1	μM;	black	bars)	and	 in	 the	presence	of	 losartan	(100	nM;	Grey	bars).	No	significant	attenuation	 of	 the	 FK506-induced	 change	 in	 vessel	 diameter	 was	 observed	 when	losartan	 was	 present	 indicating	 FK506-induced	 vasoconstriction	 of	 vasa	 recta	 by	pericytes	is	not	mediated	via	AT1	receptors.	Data	are	mean	±	SEM,	n=7	(7),	P>0.05.			
4.5	 The	effect	of	hydrochlorothiazide	in	combination	with	CNIs	on	in	situ	vasa	




















role	 of	 NCC	 up-regulation	 and	 to	 what	 extent	 inhibiting	 NCC	 had	 on	 pericyte	contraction	in	the	presence	of	CNI’s.	





Figure	4.2	 Superfusion	 of	 live	 kidney	 tissue	 with	 hydrochlorothiazide	 does	












































	Given	 that	HCT	had	no	 significant	 effect	 on	 vasa	 recta	 diameter	 alone,	 the	 effect	 of	combining	HCT	and	FK506	was	investigated.	Referring	back	to	the	work	by	Hoorn	et	
al	 (Hoorn	 et	 al.	 2011),	 they	 were	 able	 to	 demonstrate	 in	 NCC	 knockout	 mice	 the	significant	reduction	 in	blood	pressure	after	being	treated	with	FK506	compared	to	wild	 type	 mice	 treated	 with	 FK506.	 Interestingly,	 Melnikov	 et	 al	 have	 also	 shown	similar	effects	with	the	use	of	CsA	(Melnikov	et	al.	2011)	suggesting		that	CNIs	cause	some	 form	 of	 salt	 sensitive	 hypertension	 via	 upregulation	 of	 the	 NCC.	With	 this	 in	mind,	the	effect	of	FK506	in	combination	with	HCT	was	used	to	explore	the	potential	role	of	pericytes	and	HCT	in	the	progression	of	CNI-induced	hypertension.		Superfusion	 (~700	 s)	 of	 FK506	 and	 HCT	 (3	 &	 1	 μM,	 respectively)	 resulted	 in	 a	significantly	reduced	reversible	constriction	of	vasa	recta	capillaries	when	compared	to	 that	 evoked	 following	 exposure	 of	 kidney	 slices	 to	 FK506	 alone	 (Figure	 4.3).	Vasoconstriction	 induced	 by	 FK506	 and	 HCT	was	 significantly	 reduced	 at	 pericyte	sites	 (5.10	 ±	 1.79%)	 compared	 to	 vasoconstriction	 induced	 by	 FK506	 alone	 at	pericyte	 sites	 (12.64	 ±	 0.65%,	 n=	 9(9);	 P<0.01,	 (Figure	 4.3).	 The	 FK506	 and	 HCT	evoked	 constriction	of	 vasa	 recta	was	 reversed	upon	washout,	 and	vessel	diameter	returned	 to	 ≥	 98%	 of	 the	 original	 baseline	 vessel	 diameter	 after	 400	 s	 following	washout.	Vasoconstriction	at	pericyte	sites	induced	by	the	combination	of	FK506	and	HCT	(3	&	1	μM,	respectively)	(5.10	±	1.79%)	was	not	significantly	greater	compared	to	non-pericyte	sites	(3.79	±0.91%,	n=9	(9),	figure	4.3).		Given	 that	 HCT	 was	 able	 to	 attenuate	 FK506-medaited	 vasoconstriction	 and	 HCT	concentrations	 vary	 considerably	 between	 individuals,	 increasing	 concentrations	 of	HCT	 to	 theoretically	 completely	 inhibit	 NCC,	 in	 the	 presence	 of	 FK506	 was	investigated.			Superfusion	(~700	s)	of	FK506	(3	μM)	and	HCT	(3	&	5	μM)	resulted	in	an	increased	attenuation	 of	 FK506-mediateed	 vasoconstriction	 of	 vasa	 recta	 capillaries	 when	compared	 to	 FK506	 alone	 (Figure	 4.3).	 Vasoconstriction	 induced	 by	 FK506	 (3	 μM)	and	HCT	 (3	&	5	 μM)	was	 significantly	 reduced	 at	 pericyte	 sites	 (3.12	 ±	 0.93%	and	3.25	±	1.17%,	respectively)	compared	to	vasoconstriction	induced	by	FK506	alone	at	
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pericyte	 sites	 (12.64	 ±	 0.65%,	 n=	 9(9);	 P<0.001,	 (Figure	 4.3).	 The	 FK506	 and	HCT	evoked	constriction	of	vasa	recta,	at	all	concentrations,	was	reversed	upon	washout,	and	vessel	diameter	returned	to	≥	95%	of	the	original	baseline	vessel	diameter	after	400	 s	 following	 washout.	 Vasoconstriction	 at	 pericyte	 sites	 induced	 by	 the	combination	of	FK506	(3	μM)	and	HCT	(3	&	5	μM)	(3.12	±	0.93%	and	3.25	±	1.17%,	respectively)	 was	 not	 significantly	 greater	 compared	 to	 non-pericyte	 sites	 (1.99	±0.51%	and	3.3	±	1.17%,	respectively.	n=9	(9),	figure	4.3).								
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Figure	4.3	 	Hydrochlorothiazide	 attenuates	 the	 FK506	 evoked	




























































































4.6	 The	effect	of	diltiazem	in	combination	with	CNIs	on	in	situ	vasa	recta		Given	that	much	of	 the	 literature	suggests	 the	prominent	role	of	vasoconstriction	 is	an	 important	 factor	 in	 CNI-induced	 hypertension,	 although	 new	 insights	 via	 salt	sensitivity	are	emerging	(Melnikov	et	al.	2011;	Hoorn,	Walsh,	McCormick,	et	al.	2012),	inducing	some	form	of	vasodilation	is	an	attractive	proposition	to	combat	the	onset	of	CNI-mediated	 hypertension.	 The	most	 commonly	 used	medications	 to	 combat	 CNI-induced	 renal	 vasoconstriction	 are	 calcium	 channel	 blockers	 (CCB’s)	 (Ladefoged	 &	Andersen	 1994;	 Baroletti	 et	 al.	 2003).	 Although	 CCBs	 fall	 into	 two	 major	 classes;	dihydropyridines	and	nondihydropyridines,	 they	both	work	 to	 inhibit	voltage-gated	calcium	 channels	 from	 opening	 and	 preventing	 contraction	 in	 various	 types	 of	contractile	cells.	Given	the	fact	that	in	addition	to	VSMCs,	pericytes	are	also	described	as	smooth	muscle	“like”	cells	since	they	contain	similar	contractile	proteins	(Shepro	&	Morel	1993;	 S.	W.	 Smith	et	al.	 2012)	 therefore	 the	 effect	of	 superfusing	 live	kidney	tissue	with	a	combination	of	CCBs	with	CNIs	was	investigated	to	assess	the	possible	contribution	 of	 calcium	 channel	 regulation	 in	 the	 pericyte-mediated	 contraction	 of	vasa	recta	induced	by	CNIs.			
4.6.1	 Effect	of	diltiazem	on	in	situ	vasa	recta	diameter		Given	 that	 diltiazem	 has	 already	 been	 used	 clinically	 to	 treat	 CNI-induced	hypertension	 and	 also	 used	 to	 investigate	 calcium	 responses	 in	 isolated	 pericyte	experiments	(Kumana	et	al.	2003;	Becker	et	al.	1996;	Ingsathit	et	al.	2006;	Z.	Zhang	et	
al.	2004;	Z.	Zhang	et	al.	2002),	 it	was	reasonable	 to	 investigate	 this	drug	 in	 the	 live	kidney	 slice	 preparation	 to	 explore	 its	 potential	 for	 attenuation	 of	 CNI-mediated	vasoconstriction.		Superfusion	(~700	s)	of	diltiazem	alone	(100	&	400	nM)	resulted	in	no	significant	change	of	vasa	recta	capillary	diameter	(Figure	4.5).	When	a	change	in	diameter	was	observed	at	100	and	400	nM,	it	was	not	significantly	greater	at	pericyte	sites	(1.67	±	0.44%	and	0.86	±	1.56%,	respectively)	compared	to	non-pericyte	sites	(1.94	±	0.83%	and	1.41	±	1.01%,	 respectively	n=10	(9);	P>0.05)	 (Figure	4.5).	Upon	washout,	 vessel	 diameter	 continued	 to	be	 stable	 and	 rarely	dropped	below	96%	of	the	original	baseline	vessel	diameter	after	400	s,	and	up	to	1000	s,	following	washout	of	 diltiazem.	 Although	 diltiazem	 has	 been	 thought	 to	 stick	 to	 perfusion	 lines,	perfusion	 using	wider	 tubing	 and	 slower	 perfusion	 rates	 (personal	 communication	with	Pallone	lab),	no	residue	was	observed	or	seen	to	effect	subsequent	experiments.		
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Figure	4.5	 Diltiazem	 hydrochloride	 attenuates	 the	 CsA	 evoked	








































4.6.3	 Effect	of	diltiazem	on	in	situ	vasa	recta	in	combination	with	FK506	Superfusion	(~700	s)	of	FK506	(1	μM)	and	diltiazem	(100	&	400	nM)	resulted	in	an	attenuation	 of	 FK506-mediated	 vasoconstriction	 of	 vasa	 recta	 capillaries	 when	compared	 to	 FK506	 alone	 (Figure	 4.6).	 Vasoconstriction	 induced	 by	 FK506	 (1	 μM)	and	 diltiazem	 (100	 &	 400	 nM)	 was	 significantly	 reduced	 at	 pericyte	 sites	 (6.22	 ±	1.65%	 and	 3.83	 ±	 1.56%,	 respectively)	 compared	 to	 vasoconstriction	 induced	 by	FK506	 alone	 at	 pericyte	 sites	 (12.85	 ±	 0.85%,	 n=	 10	 (9);	 P<0.01,	 P<0.001,	 (Figure	4.6).	The	FK506	and	diltiazem	evoked	constriction	of	vasa	recta,	at	all	concentrations,	was	reversed	upon	washout,	and	vessel	diameter	returned	to	≥	95%	of	 the	original	baseline	 vessel	 diameter	 after	 400	 s	 following	 washout.	 Vasoconstriction	 at	 non-pericyte	sites	induced	by	the	combination	of	FK506	(1	μM)	and	diltiazem	(100	&	400	nM)	 (6.22	 ±	 1.65%	 and	 3.83	 ±	 1.56%,	 respectively)	 was	 not	 significantly	 greater	compared	 to	vasoconstriction	 induced	by	FK506	alone	at	non-pericyte	sites	 (4.55	±	2.52%	and	3.22	±	1.25%,	respectively	n=10	(9),	(Figure	4.6)).			
	
	
Figure	4.6	 Diltiazem	 hydrochloride	 attenuates	 the	 FK506	 evoked	





















4.7	 The	effect	of	isradipine	in	combination	with	CNIs	on	in	situ	vasa	recta		Given	 that	 CCBs	 are	 grouped	 into	 two	major	 classes,	 and	 each	 class	 having	 subtle	differences	 in	 terms	 of	 specificity,	 for	 example	 dyhydropyridines	 work	 better	 for	cardiac	muscle	 inhibition,	 it	 is	 interesting	 that	both	classes	have	been	used	 to	 treat	CNI-induced	hypertension	(Aparicio	et	al.	2013).	An	important	point	to	mention	is	the	use	of	 nondyhydropyridines	 in	 combination	with	CNI’s	 greatly	 increases	 the	 serum	levels	of	CNIs	 soon	after	 combination	 therapy	 (Åsberg	et	al.	 1999;	Xue	et	al.	 2010).	This	 has	 detrimental	 clinical	 consequences,	 requiring	 further	 therapeutic	 drug	monitoring	 (TDM)	 and	 an	 increased	 strain	 on	 already	weakened	 clinical	 resources	(Ekser	et	al.	2015).	However,	 as	 diltiazem,	 a	 nondyhydropyridine,	 has	 already	 been	 used	 clinically	 to	treat	CNI-induced	hypertension	(Xue	et	al.	2010;	Kumana	et	al.	2003),	it	is	clear	that	combination	 therapy	with	 these	 types	 of	 antihypertensive	 drugs	 are	 efficacious.	 In	addition,	 previous	 results	within	 this	 chapter	 have	 shown	 diltiazem	 to	 inhibit	 CNI-induced	 pericyte	 vasoconstriction.	 Therefore,	 the	 combination	 of	 dyhydropyridines	with	 CNIs	 to	 investigate	 pericyte-mediated	 constriction	 of	 vasa	 recta	 should	 be	investigated,	especially	as	dyhydropyridines	have	been	shown	to	significantly	reduce	CNI	 hypertension	 compared	 to	 angiotensin	 converting	 enzyme	 inhibitors	 (ACEi’s)	(Midtvedt,	Hartmann,	Holdaas,	et	al.	2001;	Midtvedt,	Hartmann,	Foss,	et	al.	2001).			
4.7.1	 Effect	of	isradipine	on	in	situ	vasa	recta	diameter			Superfusion	(~700	s)	of	live	tissue	with	isradipine	alone	(27	&	270	nM)	resulted	in	no	significant	 change	 of	 vasa	 recta	 capillary	 diameter	 (Figure	 4.7).	When	 a	 change	 in	vessel	diameter	was	observed	at	27	and	270	nM,	 it	was	not	 significantly	greater	at	pericyte	 sites	 (1.23	 ±	 0.88%	 and	 2.36	 ±	 1.23%,	 respectively)	 compared	 to	 non-pericyte	 sites	 (0.98	 ±	 0.65%	 and	 0.56	 ±	 0.95%,	 respectively	 n=10	 (9);	 P>0.05),	(Figure	 4.7).	 Upon	 washout,	 vessel	 diameter	 continued	 to	 be	 stable	 and	 rarely	dropped	 below	 95%	 of	 the	 original	 baseline	 vessel	 diameter	 after	 400	 s	 following	washout.				
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Figure	4.7	 Isradipine	 attenuates	 the	 CsA	 evoked	 vasoconstriction	 of	 in	 situ	





































































4.8	 Discussion			The	main	aim	of	 this	 study	was	 to	determine	whether	antihypertensive	medication	impacts	 upon	 the	 previously	 known	 effects	 of	 CNIs	 on	 vasa	 recta	 diameter.		Previously	 established	 experiments	 have	 shown	 pericytes	 are	 key	 in	 mediating	effects	 of	 CNIs	 on	 vasa	 recta	 diameter,	 as	 seen	 in	 chapter	 3.	 Data	 yielded	 here	demonstrates	 that	 certain	antihypertensives	may	also	act	via	pericytes	 to	attenuate	the	CNI-mediated	vasoconstriction	of	vasa	recta	by	pericytes.	Thus	it	is	possible	that	these	antihypertensives	ameliorate	CNI-induced	hypertension.	The	main	 findings	 from	this	 investigation	have	revealed	the	potential	role	pericytes	have	 in	 contribution	 to	 CNI-induced	 hypertension	 through	 reduction	 of	 RMBF	 and	how	 the	 use	 of	 selective	 antihypertensives,	 particularly	 CCBs	 and	 diuretics,	 could	reduce	 the	 risk	 for	 the	 onset	 of	 CNI-induced	 hypertension	 in	 renal	 transplant	patients.					It	is	now	well	established	that	CNIs	lead	to	the	activation	of	the	RAAS,	and	as	a	result,	leads	 to	 a	 rise	 in	 systemic	blood	pressure	 leading	 to	hypertension	due	 to	 local	 and	systemic	vasoconstriction.	The	mechanism	through	which	CNIs	activate	the	RAAS	is	still	debatable	with	CNIs	being	shown	to	activate	RAAS	directly,	through	stimulation	of	 juxtaglomerular	cells	 to	 increase	 the	release	of	 renin	 (Kurtz	et	al.	1988)	but	also	through	 indirect	 activation,	of	which,	 two	mechanisms	have	been	proposed.	Firstly,	researchers	have	shown	that	CNIs	decrease	the	levels	of	circulating	vasodilators,	NO	for	 example,	 and	 simultaneously	 increase	 the	 levels	 of	 vasoconstrictors,	 endothelin	and	 adenosine	 (Ruester	 &	 Wolf	 2006).	 These	 simultaneous	 alterations	 ultimately	result	 in	 increased	 vasoconstriction	 and	 therefore	 increase	 blood	 pressure	 and	associated	 hypertension.	 Secondly,	 it	 has	 been	 suggested	 that	 increased	vasoconstriction	 results	 in	 reduced	 renal	 blood	 flow,	 through	 ANG	 II-mediated	vasoconstriction,	 which	 results	 in	 altered	 hemodynamics	 seen	 with	 CNI	 use.	 This	latter	 mechanism	 increases	 arteriole	 vasoconstriction	 and	 represents	 a	 malicious	circle	of	damage	 through	 increased	renal	vasoconstriction	with	 limited	vasodilation	(Naesens	 et	 al.	 2009).	 This	 can	 be	 seen	 in	 figure	 1.8	 of	 chapter	 1	 (general	introduction).	 In	addition	 to	direct	activation	of	ANG	II,	CsA	use	has	been	shown	to	recruit	 renin	 containing	 cells	 to	 the	 afferent	 arterioles	 (Iijima	 et	 al.	 2000)	 and	interestingly,	also	suggested	to	intensify	ANG	II	vasoconstriction	through	alterations	of	 calcium	 signalling,	 increased	 channel	 sensitivity	 and	 release	 of	 internal	 calcium	
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stores,	in	smooth	muscle	cells	(Lassila	2002).	It	therefore	appears	the	dominant	effect	of	 CNIs	 on	 the	 RAAS	 is	 through	 increased	 vasoconstriction	 via	 increased	 ANG	 II	release	or	augmented	contractile	responses	to	ANG	II.		As	previously	mentioned,	the	use	for	ARBs	and	ACEi’s	for	treatment	of	hypertension	and	reducing	the	progression	of	chronic	kidney	failure	in	the	general	population	has	been	 well	 accepted	 (Krause	 et	 al.	 2011).	 However,	 their	 use	 for	 lowering	hypertension	in	transplant	patients	has	not	been	as	successful	compared	to	their	non-transplant	 counterparts.	 There	 have	 been	 several	 indications	 for	 this	 observation;	ACEi’s	 and	 ARBs	 can	 induce	 a	 decrease	 in	 GFR	 (Curtis	 et	 al.	 1993)	 and	 have	 the	potential	to	mask	any	early	signs	of	acute	rejection,	of	which	a	decrease	in	GFR	being	one	 of	 these	 indications.	 Secondly,	 ACEi’s	 and	 ARBs	 can	 exacerbate	 the	 degree	 of	hyperkalaemia	(Mangray	&	Vella	2011),	a	common	metabolic	abnormality	after	renal	transplant	that	can	be	associated	with	delayed	graft	function	and	CNI	nephrotoxicity	(Palmer	 2002).	 Lastly,	 ACEi’s	 and	 ARBs	 can	 induce	 anaemia	 in	 transplant	 patients	(Vlahakos	et	al.	1991),	exacerbated	with	the	use	of	CsA	(Gaston	et	al.	1994)	and	result	in	 an	 increase	 of	 up	 to	 50%	 chance	 of	 thrombotic	 complications	 (Mangray	&	 Vella	2011).	A	 systematic	 review	 of	 all	 recent	 trials,	 which	 included	 the	 selection	 criteria	 of	antihypertensive	 treatment	 in	 renal	 transplant	 patients,	 has	 been	 performed	 by	Hiremath	 et	 al	 (Hiremath	 et	 al.	 2007).	 The	 review	 focuses	 on	 clinical	 trials,	 which	have	 2	main	 outcomes;	 overall	 kidney	 function	 and	 corresponding	 blood	 pressure.	The	 analysis	 suggested	 that	 ARB	 or	 ACEi	 use	 significantly	 reduced	 GFR	 and	proteinuria	compared	to	non-treated	matched	controls.	Disappointingly,	due	to	 lack	of	 sufficient	 timing	 of	 trials,	 lack	 of	 randomized	 trials	 and	 insufficient	 patient	numbers,	the	review	had	no	outcomes	for	patient	or	graft	survival,	which	ultimately	is	the	end	goal	for	any	transplant	patient.	Given	 that	 the	 protective	 mechanism	 of	 ARBs	 and	 ACEi’s	 involves	 a	 reduction	 in	glomerular	pressure,	 it	 is	disappointing	 to	 suggest	 they	have	 little	 clinically	proven	benefits	with	the	use	of	CNIs,	especially	with	the	known	affects	of	CNIs	and	local	ANG	II	 release	 (Lassila	 2002;	 D.	 B.	 Lee	 1997).	 Nonetheless,	 ARBs	 and	 ACEi’s	 do	 have	beneficial	effects	 for	reduction	of	hypertension	as	can	be	clearly	demonstrated	with	the	wealth	of	literature	surrounding	their	use	(Frishman	2007;	Tziomalos	et	al.	2013;	Lewis	 et	 al.	 1993;	 Duarte	 &	 Cooper-DeHoff	 2010;	 Zachariah	 et	 al.	 1993)	 however	
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when	used	 in	 the	 renal	 transplant	 setting,	 their	 effectiveness	 is	 drastically	 reduced	compared	to	that	of	non-transplant	patients.			Previous	data	by	Crawford	et	al	has	shown	the	considerable	vasoconstrictive	effects	of	ANG	II	on	pericyte-mediated	vasoconstriction	of	vasa	recta	(Crawford	et	al.	2012).	Additionally,	 the	 authors	 have	 also	 shown	 that	 ARBs,	 namely	 losartan,	 completely	abolishes	ANG	II	induced	vasoconstriction	of	DVR	(Crawford	et	al.	2012),	this	in	turn	could	suggest	a	role	for	pericyte	contraction	in	contribution	towards	hypertension	in	response	to	increased	renal	and	systemic	ANG	II	concentrations.	Although	RMBF	may	only	contribute	to	1%	of	the	total	renal	blood	flow	(Cowley	et	al.	1995),	studies	have	shown	 that	 dysregulation	 of	 blood	 flow	 in	 this	 sensitive	 region	 can	 result	 in	 renal	decline	without	changes	in	cortical	blood	flow	being	observed	(Mattson	et	al.	1992).	Therefore,	 dysfunction	 of	 RMBF	may	 have	 a	major	 impact	 on	 long-term	 control	 of	blood	pressure	regulation	and	urine	concentration	capabilities	of	the	kidneys	due	to	dysfunction	of	the	cortical–medullary	countercurrent	gradient.		With	what	 is	known	 in	 the	 literature,	 it	 is	disappointing	 to	note	 the	 results	 seen	 in	this	 chapter	 regarding	 ARBs.	 Losartan	 failed	 to	 significantly	 reduce	 the	 pericyte-mediated	vasoconstriction	of	vasa	recta	induced	by	CNIs.	As	such,	the	results	suggest	CNI-induced	 vasoconstriction	 of	 vasa	 recta	 via	 pericytes	 may	 be	 through	 another	mechanism	 other	 than	 ANG	 II.	 As	mentioned,	 data	 has	 been	 previously	 shown	 the	substantial	vasoconstrictive	effects	ANG	II	has	on	the	live	slice	model	and	how	ARB’s	are	 able	 to	 completely	 abolish	 such	 effects	 (Crawford	 et	 al.	 2012),	 therefore,	 CNI-	meditated	 vasoconstriction	 of	 vasa	 recta	 might	 not	 necessarily	 involve	 direct	activation	 of	 AT1	 receptors	 or	 an	 increase	 in	 local	 concentrations	 of	 ANG	 II.	 The	vasoconstriction	 observed	 could	 stem	 from	 the	 decrease	 of	 vasodilators	 or	 the	increase	 of	 endothelin	 1,	 both	 of	 which	 are	 seen	 in	 CNI-induced	 hypertension	(Naesens	et	al.	2009),	importantly,	both	these	mechanisms	have	been	shown	to	alter	vasa	 recta	 diameter	 in	 the	 live	 slice	model	 (Crawford	 et	 al.	 2012).	 Therefore,	 it	 is	reasonable	 to	 suggest	 CNI-induced	 vasoconstriction	 of	 vasa	 recta	 is	 not	 exclusively	dependent	on	ANG	II	or	the	RAAS.	In	addition,	the	use	of	ARBs	and	ACEi’s	within	the	transplant	 setting	 has	 not	 been	 shown	 to	 have	 significant	 benefits	 in	 reducing	 CNI	induced	 hypertension	 (Naesens	 et	 al.	 2009),	 further	 highlighting	 their	 lack	 of	effectiveness	 for	 prevention	 of	 hypertension.	 Regardless	 of	 which	 vasoconstrictor	agents	are	involved,	evidence	here	indicates	a	clear	role	for	pericytes	in	CNI-mediated	vasoconstriction	of	vasa	recta	and	in	turn,	reduction	of	medullary	blood	flow.	
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	An	interesting	observation	from	this	chapter	was	the	hydrochlorothiazide-mediated	reduction	in	CNI-mediated	vasoconstriction	of	vasa	recta	specifically	via	pericytes.		The	initial	rational	for	this	experiment	was	due	to	the	recent	works	of	Hoorn	et	al	and	Melnikov	et	al	(Hoorn	et	al.	2011;	Melnikov	et	al.	2011)	who	demonstrated	that	CNIs	induced	 a	 form	 of	 salt-sensitive	 hypertension	 through	 non	 vascular	 mechanisms.	After	 treatment	with	 CNIs,	 the	 sodium-chloride-cotransporter,	 a	major	 sodium	 and	chloride	reabsorbing	cotransporter	in	the	distal	convoluted	tubule,	was	significantly	upregulated.	 This	 in	 turn	 suggests	 that	 CNIs	 have	 a	 salt-retaining	 effect	 and	 may	regulate	NCC	function.	The	role	of	NCC	in	hypertension	was	further	highlighted	with	the	use	of	a	NCC	knock	out	mouse,	which	failed	to	develop	hypertension	after	being	treated	 with	 CNIs	 (Hoorn	 et	 al.	 2011).	 This	 further	 highlights	 a	 role	 for	 NCC	 and	sodium	retention	in	development	of	CNI-induced	hypertension.		Hydrochlorothiazide	 is	 a	 thiazide	diuretic	used	 to	 treat	hypertension	and	edema.	 It	works	 by	 inhibiting	 sodium	 reabsorption	 through	 the	NCC	 in	 the	 distal	 convoluted	tubule,	therefore	inducing	natruesis	and	subsequent	water	loss	(A.	D.	A.	Hughes	2004;	Duarte	 &	 Cooper-DeHoff	 2010).	 Given	 that	 CNIs	 are	 able	 to	 acutely	 increase	expression	of	the	NCC	(Blankenstein	et	al.	2014)	and	hydrochlorothiazide	is	used	to	inhibit	NCC-mediated	sodium	retention,	if	 	used	together,	this	drug	combination	can	provide	an	inexpensive	and	more	importantly,	safe	regime	to	reduce	the	risk	of	CNI-induced	hypertension	(Hoorn	et	al.	2011).	Despite	 this	 possible	mechanism	 for	 HCT	 in	 reducing	 CNI-induced	 hypertension,	 it	does	 not	 explain	 the	 observation	 that	 hydrochlorothiazide	 inhibited	 CNI-induced	vasoconstriction	 of	 vasa	 recta	 via	 pericytes	 in	 live	 tissue	 slices.	 Interestingly,	thiazides	 have	 been	 shown	 to	 have	 direct	 vasodilatory	 effects	 (Duarte	 &	 Cooper-DeHoff	 2010)	which	 could	 be	 the	mechanism	 for	 the	 above	 observation.	 This	 is	 in	addition	 to	 HCT	 also	 being	 found	 to	 attenuate	 vasoconstriction	 of	 known	vasoconstrictive	 agents,	 ANG	 II	 and	 noradrelinnie	 (Colas	 et	 al.	 2000)	 in	 an	endothelium	NO	derived	manner	(Colas	et	al.	2000).	Of	 particular	 interest,	 Zhu	 et	 al	 revealed	 that	 thiazides	 inhibited	 ANG	 II-induced	vasoconstriction	 of	 aorta	 through	 calcium	 desensitization	 of	 VSMC’s,	 while	 still	observing	the	same	increase	of	calcium,	mediated	by	inhibition	of	the	Rho-Rho	kinase	pathway	 (Zhu	 et	 al.	 2005).	 Under	 normal	 conditions,	 Rho	 and	 Rho	 kinase	 are	responsible	 in	 phosphorylation	 of	myosin	 light	 chain	 (MLC),	 resulting	 in	 increased	
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myosin	 II	 ATPase	 activity	 and	 muscle	 contraction	 (Fukata	 et	 al.	 2001)	 but	 also	inhibiting	MLC	phosphatase,	 leading	 to	 increased	MLC	phosphorylation	 and	muscle	contraction	(Fukata	et	al.	2001).	Edwards	et	al	demonstrated	that	use	of	MLC	kinase	inhibitors	were	highly	 effective	 in	 reducing	 calcium	dependent	 chloride	 currents	 in	DVR	pericytes	 (Vates	et	al.	 2010).	However,	 hydrochlorothiazide	 also	 increases	 the	reabsorption	of	calcium	into	cells	(Lajeunesse	et	al.	1994),	which	can	open	calcium-activated	chloride	 (CLCa)	channels	 (Hamilton	et	al.	2010).	This,	 in	combination	with	high	intracellular	chloride	concentrations	of	pericytes	enables	chloride	to	exit	the	cell	producing	 increased	 depolarization	 and	 increased	 activation	 of	 voltage	 operated	calcium	 channels	 (VOCC)	 (Kawamura	 et	 al.	 2002),	 VOCCs	 being	 the	 main	 channel	responsible	for	muscle	contractions	.	Taken	together,	along	with	data	produced	here,	it	 could	 be	 speculated	 that	 the	 use	 of	 hydrochlorothiazide	 on	 the	 live	 slice	 model	inhibits	 Rho	 and	 Rho	 kinase	 activity,	 in	 turn,	 decreases	 MLC	 phosphorylation	 and	attenuating	 the	contractile	effects	of	CNIs	acting	 through	pericytes.	Although	only	a	speculation,	 the	preliminary	data	presented	here	warrants	 the	 further	 investigation	of	 diuretics	 and	 their	 interaction	 with	 CNIs	 to	 elude	 additional	 pathways	 for	 the	prevention	of	CNI-induced	hypertension.			The	 other	 group	 of	 antihypertensives	 used	 in	 this	 chapter	 belong	 to	 the	 class	 of	calcium	 channel	 blockers	 (CBBs).	 They	 work	 by	 inhibiting	 the	 opening	 of	 calcium	channels,	 and	 depending	 on	which	 type	 of	 Ca2+	 channels	 are	 expressed,	 inhibit	 the	contraction	 of	 specific	 muscle	 fibres.	 Most	 CBBs	 block	 L-type	 voltage	 operated	calcium	channels	 (VOCC),	which	are	 responsible	 for	 contraction	of	 skeletal,	 smooth	and	 cardiac	 muscle	 through	 membrane	 depolarisation	 (Hamilton	 et	 al.	 2010).	Although	 CCBs	 can	 be	 classed	 as	 dihydropyridines	 and	 nondihydropyridines,	 their	mechanism	 of	 actions	 are	 similar	 in	 the	 end	 point	 by	 inhibiting	 calcium	 ion	 flow.	Their	 affinity	 for	 particular	 muscle	 types	 can	 differ	 drastically,	 with	 non-dihydropyridines	having	higher	affinity	for	cardiac	muscle	(Mangray	&	Vella	2011).	The	 results	 from	 this	 chapter	 indicated	 that	 diltiazem	 and	 isradipine,	 a	nondihydropyridine	 and	 dihydropyridine,	 respectively,	 are	 able	 to	 significantly	reduce	 pericyte-mediated	 vasoconstriction	 of	 vasa	 recta	 induced	 by	 CNIs,	 with	diltiazem	 able	 to	 attenuate	 both	 CsA	 and	 FK506-mediated	 vasoconstriction	 to	 a	greater	degree	compared	to	that	of	isradipine.		
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The	classic	randomized	trial	carried	out	by	Midvedt	et	al	highlighted	the	use	of	CCBs	against	ACEi’s	in	transplant	patients	for	the	protection	of	graft	function	and	improved	GFR	(Midtvedt	&	Hartmann	2002a).	Unfortunately	the	trial	failed	to	measure	GFR	as	an	outcome	and	also	showed	no	significant	improvement	in	blood	pressure	when	the	two	groups	were	compared	(Midtvedt,	Hartmann,	Foss,	et	al.	2001).	Nonetheless,	CCBs	are	typically	thought	as	first-line	medications	for	the	treatment	of	hypertension	 after	 renal	 transplant	 (Mangray	 &	 Vella	 2011)	 and	 a	 Meta	 analysis	carried	out	some	20	years	ago	investigated	the	use	of	CCBs	in	combination	with	CNIs	for	 the	 protection	 of	 long-term	 kidney	 grafts	 (Ladefoged	 &	 Andersen	 1994).	 The	published	results	were	conflicting,	with	the	randomised	open	studies	 involving	CCB	treatment	 having	 reduced	 rates	 of	 delayed	 graft	 function	 but	 no	 effect	 on	 rates	 of	rejection	and	graft	survival,	 in	addition	to	no	significant	evidence	 in	 improved	graft	function	over	time.	 Interestingly,	blood	pressure	was	reduced	 in	most	cases	treated	with	 CCBs,	 although	 not	 considered	 statically	 significant	 (Ladefoged	 &	 Andersen	1994)	 and	 could	 originate	 from	 the	 reduced	 dosage	 of	 CNIs	 needed	 for	immunosuppression	while	on	CCBs	due	to	pharmacokinetic	 interactions	(Ladefoged	&	Andersen	1994).	How	CCBs	are	able	to	inhibit	CNI-induced	pericyte	mediated	vasoconstriction	of	vasa	recta	 is	 still	 unknown,	 however	 it	 can	 be	 suggested	 this	 mechanism	 is	 through	blocking	of	VOCCs.	Zhang	et	al	have	shown	constriction	of	descending	vasa	recta	via	pericytes	 is	mediated	 by	 voltage	 gated	 calcium	 entry	 (Z.	 Zhang	 et	al.	 2002)	 and	 as	such	their	results	indicate	that	pericyte	contraction	is	stimulated	through	opening	of	VOCCs,	depolarisation	of	the	membrane,	and	contraction	of	pericytes	which	would	fit	with	the	observations	that	CCBs	attenuate	CNI-mediated	vasoconstriction	 in	studies	demonstrated	 here.	 The	 same	 group	 of	 authors	 further	 highlighted	 evidence	 of	voltage	 operated	 calcium	 entry	 into	 vasa	 recta	 with	 the	 use	 of	 the	 L-type	 channel	blocker,	 diltiazem,	 showing	 reduced	 vasoconstriction	 when	 treated	 with	 a	 high	potassium	saline	solution	(Z.	Zhang	et	al.	2002).	Given	that	CNIs	have	been	shown	to	increase	intracellular	calcium	signalling	in	contractile	myocytes	(Frapier	et	al.	2001),	it	 is	 likely	 that	 they	 also	 increase	 calcium	 levels	 in	 renal	 pericytes	 to	 induce	 DVR	vasoconstriction.	Delineating	 this	 possible	mechanism	 could	prove	 to	 be	 a	 valuable	insight	 into	 the	 pathways	 of	 pericyte-mediated	 contraction	 and	 further	 calcium	imaging	studies	may	facilitate	a	better	understanding	of	the	mechanisms	involved.	
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Data	presented	here,	along	with	data	presented	by	Zhang	et	al	(Z.	Zhang	et	al.	2002),	suggests	 a	 role	 for	 calcium	 entry	 via	 VOCCs	 and	 the	 subsequent	 constriction	 of	pericytes	in	CNI-induced	pericyte	constriction	of	vasa	recta.		The	 data	 also	 suggests	 both	 types	 of	 CCBs	 are	 able	 to	 inhibit	 CNI-induced	 pericyte	vasoconstriction,	 which	 is	 clinically	 important	 when	 considering	 pharmacokinetic	interactions	 of	 CCB’s	 and	 CNIs.	 Nondihydropyridines	 are	 potent	 inhibitors	 of	 CYP	P450	C3A4	enzymes,	which	 if	used	 in	conjunction	with	CNIs,	cause	plasma	levels	of	CNIs	 to	 increase	 significantly	 shortly	 after	 administration	 (Kovarik	 et	 al.	 2005).	Therefore,	ensuring	a	careful	choice	of	CCB,	to	be	used	in	conjunction	with	CNIs	may	help	 to	 reduce	pericyte-mediated	 constriction	of	 vasa	 recta	and	 reduce	 risk	of	CNI-induced	hypertension.		Following	personal	communication	with	the	Burdyga	lab,	it	was	suggested	that	a	high	K+	 depolarisation	 experiment	 following	 application	 of	 CNI’s	 and	 either	 CCB,	particularly	 isradipine,	 should	 be	 performed	 to	 clearly	 identify	 the	 washable	preparation	of	CCB’s	in	PSS.	It	has	been	suggested	that	CCB’s	are	particularly	“sticky”	to	 inorganic	 polypropylene	 tubing	 and	 therefore	 their	 inhibitory	 actions	 on	 Ca2+	channels	 can	 last	 much	 longer	 than	 assumed.	 However,	 given	 personal	communication	with	the	Pallone	lab	and	ability	of	ANG-II	to	induce	vasoconstriction	after	 CCB	 and	 CNI	 washout,	 although	 ANG-II	 induced	 vasoconstriction	 is	 not	 from	direct	membrane	depolarisation,	 the	 ability	 of	 Ca2+	washout	 should	be	 investigated	further.	 As	 previously	 shown	 by	 the	 Pallone	 lab,	 high	 K+	bath	 solution	was	 able	 to	induce	 isolated	 perfused	 DVR	 vasoconstriction,	 through	 direct	 pericyte	 membrane	depolarisation	(Z.	Zhang	et	al.	2002)	and	 inhibited	with	 the	 incubation	of	diltiazem.	Although	 not	 demonstrated	 in	 their	 paper	 (Z.	 Zhang	 et	 al.	 2002),	 the	 group	 have	informed	our	lab	that	the	depolarisation	was	repeatable	after	diltiazem	washout.	The	same	experimental	approach	in	the	presence	of	CNI’s	would	be	able	to	clearly	identify	a	possible	mode	of	action	of	CNI’s	on	pericyte	and	EC	membrane	depolarization	and	a	molecular	pathway	 for	CNI-induced	pericyte	vasoconstriction.	This	could	be	 further	investigated	 with	 the	 use	 of	 fluorescent	 probes	 and	 Ca2+	 imaging	 techniques	 to	identify	 a	 possible	 novel	 mechanism	 of	 CNI-induced	 vasoconstriction	 and	 help	ascertain	therapeutic	strategies	 for	prevention	of	RMBF	dysfunction	with	the	use	of	CNI’s.					 	
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5.	 Perfusion	 of	 in	 situ	 vasa	 recta	 for	 delineating	 CNI	
Nephrotoxicity		
	
5.1	 Introduction		The	live	kidney	slice	model,	first	described	by	Crawford	et	al	(Crawford	et	al.	2012),	gave	a	novel	 approach	 for	 investigating	 the	 role	of	 renal	pericytes	 in	 	physiological	settings.	Importantly,	the	initial	studies	revealed	the	importance	of	pericyte-mediated	tubular	vascular	crosstalk	between	vascular	and	tubular	sections	of	the	nephron.	This	has	been	further	highlighted	by	other	groups	(O'Connor	&	Cowley	2012;	Dickhout	et	
al.	2002;	Tasnim	&	Zink	2012)	and	emphasises	the	role	of	pericytes	in	the	regulation	and	coordination	of	tubular	and	vascular	function	within	the	medulla.	Conversely,	it	is	near	 impossible	 to	 understand	 the	 in	 vivo	 setting	 of	 the	 medulla	 due	 to	 its	inaccessibility.	With	the	development	of	the	in	situ	live	slice	model	by	Crawford	et	al	(Crawford	et	al.	2012),	 the	 role	of	pericytes	 in	control	of	vasa	 recta	diameter	while	being	 in	 constant	 contact	 and	 communication	 with	 surrounding	 tissue	 enabled	 a	better	understanding	of	 the	molecular	and	cellular	events	occurring	physiologically.	Nonetheless,	the	live	slice	model	lacks	single	vessel	perfusion	and	in	turn,	the	entire	tissue	 is	 subjected	 to	 drug	 insult	 via	 superfusion.	 This	 would	 not	 be	 seen	physiologically	 or	 in	 vivo	 and	 only	 drug	 exposure	 via	 the	 blood	 stream	would	 be	expected.	With	this	in	mind,	the	aim	of	this	chapter	was	to	develop	a	model	for	single	vessel	 perfusion	 in	 the	 live	 kidney	 slice	 for	 investigating	 the	 cellular	 mechanisms	involved	when	vasoactive	agents	and	CNIs	where	luminally	perfused	in	vasa	recta.			
5.1.2	 Initial	pericyte	studies		Pallone	 and	 colleagues	 carried	 out	 much	 of	 the	 early	 work	 characterising	 renal	pericytes	and	 their	 role	of	blood	 flow	regulation	(Pallone	et	al.	1994;	Pallone	1994;	Pallone	 1991).	 The	 initial	 observations	 that	 pericytes	 could	 contract	 under	 the	influence	of	certain	endogenous	vasoactive	mediators	led	to	the	notion	that	pericytes	are	 responsible	 for	 regulating	medullary	 blood	 flow	 (MBF)	 through	 control	 of	 vasa	recta	diameter	(Pallone	&	Silldorff	2001).		The	experiments	carried	out	by	the	Pallone	laboratory	included	the	use	of	the	isolated	perfused	DVR	technique.	This	involves	the	removal	 of	 medulla	 segments	 from	 an	 intact	 kidney,	 microdissection	 of	 DVR	 from	medulla	 strips,	 complete	 removal	 of	 any	 surrounding	 tissue	 (intact	 DVR	 with	
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pericytes	 attached)	 and	 superficially	 “gluing”	 the	 vessel	 to	 a	 submerged	 perfusion	bath	(Pallone	et	al.	1994)	as	seen	in	figure	5.0.	To	carry	out	perfusion,	 they	adapted	a	 technique	used	 for	 isolated	tubule	perfusion	first	described	by	Burg	(Burg	1972).	A	concentric	pipette	arrangement	was	set	up	(a	single	perfusion	pipette	within	a	larger	holding	pipette)	to	allow	the	sealing	of	single	DVR	(within	 the	holding	pipette)	and	constant	perfusion	(via	 the	perfusion	pipette)	(Pallone	1994).	At	the	opposite	end	of	the	vessel,	a	collecting	pipette	was	situated	and	researchers	were	able	 to	 collect	perfused	 liquid	or	block	 flow	with	an	adapted	seal	(Pallone	et	al.	1994;	Sendeski	et	al.	2012).	The	concentric	pipette	system	can	be	seen	in	Figure	5.0.		
	








The	obvious	advantage	of	 the	 isolated	DVR	technique	was	that	 for	 the	 first	 time,	an	understanding	of	the	inner	renal	medulla	microcirculation	was	able	to	be	visualised,	in	 real	 time,	 and	 not	 through	 computer	 modelling	 or	 laser	 Doppler	 recordings	 of	changes	 in	 regional	 flow.	As	 previously	mentioned,	 the	 inner	medulla	 is	 practically	inaccessible	in	vivo,	therefore,	in	vitro	experiments	are	currently	the	only	dependable	way	for	visualisation	and	relatively	accurate	interpretation	of	its	physiology	(Pallone,	Z.	Zhang,	et	al.	2003).	The	main	disadvantage	of	the	isolated	DVR	technique	is	that	the	experimental	 preparation	 is	 void	 of	 any	 surrounding	 architecture	 that	 would	normally	be	found	in	vivo.	For	example,	the	DVR	is	stripped	of	any	supporting	tissue	like	 interstitial	 cells	 but	 also	 completely	 removed	 from	 surrounding	 tubules	 and	additional	vasa	recta.		Given	 that	 it	 is	 now	 known	 pericytes	 are	 able	 to	 communicate	 with	 other	neighbouring	 pericytes	 and	 cell	 types	 (Q.	 Zhang	 et	 al.	 2006;	 Z.	 Zhang	 et	 al.	 2014;	Burdyga	 &	 Borysova	 2014;	 Özen	 et	 al.	 2014),	 but	 also	 respond	 to	 stimuli	 from	supporting	 structures	 and	 tubules	 (Crawford	 et	 al.	 2011;	 Crawford	 et	 al.	 2012;	Silldorff	 &	 Pallone	 2001;	 O'Connor	 &	 Cowley	 2012),	 complete	 removal	 of	 the	surrounding	structures	found	in	vivo	means	the	model	does	not	ideally	replicate	the	
in	vivo	setting.			An	 example	 for	 cross	 communication	 has	 been	 shown	 in	 a	 study	 carried	 out	 by	Dickhout	et	al	who	demonstrated	a	 role	 for	NO	production	 in	 tubules	being	able	 to	impair	 ANG	 II-mediated	 vasoconstriction	 of	 vasa	 recta	 (Dickhout	 et	al.	 2002).	 This	has	highlighted	a	role	for	pericytes	acting	as	mediators	of	tubular	vascular	cross-talk	and	 possibly	 responsible	 for	 pathological	 conditions	 such	 as	 ischemia	 reperfusion	injury,	previously	thought	to	have	no	identified	single	cause	(Yamagishi	&	Imaizumi	2005;	Dalkara	et	al.	2011;	Tasnim	&	Zink	2012).	CNI	nephrotoxicity	similarly	has	no	single	 identified	cause	and	could	provide	a	novel	 role	 for	pericytes	as	mediators	or	augmenters	of	the	initial	insult	for	nephrotoxicity.			
5.1.3	 Tubular-vascular	cross-talk	Within	 the	medulla,	 tubular	 and	vascular	 structures	often	 run	 in	parallel	with	 each	other,	suggesting	there	could	be	potential	for	communication	between	arrangements,	as	seen	in	figure	5.1.	It	has	been	suggested	that	pericytes	act	as	cellular	messengers	between	tubules	and	vessels	in	response	to	release	of	local	mediators	and	are	able	to	respond	 to	 endogenous	 stimuli	 released	 from	both	 structures	 to	 inform	 function	of	
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Figure	5.1	 Schematic	 diagram	 showing	 possible	 mechanisms	 involved	 in	





5.1.4	 Experimental	model	advances			As	 previously	 stated,	 the	 isolated	 DVR	 technique	 was	 at	 the	 forefront	 of	 renal	research	when	 it	 first	 characterised	 the	role	of	pericytes	 in	regulation	of	vasa	recta	diameter	and	subsequently	MBF	(Pallone	et	al.	1994).	However,	 some	twenty	years	have	 gone	 by	 since	 its	 first	 publication	 and	 the	 technique	 is	 still	 used	 to	 this	 day,	confirming	its	influential	role	in	the	understanding	of	pericyte	physiology.		Although	modifications	have	made	the	technique	more	advanced,	with	simultaneous	fluorescence	imaging	and	patch	clamp	recordings	of	pericytes	(Sendeski	et	al.	2013;	Sendeski	 et	 al.	 2012;	 Q.	 Zhang	 et	 al.	 2006),	 the	 fundamental	 experimental	 setup	remains	the	same,	i.e.	isolation	of	DVR	from	supporting	structures.					It	is	clear	the	role	for	surrounding	tissues	in	understanding	renal	pericyte	physiology	is	 becoming	 increasingly	 significant,	 therefore	 an	 experimental	 model	 with	 intact	surrounding	tissue	would	be	advantageous.			The	live	kidney	slice	model,	first	established	by	Crawford	et	al	(Crawford	et	al.	2012),	is	a	novel	model	for	investigating	in	situ	renal	pericytes	and	their	contribution	to	vasa	recta	vasoconstriction	under	certain	pathological	conditions.		Unlike	in	vitro	isolated	DVR,	the	live	slice	model	enables	complete	in	situ	tissue	to	be	investigated	 by	 taking	 transverse	 sections	 of	 a	 whole	 “live”	 kidney	 to	 leave	 all	surrounding	and	supporting	 structures	 intact.	The	obvious	advantage	of	 this	model	over	 the	 isolated	 DVR	 is	 that	 mechanisms	 and	 pathways	 involved	 in	 vascular	 and	tubular	 physiology	 can	 be	 investigated	 together,	 and	 even	 in	 combination	 through	vascular	and	tubular	stimulation	(Crawford	et	al.	2013).	This	model	has	been	shown	to	 highlight	 the	 importance	 of	 tubular-vascular	 cross-talk	 with	 relation	 to	 tubular	injury	and	disease	(Crawford	et	al.	2011;	Crawford	et	al.	2013).	Although	the	kidney	slice	model	has	been	beneficial	in	our	understanding	of	pericytes	in	particular	disease	settings,	 nephrotoxicity	 for	 example	 (Peppiatt-Wildman	 et	 al.	 2013,	 unpublished	data),	the	central	disadvantage	of	the	model	is	the	lack	of	perfusion	within	vascular	or	tubular	 structures.	 Although	 technically	 challenging,	 perfusion	 of	 structures	within	the	 slice	 would	 offer	 a	 more	 accurate	 physiological	 setting	 to	 assess	 intraluminal-signalling	pathways	involved	in	pericyte	regulation	of	vasa	recta.				Recent	experiments	by	O’Connor	et	al	 have	 tried	 to	overcome	 the	 lack	of	perfusion	within	vascular	or	tubular	structures	 in	their	own	experimental	model	(O'Connor	&	Cowley	2012).		Similar	to	isolated	DVR,	their	model	encompasses	isolation	of	medulla	
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strips	 consisting	 of	 vasa	 recta	 and	 adjacent	 tubules.	 They	 are	 then	 able	 to	 perfuse	vessels	while	having	tubular	structures	intact,	and	in	close	proximity.		The	model	has	highlighted,	 again,	 the	 role	 of	 tubular	 vascular	 cross-talk	 for	 pericyte	 regulation	 of	vasa	 recta	 diameter	 under	 pathological	 conditions	 (O'Connor	&	 Cowley	 2012),	 and	provides	a	novel	methodology	for	investigations	into	renal	medulla	physiology.				However,	 their	 model	 is	 similar	 to	 the	 isolated	 DVR	 as	 it	 requires	 stripping	 away	segments	of	medulla	to	find	specific	areas	of	in	vitro	vasa	recta	and	adjacent	tubules	(O'Connor	 &	 Cowley	 2012).	 This	 not	 only	 subjects	 the	 tissue	 to	 vigorous	 physical	damage,	 but	 also	 increases	 the	 risk	 of	 molecular	 damage	 through	 ROS	 generation,	release	of	ATP	and	NO	due	to	shear	stress	and	cell	apoptosis.		Given	 that	 there	 is	 no	 currently	 known	model	 that	 encompasses	 both	 intact	 in	situ	tissue	(vasa	recta	and	surrounding	structures)	and	 luminal	perfusion	of	vascular	or	tubular	 structures,	 is	 the	 already	 acknowledged	 live	 slice	 model	 an	 experimental	technique	that	could	be	enhanced	via	luminal	perfusion	to	further	our	understanding	of	pericyte	physiology?			The	aim	of	this	study	was	to	establish	the	feasibility	of	in	situ	vasa	recta	perfusion	in	the	live	kidney	slice	model	to	aid	the	investigation	of	the	role	pericytes	in	regulation	of	vasa	 recta	diameter	when	vasa	 recta	are	perfused	with	CNIs	under	physiological	conditions	and	pressures.															
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5.2	 Methods			Intact	 live	kidney	 slices	were	obtained	as	described	 in	 chapter	2:	General	Methods.	Live	kidney	slices	were	continually	superfused	with	95%	O2	/	CO2	PSS	and	individual	vasa	 recta	perfused.	Luminal	perfusion	of	 vasa	 recta	 is	 also	described	 in	 chapter	2:	General	 Methods.	 In	 brief,	 in	 experiments	 to	 determine	 the	 effect	 on	 luminal	perfusion	 on	 vasa	 recta	 diameter,	 a	 controlled	 perfusion	 experiment	with	 PSS	was	carried	out	to	determine	the	effect	of	luminal	perfusion	alone	on	vasa	recta	diameter.	The	 perfusion	 was	 carried	 out	 at	 a	 set	 pressure,	 25	 mmHg	 via	 attached	sphygmomanometer,	 see	 general	 methods	 for	 details.	 Following	 initial	 control	experiments,	 individual	 vasa	 recta	 were	 perfused	 with	 a	 range	 of	 vasoactive	substances	known	to	affect	vasa	recta	diameter	when	superfused,	ANG	II,	ET-1,	PGE2	and	 NO.	 Similar	 experiments	 were	 performed	with	 cyclosporine	 A,	 tacrolimus	 and	rapamycin	 to	 investigate	 their	 action	 on	 vasa	 recta	 once	 perfused	 luminally	 and	compared	 to	 the	effects	of	 superfusion.	Video	recording	analysis	of	 changes	 in	vasa	recta	diameter	has	been	described	previously	in	chapter	2:	General	Methods.		In	brief,	each	experiment	was	analysed	using	the	free	public	domain	software	IMAGE	J	(NIH;	http://rsb.info.nih.gov).	 For	 each	 perfusion	 experiment,	 a	 pericyte	 site	 and	 non-pericyte	site	were	identified	on	a	single	vasa	recta	capillary	acting	as	a	paired	control.	The	 diameter	 of	 the	 vasa	 recta	 at	 both	 of	 these	 locations	was	measured	 every	 five	frames	for	the	duration	of	the	experiment.	An	average	of	the	first	five	measurements	was	 taken	 to	 represent	 the	 resting	 perfusion	 diameter	 value	 (i.e.	 100%)	 for	 the	selected	pericyte	 and	non-pericyte	 sites.	 All	 subsequent	 diameter	measurements	 at	both	 sites	 were	 calculated	 as	 a	 percentage	 change	 of	 the	 corresponding	 resting	diameter	value.			
5.2.1	 Statistics		All	data	are	presented	as	mean	values	±	SEM;	n	numbers	are	displayed	as	number	of	kidney	 slices,	 and	 where	 appropriate,	 (number	 of	 animals).	 All	 experiments	 were	performed	in	at	least	six	different	animals.	Statistical	assessment	was	performed	with	GraphPad	Prism		(v5.0f;	GraphPad	software,	San	Diego,	CA,	USA).	When	two	groups	were	compared,	a	Student’s	t-test	(two-tailed,	paired	or	unpaired	where	appropriate)	was	used.	A	value	of	P	<	0.05	was	considered	significant.			
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5.3	 Results	
5.3	 Determining	the	effect	luminal	perfusion	pressure	has	on	flow	rate		After	initial	practicality	studies	to	investigate	vessel	stability	and	feasibility	of	single	vessel	perfusion	via	observational	studies	of	perfused	PSS	alone	in	single	vasa	recta,	it	was	apparent	that	 in	situ	vasa	recta	were	able	to	be	luminally	perfused	for	constant	periods	 of	 time	 at	 set	 pressures.	 Given	 the	 fact	 that	 there	 are	 only	 a	 handful	 of	laboratories	 that	still	carry	out	 isolated	perfused	DVR	experiments,	 the	protocol	 for	perfusing	in	situ	vessels	was	adapted	from	this	methodology	(Burg	1972;	Z.	Zhang	&	Pallone	2004;	K.	K.	Evans	et	al.	2015).	Interestingly,	 out	 of	 the	 laboratories	 that	 still	 perform	 the	 isolated	 DVR	 technique,	they	 vary	with	 regards	 to	 their	 vessel	 perfusion	 pressure	 and	 flow	 (Pallone	 1994;	O'Connor	&	Cowley	2012;	Sendeski	et	al.	2012).	 	Though	there	 is	no	set	method	for	determining	 DVR	 flow	 rate	 or	 pressure	 in	 vivo,	 it	 has	 been	 suggested	 that	 the	physiological	 pressure	 is	 approximately	 25	 mmHg	 (Z.	 Zhang	 &	 Pallone	 2004;	Crawford	et	al.	2012)	under	normal	conditions.		The	 labs	 of	 Pallone	 and	 colleagues	 (Pallone	 1991;	 Pallone	 et	 al.	 1994;	 Z.	 Zhang	 &	Pallone	 2004)	 and	 Sendeski	 et	al	 (Sendeski	 et	al.	 2013;	 Sendeski	 et	al.	 2012)	 have	used	 this	 approximation	 of	 pressure	 to	 conduct	 most	 of	 their	 isolated	 DVR	experiments.	However,	Cowely	et	al	(O'Connor	&	Cowley	2012)	have	used	a	different	measurement	 and	 instead	 of	 measuring	 luminal	 pressure,	 they	 have	 taken	 into	account	 luminal	 flow	 rate	 of	 DVR.	 Again,	 there	 is	 no	 accurate	way	 for	 determining	absolute	luminal	flow	rate	of	vasa	recta	in	vivo,	however	it	has	been	suggested	that	it	ranges	from	5-20	nl/min	(O'Connor	&	Cowley	2012;	Holliger	et	al.	1983;	Pallone	et	al.	1994).	Interestingly,	Pallone	et	al	who	carried	out	much	of	the	very	first	isolated	DVR	research,	has	carried	out	experiments	with	flow	rate	instead	of	pressure	(Pallone	et	
al.	 1994),	 which	 highlights	 the	 acknowledged	 interchangeable	 use	 of	 both	 these	parameters	for	experimentation.	The	use	of	both	measurements	most	probably	stems	from	 the	 perfusion	 model	 that	 which	 the	 isolated	 DVR	 was	 adapted	 (the	 isolated	perfused	tubule)	which	commonly	uses	flow	rate	instead	of	pressure,	as	tubular	flow	is	more	readily	measured	in	vivo	(Burg	1972)	via	micropuncture	experiments.		Therefore,	 the	 aim	 of	 this	 initial	 study	was	 to	 determine	 the	 relationship	 between	luminal	 perfusion	 pressures	 and	 flow	 rates	 of	 in	 situ	 vasa	 recta.	 In	 addition,	
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investigate	 the	 effects	 of	 altering	 intraluminal	 flow	 and/or	 pressure	 on	 pericyte	contractility.		To	 ascertain	 what	 relationship	 pressure	 had	 with	 flow,	 a	 reliable	 method	 for	 the	measurement	of	 flow	rate	 in	perfused	vasa	recta	was	required.	To	establish	this,	an	approach	published	by	O’Connor	et	al	(O'Connor	&	Cowley	2012)	was	adapted	for	use	in	 the	 live	 slice	 model.	 A	 pre-pulled	 glass	 capillary	 tube,	 see	 general	 methods	 for	specific	details,	was	filled	with	1	μl	 filtered	PSS	previously	bubbled	in	95%	O2	/	CO2		(through	0.20	μM	sterile	syringe	filter,	Cole-Parmer,	London,	UK)	and	placed	within	a	capillary	 tube	 holder	 of	 a	 manual	 micromanipulator	 (LBM-7	 manual	 manipulator,	Scientifica,	Surrey,	UK).	After	vasa	recta	puncture,	a	set	pressure	was	applied	using	an	attached	sphygmomanometer.	Perfusion	of	vasa	recta	continued	until	no	further	PSS	was	present	 in	 the	pipette.	 The	 total	 volume	of	PSS	 (1	μl)	was	divided	by	 the	 time	taken	 for	 the	 perfusion	 to	 finish,	 to	 establish	 an	 approximate	 flow	 rate	 within	perfused	vasa	recta.			To	determine	flow	rate	at	a	range	of	pressures,	in	situ	vasa	recta	were	perfused	at	a	range	of	pressures,	0,	20,	25,	40,	60	80	and	100	mmHg.	The	time	taken	for	1	μl	of	PSS	to	 clear	 the	 pipette	 at	 each	 pressure	 was	 used	 to	 approximate	 flow	 rate	 and	 was	plotted	against	its	corresponding	pressure,	as	seen	in	figure	5.2.	Perfusion	 of	 vasa	 recta	 at	 20	 mmHg	 resulted	 in	 a	 perfusion	 rate	 of	 18.325	 ±	 2.8	nl/min	 (n=6	 (6)),	 figure	 5.2.	 Perfusion	 pressures	 of	 25,	 40,	 60,	 80	 and	 100	mmHg	resulted	in	perfusion	rates	of	21.67	±	3.44,	31.35	±	4.39,	56.37	±	4.38,	102.64	±	9.54	and	 135.2	 ±	 3.76	 nl/min,	 respectively	 (n=6	 (6)).	 Corresponding	 pressure	 and	 flow	rate	values	were	plotted	against	 each	other	 to	 establish	 if	 luminal	pressure	of	 vasa	recta	had	a	linear	relationship	with	luminal	flow	rate	and	if	perfusion	of	single	vasa	recta	within	 the	 live	 slice	model	was	 a	 valid	model	 for	 further	 investigation,	 figure	5.2.						
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Figure	5.2	 Increasing	 the	 luminal	 perfusion	 pressure	 effects	 flow	 rate	 of	 in	
situ	vasa	recta.		Individual	vasa	recta	were	perfused	with	PSS	at	varying	pressures,	20-100	mmHg,	to	determine	 luminal	 perfusion	 rate	 at	 corresponding	 pressures.	 Values	 are	 mean	 ±	SEM.	n=6	(6).			






















However,	 Zhang	 et	 al	 have	 challenged	 this	 notion	 using	 isolated	 DVR	 (Z.	 Zhang	 &	Pallone	 2004).	 Interestingly,	 the	 authors	 found	 that	 with	 an	 increased	 luminal	pressure,	intracellular	endothelium	calcium	levels	also	increased.	Moreover,	they	also	discovered	 increased	 levels	 of	 NO	 production	 with	 the	 associated	 increase	 in	pressure	 (Z.	 Zhang	 &	 Pallone	 2004).	 This	 suggests	 that	 vasa	 recta	 are	mechanosensitive	 and	 can	 respond	 to	 luminal	 pressure	 through	 calcium	 signalling	and	 NO	 production	 to	 increase	 or	 decrease	 vessel	 tone,	 independent	 of	 regulation	from	 arteriole	 pressure.	 It	must	 be	 noted	 that	 an	 increased	 pressure	 in	 vasa	 recta	must	 be	 initiated	 upstream	 via	 arteriole	 pressure	 therefore	 complete	 independent	regulation	is	sceptical.	With	 this	 in	mind,	 the	 aim	 of	 this	 study	was	 to	 investigate	 the	 effect	 of	 increasing	pressure	 on	 vasa	 recta	 diameter	 and	 to	 identify	 if	 pericytes	 are	 able	 to	 respond	 to	altered	luminal	pressure.			
In	situ	vasa	recta	were	perfused	at	<5	mmHg	and	 left	 to	equilibrate	 for	10	minutes.	Following	equilibrium,	 luminal	vasa	 recta	pressure	was	 increased	 to	20	mmHg	and	left	 for	a	further	10	minutes	to	stabilise.	This	was	then	increased	incrementally	in	a	stepwise	 fashion	to	pressures	of	40,	60,	80	and	100	mmHg.	Live	video	recording	of	the	perfused	vasa	recta	was	carried	throughout	the	experiment	and	vessel	diameter	analysed	later	offline	(see	methods	for	details).		Vasa	recta	diameter	at	0-5	mmHg	was	considered	as	baseline;	therefore	any	changes	in	 diameter	 after	 increase	 of	 pressure	 were	 measured	 as	 a	 percentage	 change	 of	baseline	diameter.	Perfused	vasa	recta	diameter	was	measured	at	a	pericyte	site	and	non-pericyte	site	of	a	single	vessel	(figure	5.3).			Increasing	 the	 pressure	 from	0	 to	 20	mmHg	within	 vasa	 recta	 resulted	 in	 a	 3.73	 ±	1.5%	 increase	of	diameter	at	pericyte	sites	while	non-pericyte	sites	 increased	1.8	±	1.2%	 (n=8	 (8),	 figure	 5.3).	 The	 pressure	 increase	 did	 not	 result	 in	 a	 significant	difference	in	vasa	recta	diameter	at	pericytes	compared	with	that	measured	at	non-pericyte	sites.				Increasing	 the	 pressure	 from	 20	 to	 40	 mmHg	 resulted	 in	 an	 increase	 diameter	 at	pericyte	sites	(9	±	2.7	%)	that	was	significantly	greater	than	the	increase	of	diameter	measured	at	non-pericyte	sites	(2.92	±	2.5%,	n=8	(8),	P<0.01),	figure	5.3.	
	 144	
Increasing	the	luminal	pressure	in	a	stepwise	manner	from	40	to	100	mmHg	resulted	in	an	increase	diameter	at	pericyte	sites	(14.12	±	2.1,	15.25	±	3.8	and	16.15	±	4.2%,	respectively)	 that	 was	 significantly	 greater	 than	 increase	 of	 diameter	 measured	 at	non-pericyte	 sites	 (4.56	 ±	 3.1,	 5.19	 ±	 3.6	 and	 6.54	 ±	 4.31%,	 respectively,	 n=8	 (8),	P<0.01),	figure	5.3.	
	
Figure	5.3	 Increasing	 luminal	 perfusion	 flow	 increases	 diameter	 of	 in	 situ	
vasa	recta.	Increasing	the	perfusion	flow	of	vasa	recta	in	a	stepwise	manner	resulted	in	a	significantly	greater	increase	in	diameter	of	vasa	recta	at	pericyte	sites	compared	to	 that	 was	 measured	 at	 non-pericyte	 sites.	 Values	 are	 mean	 ±	 SEM.	 n=8	 (8),	 **	P<0.01.		
	
5.4	 The	 effect	 of	 luminally	 perfused	 ANG	 II	 and	 ET-1	 on	 in	 situ	 vasa	 recta	
diameter			With	 perfusion	 of	 in	 situ	 vasa	 recta	 being	 possible,	 vessel	 perfusion	 of	 vasoactive	agents	 needed	 to	 be	 investigated	 to	 ascertain	 how	 accurate	 vasoactive	 responses	were	in	comparison	to	already	established	models	(Crawford	et	al.	2012;	Z.	Zhang	et	
al.	2004).	Perfusion	of	damaged	or	dead	vessels	would	be	pointless	with	respect	 to	investigating	pericyte-mediated	control	of	vasa	recta	diameter	therefore	if	perfusion	
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with	a	known	vasoconstrictor	produced	no	response,	the	model	would	be	invalid	or	irrelevant	to	investigate	further.			As	the	live	slice	model	had	already	been	investigated	for	its	viability	(Crawford	et	al.	2012),	it	was	assumed	that	perfusion	setup	would	have	no	effect	on	this.	Therefore,	a	significant	majority	of	the	tissue	would	still	be	“alive”.	Using	the	isolated	DVR	technique,	Pallone	et	al	have	shown	luminal	perfused	ANG	II	had	 no	 significant	 effect	 on	 vessel	 diameter	 until	 concentrations	 of	 10	 nM	 were	reached	(Pallone	1994).	Interestingly,	lower	concentrations	added	to	the	surrounding	bath	 solution,	 and	 not	 directly	 into	 the	 lumen,	 evoked	 a	 much	 more	 significant	constriction	of	pericytes	and	consequently	 reduced	vessel	diameter	 (Pallone	1994).	This	 is	 more	 than	 likely	 due	 to	 bath	 application	 of	 drug	 having	 a	 direct	 effect	 on	pericytes	 whereas	 luminal	 perfusion	 relies	 on	 endothelial	 cell	 to	 pericyte	communication.	 Nonetheless,	 the	 same	 group	 has	 shown	 luminal	 perfusion	 of	 a	variety	of	vasoactive	substances	(PGE2,	ANG	II	and	ET-1)	are	able	to	mediate	pericyte-induced	 changes	 in	 DVR	 diameter,	 even	 after	 DVR	 were	 isolated	 and	 stripped	 of	supporting	tissue	(Pallone	1991;	Rhinehart	&	Pallone	2001a;	Pallone	1994;	Pallone	&	Silldorff	2001).	Experiments	performed	using	 live	kidney	slices	have	 shown	similar	results	 in	 that	bath	application	of	a	variety	of	vasoactive	compounds	 (ANG	 II,	ET-1,	NO	donors	and	PGE2)	resulted	in	changes	in	vasa	recta	diameter	due	to	the	action	of	pericytes	 (Crawford	 et	 al.	 2012).	 Taken	 together,	 it	 is	 reasonable	 to	 suggest	 that	perfusion	of	vasa	recta	with	vasoactive	compounds	within	the	live	slice	model	should	produce	 similar	 results	 to	what	 has	 been	 previously	 observed	 both	 isolated	 and	 in	
situ.				
In	situ	vasa	recta	were	perfused	with	ANG	II	(100	nM)	at	25	mmHg	while	tissue	slices	were	constantly	superfused	with	95%	O2	/	CO2	PSS.	Perfusion	of	ANG	II	resulted	in	a	sustained	 constriction	 of	 vasa	 recta	 capillaries	 (Figure	 5.4).	 Vasoconstriction	 was	significantly	greater	at	pericyte	sites	(39.21	±	3.6%)	compared	with	that	measured	at	non-pericyte	sites	(10.96	±	1.37%,	n=9	(8),	P<0.001),	 figure	5.4.	The	ANG	II	evoked	constriction	 remained	 constant	 throughout	 perfusion	 and	 only	 reversed	 when	perfusion	was	stopped	after	pipette	removal.	Due	to	 the	experimental	nature	of	 the	perfusion	 setup,	 single	 pipette	 perfusion,	 solution	 change	 is	 not	 possible	 therefore	unable	 to	 washout	 any	 drug	 that	 may	 remain	 within	 the	 vessel.	 This	 is	 discussed	further	in	the	discussion	section	of	this	chapter.		
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The	initial	concentration	used	in	this	experiment	is	taken	from	the	primary	studies	by	Crawford	 et	 al	 (Crawford	 et	 al.	 2012)	 using	 the	 live	 slice	 model.	 As	 mentioned,	Pallone	et	al	did	not	notice	any	significant	constriction	until	a	concentration	of	10	nM	was	luminally	perfused	(Pallone	1994),	however	did	see	a	response	when	superfused	abluminally	with	 lower	concentrations.	Therefore,	a	 range	of	ANG	 II	 concentrations	(10-50	 nM)	 would	 be	 perfused	 to	 ascertain	 the	 concentration	 dependent	 effect	 of	ANG	II	on	pericyte	mediated	of	constriction	of	vasa	recta.			
In	situ	vasa	recta	were	perfused	with	ANG	II	(10,	30	and	50	nM)	at	25	mmHg	while	tissue	slices	were	constantly	superfused	with	95%	O2	/	CO2	PSS.	Perfusion	resulted	in	a	 sustained	 constriction	 of	 vasa	 recta	 capillaries	 at	 all	 concentrations	 (Figure	 5.4).	Vasoconstriction	was	significantly	greater	at	pericyte	sites	(17.98	±	1.78,	19.90	±	3.10	and	22.43	±	2.13%,	respectively)	compared	with	that	measured	at	non-pericyte	sites	(4.70	±	1.90,	5.30	±	3.10	and	7.39	±	2.01%,	respectively,	n=9(8),	P<0.001),	figure	5.4.	The	ANG	II	evoked	constriction	at	all	 concentrations	remained	constant	 throughout	perfusion	and	only	reversed	when	perfusion	was	stopped	after	pipette	removal.						
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Figure	5.4	 Luminal	 perfusion	 of	 ANG	 II	 induces	 pericyte-mediated	





























































substantial	 constriction	 of	 vasa	 recta	 via	 pericytes,	 mediated	 through	 ETA	receptor	activation,	at	~65%	at	10	nM	(Silldorff	et	al.	1995).		
	




of	 in	 situ	 vasa	 recta.	 Luminal	 perfusion	 of	 ET-1	 (10	 nM)	 induced	 a	 significant	vasoconstriction	 of	 in	 situ	 vasa	 recta	 at	 pericyte	 sites	 (black	 bars)	 compared	with	non-pericyte	sites	(grey	bars).	Data	are	mean	±	SEM,	***p<0.001;	n=	7	(7).	
5.4.1	 The	effect	of	luminally	perfused	PGE2	and	SNAP	on	in	situ	vasa	recta	diameter		Given	 the	 fact	 it	has	been	shown	pericytes	able	 to	 relax	 in	 response	 to	endogenous	and	exogenous	vasoactive	dilators	and	hence	vessel	diameter	increases	(Crawford	et	


























Cowley	2012).	Interestingly,	isolated	perfused	DVR	have	been	shown	to	produce	NO	independently	of	exogenous	stimuli	(Rhinehart	&	Pallone	2001a).	Using	the	isolated	perfused	DVR	 technique,	Rhinehart	and	Pallone	where	able	 to	 show	DVR	 increased	production	 of	 NO	 when	 exposed	 to	 l-arginine	 but	 also	 produced	 NO	 when	 being	perfused	 with	 physiological	 saline	 and	 left	 for	 several	 hours	 (Rhinehart	 &	 Pallone	2001b)	 suggesting	 a	 role	 for	NO	 in	 the	 normal	 regulation	 of	 physiological	 pericyte	tone.		Both	 NO	 and	 PGE2	 are	 endogenous	 vasodilators	 and	 as	 such	 S-nitroso-N-acetylpenicillamine	 (SNAP),	 a	 stable	 analogue	 of	 endogenous	 S-nitroso	 compounds,	was	used	in	experiments	here	to	represent	a	NO	donor	and	has	previously	been	used	
in	vivo	and	in	vitro	(Wilcox	&	Welch	2000;	Crawford	et	al.	2012)	and	exogenous	PGE2	applied	to	mimic	endogenous	release.	The	aim	of	this	study	being	to	 investigate	the	effect	 of	 luminal	 perfusion	 of	 vasodilators	 on	 vasa	 recta	 diameter	 and	 pericyte	contractility.			
	
In	situ	vasa	recta	were	perfused	with	PGE2	(10	μM)	at	25	mmHg	while	 tissue	slices	were	constantly	superfused	with	95%	O2	/	CO2	PSS.	Perfusion	resulted	in	a	sustained	dilation	 of	 vasa	 recta	 capillaries	 (Figure	 5.6).	 Vasa	 recta	 diameter	was	 significantly	greater	at	pericyte	sites	(9.52	±	2.63%)	compared	with	that	measured	at	non-pericyte	sites	(1.6	±	0.63%,	n=8	(8),	P<0.01)	(Figure	5.6).	The	PGE2	evoked	dilation	remained	constant	throughout	perfusion	and	only	reversed	when	perfusion	was	stopped	after	pipette	removal.				
	






Figure	5.6	 Luminal	 perfusion	 of	 PGE2	and	 SNAP	 induces	 pericyte-mediated	



















































5.5.1	 CsA	perfusion		Having	established	that	 luminal	perfusion	of	vasa	recta	with	endogenous	vasoactive	agents	resulted	in	similar	responses	to	when	agents	were	superfused,	the	model	was	then	used	 to	explore	 the	 role	of	CNIs	on	vasa	 recta	diameter	and	 the	potential	 role	pericytes	might	have	in	contributing	towards	CNI-induced	nephrotoxicity	and	if	CNI-mediated	vasoconstriction	is	via	their	presence	within	the	blood	stream.	
In	 situ	 vasa	 recta	 were	 perfused	 with	 CsA	 (3	 μM,	 maximum	 clinically	 recommend	trough	concentration	 (360	ng/ml))	at	25	mmHg	while	 tissue	slices	were	constantly	superfused	with	95%	O2	/	CO2	PSS.	Perfusion	resulted	 in	a	sustained	constriction	of	vasa	 recta	 capillaries	 (Figure	 5.7).	 Vasoconstriction	 was	 significantly	 greater	 at	pericyte	 sites	 (22.55	 ±	 1.85%)	 compared	 to	 that	 measured	 at	 non-pericyte	 sites	(11.96	±	2.10%,	n=9	(8),	P<0.01)	(Figure	5.7).	The	CsA	evoked	constriction	remained	constant	throughout	perfusion	and	only	reversed	when	perfusion	was	stopped	after	pipette	removal.					For	 consistency	 and	 comparison,	 in	 situ	 vasa	 recta	 were	 perfused	 at	 the	 same	concentrations	used	for	superfusion	experiments.		
In	situ	vasa	recta	were	perfused	with	CsA	(1,	5	and	10	μM)	at	25	mmHg,	while	tissue	slices	 were	 constantly	 superfused	 with	 95%	 O2	/	 CO2	 PSS.	 Perfusion	 resulted	 in	 a	sustained	 constriction	 of	 vasa	 recta	 capillaries	 at	 all	 concentrations	 (Figure	 5.7).	Vasoconstriction	was	significantly	greater	at	pericyte	sites	(20.20	±	3.80,	25.52	±	2.91	and	 33.04	 ±	 3.9%,	 respectively	 compared	 to	 that	 measured	 at	 non-pericyte	 sites	(10.01	±	2.09,	11.51	±	1.02	and	10.97	±	4.42%,	respectively,	n=9	(8),	P<0.05)	(Figure	5.7).	The	CsA	evoked	constriction	at	all	concentrations	remained	constant	throughout	perfusion	and	only	reversed	when	perfusion	was	stopped	after	pipette	removal.					
	 152	
	
Figure	5.7	 Luminal	perfusion	of	 CsA	 induces	pericyte-mediated	 constriction	




























































5.6	 FK506	perfusion			Given	 data	 in	 previous	 chapters	 has	 demonstrated	 both	 CsA	 and	 FK506	 induce	changes	 in	vessel	diameter	via	 their	action	pericytes,	 investigating	FK506	perfusion	would	 enable	 direct	 comparison	 against	 superfusion	 and	 aid	 in	 understanding	endothelial	cell	to	pericyte	communication.			In	situ	vasa	recta	were	perfused	with	FK506	(1	μM)	at	25	mmHg	while	tissue	slices	were	constantly	superfused	with	95%	O2	/	CO2	PSS.	Perfusion	resulted	in	a	sustained	constriction	of	vasa	recta	capillaries	 (Figure	5.9).	Vasoconstriction	was	significantly	greater	at	pericyte	sites	(29.82	±	4.50%)	compared	to	that	measured	at	non-pericyte	sites	 (6.96	±	1.40%,	n=9	 (8),	P<0.001)	 (Figure	5.9).	The	FK506	evoked	constriction	remained	 constant	 throughout	 perfusion	 and	 only	 reversed	 when	 perfusion	 was	stopped	after	pipette	removal.				As	with	CsA,	to	enable	direct	comparison	between	luminal	perfusion	and	superfusion,	
in	 situ	 vasa	 recta	 were	 perfused	 at	 the	 same	 concentrations	 used	 for	 superfusion	experiments.		




Figure	5.9	 Luminal	 perfusion	 of	 FK506	 induces	 pericyte-mediated	
















































recta	diameter			As	 was	 seen	 with	 CsA,	 all	 concentrations	 of	 FK506	 (including	 the	 lowest	 clinical	trough	 concentration)	 evoked	 a	 significant	 vasoconstriction	 of	 vasa	 recta	 pericytes.	Therefore,	 comparing	 the	 pericyte-mediated	 vasoconstriction	 induced	 by	 perfusion	with	superfusion	would	highlight	the	physiological	relevance	perfusion	of	FK506	has	on	DVR.	In	addition,	direct	comparison	of	perfusion	and	superfusion	would	enable	an	understanding	to	the	cell-to-cell	signalling	events	depending	on	which	site	at	which	FK506	is	exposed	i.e.	direct	action	on	pericytes	via	superfusion	or	endothelial	cell	to	pericyte	communication	via	perfusion.			Perfusion	 of	 FK506	 (8x10-4,	 0.05,	 0.1	 and	 1	 μM)	 resulted	 in	 a	 significant	vasoconstriction	of	DVR	at	pericyte	sites	(15.17	±	2.50,	17.38	±	3.70	and	21.88	±	2.18	and	 29.82	 ±	 4.50%,	 respectively)	 compared	 to	 that	 measured	 at	 pericyte	 sites	 via	superfusion	 of	 FK506	 (4.87	 ±	 0.99,	 8.03	 ±	 1.36,	 9.77	 ±	 0.54,	 11.34%,	 respectively,	*P<0.05,	n=	7	(7)),	figure	5.10.	
	
Figure	5.10	 Luminal	 perfusion	 of	 FK506	 has	 an	 enhanced	 vasoconstrictive	
























5.7	 Rapamycin	perfusion		Rapamycin	failed	to	evoke	any	significant	vasoconstriction	at	pericytes	of	in	situ	vasa	recta	 when	 superfused,	 thus	 the	 effect	 of	 luminally	 perfusing	 rapamycin	 was	investigated	to	determine	whether	any	changes	in	vessel	diameter	were	evoked.			




Figure	5.11	 Luminal	 perfusion	 of	 rapamycin	 does	 not	 induce	 pericyte-









































situ	vasa	recta		Perfusion	 of	 rapamycin	 (0.05,	 0.1	 and	 1	 μM)	 failed	 to	 evoke	 significant	vasoconstriction	of	 in	situ	vasa	recta.	Similarly,	superfusion	also	 failed	 to	evoke	any	significant	vasoconstriction.		The	change	 in	vasa	recta	diameter	at	pericyte	sites	 through	perfusion	of	rapamycin	(0.42	±	2.7,	3.16	±	1.01	and	4.4	±	1.66%,	respectively)	was	not	significantly	different	when	 compared	 to	 diameter	 measured	 at	 pericyte	 sites	 during	 superfusion	 of	rapamycin	(4.30	±	2.5,	3.30	±	0.87	and	4.98	±	1.30%,	respectively,	P>0.05,	n=7	(7)),	figure	5.12.	
	
Figure	5.12	 Luminal	perfusion	of	rapamycin	has	no	enhanced	vasoconstrictive	





















5.8	 Discussion			The	aim	of	this	chapter	was	to	develop	a	model	for	single	vessel	perfusion	in	the	live	kidney	 slice	 for	 investigating	 the	 cellular	 mechanisms	 involved	 when	 vasoactive	agents	and	CNIs	where	luminally	perfused	in	vasa	recta.	The	main	 findings	 of	 this	 investigation	 are	 the	 successful	 perfusion	 of	 in	 situ	vasa	recta	capillaries	 in	 the	 live	 slice	model	and	 the	 results	 suggest	 luminal	perfusion	of	vasoactive	 compounds	 caused	 more	 potent	 effects	 on	 vessel	 diameter	 than	superfusion.	 Similarly,	 perfusion	 of	 CNIs	 evoked	 a	 substantial	 pericyte-mediated	vasoconstriction	of	vasa	recta	that	consequently	reduces	vessel	diameter	and	is	likely	to	 impede	MBF.	These	results,	 in	combination	with	previous	chapters,	highlight	 the	potential	role	of	MBF	in	contribution	to	CNI-mediated	nephrotoxicity.	In	addition,	the	results	 shown	 here	 merit	 further	 investigations	 into	 endothelial	 cell	 to	 pericyte	communication	 for	 understanding	 the	molecular	mechanisms	 of	 luminally	 exposed	vasoactive	 agents	 for	 further	 understanding	 the	 role	 of	 DVR	 in	 regulation	 of	 MBF.	Taken	 together,	 targeting	 renal	 pericytes	 during	 CNI	 treatment	 could	 be	 a	 novel	method	for	attenuation	of	CNI	nephrotoxicity.			For	the	past	two	decades,	use	of	the	isolated	perfused	vasa	recta	technique	has	been	fundamental	in	aiding	the	understanding	of	MBF	and	physiology	of	the	renal	pericyte.	One	 of	 the	 first	 publications	 by	 Pallone	 et	 al	 (Pallone	 et	 al.	 1994),	 described	 the	method	as	 an	 adaptation	 from	 isolated	perfused	 tubule	 experiments	 carried	out	by	Burg	 (Burg	 1972).	 The	 two	 techniques	 are	 similar,	 as	 previously	 mentioned,	 and	involve	dissection	and	removal	of	any	surrounding	and	supporting	tissue	in	order	to	carry	 out	 free	 flow	 perfusion	 (Pallone	 et	 al.	 1994;	 Burg	 1972).	 Given	 the	inaccessibility	 of	 the	 renal	 medullary	 architecture	 in	 vivo,	 this	 technique	 advanced	our	 understanding	 of	 the	 complex	 and	 intricate	 pathways	 involved	 in	 blood	 flow	circulation	and	renal	osmotic	changes.		However,	 as	with	most	 experimental	scientific	models,	 it	 is	 not	 perfect.	 Firstly,	 the	technique	is	in	vitro,	therefore	not	as	relevant	or	closely	matched	to	in	vivo.	If	it	were	possible	to	perform	techniques	similar	to	micropuncture	studies	in	the	vasculature	of	the	medulla	in	vivo	(Sakai	et	al.	1965),	perfusion	of	DVR	in	vivo	would	be	far	superior	compared	 to	 isolated	 techniques.	 Unfortunately,	 this	 is	 technically	 too	 demanding,	even	with	 recent	 technological	 advances.	 Isolation	 of	 the	 DVR	 involves	mechanical	stress	 inflicted	upon	the	tissue;	 this	not	only	 increases	the	risk	 for	physical	damage	
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but	 also	 increases	 the	 risk	 of	 molecular	 damage	 including	 ROS	 generation,	 cell	apoptosis	and	even	receptor	desensitisation	due	 to	 shear	 stress	 inducing	 release	of	NO,	ET	and	ATP	(Beierwaltes	2013).	Secondly,	 removing	 the	supporting	structures	of	DVR	 including	 the	renal	medullary	interstitial	 cells	 (RMIC)	 and	 surrounding	 interstitum,	 increases	 the	 risk	 for	misinterpretation	 of	 results.	 For	 example,	 an	 agonist-induced	 vasoconstriction	 of	isolated	DVR	might	not	equate	to	the	same	magnitude	of	constriction	observed	in	vivo	with	supporting	cells	and	structures	 intact,	which	play	a	part	 in	vessel	stability	and	acting	 as	 restricting	 structures.	 It	 must	 also	 be	 noted	 that	 these	 surrounding	structures	 may	 also	 contribute	 towards	 pericyte-mediated	 vasoconstriction	 or	vasodilation	 through	 release	 of	 paracrine	 mediators	 (Crawford	 et	 al.	 2011).	 Renal	pericytes	 are	 also	 known	 to	 play	 a	 crucial	 role	 in	 vessel	 stabilisation	 (Peppiatt-Wildman	 2013)	 therefore	 possibly	 require	 information,	 growth	 factors	 for	 vessel	regeneration	 for	 example,	 from	 surrounding	 cells	 to	 fully	 function	 and	 maintain	endothelial	cell	to	pericyte	communication.	RMIC	are	a	known	source	of	endogenous	PGE2	(Crawford	 et	 al.	 2012),	 which	 has	 been	 shown	 to	 attenuate	 ANG	 II-mediated	constriction	of	in	situ	vasa	recta	and	cause	dilation	of	vasa	recta	when	applied	alone	(Crawford	 et	 al.	 2012;	 Pallone	 1994;	 Silldorff	 et	 al.	 1995).	 Given	 these	 established	mechanisms	of	vessel	diameter	regulation	in	situ	following	superfusion	of	agents	it	is	or	 seems	 important	 to	 investigate	 the	 effect	 of	 luminal	 exposure	 to	 these	 agents	 to	recapitulate	the	in	vivo	blood	perfused	setting.		Unlike	in	situ	preparations,	isolated	perfused	DVR	do	not	have	the	localised	signalling	mechanisms	derived	from	surrounding	tissue	which	enables	vessels	to	communicate	with	 other	 surrounding	 tissue	 and	 specifically,	 unable	 to	 communicate	 with	 renal	tubules.	The	 idea	of	 tubular-vascular	 cross-talk	 is	 still	 in	 its	 infancy,	however	given	that	 the	medullary	microcirculation	 responds	 to	minute	 changes	 in	 blood	 flow	 and	osmolality	via	alternations	in	tubular	flow	rate,	it	is	reasonable	to	suggest	that	small	changes	 in	 communication	 between	 vessels	 and	 tubules	 may	 play	 a	 larger	 role	 in	medullary	circulation	than	once	thought.	Vasoconstriction	 of	 DVR	 induced	 by	 ANG	 II	 during	 isolated	 perfusion	 experiments	(Pallone	1994)	was	at	a	similar	magnitude	to	that	of	in	situ	superfusion	(Crawford	et	
al.	 2012),	 suggesting	 a	 similarity	 of	 contractile	 response.	 However,	 the	 pathways	involved	 could	 be	 completely	 distinctive	 due	 to	 in	 situ	 superfusion	 utilising	subsurface	 vessels,	 and	 therefore	 not	 having	 direct	 exposure	 to	 drugs	 at	 applied	
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concentrations	 due	 to	 drug-tissue	 diffusion	 and	 distribution	 per	 se,	 while	 isolated	perfusion	 experiments	 have	 direct	 contact	with	 ANG	 II	 from	 the	 abluminal	 surface	(Pallone	 1994).	 In	 situ	 perfusion	 relies	 on	 signals	 advancing	 from	 the	 luminal	endothelial	cells	 to	pericytes	residing	on	the	abluminal	wall	of	vasa	recta	and	given	that	 endothelial	 cells	 and	 pericytes	 are	 known	 to	 have	 peg	 and	 socket	 contacts	(Armulik	 et	 al.	 2005),	 the	 time	 taken	 for	 communication	 is	 not	 going	 to	 be	 as	instantaneous	 as	 applying	 drug	 to	 the	 abluminal	 surface	 of	 vasa	 recta	 and	 direct	contact	with	pericytes.		This	can	be	further	seen	using	ET	in	isolated	perfusion	and	in	
situ	 superfusion	 experiments.	 Pallone	 et	 al,	 using	 isolated	 perfusion,	 were	 able	 to	show	 almost	 complete	 closure	 of	 DVR,	 >90%,	 when	 perfused	 with	 ET	 at	 10	 pM	(Silldorff	et	al.	1995).	Conversely,	Crawford	et	al,	using	in	situ	superfusion,	were	only	able	 to	 demonstrate	 a	 10%	 vasoconstriction	 using	 10	 nM	 of	 ET	 (Crawford	 et	 al.	2012).				A	 study	 by	 Crawford	 et	 al	 highlighted	 the	 role	 for	 tubular-vascular	 crosstalk	 by	inducing	 hypotonic	 shock	 in	 the	 live	 slice	 model	 (Crawford	 et	 al.	 2012).	 This	subsequently	 induced	 ATP-mediated	 vasodilation	 of	 vasa	 recta	 via	 pericytes,	 ATP	vasoactivity	 is	 concentration	 dependent,	 and	 suggests	 a	 role	 for	 pericytes	 in	preserving	the	cortico-medullary	gradient	and	reducing	localised	ischemia	(Peppiatt-Wildman	 2013).	 Pericytes	 therefore	 are	 able	 to	 sense	 a	 change	 in	 extracellular	nucleotides	 and	 respond	 by	 causing	 changes	 in	 vasa	 recta	 diameter	 and	 therefore	potentially	MBF.	More	recently,	O’Connor	and	Cowley	have	similarly	highlighted	the	importance	 of	 tubular-vascular	 crosstalk	 in	 their	 DVR	 with	 attached	 tubules	preparation	(O'Connor	&	Cowley	2012).	The	authors	performed	DVR	perfusion,	intact	surrounding	 tubules,	 and	 demonstrated	 buffering	 of	 ANG	 II-mediated	vasoconstriction	of	DVR,	 through	NO	 release	 from	medullary	 thick	 ascending	 limbs	demonstrating	 direct	 tubular-vascular-crosstalk	 (O'Connor	 &	 Cowley	 2012).	Furthermore,	 the	 authors	 data	 also	 highlighted	 that	 reduced	 NO	 bioavailability	enhances	 pericyte	 mediated	 vasoconstriction	 in	 response	 to	 ANG	 II	 (O'Connor	 &	Cowley	2012).	Taken	together,	although	the	use	of	 isolated	perfused	DVR	was	fundamental	for	our	initial	understanding	of	pericyte	physiology	and	MBF	regulation,	 it	 is	clear	from	the	increasing	amount	of	evidence,	that	many	factors	involved	in	the	physiological	setting	
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of	the	renal	medulla	are	neglected	in	this	preparation	that	only	allows	investigation	of	a	single	isolated	vessel.			The	 live	 kidney	 slice	model	 aims	 to	 address	 the	 problems	 that	 are	 associated	with	isolated	 perfusion.	 Importantly,	 the	 tissue	 receives	 much	 less	 physical	 stress	 and	damage	when	being	prepared	(Crawford	et	al.	2012),	but	also	keeps	the	surrounding	supporting	 structures	 intact	 and	 allows	 communication	 between	 cells	 from	 nearby	locations	(Crawford	et	al.	2012).		Although	the	live	slice	model	has	shown	some	interesting	insights	into	possible	renal	insults	from	various	nephrotoxic	compounds	(Kennedy-Lydon	et	al.	2012),	the	model	has	 its	 limitations,	 which	 include	 investigation	 of	 acute	 injury	 only	 but	 more	importantly,	the	lack	of	vessel	perfusion.	Through	superfusion,	the	entire	kidney	slice	is	 exposed	 to	 the	 compound	 of	 interest	 and	 subsequently	 does	 not	 exactly	 match	what	would	be	expected	in	vivo.	This	is	particularly	important	for	this	investigation	as	CNIs	are	not	circulated	superficially	and	only	exert	their	effect	via	the	blood	stream.		In	 addition,	 the	model	 uses	 subsurface	 vessels;	 therefore	 the	 concentration	 at	DVR	investigated	 may	 not	 be	 which	 is	 applied	 to	 the	 bath	 for	 superfusion,	 therefore	 a	hypothesis	of	drug	concentration	reaching	the	specific	target	area	must	be	assumed	(Kennedy-Lydon	et	al.	2012).		Ideally,	 perfusion	 of	 vessels	within	 the	 live	 slice	would	 enable	 a	 far	more	 accurate	representation	of	physiological	 settings,	via	 an	 in	situ	model,	 and	 in	 addition,	 allow	precise	concentrations	of	drugs	to	reach	the	target	area	via	perfusion	of	single	vessels	with	concentrations	required.		This	chapter	has	demonstrated	 for	 the	 first	 time	perfusion	of	 individual	 in	situ	vasa	recta	in	the	live	slice	model.	Results	here	have	shown	validation	of	the	model,	using	what	 is	 available	 within	 the	 literature,	 and	 is	 possible	 to	 demonstrate	 reliability,	similar	 to	 that	 of	 isolated	 perfusion	 and	 superfusion,	 to	 investigate	 renal	 pericytes	and	 their	 contribution	 to	 alterations	 in	MBF	 and	 renal	 injury.	 Interestingly,	 results	using	perfused	ANG	II	have	shown	results	similar	to	that	of	superfusion	 in	terms	of	vasoconstriction.	 Perfusion	 of	 ANG	 II	 using	 isolated	 DVR	 resulted	 in	 very	 little	contractile	response	until	a	much	higher	concentration	was	perfused,	or	remarkably,	applied	 to	 the	 bath	 and	 acting	 abluminally	 (Pallone	 1994).	 On	 the	 other	 hand,	superfusion	 of	ANG	 II	 had	 a	 significant	 contractile	 effect	 of	 pericytes	when	used	 at	concentrations	similar	to	isolated	perfusion	(Crawford	et	al.	2012).	Perfusion	of	ANG	II	 in	 the	 live	slice	model	generated	results	 similar	 to	 that	of	 superfusion	suggesting	
	 164	
ANG	 II	 can	 act	 at	 both	 pericytes	 and	 endothelial	 cells	 to	 mediate	 ANG	 II-evoked	vasoconstriction,	 therefore	 multiple	 cellular	 pathways	 might	 contribute	 to	 the	 net	contractile	effect.	This	is	further	highlighted	by	the	addition	of	ANG	II	to	the	bath	of	perfused	 isolated	 DVR	 which	 resulted	 in	 significant	 vasoconstriction	 compared	 to	that	of	luminal	perfusion	(Pallone	1994).	On	 the	 contrary,	 when	 using	 ET-1,	 luminal	 perfusion	 via	 the	 live	 slice	 model	generated	results	similar	to	that	of	isolated	DVR	perfusion.	ET-1	perfusion	of	in	situ	vasa	recta	produced	significant	vasoconstriction,	>40%,	of	vasa	recta.	Similarly,	using	isolated	DVR,	ET-1	evoked	almost	complete	closure,	>90%,	of	perfused	DVR	(Silldorff	
et	 al.	 1995).	 Superfusion	 of	 ET-1	 using	 the	 live	 slice	 induced	 significant	vasoconstriction,	~10%,	compared	to	that	measured	at	non-pericyte	sites	but	not	at	the	 magnitude	 of	 either	 in	 situ	 or	 isolated	 perfusion	 (Crawford	 et	 al.	 2012).	Interestingly,	ET	administration	to	healthy	humans	has	been	shown	to	reduce	renal	plasma	flow	by	25%	and	an	increase	in	renal	vascular	resistance	of	45%	(Weitzberg	
et	al.	1991)	which	would	suggest	that	single,	in	situ,	vessel	perfusion	corresponds	to	the	physiologically	seen	events	after	ET	administration.		Taken	 together,	 both	 sets	 of	 results	 show	 different	 magnitudes	 of	 response,	depending	on	mode	of	drug	application.	However,	in	situ	perfusion	suggests	bridging	the	 gap	 between	 isolated	 perfusion	 and	 in	 situ	 superfusion,	 and	 emphasises	 the	potential	 role	 of	 in	 situ	 perfusion	 of	 DVR	 for	 investigating	 medullary	 physiology.	Moreover,	 in	 situ	 perfusion	 of	 vasodilatory	 substances	 resulted	 in	 significant	vasodilation	 via	 pericytes.	 This	 suggests	 that	 in	 situ	perfusion	 is	 a	 stable	model	 to	investigate	endothelial	cell	and	pericyte	interactions	as	previous	reports	have	shown	that	 an	 increased	 perfusion	 rate	 of	 isolated	 perfused	 DVR	 is	 able	 to	 induce	vasoconstriction	 via	 sheer	 stress	 and	 altered	 vasodilatory	mechanisms	 (Z.	 Zhang	&	Pallone	 2004)	 and	 illustrates	 the	 validation	 of	 in	 situ	 vasa	 recta	 perfusion	 to	investigate	alterations	of	vessel	diameter	and	therefore	MBF	regulation.			Although	 in	situ	 perfusion	might	more	 closely	 recapitulate	 the	physiological	 setting	for	 investigating	 physiological	 settings	 in	 the	 medulla,	 it	 is	 still	 not	 a	 perfect	experimental	 model.	 Technical	 challenges	 are	 the	 requirement	 of	 an	 upright	microscope,	unlike	isolated	perfusion,	which	uses	an	inverted	microscope	(Sendeski	
et	al.	2013),	and	use	of	precise	manipulators	to	enable	accurate	single	wall	puncture	of	 selected	 vessels.	 Single	 wall	 puncture	 allows	 for	 improved	 stable	 perfusion	
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compared	 to	 the	 easier	 to	 perform	 double	wall	 puncture	 technique	 in	 situ.	 Double	wall	puncture	results	in	multiple	entry	points	within	perfused	vessels	and	perfusion	is	 therefore	 less	 stable	 due	 to	 loss	 of	 vessel	 integrity	 and	 multiple	 puncture	 sites	(Ishiguro	&	Steward	2011).	Importantly,	 using	 isolated	 perfused	 DVR	 enables	 a	 concentric	microscopic	 pipette	system	to	be	established.	The	major	advantage	of	this	 is	perfusate	exchange.	Within	the	 perfusion	 pipette	 of	 the	 concentric	 preparation,	 the	 user	 is	 able	 to	 exchange	perfusion	 solution	within	 a	matter	 of	minutes	 to	 investigate	 the	 effects	 of	multiple	solutions	which	 unfortunately	 due	 to	 technical	 difficulties,	 cant	 be	 accomplished	 in	the	 current	 in	situ	 perfusion	at	 this	 time.	When	perfusing	 in	situ	DVR,	only	 a	 single	perfusion	pipette	is	applied	therefore	only	one	solution	can	be	continuously	perfused.	However,	during	solution	change	using	a	concentric	pipette,	the	luminal	pressure	has	to	be	dropped	to	enable	the	changing	of	perfusate	(Burg	1972)	this	has	consequences	which	 are	 discussed	 below.	 For	 example,	 although	 isolated	 perfusion	 enables	 a	control	solution	to	be	followed	by	an	experimental	solution	and	back	to	control,	the	luminal	pressure	within	the	vessel	is	not	constant	and	has	to	be	dropped	each	time	to	enable	solution	exchange	(Sendeski	et	al.	2013).	Given	that	it	has	been	shown	luminal	pressure	 changes	 effect	 vasa	 recta	 contractility	 (Z.	 Zhang	&	Pallone	2004),	 this	 not	ideal	for	investigating	drug	solutions	via	in	situ	perfusion	and	hence	not	used	in	this	study.			The	 perfusion	 of	 in	 situ	 vasa	 recta	 performed	 in	 this	 study	 therefore	 offers	 an	enhanced	physiological	setting	to	investigate	renal	medullary	physiology.	By	adapting	isolated	 DVR	 perfusion	 with	 the	 in	 situ	 tissue	 model	 used	 by	 Crawford	 et	 al,	 the	current	model	allows	for	single	vessel	perfusion	of	intact	in	situ	tissue	to	recapitulate	the	 more	 relevant	 physiological	 setting	 that	 would	 be	 observed	 in	 vivo.	 Although	technically	 demanding,	 it	 would	 be	 possible	 to	 overcome	 the	 problem	 of	 fluid	exchange	 within	 in	 situ	 perfusion.	 Unfortunately	 it	 is	 outwith	 the	 scope	 of	 this	investigation,	 however	 would	 be	 an	 interest	 of	 this	 author	 to	 achieve	 an	 almost	complete		“in	vivo”	physiological	setting.			The	results	from	this	chapter	have	also	shown	for	the	first	time	the	effect	of	CNIs	on	luminally	 perfused	 vasa	 recta	 diameter	 and	 the	 possible	 role	 pericytes	 have	 in	contributing	 to	 CNI-mediated	 nephrotoxicity.	 Results	 from	 previous	 chapters	 have	shown	that	superfusion	of	CNIs	are	able	to	decrease	vasa	recta	diameter,	specifically	
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at	pericytes,	which	could	potently	impede	MBF	in	vivo	and	therefore	have	a	damaging	effect	on	overall	renal	function.	In	addition,	perfusion	of	 in	situ	vasa	recta	with	CNIs	has	 shown	an	enhanced	vasoconstrictive	effect	over	 superfusion,	which	 likely	 to	be	observed	with	in	vivo	exposure	of	CNIs.	CsA	perfusion	resulted	in	>	30%	decrease	of	vasa	 recta	diameter,	which	using	Pousiles	 law	 for	 an	 approximation	of	 flow,	would	increase	resistance	to	blood	flow	by	~5	fold	and	thus	a	~70%	decrease	in	blood	flow	(Peppiatt	 et	 al.	 2006;	 Crawford	 et	 al.	 2012).	 Given	 the	 extensive	 knowledge	 we	already	know	about	CNIs	and	total	renal	blood	flow,	it	is	interesting	to	note	that	very	little	research	has	been	carried	out	on	the	microcirculation	and	as	already	mentioned,	dysfunction	 of	 blood	 flow	 in	 the	 medullary	 microcirculation	 can	 precede	 that	 of	cortical	dysfunction	(Mattson	et	al.	1993).		Therefore,	this	previous	area	assumed	not	to	 be	 an	 influential	 part	 of	 the	 development	 of	 overall	 nephrotoxicity,	 is	 now	questionable	 due	 to	 the	 understanding	 that	 MBF	 may	 play	 a	 larger	 role	 in	 RBF	regulation	than	previously	thought.	Perfusion	 of	 rapamycin	 failed	 to	 evoke	 any	 significant	 alterations	 of	 vasa	 recta	diameter.	 This	was	 similarly	 seen	with	 superfusion,	which	 corresponds	 suitably	 to	clinical	 observations	 associated	 with	 rapamycin	 therapy	 (Kreis	 et	 al.	 2000;	 Sehgal	2003;	V.	W.	Lee	&	Chapman	2005).	These	results	not	only	highlight	the	validity	of	in	
situ	vessel	perfusion	experiments	but	also	highlight	the	beneficial	effects	rapamycin	may	have	over	CNIs	with	regards	to	their	reduced	nephrotoxicity.			Unfortunately,	 the	 results	 from	 this	 chapter	 still	 fail	 to	 identify	 a	 single	mechanism	responsible	 for	 CNI	 nephrotoxicity.	 With	 what	 we	 know	 about	 CNIs,	 they	 are	 still	poorly	 defined	 in	 terms	 of	 renal	 injury.	 How	 CNIs	 are	 able	 to	 induce	 pericyte-mediated	vasoconstriction	of	vasa	recta	from	luminal	perfusion	is	still	a	question	that	remains	unanswered.	Nonetheless,	 in	 spite	 of	 this,	 it	 is	well-known	endothelial	 cell	and	 pericyte	 communications	 exists,	 via	 specific	 channels	 or	 junctions	 and	 are	important	 to	 identify	 for	 pursing	 pericyte	 regulation	 in	 disease	 states.	 Peg-socket	contacts	are	membrane	invaginations	that	extend	from	pericyte	and	endothelial	cells	to	 enable	 communication	 between	 the	 two	 cell	 types	 (Armulik	 et	 al.	 2005).	 Peg	contacts,	tight,	gap	and	adherence	junctions	have	all	been	expressed	as	being	present	between	pericytes	and	endothelial	cells	and	may	allow	a	variety	of	chemical	signals	to	be	 transferred	 from	one	 cell	 to	 another	 (Gerhardt	&	Betsholtz	 2003;	Armulik	et	al.	2005;	Diaz-Flores	et	al.	2009).	Interestingly,	because	pericyte	processes	often	spread	
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to	 be	 in	 contact	 with	 several	 endothelial	 cells,	 they	 may	 integrate	 and	 coordinate	neighbouring	endothelial	cell	responses.	This	has	been	recently	investigated	by	Zhang	
et	al	(Q.	Zhang	et	al.	2006)	using	patch	clamp	electrophysiology.	The	author’s	results	suggest	 that	 coupling	 between	 pericytes	 and	 endothelial	 cells	 is	 mediated	 mainly	through	 open	 gap	 junctions	 (Q.	 Zhang	 et	 al.	 2006).	 They	 also	 highlight	 the	 role	 of	pericytes	in	membrane	de/hyperpolarisation	and	“spreading”	of	electrical	waves	(Q.	Zhang	et	al.	2006).	Interestingly,	 they	 have	 been	 able	 to	 show	 Lucifer	 yellow	 transfers	 between	 gap	junctions	 in	 DVR	 and	 endothelial	 cells,	 Lucifer	 yellow	 is	 a	 457	 Dalton	 fluorescent	marker	 which	 demonstrates	 small	 molecule	 communication	 between	 the	 two	 cells	and	can	be	further	investigated	to	 include	cAMP,	cGMP,	Ca2+	and	NO	(Q.	Zhang	et	al.	2006).		This	suggests	that	perfusion	of	CNIs	could	have	an	effect	on	endothelial	cell	function,	which	 has	 also	 previously	 been	 demonstrated	 via	 endothelial	 cell	 dysfunction,	increased	 ROS	 generation,	 endothelial	 cell	 apoptosis	 and	 increased	 release	 of	vasoconstrictors	 (Morris	 et	 al.	 2000;	 Diederich	 et	 al.	 1994;	 Navarro-Antolin	 et	 al.	2001;	Naesens	et	al.	 2009),	 and	 subsequently	 result	 in	 pericyte	 vasoconstriction	 of	DVR,	 instigating	 the	 progression	 of	 renal	 medullary	 ischemia	 and	 development	 of	nephrotoxicity.		Moreover,	it	is	known	that	DVR	pericytes	produce	superoxide	(Z.	Zhang	et	al.	2004),	which	may	be	conducted	across	myoendothelial	junctions	to	limit	NO	bioavailability	and	 because	 CNIs	 have	 been	 shown	 to	 inhibit	 NO	 production	 through	 endothelial	dysfunction	(Naesens	et	al.	2009;	Oriji	&	Keiser	1999;	Hamalainen	et	al.	2002;	Lungu	




6.1	 Introduction		An	established	complication	of	calcineurin	inhibitor	nephrotoxicity	is	the	inability	to	directly	measure	the	degree	of	injury	above	and	beyond	the	established	damage	due	to	 cellular	 mechanisms	 CNIs	 effect.	 Once	 instigated,	 CNI	 nephrotoxicity	 has	historically	been	only	identifiable	after	acute	functional	changes	have	been	identified	(Naesens	 et	 al.	 2009;	 Tsechan	 2002;	 Krejci	 et	 al.	 2010;	 Pallet	 et	 al.	 2011).	 The	progression	 of	 nephrotoxicity	 is	 still	 poorly	 understood	 and	 given	 that	 there	 is	 no	identifiable	 marker	 for	 progressive	 nephrotoxicity,	 regardless	 of	 cause,	 thus	diagnosis	 is	dependent	on	clinical	measures	such	as	altered	serum	creatinine	 levels	and	GFR	(Fervenza	et	al.	2004;	Pallet	et	al.	2011).		Previous	 chapters	 have	 noted	 the	 inaccessibility	 of	 the	 renal	 medulla	 in	 vivo,	 and	using	the	live	slice	model,	have	demonstrated	that	CNIs	act	at	medullary	pericytes	to	alter	 vasa	 recta	 diameter	 and	 thus	 potentially	 reducing	 MBF.	 In	 order	 to	 better	understand	 the	 underlying	molecular	 and	 cellular	 events	 involved	 in	 CNI-mediated	alterations	of	vasa	 recta	diameter,	multiphoton	 imaging	of	 live	kidney	slices	 loaded	with	specific	 fluorophores	 in	the	presence	of	CNIs	was	carried	out	to	ascertain	how	CNIs	alter	mitochondrial	membrane	potential	and	ROS	production	to	induce	pericyte-mediated	constriction.	The	evidence	for	these	investigations	will	be	further	discussed	below.			
6.1.2	 Mechanisms	of	CNI	nephrotoxicity		With	the	known	combination	of	factors	contributing	towards	CNI	nephrotoxicity,	an	increasing	 amount	 of	 research	 is	 being	 focused	 on	 the	molecular	 level	 in	 order	 to	elucidate	 possible	 mechanisms	 involved	 to	 enable	 for	 earlier	 detection	 and	prevention.	As	 previously	 highlighted,	 the	 CNI-mediated	 increase	 of	 vasoconstrictors	 originate	from	a	variety	of	pathways	including	increased	RAAS	activation,	increased	ANG	II	and	endothelin	production	 and	 increased	 sympathetic	 nerve	 stimulation	 (Naesens	et	al.	2009;	Abraham	et	al.	2012;	Nishiyama	et	al.	1990;	Morris	et	al.	2000).	The	decrease	of	vasodilators	 is	 thought	 to	 originate	 from	 endothelial	 dysfunction	 and	 decreased	bioavailability	 of	NO	 and	PGE2	 (Morris	et	al.	 2000;	 Eguchi	et	al.	 2013;	Amore	et	al.	1995;	 Hamalainen	 et	 al.	 2002).	 These	 acute	 changes,	 coupled	 with	 cell	 apoptosis,	
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Although	 it	 is	 thought	 that	 the	 acute	 changes	 are	 the	 most	 fundamental	 for	development	of	CNI-mediated	nephrotoxicity	(Burdmann	et	al.	2003;	M.	D.	Colombo	
et	al.	2013;	Bennett	&	Pulliam	1983;	Naesens	et	al.	2009),	we	still	poorly	understand	the	mechanisms	involved.		Given	 that	 calcineurin	 is	 ubiquitous	within	 the	body	 and	 is	 involved	 in	 a	 variety	of	physiological	 roles,	 other	 than	 just	 T-cell	 activation	 (Rusnak	 &	 Mertz	 2000),	 it	 is	possible	 that	 inhibition	 of	 this	 enzyme	 in	 one	 target	 organ	might	 have	 detrimental	effects	in	others.	For	example,	calcineurin	is	thought	to	be	involved	in	left	ventricular	hypertrophy	 upon	 load-induced	 hypertrophy	 of	 hypertensive	 patients	 (Lim	 et	 al.	2000).	When	calcineurin	was	attenuated	via	CsA,	 load	 induced	cardiac	hypertrophy	was	 reduced	 in	 a	 concentration-dependent	 manner	 and	 also	 reduced	 histological	findings	of	pressure-overload	hypertrophy	(Lim	et	al.	2000).	Preliminary	evidence	points	to	there	being	a	role	for	mitochondrial	dysfunction	and	ROS	 generation	 in	 the	 CNI-mediated	 nephrotoxicity	 detected	 experimentally	 and	clinically	 (Perez	 de	Hornedo	 et	al.	 2007;	 van	 der	 Toorn	 et	al.	 2007;	 Edwards	 et	al.	2011;	H.-W.	Chen	et	al.	2002).	The	role	foe	these	parameters	will	be	discussed	below.			
6.1.3	 Mitochondrial	dysfunction		Mitochondria	 are	 complex	 membrane	 bound	 organelles,	 which	 are	 commonly	referred	 to	 as	 the	 “powerhouse”	 of	mammalian	 cells.	 They	 are	 responsible	 for	 the	production	 of	 cellular	 adenosine	 triphosphate	 (ATP),	 through	 oxidative	phosphorylation,	 as	 well	 as	 the	 regulation	 of	 cell	 growth,	 cell	 signalling,	differentiation	and	cell	death	(McBride	et	al.	2006;	Hall	et	al.	2009;	Cossarizza	et	al.	1994;	 Kroemer	 et	 al.	 2007;	 Ferrand-Drake	 et	 al.	 1999).	 They	 are	 comprised	 of	 5	specialised	regions:	 the	outer	mitochondrial	membrane	 (OMM),	 the	 intermembrane	space,	 the	 inner	 mitochondrial	 membrane	 (IMM),	 the	 cristae	 and	 the	 matrix	(Wojtczak	&	Zabłocki	2008).			The	IMM	is	the	main	site	of	oxidative	phosphorylation.	In	addition,	the	IMM	is	the	site	of	electron	flow	through	protein	complexes	of	 the	respiratory	chain,	 this	coupled	to	the	exit	of	protons	 to	 the	 intermembrane	space	 is	 responsible	 for	generation	of	 the	mitochondrial	 membrane	 potential	 (ΔΨm)	 (Wojtczak	 &	 Zabłocki	 2008).	 ATP	production	 is	 generated	 by	 the	 flux	 of	 protons	 into	 the	 matrix	 through	 the	 ATP	synthase	enzyme	on	the	IMM	(Jackson	et	al.	2002).	
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Given	 the	 fundamental	 role	 mitochondria	 play	 in	 normal	 cell	 function,	 it	 is	 not	surprising	 that	dysfunction	of	 such	 an	 imperative	organelle	would	 result	 in	 further	complications	at	the	cellular	and	organ	level.	Interestingly,	mitochondrial	 production	 of	 ROS	 is	 significant	 through	 its	 volume	 of	production,	 just	 under	 50%	 in	 the	 kidney,	 and	 contributes	 to	 oxidative	 damage	 of	cells	and	membranes	and	retrograde	cell	redox	signalling	of	nuclear	alterations	due	to	feedback	of	calcium	dynamics	and	altered	mitochondrial	function	(de	Arriba	et	al.	2013;	Perez	de	Hornedo	et	al.	 2007).	Mitochondrial	ROS	production	 is	discussed	 in	section	6.2.3.		Several	groups	utilising	a	variety	of	renal	cell	lines	have	recently	demonstrated	CNI-induced	 mitochondrial	 dysfunction.	 Arriba	 et	 al	 showed	 that	 CsA	 disarranged	 the	IMM	through	cardiolipin	oxidation	(de	Arriba	et	al.	2013).	Cardiolipin	is	a	membrane	lipid	 responsible	 for	 structure	 and	 fluidity	 (Unsay	 et	 al.	 2013)	 and	 oxidation	 of	cardiolipin	 results	 in	 altered	 IMM	 fluidity	 and	 modified	 interactions	 with	 other	membrane	components	 including	cholesterol	and	channel	components	 (Unsay	et	al.	2013).	Arriba	et	al’s	data	also	demonstrated	the	effect	of	CsA	on	the	OMM,	the	effect	of	 which	 resulted	 in	 membrane	 permeabilisation	 and	 apoptosis.	 Apoptosis	 was	 a	result	 of	 OMM	 permeabilisation	 and	 the	 contents	 of	 the	 intermembrane	 space	(cytochrome	C,	endonuclease	G	and	apoptosis	inducing	factor)	travelling	freely	to	the	cytosol	which	induced	unregulated	damage	of	membranes	and	apoptosis	(de	Arriba	
et	al.	2013).		Experiments	performed	in	cultured	endothelial	cells	revealed	that	CNIs	are	cytotoxic	or	cytoprotective	at	high	or	 low	concentrations,	respectively	(Caramelo	et	al.	2004).	The	biphasic	response	to	CNIs	in	endothelial	cells	depends	on	the	interaction	of	CNI	with	 cyclophiln	 D	 (CyD)	 rather	 than	 with	 calcineurin.	 This	 was	 contradictory	 to	previous	 studies	 that	 reported	 CNIs	 interaction	 with	 calcineurin	 being	 the	 most	significant	through	systemic	interactions	(Naesens	et	al.	2009).	Proximal	tubules	and	endothelial	cells	are	 thought	 to	adapt	 to	 the	presence	of	CNI’s,	 to	 limit	cell	damage.	This	 is	 thought	 to	 be	 due	 to	 CsA-mediated	 increases	 in	 the	 mitochondrial	concentration	of	CyD	as	well	as	the	synthesis	of	chaperon	molecules	involved	in	CyD	exportation	 to	 mitochondria,	 heat	 shock	 protein	 70	 (HSP70)	 (Ortiz	 et	 al.	 2008).	Studies	 performed	 in	 bacteria	 show	 that	 inhibition	 of	 HSP70	 with	 geldanamycin	increases	endothelial	toxicity	of	CsA	via	calcineurin	inhibition	(Cardenas	et	al.	1999).	
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Vascular	endothelial	growth	factor	(VEGF)	is	also	thought	to	be	a	substantial	factor	in	the	 cytoprotective	 effect	 of	 CsA	 (Alvarez-Arroyo	 et	al.	 2002).	 Studies	 performed	 in	renal	 proximal	 tubule	 cells	 and	 animal	 models	 have	 shown	 endogenous	 VEGF	protects	 against	 CsA	 toxicity	 both	 in	 vitro	 and	 in	 vivo	 (Slattery	 et	 al.	 2005).	Furthermore,	 proximal	 cells	 preconditioned	 with	 CsA	 have	 been	 shown	 to	 be	resistant	to	FK506	toxicity,	and	vice	versa	(Ortiz	et	al.	2008).		The	main	effect	CsA	has	on	proximal	tubule	mitochondria	specifically	is	thought	to	be	inhibition	 of	 Ca2+	 activation	 of	 CyD	by	 the	 formation	of	 a	 CsA–CyD	 complex,	 rather	than	CsA-calcineurin	complex	(Naesens	et	al.	2009;	Ortiz	et	al.	2008;	de	Arriba	et	al.	2013).	CyD,	along	with	other	proteins,	form	the	mitochondrial	permeability	transition	pore	 (MPTP),	 resulting	 in	 loss	 of	 ΔΨm	 (Schubert	 &	 Grimm	 2004).	 Loss	 of	 ΔΨm	 is	associated	 with	 cell	 apoptosis	 and	 ROS	 generation	 (Kroemer	 et	 al.	 2007).	 Studies	performed	 in	 animal	 models	 have	 demonstrated	 CsA	 binding	 to	 CyD	 prevents	 its	binding	 to	 the	 adenine	 nucleotide	 translocator	 (ANT)	 and	 hence	 prevents	 MPTP	activation	 due	 to	 the	 resulting	 increase	 in	 mitochondrial	 calcium	 concentrations	(Nakagawa	 et	 al.	 2005),	 this	 can	 be	 seen	 in	 figure	 6.20.	 Acutely,	 this	 can	 protect	against	nephrotoxic	compounds	where	toxicity	 is	mediated	by	direct	opening	of	 the	MPTP,	 CsA	 and	 Sanglifehrin	 for	 example	 (Halestrap	 et	al.	 2004)	 and	 highlights	 the	unexpected	 clinical	 findings	 in	 patients	 treated	with	 CsA	 to	 prevent	 graft	 rejection	(Hortelano	et	al.	2000;	Alvarez-Arroyo	et	al.	2002).	However	in	a	chronic	setting,	the	lack	 of	 MPTP	 actively	 accelerates	 mitochondrial	 calcium	 uptake	 while	 maintaining	oxidative	 phosphorylation	 (Ortiz	 et	 al.	 2008).	 The	 progressive	 increase	 of	intracellular	calcium	subsequently	overcomes	CsA	binding	to	CyD,	and	the	resulting	MPTP	 opening	 becomes	 irreversible	 (Hortelano	 et	 al.	 2000)	 with	 loss	 of	mitochondrial	potential	and	release	of	cytochrome	c	and	other	proapoptotic	 factors	into	the	cytosol.	The	initial	 inhibition	of	MPTP	by	CsA	is	also	observed	with	analogs	able	to	bind	cyclophiln	but	lack	anti-calcineurinic	activity	(Readnower	et	al.	2011).	Taken	 together,	 it	 is	 becoming	 clear	 that	 mitochondrial	 dysfunction	 via	 direct	 or	indirect	insult	from	CNIs	is	a	characteristic	pathway	for	progression	of	CNI-mediated	nephrotoxicity.	 Prevention	of	mitochondrial	 dysfunction	 could	 therefore	 be	 a	 novel	mechanism	for	the	delay	of	cell	and	organelle	apoptosis,	which	would	ultimately	lead	to	graft	and	patient	survival.					
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6.2	 ROS	generation		ROS	are	 chemically	 reactive	molecules	derived	 from	oxygen.	They	are	generated	as	part	 of	 normal	 cell	metabolism	 and	have	 been	well	 documented	 to	 have	 important	roles	 in	 renal	 cell	 signalling	and	homeostasis	 (Wilcox	2002).	ROS	 include	 the	 super	oxide	 anion	 (O2-	 .),	 hydrogen	 peroxide	 (H2O2),	 hydroxyl	 radical	 (OH	 .)	 and	 singlet	oxygen	(1O2)	(Kaelin	2005).	Unfortunately,	ROS	overproduction	during	cell	stress	can	have	a	detrimental	effect	on	cells	 and	 tissue	 and	 can	 result	 in	 oxidative	 damage	 of	 cellular	 structures	 including	mitochondria,	 endoplasmic	 reticulum,	 plasma	 membranes	 and	 DNA	 (Cooke	 et	 al.	2003;	Baud	&	Ardaillou	1986).	ROS	 research	 is	 increasing	with	an	exponential	 rate	due	to	their	common	role	in	many	pathological	diseases.	The	kidney	in	particular,	is	a	major	 source	 of	 ROS-generating	 oxidases	 (Bryan	 et	 al.	 2009),	 therefore	 it	 is	reasonable	to	suggest	that	ROS	could	be	involved	in	a	number	of	renal	diseases.					
6.2.1	 Renal	ROS	Production	of	ROS	 in	 the	kidney,	and	 its	relation	to	disease,	was	 first	highlighted	 in	the	1990’s	(Chakraborti	et	al.	1998;	Brezis	et	al.	1991)	specifically	not	long	after	NO’s	discovery	 as	 a	 signalling	 molecule	 (Arnold	 et	 al.	 1977;	 Katsuki	 et	 al.	 1977).	 It	 is	thought	that	the	enzyme	NADPH	oxidase	(NOX)	produces	the	majority	of	renal	ROS,	however	6	 isoforms	have	been	discovered	in	the	 last	20	years	with	NOX2	being	the	most	 comprehensively	 studied	 and	 NOX4	 being	 the	 foremost	 isoform	 found	 in	 the	kidney	 (Wilcox	 2002).	 The	 specific	 roles	 of	 each	 NOX	 isoform	 are	 still	 poorly	understood.	 Despite	 this,	 studies	 using	 wild	 type	 and	 salt	 sensitive	 rats	 have	demonstrated	 that	 NADPH	 oxidase	 accounts	 for	 over	 half	 of	 all	 ROS	 production	within	the	kidney	(Taylor	et	al.	2006;	Zou	et	al.	2001).	Mitochondrial	ROS	production	accounts	 for	 the	remainder	and	will	be	discussed	below	(Wilcox	2002;	Cowley	et	al	2015a).	Production	of	ROS	via	NADPH	and	other	sources	can	been	seen	in	figure	6.1.	Interestingly,	the	outer	medulla	has	been	shown	to	generate	the	greatest	amount	of	ROS	 in	 the	 kidney	 (Cowley	 et	 al	 2015a).	 Coincidently,	 this	 is	 also	 the	 area	 of	 the	kidney	 with	 the	 greatest	 abundance	 of	 pericytes	 (Crawford	 et	 al.	 2012;	 Pallone	 &	Silldorff	2001;	Pallone,	Z.	Z.	Zhang,	et	al.	2003)	and	 therefore	ROS	generation	could	play	a	major	role	in	the	vasoconstriction	of	vasa	recta	via	pericytes,	which	have	been	
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shown	 to	 constrict	upon	exposure	 to	ROS	 (Z.	Zhang	&	Pallone	2004;	Z.	Zhang	et	al.	2004).		
		














bioavailability,	via	degradation,	resulted	in	attenuated	contraction.	This	suggests	ROS	may	act	directly	through	VSMCs	to	cause	vasoconstriction.	In	addition,	ROS	has	been	shown	to	 induce	vasoconstriction	through	the	 juxtaglomerular	apparatus	(Wilcox	&	Welch	 2000).	 Reabsorption	 of	 NaCl	 triggers	 tubuloglomerular	 feedback	 which	simultaneously	 induces	 adenosine-induced	 vasoconstriction	 (D.	 Sun	 et	 al.	 2001).	Reduction	 of	 tubuloglomerular	 feedback	 through	 ROS	 degradation	 reduces	 the	adenosine-mediated	vasoconstrictive	response	in	spontaneously	hypertensive	(SHR)	rats	 (Wilcox	&	Welch	 1998).	 SHR	 are	well	 known	 to	 have	 increased	 production	 of	superoxide	in	the	kidney	while	also	having	reduced	bioavailability	of	NO	in	the	kidney	(Paravicini	&	Touyz	2008).	Collectively,	evidence	suggests	that	the	production	of	ROS	by	 juxtaglomerular	 apparatus	 leads	 to	 ROS-mediated	 vasoconstriction	 of	 afferent	arterioles	and	thus	NO	can	inhibit	tubuloglomerular	feedback.		
6.2.2	 CNI-induced	ROS	CNIs	 are	 well	 documented	 to	 reduce	 the	 production	 of	 NO	 and	 PGE2	 through	endothelial	 cell	 dysfunction	 (Morris	 et	al.	 2000;	 Perico	 et	al.	 1990;	 Diederich	 et	al.	1994)	however,	their	role	in	ROS	production	is	less	well	characterised.	Both	CsA	and	FK506	have	been	shown	 to	up-regulate	 the	expression	of	endothelial	NOS	 (eNOS)	 in	 tumour	 cells	 lines	 (Navarro-Antolin	 et	 al.	 1998)	 and	 vascular	endothelial	 cells	 (LopezOngil	 et	 al.	 1996).	 This	would	 initially	 suggest	 a	 protective	mechanism	 due	 to	 increased	 production	 of	 NO.	 However,	 the	 increased	 eNOS	expression	is	mediated	through	the	direct	production	of	ROS	via	a	negative	feedback	mechanism	trying	to	overcome	the	excess	production	of	ROS	(LopezOngil	et	al.	1996;	Navarro-Antolin	 et	 al.	 1998).	 Given	 the	 fact	 that	 ROS	 and	 NO	 combine	 to	 form	peroxynitrite,	one	of	the	most	potent	oxidants	within	the	body	(Wilcox	&	Welch	2000;	Navarro-Antolin	 et	 al.	 2001),	 increased	 expression	 of	 eNOS	 via	 CNIs	 can	 have	detrimental	effects	on	cell	function.	As	 has	 been	 previously	 highlighted,	 treatment	 with	 CNIs	 induces	 the	 increased	production	 of	 ANG	 II	 (Naesens	 et	 al.	 2009).	 Interestingly,	 increased	 production	 of	ANG	II	has	also	been	linked	with	increased	ROS	production	(Nishiyama	et	al.	2003).	Nishiyama	et	al	demonstrated	the	simultaneous	increase	of	both	ANG	II	and	ROS	with	CsA	treatment	in	animal	models	(Nishiyama	et	al.	2003).	In	this	study,	AT1	receptor	inhibition	resulted	 in	a	 significant	decrease	 in	ROS	production	and	savaging	of	ROS	with	 tempol,	 a	 super	 oxide	 dismutase	 (SOD)	 mimetic,	 also	 produced	 a	 significant	decrease	 in	 ROS	 (Nishiyama	 et	 al.	 2003).	 This	 data	 highlights	 the	 role	 for	 AT1	
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receptor	activation	 in	CsA-induced	ROS	production	but	 also	 the	potential	beneficial	effect	 of	 including	 antioxidant	 therapy	 in	 patients	 treated	 with	 CNIs.	 Interestingly,	their	 results	 not	 only	 highlighted	 a	 reduced	 ROS	 production,	 but	 also	 a	 reduced	hypertensive	and	nephrotoxic	effect,	mediated	through	a	reduced	production	of	ANG	II	(Nishiyama	et	al.	2003).		Many	 antioxidants	 have	 however	 featured	 in	 clinical	 trials	 in	 the	 aim	 being	 to	minimise	the	ROS	damage	induced	by	CNI	therapy	(Galletti	et	al.	2005;	Nishiyama	et	
al	2003;	 Jenkins	et	al.	2001).	Vitamin	E	has	been	the	most	extensively	studied,	with	results	 proving	 to	 be	 inconsistent.	 Wang	 et	 al	 were	 able	 to	 demonstrate	 the	 lipid	peroxidation	 effects	 of	 CsA	 nephrotoxicity	 in	 animal	 studies.	 Peroxidation	 was	initiated	through	ROS	generation,	however,	supplementation	of	vitamin	E	attenuated	both	lipid	peroxidation	and	ROS	generation	(Wang	&	Salahudeen	1995).	In	addition,	Jenkins	et	al	were	able	to	demonstrate	the	protective	effects	of	vitamin	E	against	CsA	nephrotoxicity	via	a	variety	of	pathways	(Jenkins	et	al.	2001).	Their	results	indicated	that	vitamin	E	attenuates	up	regulation	of	COX	I	and	II	and	TGF-β	after	CNI	treatment.	Both	COX	and	TGF-β	have	been	shown	to	be	involved	in	CNI	nephrotoxicity	(de	Vries	
et	 al.	 2006).	 With	 vitamin	 E	 supplementation,	 Jenkins	 et	 al	 demonstrated	 the	significant	reduction	of	nephrotoxicity,	hypertension	and	inflammatory	mediators.	Conversely,	 it	has	recently	been	suggested	that	vitamin	E’s	protective	mechanism	is	not	 entirely	 through	 an	 antioxidant	 pathway.	 De	 Vries	 et	 al	 have	 shown	 that	supplementation	of	vitamin	E	and	C	have	the	ability	to	reduce	blood	concentrations	of	CNIs	(de	Vries	et	al.	2006).	The	exact	mechanism	by	which	this	occurs	is	still	unclear	however	a	suggestion	of	increased	CYP	metabolism	has	been	put	forward	(Jenkins	et	
al.	2001;	de	Vries	et	al.	2006).		Therefore,	 although	 initial	 antioxidant	 studies	 have	 shown	 promising	 results,	 the	exact	pathways	involved	in	the	antioxidant	amelioration	of	some	CNI	side	effects	still	remain	elusive	and	may	not	be	solely	due	to	antioxidation	reactions.		










calcineurin-independent	mechanism	 for	 detrimental	 ROS	 production	 (A.	 Y.	 Zhou	 &	Ryeom	2014).		Additionally,	 de	Arriba	 et	al,	 using	 a	 renal	 tubule	 cell	 line,	were	 able	 to	 highlight	 a	specific	mechanism	for	CNI-induced	ROS	production	(de	Arriba	et	al.	2013).	CsA	was	shown	 to	 inhibit	 the	 activity	 of	 glutathione	 (endogenous	 antioxidant)	 while	simultaneously	 increasing	 ROS.	 In	 addition,	 CsA	 was	 able	 to	 induce	 ΔΨm	depolarisation	 through	 IMM	 and	 OMM	modifications	 while	 allowing	 IMM	 contents	(cytochrome	C)	to	reach	the	cytosol	(de	Arriba	et	al.	2013).	Intriguingly,	the	authors	were	able	 to	 illustrate	MPTP	formation	with	 the	 treatment	of	CsA.	Previously	 it	has	been	 thought	 CsA	 inhibits	 MPTP	 construction	 and	 can	 protect	 from	 cell	 apoptosis	(Kroemer	 et	 al.	 2007;	 Perez	 de	 Hornedo	 et	 al.	 2007).	 Upon	 cell	 treatment	 with	vitamin	E,	the	authors	concluded	all	detrimental	effects	were	inhibited	and	suggests	that	mitochondrial	ROS	was	responsible	for	renal	tubule	cell	apoptosis	(de	Arriba	et	
al.	2013).		Taken	 together,	 these	 two	 recent	 studies	 have	 shown	 the	 potential	 role	 of	mitochondrial	ROS	for	mediating	toxicity	further	of	other	surrounding	cells	upstream.		The	 aim	of	 this	 study	was	 to	 investigate	 the	 role	 of	mitochondrial	 dysfunction	 and	ROS	production	 in	 CNI-mediated	 vasoconstriction	previously	 presented	via	 the	 live	slice	 model	 to	 possibly	 elucidate	 the	 mechanisms	 involved	 in	 pericyte	 mediated	vasoconstriction	and	CNI	nephrotoxicity.													
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6.3	 Methods		Live	 kidney	 slices	 were	 prepared	 as	 previously	 described	 in	 chapter	 2:	 General	Methods.		To	 investigate	 possible	mitochondrial	 membrane	 potential	 alterations,	 the	 cationic	red	fluorescent	dye	tetramethylrhodamine	methyl	ester	(TMRM)	was	used.	TMRM	is	readily	 sequestered	 in	 the	 negative	 charged	 interior	 of	 active	 mitochondria.	 The	fluorescence	signal	 is	directly	co-related	to	the	ΔΨm	of	the	IMM,	therefore,	a	 loss	in	membrane	potential	results	in	loss	of	fluorescence	(Kroemer	et	al.	2007).	TMRM	was	applied	via	 superfusion,	 similar	 to	DIC	experiments,	 although	 the	 imaging	bath	was	situated	 on	 a	 2-photon	microscope	 setup	 (see	 general	 methodology).	 Tissue	 slices	were	continually	superfused	with	TMRM	(1	μM)	followed	by	a	10-minute	wash	with	PSS	to	exclude	unloaded	TMRM	from	the	bath	prior	to	experimentation.	To	 determine	 the	 role	 of	 ROS	 in	 CNI-induced	 vasoconstriction,	 the	 superoxide	fluorescent	 probe,	 dihydroethidum	 (DHE)	 was	 used.	 DHE	 is	 naturally	 blue	 in	fluorescence,	excited	wavelength	518	nm,	until	it	is	oxidised	to	form	ethidum,	red	in	fluorescence,	emission	wavelength	605	nm.	Once	oxidised,	DHE	intercalates	with	cell	DNA	and	stains	 the	nucleus	bright	red.	A	10-minute	wash	was	also	performed	after	dye	loading	to	remove	unloaded	dye	before	experimentation.		To	 label	 other	 live	 structures	 including	 microvessels	 and	 tubules,	 tissue	 was	simultaneously	loaded	with	calcein	(1	μg/ml).	Calcein	is	a	cell	permanent	dye	used	to	determine	 cell	 viability	 by	 converting	 non-fluorescent	 calcein	 to	 green	 fluorescent	calcein	after	acetoxymethyl	ester	hydrolysis	by	 intracellular	esterase’s	 (Tenopoulou	
et	 al.	 2007).	 Therefore,	 live	 viable	 cells	 omit	 green	 fluorescence	 at	 488	 nm.	 Slices	were	simultaneously	loaded	with	calcein	and	either	TMRM	or	DHE	after	which	slices	were	washed	with	PSS	prior	to	experimentation	to	remove	any	unloaded	dye.		Live	slices	 loaded	with	 fluorophores	were	excited	with	a	MiaTai	 laser	set	at	800nM	and	enabled	light	collection	via	PMTs	attached	to	a	2-photon	microscope	fitted	with	a	665	 nm	 long-pass	 dichroic	 mirror,	 to	 collect	 red	 signal,	 and	 680	 nm	 short-pass	dichroic	laser	blocking	filter	to	collect	green	signal.		For	investigations	of	ΔΨm,	kidney	slices	were	superfused	with	oxygenated	PSS	for	30	minutes	 while	 2-photon	 images	 where	 captured	 every	 10	 minutes	 to	 establish	 a	baseline	 fluorescence	 signal.	 Slices	were	 then	 exposed	 to	CsA,	 FK506	or	 rapamycin	for	approximately	25	minutes	and	then	subjected	to	a	PSS	wash	to	assess	reversibility	of	any	affect	on	fluorescent	signal.	Analysis	of	changes	in	fluorescence	was	similar	to	
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that	of	changes	in	vessel	diameter	(General	methodology).	In	short,	each	experiment	was	 analysed	 using	 the	 free	 public	 domain	 software	 IMAGE	 J	 (NIH;	http://rsb.info.nih.gov).	For	each	experiment,	several	regions	of	 interest	(ROI)	were	chosen	using	the	bright	field	microscope	setting.	Once	chosen,	tissue	loading	of	dyes	was	assessed	by	measuring	fluorescence	intensity	per	ROI.	This	was	essential	prior	to	analysis	as	not	all	tissue	loads	fluorescent	dyes	equally.	In	addition,	although	the	live	slice	preparation	produces	relatively	parallel-sectioned	tissues,	 images	acquired	are	at	a	 specific	optical	plane	 in	 the	z	plane	and	vessels	do	not	always	remain	 in	 focus,	therefore	fluorescence	intensity	may	vary	between	subsurface.	After	ROIs	were	chosen,	the	intensity	signal	at	ROI	locations	was	captured	every	five	minutes	for	the	duration	of	the	experiment.	An	average	of	the	first	3	measurements	(30	minutes	PSS	wash	after	loading)	was	taken	to	represent	the	baseline	fluorescent	signal	(i.e.	100%).	All	subsequent	fluorescent	measurements	at	ROIs	were	calculated	as	a	percentage	change	of	the	corresponding	baseline	fluorescent	signal.				
6.3.1	 Statistics		All	data	are	presented	as	mean	values	±	SEM;	n	numbers	are	displayed	as	number	of	kidney	 slices,	 and	 were	 appropriate,	 (number	 of	 animals).	 All	 experiments	 were	performed	in	at	least	six	different	animals.	Statistical	assessment	was	performed	with	GraphPad	Prisim		(v5.0f;	GraphPad	software,	San	Diego,	CA,	USA).	When	two	groups	were	compared,	a	Student’s	t-test	(two-tailed,	paired	or	unpaired	where	appropriate)	was	 used.	 A	 value	 of	 P	 <	 0.05	 was	 considered	 significant.	
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6.4	 Results	
6.4	 Measuring	mitochondrial	membrane	potential	in	the	live	kidney	slices			Prior	 to	 initiating	 experiments	 to	 determine	 effects	 of	 CNIs	 on	 mitochondrial	membrane	 potential,	 several	 control	 experiments	 were	 performed	 to	 determine	whether	if	it	was	possible	to	monitor	changes	in	TMRM	signal	in	live	kidney	tissue.		Carbonyl	cyanide-p-trifluoromethoxyphenylhydrazone	(FCCP)	is	a	protonophore	(H+	ionophore)	and	uncoupler	of	oxidative	phosphorylation	 in	mitochondria	 (Gautier	et	



























































































































Superfusion	(~1000	s)	of	FK506	and	rapamycin	(3	and	1	μM,	respectively)	resulted	in	no	 significant	 loss	 of	TMRM	 fluorescence	 (Figure	6.5).	 TMRM	 fluorescence	 reduced	over	 time	 after	 exposure	 to	 FK506	 and	 rapamycin,	 however	 both	 were	 not	significantly	 different	 compared	 to	 time	 matched	 PSS	 controls	 (Figure	 6.5).	 60	minutes	after	exposure	to	FK506	and	rapamycin,	TMRM	fluorescence	fell	to	90.94	±	5.8%	and	99.9	±	3.3%,	respectively,	and	was	not	significantly	lower	in	comparison	to	time	matched	 PSS	 control	 (91.9	 ±	 6.3%,	 n=8	 (7),	 (Figure	 6.5).	 Calcein	 fluorescence	signal	was	significantly	greater	after	application	of	FK506	and	rapamycin	compared	to	PSS	control	(Figure	6.5).																										
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Figure	6.5	 FK506	 and	 rapamycin	 do	 not	 evoke	 a	 change	 in	 TMRM	























































































6.4.2	 Effect	of	CNIs	on	mitochondrial	membrane	permeability	transition			Mitochondrial	membrane	transition	(MMT),	through	the	orientation	of	mitochondrial	permeability	transition	pores	(MPTP),	is	thought	to	be	a	key	step	in	cell	stress	leading	to	apoptosis	and	necrosis	(He	&	Lemasters	2002).	Given	the	fact	CNIs	failed	to	evoke	depolarisation	of	mitochondria	within	the	live	slice	model,	 combined	 with	 what	 is	 known	 about	 CNI	 prevention	 of	 MMT	 (Halestrap,	Connern	&	Griffiths	1997;	AL	et	al.	1996;	Petronilli	et	al.	1994),	MPTP	formation	was	investigated.		Chenodeoxycholate	(CDCA),	an	endogenous	bile	salt,	has	been	proven	to	be	a	potent	inducer	of	MPTP	 formation	(Rolo	et	al.	2003)	and	would	 therefore	act	as	a	positive	control	 to	 investigate	 the	 effect	 of	whether	 CNIs	 block	MPTP	 formation	 in	 the	 live	slice	 model.	 TMRM	 fluorescence	 would	 represent	 the	 formation	 of	 MPTP	 with	 a	reduction	of	TMRM	signal	suggesting	MPTP	formation	and	opening	(Cho	et	al.	2014).		Superfusion	 (~1000	 s)	 of	 CDCA	 (100	 μM)	 resulted	 in	 a	 significant	 loss	 of	 TMRM	fluorescence	 (Figure	 6.6).	 TMRM	 fluorescence	 rapidly	 reduced	 over	 time	 after	exposure	 to	CDCA	and	 failed	 to	 recover	 to	baseline	 intensity	 after	washout	 (Figure	6.6).	60	minutes	after	exposure	to	CDCA,	TMRM	fluorescence	fell	to	20.6	±	2.02%	and	was	significantly	 lower	 in	comparison	 to	 time	matched	PSS	controls	 (79.3	±	5.92%,	n=7	 (8),	 P<0.001)	 (Figure	 6.6)	 indicating	 CDCA-induced	 formation	 of	 MPTP	 which	resulted	in	decrease	of	TMRM	signal	as	expected.	Calcein	fluorescence	was	unaffected	with	application	of	CDCA	and	remained	constant	during	superfusion.				
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Figure	6.6	 Chenodeoxycholate	 induces	 a	 decrease	 in	 TMRM	 fluorescence	

































































































6.5	 Measuring	production	of	ROS	in	live	kidney	slices				Given	the	fact	CNIs	failed	to	induce	depolarisation	of	mitochondria	and	CsA	inhibited	the	 CDCA-mediated	 formation	 of	MPTP	 suggesting	 the	mechanism	was	 due	 to	 CsA	inhibition	of	MPTP	formation	that	resulted	in	changes	of	ΔΨm,	further	investigation	was	 necessary	 to	 elucidate	 possible	 mechanisms	 of	 CNI-induced	 pericyte	vasoconstriction.			CNI-induced	 production	 of	 reactive	 oxygen	 species	 (ROS)	 is	 now	 becoming	 a	more	accepted	 aspect	 of	 CNI	 nephrotoxicity.	 It	 is	 well	 known	 that	 CNIs	 reduce	 the	production	and	bioavailability	of	nitric	oxide	(NO)	(Naesens	et	al.	2009;	Oriji	&	Keiser	1999;	Amore	et	al.	1995;	Dusting	et	al.	1999),	however	the	mechanisms	involved	 in	their	production	of	ROS	 is	still	unclear.	Mitochondrial	ROS	has	been	suggested	with	several	groups	confirming	its	production	in	cell	lines	(de	Arriba	et	al.	2013;	Perez	de	Hornedo	et	al.	 2007;	A.	Y.	Zhou	&	Ryeom	2014;	Nishiyama	et	al	 2003),	while	other	groups	 have	 investigated	 its	 production	 via	 alternative	 cellular	 pathways	 including	NADPH	derived	ROS	production	(Lopez-Ongil	et	al.	1998;	Navarro-Antolin	et	al.	n.d.;	van	der	Toorn	et	al.	2007;	H.W.	Chen	et	al.	2002).		With	 this	 in	mind,	 CNI-induced	ROS	production	was	 investigated	 in	 the	 live	 kidney	slice	model.			MitoSOX	 red	 is	 a	 fluorescent	 dye	 specifically	 targeted	 to	mitochondria	 in	 live	 cells.	Once	oxidised	by	superoxide,	MitoSOX	red	produces	red	 fluorescence,	emits	 light	at	605	nm,	with	excellent	retention	properties	within	the	cell	and	minimal	dye	leakage	(Carvalho	da	Costa	et	al.	2003;	Perez	de	Hornedo	et	al.	2007).		Efforts	 to	 label	 live	 kidney	 tissue	 with	 MitoSOX	 failed	 and	 no	 fluorescence	 was	detected	 in	either	control	or	H2O2	 treated	tissue.	However,	given	that	CNIs	 failed	to	depolarise	mitochondria	in	the	live	slice	model,	which	is	thought	to	be	a	key	step	in	mitochondrial	ROS	production	(Murphy	2009)	it	was	not	surprising	that	CNIs	failed	to	 increases	 the	 level	 of	 MitoSOX	 fluorescence,	 although	 this	 has	 been	 previously	observed	 in	 isolated	 cells	 (Perez	 de	 Hornedo	 et	 al.	 2007;	 Carvalho	 da	 Costa	 et	 al.	2003).	Dihydroethidium	(DHE)	is	an	alternative	probe	for	superoxide	production	(Zielonka	
et	al.	 2008).	DHE	 is	naturally	blue	 in	 fluorescence,	 emits	 light	 at	518	nm,	until	 it	 is	oxidised	 after	 which	 it	 forms	 ethidum,	 red	 in	 fluorescence,	 emits	 light	 at	 605	 nm.	
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Once	 oxidised,	 DHE	 intercalates	 with	 cell	 DNA	 and	 stains	 the	 nucleus	 brilliant	 red	(Zielonka	et	al.	2008).		To	 establish	 a	 protocol	 for	 detecting	 the	 CNI-mediated	 production	 of	 ROS	 in	 live	tissue,	 slices	 were	 exposed	 to	 hydrogen	 peroxide	 (H202)	 as	 a	 positive	 control	 and	changes	in	fluorescence	monitored.		Superfusion	 (~500	 s)	 of	 H202	 (1	 mM)	 resulted	 in	 a	 significant	 increase	 of	 DHE	fluorescence	 (Figure	 6.9).	 DHE	 fluorescence	 plateaued	 after	 exposure	 to	 H202	 and	failed	 to	 return	 to	 baseline	 intensity	 after	 30	minutes	 of	 washout	 (Figure	 6.9).	 60	minutes	after	exposure	to	H202,	DHE	fluorescence	increased	to	190	±	14.7%	and	was	significantly	 greater	 in	 comparison	 to	 time	matched	 PSS	 control	 (19.7	 ±	 5.6%,	 n=6	(7),	 P<0.001)	 (Figure	 6.9).	 DHE	 fluorescence	 with	 PSS	 control	 was	 photobleached	throughout	experimentation	and	will	be	discussed	 further	below	in	 its	own	section.				Calcein	signal	was	unaffected	with	application	of	H202	and	remained	constant	during	experimentation.																						
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Figure	6.9	 H2O2	 evokes	 an	 increase	 in	 DHE	 fluorescence	 in	medullary	 vasa	










































Once	oxidized,	DHE	 forms	oxyethidium	and	 intercalates	with	DNA	and	 is	 unable	 to	exit	 the	 cell	 or	 return	 to	 its	 unoxidized	 form.	 Therefore,	 after	 excitation	 at	preferentially	 500	 nM,	 emission	 fluorescence	 will	 be	 constant	 at	 an	 optimal	wavelength	of	580	nM.		During	 PSS	 timed	 controlled	 experiments	 of	 DHE	 fluorescence,	 it	 was	 noted	 that	fluorescence	signal	dropped	over	time.	Photobleaching	is	the	term	used	for	this	loss	in	fluorescence	and	is	from	the	irreversible	decomposition	of	fluorescent	molecules	in	the	 excited	 state	because	of	 the	 interaction	 they	have	with	oxygen	before	 emission	(Patterson	 &	 Piston	 2000).	 Photobleaching	 is	 irreversible	 and	 time	 dependent,	therefore	interpretation	of	fluorescence	intensities,	which	decrease	over	time,	can	be	problematic	 and	 lead	 to	 misinterpretation.	 In	 addition,	 DHE	 has	 been	 previously	shown	to	undergo	rapid	photobleaching	in	a	variety	of	cell	types	(Krishnamurthy	et	
al.	1990;	Zielonka	et	al.	2008;	Kundu	et	al.	2009).	To	combat	this,	bleach	correction	can	 be	 applied	 to	 standardize	 fluorescence	 intensity	 over	 time	 (Patterson	&	 Piston	2000).		Bleach	 correction	 involves	 the	 manipulation	 of	 the	 exponential	 decay	 of	 the	fluorophore	and	its	representative	value	at	any	given	time	(B.	A.	Smith	&	McConnell	1978).		Bleach	 corrector	 is	 a	 free	 plugin	 (FIJI:	 http://fiji.sc/Bleach_Correction)	 that	 utilizes	the	 free	 public	 domain	 software	 IMAGE	 J.	 The	 plugin	 uses	 an	 exponential	 fitting	method	to	determine	the	rate	of	decay	of	a	series	of	images	and	reanalyze	the	image	stack	to	take	bleaching	into	consideration.			A	 time	 series	 control	 experiment	 was	 performed	 to	 carry	 out	 the	 degree	 of	photobleaching	 and	 feasibility	 of	 bleach	 correction.	 A	 live	 kidney	 slice	 was	 loaded	with	DHE	and	after	a	30	minute	unloaded	dye	wash;	DHE	fluorescence	was	measured	every	 ten	minutes	 for	 up	 to	 two	 hours.	 Uncorrected	DHE	 fluorescence	was	 plotted	against	 time	 (Figure	 6.10).	 The	 series	 of	 images	 were	 then	 reanalyzed	 using	 the	bleach	corrector	plugin	and	plotted	against	their	respective	time	point	(Figure	6.10).	Bleach	correction	resulted	 in	a	 significant	 increase	of	DHE	 fluorescence	 intensity	at	all	time	intervals,	n=6	(6),	P<0.001.		
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Figure	6.10	 DHE	 photobleaching	 correction	 results	 in	 increased	 DHE	























































Figure	6.11	 CsA	 evokes	 an	 increase	 in	 DHE	 fluorescence	 in	 medullary	 vasa	


















































































































































































Figure	6.13	 Rapamycin	 does	 not	 induce	 an	 increase	 in	 DHE	 fluorescence	 in	
medullary	vasa	recta	and	tubules.	A:	Representative	trace	shows	the	mean	data	for	rapamycin-mediated	 change	 in	 DHE	 fluorescence	 over	 time	 compared	 to	 time	matched	 PSS	 control.	 B:	 Representative	 trace	 showing	 mean	 data	 for	 rapamycin-induced	 change	 in	 calcein	 fluorescence	 over	 time	 compared	 to	 time	 matched	 PSS	control.	Mean	fluorescence	signal	percentage	measured	in	8	tubule	and	8	vessel	ROIs	for	trace	over	time	in	6	slices	from	6	animals.	Data	are	mean	±	SEM,	*P<0.05,	n=6	(6).			Interestingly,	 both	 CNIs	 were	 able	 to	 increase	 DHE	 fluorescence	 indicating	 their	ability	 to	 induce	ROS.	 ROS	 production	was	measured	 from	 increases	 in	DHE	 signal	and	measured	within	tubule	and	vessel	ROIs.	Due	to	the	sporadic	way	ROS	is	detected	



































































However,	 it	 is	 possible	 to	 select	 random	 areas	 of	 interest	 that	 are	 vessel	 or	 tubule	specific,	 measure	 the	 rate	 of	 DHE	 fluorescence,	 and	 therefore	 identify	 which	structures	produce	ROS	first	and	to	an	extent,	what	rate.			Analysis	 of	 time	 series	 experiments	 from	which	 live	 slices	where	 loaded	with	DHE	and	 calcein	 and	 exposed	 to	 CsA	 or	 FK506	 were	 carried	 out.	 Selection	 of	 tubules	(collecting	ducts	 and/or	 thick/thin	ascending	 limbs)	 and	blood	vessels	 (vasa	 recta)	were	selected	at	random	and	regions	of	interest	(ROI)	drawn	via	ImageJ.			Superfusion	 (~1000	 s)	 of	 CsA	 (3	 μM)	 resulted	 in	 a	 significant	 increase	 of	 DHE	fluorescence	at	vessel	and	tubule	ROI’s	(Figure	6.14).	DHE	fluorescence	increased	at	a	significantly	 faster	 rate	 with	 significantly	 increased	 intensity	 at	 vessel	 ROI’s	compared	to	tubular	ROI’s.	10	minutes	after	CsA	washout,	DHE	fluorescence	of	both	vessel	and	tubule	ROI’s	plateaued,	which	was	significantly	greater	at	vessel	ROIs	(161	±	 5.5%)	 compared	 to	 tubule	 ROIs	 (130	 ±	 5.2%,	 P<0.01,	 n=6	 (6),	 figure	 6.14.	 DHE	fluorescence	began	to	decline	after	maximum	intensity,	although	rate	of	decline	was	not	statistically	different	between	each	group.		
Figure	6.14	 Medullary	ROS	production	mediated	via	 CsA	 is	greater	 in	vessels	































Superfusion	 (~1000	 s)	 of	 FK506	 (1	 μM)	 resulted	 in	 a	 significant	 increase	 of	 DHE	fluorescence	at	vessel	and	tubule	ROI’s	(Figure	6.15).	DHE	fluorescence	increased	at	a	significantly	faster	rate	with	significant	increased	intensity	at	vessel	ROI’s	compared	to	tubular	ROI’s.	Approximately	10	minutes	after	FK506	washout,	DHE	fluorescence	of	both	vessel	 and	 tubule	ROI’s	plateaued,	which	was	 significantly	greater	at	vessel	ROIs	(121.7	±	8.5%)	compared	to	tubule	ROI’s	(98.4	±	4.8%,	P<0.05,	n=6	(6),	 figure	6.15.	 DHE	 fluorescence	 began	 to	 decline	 after	maximum	 intensity,	 although	 rate	 of	decline	was	not	statistically	different	between	each	group.			
Figure	6.15	 Medullary	 ROS	 production	 mediated	 via	 FK506	 is	 greater	 in	


























6.6	 Investigation	 of	 potential	 strategies	 to	 prevent	 CNI-induced	 ROS	
production			Given	that	it	is	well	known	that	CNIs	induce	ROS	production	(Lopez-Ongil	et	al.	1998;	A.	Y.	Zhou	&	Ryeom	2014;	van	der	Toorn	et	al.	2007;	de	Arriba	et	al.	2013)	and	the	detrimental	 role	 ROS	 play	 in	 the	 medullary	 microcirculation	 (Cowley	 et	 al	 2015a;	Wilcox	2002;	Z.	Zhang	et	al.	2004;	Wilcox	&	Welch	2000),	inhibiting	their	production	may	be	a	possible	mechanism	for	attenuating	CNI-induced	nephrotoxicity.		As	previously	mentioned,	over	half	of	all	ROS	produced	within	 the	kidney	originate	from	NADPH	oxidase	 and	 its	 inhibition	 has	 already	 been	 shown	 to	 be	 beneficial	 in	variety	of	disease	states	including	diabetic	nephropathy	and	hypertension	(Asaba	et	
al.	2005;	Gill	&	Wilcox	2006).	Remarkably,	 its	role	in	CNI-nephrotoxicity	is	less	well	documented.	Khanna	et	al	were	one	of	the	first	groups	to	demonstrate	upregulation	of	NADPH	in	rats	after	treatment	with	CNIs	and	investigate	its	role	in	the	aetiology	of	CNI-induced	nephrotoxicity	(Khanna	&	Pieper	2007).	In	addition,	their	experimental	model	 utilised	 renal	 transplants	 further	 adding	 physiological	 relevance	 to	 the	evidence	 that	 suggests	 NADPH	 oxidase	 might	 have	 and	 the	 role	 in	 CNI-mediated	nephrotoxicity	 in	 renal	 transplant	 patients.	 Very	 few	 groups	 have	 further	 explored	the	role	of	NADPH	in	CNI	nephrotoxicity.		Conversely,	 there	 is	a	plethora	of	studies	 focusing	on	scavenging	of	ROS	 induced	by	CNIs	or	its	dismuation	by	SOD	mimetics	as	a	therapeutic	strategy	(Tunon	et	al.	2003;	Lopez-Ongil	 et	 al.	 1998;	 Navarro-Antolin	 et	 al.	 2005;	 Damiano	 et	 al.	 2013).	 Taken	together,	it	is	reasonable	to	suggest	that	not	only	targeting	ROS	degeneration,	but	also	inhibiting	 its	 initial	production	would	be	a	possible	mechanism	 for	 attenuating	CNI	nephrotoxicity.			Apocynin	is	the	best	well-known	NADPH	oxidase	inhibitor	(Gill	&	Wilcox	2006).	It	has	been	 shown	 to	 have	 anti-inflammatory	 properties	 and	 act	 as	 an	 antioxidant	 in	endothelial	cells	and	VSMCs	(Stolk	et	al.	1994;	Heumuller	et	al.	2008;	C.	O.	Silva	et	al.	2015).	Recently,	Ciarcia	et	al	have	demonstrated	the	beneficial	effect	apocynin	has	on	CsA-induced	 hypertension	 and	 nephrotoxicity	 (Ciarcia	 et	 al.	 2015).	 Their	 results	indicated	apocynin	was	able	 to	not	only	reduce	production	of	ROS,	but	also	restore	the	haemodynamic	changes	in	the	kidney	that	occurred	with	CsA	administration.	This	suggests	that	ROS	production,	via	NADPH	oxidase,	is	involved	in	both	nephrotoxicity	and	hypertension	during	CsA	treatment.		
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Given	the	fact	CNIs	are	able	to	induce	ROS	production	and	induce	vasoconstriction	of	vasa	recta,	coupled	to	the	fact	pericytes	are	known	to	constrict	after	exposure	to	ROS,	it	 is	 feasible	 to	 suggest	ROS	production	may	be	 involved	 in	 the	mechanism	of	 CNI-induce	 vasoconstriction	 of	 vasa	 recta.	With	 this	 hypothesis	 in	mind,	 apocynin	 was	used	to	investigate	its	possible	role	of	attenuating	CNI-induced	ROS	production.				Superfusion	 of	 apocynin	 alone	 had	 not	 significant	 effect	 on	DHE	 fluorescence.	 DHE	photobleaching	 after	 exposure	 of	 apocynin	was	 not	 significantly	 different	 (30.94	 ±	5.87%)	compared	to	timed	matched	controls	of	DHE	alone	(34.14	±	2.72%,	n=6	(6)).			Superfusion	(~1000	s)	of	CsA	(3	μM)	and	apocynin	(10	μM)	resulted	in	a	significant	decrease	of	DHE	fluorescence	compared	to	CsA	alone	(Figure	6.16).	DHE	fluorescence	plateaued	 during	 exposure	 to	 CsA	 and	 apocynin	 however	 started	 to	 decrease	 after	CsA	and	apocynin	washout.	Change	in	DHE	fluorescence	reached	a	maximum	of	82.66	±	 13.6%	 and	was	 significantly	 lower	 in	 comparison	 to	 CsA	 alone	 (179.05	 ±	 13.5%,	P<0.001,	 n=6	 (6),	 (Figure	 6.16).	 Calcein	 fluorescence	 signal	 was	 not	 significantly	different	after	application	of	CsA	and	apocynin	(150	±	9.87%)	compared	to	CsA	alone	(164	±	11.21%,	n=6(6)).	





































	Superfusion	 (~1000	 s)	 of	 FK506	 (1	 μM)	 and	 apocynin	 (10	 μM)	 resulted	 in	 a	significant	 decrease	 of	 DHE	 fluorescence	 compared	 to	 FK506	 alone	 (Figure	 6.17).	DHE	 fluorescence	 stabilised	 during	 exposure	 however	 started	 to	 decrease	 after	FK506	 and	 apocynin	washout.	 Change	 in	DHE	 fluorescence	 reached	 a	maximum	of	91.90	 ±	 9.06%	 and	 was	 significantly	 lower	 in	 comparison	 to	 FK506	 alone,	 time	matched.	 (135.13	 ±	 14.9%,	 P<0.001,	 n=6	 (6),	 (Figure	 6.17).	 Calcein	 fluorescence	signal	was	not	significantly	different	after	application	of	FK506	and	apocynin	(120	±	8.54%)	compared	to	FK506	alone	(125	±	4.49%,	n=6(6)).		
	


































fluorescence	 in	 tissue	 exposed	 to	wither	 CsA/FK506	 and	 apocynin	 occurred	 at	 the	same	time	points	in	both	vessels	and	tubules.		Superfusion	 (~1000	 s)	 of	 rapamycin	 (1	 μM)	 and	 apocynin	 (10	 μM)	 resulted	 in	 no	significant	decrease	of	DHE	fluorescence	(50	±	8.89%)	compared	to	rapamycin	alone	(60.24	 ±	 9.39%,	 n=6(6))	 (Figure	 6.18).	 DHE	 fluorescence	 continued	 to	 decrease	during	 exposure	 and	 after	 rapamycin	 and	 apocynin	 washout.	 Calcein	 fluorescence	signal	 was	 not	 significantly	 different	 after	 application	 of	 rapamycin	 and	 apocynin	(130	±	8.32%)	compared	to	rapamycin	alone	(125	±	9.67%,	n=6(6)).		
		
Figure	6.18	 Apocynin	 has	 no	 effect	 on	 rapamycin-induced	 loss	 of	 DHE	



























6.7	 Discussion			The	 aim	 of	 this	 study	 was	 to	 use	 multiphoton	 microscopy	 to	 investigate	 possible	mechanisms	of	CNI-induced	vasoconstriction	of	vasa	recta	and	the	molecular	events	underlying	development	of	CNI-induced	nephrotoxicity.	The	results	have	shown	that	mitochondrial	membrane	potential	of	medullary	vasa	recta	and	tubules	is	unaffected	by	CNIs	and	rapamycin,	but	that	mitochondrial	permeability	transition	is	inhibited	by	CsA	but	not	by	FK506	or	rapamycin.		Reactive	 oxygen	 species	 production	 is	 induced	 in	 vasa	 recta	 and	 tubular	compartments	of	the	medulla	in	response	to	CNIs	while	rapamycin	fails	to	induce	ROS	production.	 NADPH	 inhibition	 prevents	 the	 production	 of	 CNI-mediated	 ROS	indicating	CNIs	mediate	ROS	production	via	NADPH	oxidase.	Taken	together,	CNI-induced	DVR	vasoconstriction	could	possibly	originate	from	the	production	 of	 ROS,	 decreased	 bioavailability	 of	 NO,	 increased	 ET-1	 production	 and	ADP	 ribosyl	 cyclase	 production,	 all	 leading	 to	 increased	 vasoconstriction.	Additionally,	 inhibition	 of	 CNI-induced	ROS	 via	 NADPH	 inhibition	 could	 provide	 an	alternative	 method	 for	 prevention	 of	 ROS	 production	 that	 could	 lead	 to	 CNI	nephrotoxicity	and	graft	dysfunction.			Multiphoton	microscopy	(MPM)	is	an	alterative	microscopy	technique	to	fluorescence	confocal	microscopy,	which	enables	clear	advantages	for	three-dimensional	imaging,	particularly	 of	 live	 cells	 and	 intact	 tissue	 including	 slices	 and	 whole	 organs.	 MPM	permits	 far	 greater	 tissue	 penetration	 along	 with	 less	 phototoxicity	 compared	 to	conventional	confocal	imaging,	therefore	enables	a	distinct	advantage	for	imaging	of	subsurface	cellular	structures	(Hall	et	al.	2011).		MPM	was	a	 concept	 first	described	 in	 the	1930’s	by	Maria	Goeppert-Mayer	but	not	put	into	practical	use	some	30	years	later	(Göppert-Mayer	1931).	In	principle,	MPM	is	based	on	the	conception	that	2	photons	of	lower	energy	than	required	for	one	photon	(confocal)	 excitation	 can	 also	 excite	 a	 fluorophore	 simultaneously	 (Göppert-Mayer	1931).	The	longer	 length	photons	must	arrive	simultaneously	at	the	focal	plane	and	hence	the	wavelength	of	exciting	photons	is	larger	than	emitted	light	(Williams	et	al.	2001).	Therefore,	each	photon	has	approximately	half	 the	energy	required	to	excite	the	fluorophore	and	results	in	reduced	phototoxicity.	Both	 confocal	 and	 MPM	 require	 the	 use	 of	 lasers	 instead	 of	 fluorescence	 mercury	lamps	or	LED’s	 to	excite	 fluorophores.	MPM	typically	uses	 titanium:	sapphire	 (Ti:S)	
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lasers	which	offer	a	far	greater	use	of	longer	wavelength	light	and	tunability	(typically	700-1200	nanometres).	MPM	 lasers	also	 typically	do	not	 require	water	 cooling	 like	confocal	laser	sources,	however	are	significantly	more	expensive,	combined	with	the	more	 expensive	microscope	 setup,	 makes	MPM	 a	 significant	 burden	 on	 laboratory	funding.		Confocal	microscopy	requires	the	use	of	a	pinhole	aperture	to	reduce	out	of	focus	 light	due	to	fluorescence	being	excited	throughout	the	entire	sample	and	thus	only	light	close	to	the	optical	plane	will	be	detected	(Williams	et	al.	2001).		Although	a	large	proportion	of	sample	will	be	excited,	point	illumination	is	achieved	by	the	use	of	a	pinhole	aperture	and	reduces	out	of	 focus	light.	 In	turn,	the	pinhole	aperture	only	enables	a	small	fraction	of	light	through	from	the	focal	plane	and	results	in	increased	resolution	and	increased	sample	intensity	(Nwaneshiudu	et	al.	2012).	Unlike	 confocal	 microscopy,	 MPM	 does	 not	 require	 a	 pinhole	 aperture.	 2-photon	excitation	 only	 produces	 fluorescence	 at	 the	 focal	 plane	 and	 therefore	 background	fluorescence	 is	not	produced	and	no	pinhole	apertures	are	required	(Williams	et	al.	2001).	 This	 distinct	 advantage	 enables	 only	 the	 focal	 plane	 to	 be	 imaged	 without	possibility	 of	 background	 fluorescence	 compromising	 the	 signal.	 In	 addition,	 this	reduced	 exposure	 minimises	 photobleaching	 and	 phototoxicity.	 Figure	 6.19	demonstrates	 the	 degree	 of	 fluorescence	 from	 out	 of	 focus	 planes	 by	 confocal	microscopy	and	fluorescence	from	the	focal	spot	via	multiphoton	microscopy.		
	
Figure	6.19	Visualisation	of	focal	plane	excitation	in	confocal	and	multiphoton	
microscopy.	Confocal	microscopy	excites	the	fluorescence	above	and	below	the	focal	plane	whereas	multiphoton	microscopy	only	excites	 fluorescence	at	 the	 focal	plane.	Adapted	from	(Zipfel	et	al.	2003).	
Confocal(( Mul$Photon*
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	MPM	has	a	distinct	advantage	on	live	cell	imaging	compared	to	confocal	imaging	due	to	reducing	out	of	focus	light,	greater	tissue	penetration	and	reduced	photobleaching.	However,	MPM	is	not	without	its	limitations.	Due	to	longer	wavelengths	being	utilised	(energy	of	a	photon	is	inversely	proportional	to	its	wavelength,	therefore	2	absorbed	photons	must	equal	a	wavelength	twice	of	that	for	confocal	excitation	(Williams	et	al.	2001),	MPM	actually	results	in	a	larger	resolution	spot.	This	increased	resolution	spot	correlates	 to	 Abbe’s	 law	 that	 states	 the	 resolution	 of	 a	 microscope	 is	 inversely	proportional	 to	 the	wavelength	of	 light	used	 (Heintzmann	&	Ficz	2006).	Therefore,	for	 any	 given	 fluorophore,	 2-photon	 excitation	 uses	 approximately	 twice	 the	wavelength	 of	 one-photon	 excitation	 and	 subsequently	 approximately	 half	 the	resolution.	 This	 can	 result	 in	 poorer	 defined	 images	 of	 cellular	 structures	 and	hampered	image	analysis.		Although	MPM	follows	this	principle,	improved	imaging	technology	has	decreased	the	loss	of	resolution	and	is	therefore	not	directly	in	relation	to	loss	of	half	the	resolution.	It	 is	 now	 generally	 accepted	 that	 MPM	 resolution	 is	 no	 less	 compared	 to	 that	 of	confocal	 microscopy	 because	 if	 a	 biological	 sample	 cannot	 be	 resolved	 using	 a	confocal	microscope,	it	similarly	will	not	be	resolved	using	a	MP	microscope.		As	 a	 whole,	 MPM	 offers	 a	 distinct	 advantage	 over	 conventional	 fluorescence	microscopy	 for	deeper	3-dimensional	 imaging	of	 living	tissue	without	 the	 increased	risks	of	photobleaching	and	phototoxicity.		These	advantages	have	already	helped	us	better	understand	the	physiology	of	whole	organs	 including	 the	 kidney.	 Hall	 et	 al	 have	 been	 able	 to	 use	 MPM	 on	 a	 isolated	perfused	 kidney	 model	 to	 study	 the	 cell	 structure	 and	 physiology	 of	 a	 whole	functional	 kidney	 (Hall	et	al.	 2011).	 The	 study	 allowed	visualisation	of	 endogenous	and	 exogenous	 fluorophores	 for	 investigations	 of	 renal	 function	 under	 certain	pathological	 conditions.	 In	 addition,	 it	 also	 highlighted	 the	 importance	 of	mitochondria	 structure	 and	 function	 during	 ischemia	 and	 reperfusion	 but	 also	 the	production	 of	 ROS	 for	 mediating	 changes	 in	 renal	 function	 under	 oxidative	 stress.	These	 changes	 are	 similarly	 seen	 in	 CNI-induced	 nephrotoxicity	 with	 altered	mitochondrial	 function	and	 increased	ROS	production	 (Buffoli	et	al.	 2005;	Perez	de	Hornedo	 et	al.	 2007;	 de	 Arriba	 et	al.	 2013;	Weir	 et	al.	 1992),	 therefore	 it	 could	 be	possible	to	identify	similar	pathways	in	their	pathogenesis	and	help	identify	common	targets	for	their	prevention.		
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Using	 MPM	 within	 the	 live	 slice	 model	 enables	 a	 more	 detailed	 view	 of	 cellular	changes	 of	 the	medulla	 during	 chemical	 insult	 including	CNIs	 and	potentially	 helps	identify	therapeutic	targets	for	prevention	of	nephrotoxicity.			The	results	from	this	chapter,	in	which	MPM	imaging	of	a	variety	of	fluorophores	was	used	 to	 investigate	CNI-mediated	 changes	 in	 cell	 function,	 suggest	 that	CNIs	do	not	alter	mitochondrial	membrane	potential	 (ΔΨm)	as	an	event	 leading	 to	CNI-induced	vasoconstriction.	 Pericyte-mediated	 vasoconstriction	 could	 not	 be	 measured	 using	MPM	due	to	the	lack	of	brightfield	microscopy	resolution	however	changes	in	vessel	diameter	 during	 superfusion	 of	 CNIs	 correspond	 to	 the	 timings	 of	 increased	 ROS	production	 visualised	 during	 MPM	 microscopy.	 As	 discussed	 previously,	 ΔΨm	 is	generated	 in	 the	 inner	 mitochondria	 membrane	 via	 electron	 flow	 through	 protein	complexes	 of	 the	 respiratory	 chain,	 coupled	 to	 the	 exit	 of	 protons	 from	 the	intermembrane	 space	 which	 generates	 the	 highly	 negative	 potential	 across	 the	mitochondria	membrane	(McBride	et	al.	2006).	Alterations	in	ΔΨm	have	been	shown	to	alter	mitochondrial	function	and	are	further	discussed	below.		Mitochondrial	 dysfunction	 has	 been	 shown	 to	 participate	 in	 the	 induction	 of	apoptosis	 and	possibly	 central	 to	 the	 apoptotic	 pathway	of	 all	 living	 cells	 (Ly	et	al.	2003).	 Loss	 of	 ΔΨm	 may	 be	 an	 early	 event	 in	 apoptosis	 leading	 loss	 of	 oxidative	phosphorylation	and	release	of	apoptogenic	factors	(Ly	et	al.	2003).		Changes	 in	 ΔΨm	 have	 been	 observed	 before	 any	 morphological	 adaptions	 (DNA	fragmentation	cell	shrinking)	in	isolated	embryonic	cells	suggesting	that	loss	of	ΔΨm	may	precede	any	changes	in	the	apoptotic	pathway	(Vayssiere	et	al.	1994;	Zamzami	et	
al.	1995).	However	other	studies	demonstrated	that	ΔΨm	is	 lost	after	apoptosis	via	DNA	damage	and	apoptosis	regulator	BAX	(Bax)	 translocation	 to	mitochondria,	and	therefore	 is	 not	 useful	 for	 early	 identification	 of	 apoptosis	 (Cossarizza	 et	 al.	 1994;	Karpinich	et	al.	2002)	and	suggests	the	different	rationale	of	ΔΨm	being	lost	due	to	apoptosis	 and	 not	 vice	 versa.	 It	 therefore	 suggests	 that	 2	 pathways	 are	 thought	 to	exist	 for	 linking	 changes	 of	 ΔΨm	with	 apoptosis,	 however	 neither	 of	 the	 two	 have	been	independently	confirmed.	Nonetheless,	 it	 is	 well	 regarded	 that	 mitochondrial	 dysfunction	 is	 central	 to	 cell	apoptosis,	whether	it	is	a	cause	or	effect	is	still	debateable,	and	mitochondrial	death	undoubtedly	results	in	cell	and	tissue	apoptosis.		It	has	been	previously	shown	that	FCCP	is	capable	of	ΔΨm	depolarisation	in	renal	cell	lines	 along	 with	 intact	 kidney	 tissue	 (Schnellmann	 et	 al.	 1994;	 Hall	 et	 al.	 2009)	
	 213	
therefore	 suitable	 as	 a	 positive	 control	 in	 the	 live	 kidney	 slice.	 Accordingly,	administration	of	FCCP	to	 live	kidney	slices	significantly	reduces	ΔΨm	and	thus	the	live	 slice	model	was	used	 to	 investigate	 the	effects	of	CNIs	on	ΔΨm.	Superfusion	of	CNIs	failed	to	significantly	alter	ΔΨm	therefore	suggesting	that	mitochondrial	(hyper)	depolarisation	 is	not	 involved	 in	pericyte-mediated	DVR	vasoconstriction.	Although	changes	in	vessel	diameter	could	not	be	directly	measured	using	MPM	per	se,	due	to	lack	 of	 brightfield	 images	 (MPM	 set-up	with	 this	 particular	model	 requires	manual	switching	 between	 DIC	 and	 MPM	 condensers)	 and	 bleaching	 of	 fluorophores,	 the	acute	 changes	 in	 vessel	 diameter	 observed	 during	 superfusion	 correspond	 to	 the	acute	changes	seen	in	MPM	when	changes	in	fluorescence	was	monitored.			Interestingly,	CNIs	have	been	shown	to	 induce	mitochondria	depolarisation	in	renal	cell	lines.	De	arriba	et	al,	Hornedo	et	al	and	Zhou	et	al	have	all	been	able	to	show	CsA	induced	 changes	 in	 mitochondrial	 membrane	 potential	 using	 TMRM	 or	 TMRE	(analogue	of	TMRM)	in	renal	cell	lines	(de	Arriba	et	al.	2013;	Perez	de	Hornedo	et	al.	2007;	A.	Y.	Zhou	&	Ryeom	2014).	However,	the	author’s	models	have	used	confluent	cells	treated	with	CsA	for	24	hours	or	more.	Superfusion	of	CsA	using	the	live	kidney	slice	model	ultimately	exposes	the	tissue	to	CsA	for	up	to	30	minutes.		Furthermore,	 it	has	been	shown	that	acute	exposure	of	CsA	offers	a	protective	role,	preventing	mitochondrial	 dysfunction	 induced	by	oxidised	 low-density	 lipoproteins	in	 an	 in	 vivo	 skeletal	 muscle	 model	 via	 inhibition	 of	 MPTP	 opening	 (Merlini	 et	 al.	2008),	 hence	 offering	 a	 protective	 role	 against	mitochondrial	 dysfunction.	 This	 has	been	 further	highlighted	by	Halestrap	et	al	 (Halestrap	et	al.	1997)	who	used	CsA	to	prevent	 mitochondrial	 dysfunction	 in	 a	 heart	 ischemia/reperfusion	 in	 vivo	 model.	Their	 results	 suggests	 that	 CsA	 binding	 to	 cyclophiln	D	 (CsA’s	 intracellular	 binding	molecule)	 renders	 it	 incapable	 of	 effecting	 ΔΨm,	 cyclophiln	 D	 has	 been	 previously	thought	 to	 be	 key	 in	 ΔΨm	 depolarisation	 through	 MPTP	 formation	 (Schubert	 &	Grimm	2004;	Nakagawa	et	al.	2005),	figure	6.20.	Taken	 together,	 it	 is	 clear	 that	 CNI	 effects	 on	 ΔΨm	 are	 somewhat	 contradictory	depending	 on	 which	 model	 used.	 Interestingly,	 it	 is	 now	 becoming	 clear	 that	investigating	 ΔΨm	 as	 a	 component	 of	 cellular	 apoptosis	 is	 dependent	 on	 the	 cell	system	being	used	and	evidence	to	date	regarding	whether	changes	in	ΔΨm	is	a	cause	or	effect	of	apoptosis	varies	depending	on	 the	experimental	model	 (Ly	et	al.	 2003).	For	example,	rat	embryonic	cells	induced	to	undergo	acute	apoptosis,	via	SV40	large	antigen,	 show	 early	 signs	 of	 lowered	 ΔΨm	 and	 reduced	 mitochondrial	 respiration	prior	 to	 apoptosis	 (H.	H.	Winkler	&	Lehninger	 1968),	while	 rat	 thymocytes	 treated	
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protect	from	mitochondrial	permeability	transition.		Chenodeoxycholate	 (CDCA)	 is	 a	 naturally	 occurring	 bile	 salt	 with	 potent	 ability	 to	induce	MPTP	formation	without	directly	effecting	ΔΨm	(Rolo	et	al.	2003;	Rolo	et	al.	2001).	 CDCA	was	 able	 to	 significantly	 reduce	 TMRM	 fluorescence	 after	 application	however	 in	 the	 presence	 of	 CsA,	 CDCA	 had	 no	 effect	 on	 TMRM	 signal.	 FK506	 and	rapamycin	had	no	such	inhibitory	effect	with	CDCA.		The	prevention	of	MPTP	opening	via	CsA	could	potentially	help	explain	its	protective	role	 in	certain	pathological	conditions.	As	previously	mentioned,	CsA	has	been	used	to	 prevent	 mitochondrial	 dysfunction	 in	 a	 variety	 of	 in	 vivo	 disease	 models	(Halestrap,	et	al.	1997;	Merlini	et	al.	2008)	and	could	be	due	 to	 its	 interaction	with	cyclophiln	 D	 (Cyp	 D).	 As	 seen	 in	 figure	 6.20,	 under	 normal	 conditions	without	 the	presence	of	CsA,	Cyp	D	 is	 a	part	of	MPTP	 formation	along	with	other	pore	 forming	proteins.	In	the	presence	of	CsA,	Cyp	D	is	unable	to	form	the	MPTP.		It	is	generally	thought	that	Cyp	D	is	needed	for	MPTP	formation	and	within	the	inner	membrane,	 adenine	 nucleotide	 translocase	 (ANT)	 and	 Cyp	D	 form	 the	MPTP	 along	with	the	outer	membrane	voltage-dependent	anion	channel	(VDAC)	to	complete	pore	assembly	(Kroemer	et	al.	2007).	Inhibition	of	Cyp	D	and	ANT	prevents	the	formation	of	 the	 pore	 and	 therefore	 stops	 mitochondrial	 transition	 to	 apoptosis.	 It	 must	 be	noted	that	this	model	is	still	a	working	hypothesis	and	no	definitive	model	has	been	published	 (Tsujimoto	 &	 Shimizu	 2007).	 CsA	 normally	 binds	 to	 Cyp	 D	 to	 inhibit	calcineurin	 translocation	 to	 the	 nuclease	 and	 activation	 of	 T	 cells,	 however	 as	 a	secondary	 mechanism,	 CsA	 also	 inhibits	 Cyp	 D	 complexing	 to	 ANT	 and	 prevents	MPTP	 formation.	 Tacrolimus	 and	 rapamycin	 do	not	 bind	 to	 Cyp	D	 therefore	would	not	inhibit	the	formation	of	the	MPTP.	This	is	in	fitting	with	the	results	produced	here	showing	that	tacrolimus	and	rapamycin	fail	to	prevent	the	loss	of	TMRM	fluorescence	after	 CDCA	 exposure,	 which	 was	 in	 contrast	 with	 CsA,	 which	 prevented	 MPTP	formation.	 The	 interaction	 on	 CNIs	 and	 rapamycin	 with	 intracellular	 proteins	 for	MPTP	regulation	can	be	seen	in	figure	6.21.	The	protective	 effect	 of	MPTP	 inhibition	has	been	 shown	 in	 a	 variety	 of	 conditions	including	 ischemic	 reperfusion	 and	 neurodegeneration	 (Brustovetsky	 &	 Dubinsky	2000;	Matsumoto	et	al.	1999)	however	 increasing	evidence	 is	 suggesting	 that	 there	are	 two	 forms	 of	 MPTP,	 CsA	 sensitive	 and	 CsA	 insensitive	 (Jung	 et	 al.	 1997;	 He	 &	Lemasters.	2001).	CsA	insensitive	MPTP	regulation	is	thought	to	be	regulated	through	chaperone	 proteins	 and	 protein	 clusters	 formed	 from	 oxidative	 damage.	 CsA-insensitive	MPTP	opening	results	 from	an	overload	of	protein	clusters	and	reduced	
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Figure	6.21		 CNI	 and	 rapamycin	 interactions	 with	 intracellular	 proteins	 for	










Within	 the	kidney,	 there	are	 two	major	 sources	of	ROS:	NADPH	oxidase	 (NOX)	and	mitochondria.	 NOX	 accounts	 for	 just	 over	 half	 of	 all	 renal	 ROS	 production	 while	mitochondria	 supply	 the	 reminder	 (Taylor	 et	 al.	 2006;	 Cowley,	 M.	 Abe,	 Mori,	O'Connor,	 Ohsaki	 &	 Zheleznova	 2015a).	 Given	 the	 fact	 CNIs	 were	 unable	 to	 alter	ΔΨm,	 a	major	 step	 in	production	of	mitochondrial	ROS	 (Murphy	2009),	 it	 is	 fair	 to	postulate	that	mitochondria	are	unlikely	to	be	sources	of	superoxide	or	ROS.	This	was	unable	 to	 be	 investigated	 due	 to	 poor	 loading	 of	 MtioSox	 in	 live	 kidney	 tissue	therefore	the	majority	of	the	discussion	will	be	focused	on	NOX	ROS	production.		NADPH	oxidases	are	a	family	of	ROS	producing	enzymes	consisting	of	seven	isoforms:	NOX1,	NOX2,	NOX3,	NOX4,	NOX5,	Doux1	and	Duox2	 (Kawahara	et	al.	 2007).	Under	normal	 conditions,	 NADPH	 derived	 ROS	 play	 important	 roles	 in	 many	 cellular	signalling	 pathways	 and	 defences	 including	 regulation	 of	 ion	 channels,	 gene	expression	and	cell	growth	(Kaelin	2005;	Sedeek	et	al.	2010).	However	under	stress,	cells	overproduce	ROS,	which	can	lead	to	 lipid	peroxidation	and	membrane	damage	(Murphy	 2009)	 and	 have	 been	 linked	 to	 several	 renal	 diseases	 including	 ischemia	reperfusion,	 allograft	 rejection	 and	 glomerulonephritis	 (Baud	 &	 Ardaillou	 1986).	NADPH	 oxidase	 is	 well	 expressed	 within	 the	 kidney	 with	 NOX1	 and	 4	 being	 the	dominant	 isoforms	 (Nistala	et	al.	 2008).	There	 is	 a	 prominent	 expression	of	NOX	1	and	 4	 in	 renal	 vessels,	 glomeruli,	 thick	 ascending	 loop	 of	 Henle,	 distal	 tubules,	collecting	ducts	and	macula	densa	(Gill	&	Wilcox	2006).	It	 is	 now	 well	 established	 that	 ROS	 production	 has	 a	 role	 to	 play	 in	 CNI-induced	nephrotoxicity,	however	to	what	extent,	 is	still	unknown.	Both	CsA	and	FK506	have	been	 shown	 to	 up-regulate	 eNOS	 in	 cultured	 endothelial	 cells	 and	 would	 initially	suggest	a	protective	role	through	the	subsequent	production	of	NO	and	vasodilation	(LopezOngil	et	al.	 1996;	Navarro-Antolin	et	al.	 1998).	However	 this	upregulation	of	eNOS	 proceeds	 the	 initial	 production	 of	 ROS	 as	 the	 cells	 try	 to	 overcome	 excess	production	of	ROS	and	decreased	bioavailability	of	NO.	NO	rapidly	reacts	with	ROS	to	form	 peroxynitrite,	 an	 alternative	 source	 of	 ROS,	 which	 ultimately	 reduces	 NO	bioavailability,	reduces	vasodilation	and	promotes	platelet	aggregation	and	leukocyte	aggregation	 (Muller	&	Morawietz	2009).	As	discussed	previously	 in	 chapter	1,	CNI-induced	 ROS	 production	 has	 also	 been	 shown	 to	 be	 involved	 in	 ANG	 II-mediated	hypertension.	Nishiyama	et	al	and	Chander	et	al	have	both	shown	that	treatment	with	CNIs	increase	the	production	of	ANG	II	and	subsequent	increased	levels	of	circulating	ROS	 (Nishiyama,	 et	 al.	 2004).	 Authors	 found	 that	 Inhibiting	 ANG	 II	 signalling	with	specific	 AT1	 receptor	 antagonists	 resulted	 in	 a	 reduction	 in	 the	 level	 of	 ROS	
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production,	 significant	 reduction	 in	 hypertension	 and	 overall	 nephrotoxicity	 was	attenuated.	 In	 addition,	 CNI-induced	 ROS	 production	 has	 been	 shown	 to	 increase	independent	of	ANG	II	production	(Jennings	et	al.	2007;	de	Arriba	et	al.	2013).	This	suggests	CNIs	 are	 capable	of	ROS	production	 through	various	pathways	and	makes	identification	of	specific	therapeutic	targets	even	more	challenging.		Importantly,	 ROS	 production	 was	 not	 induced	 via	 rapamycin,	 which	 correlates	 to	current	literature	and	clinical	observations	that	demonstrate	rapamycin’s	inability	to	induce	ROS	production	in	cell	lines	but	also	in	human	transplant	settings	(Arceci	et	al.	1992;	Tunon	et	al.	2003;	Shin	et	al.	2011;	MacDonald	2003).	Given	the	fact	rapamycin	failed	 to	 induce	 pericyte-mediated	 vasoconstriction	 and	 also	 failed	 to	 induce	 ROS	production	whereas	both	CNIs	had	the	opposite	effect,	it	could	be	suggested	that	ROS	signalling	 may	 be	 involved	 in	 CNI-mediated	 vasoconstriction	 and	 potentially	 CNI-induced	nephrotoxicity,	as	has	been	demonstrated	 in	animal	models	with	 increased	free	radical	production	correlating	to	nephrotoxicity	(A.	Y.	Zhou	&	Ryeom	2014).	ROS	 production	 within	 the	 cortex	 has	 already	 been	 shown	 to	 be	 influential	 in	 the	regulation	of	tubuloglomerular	feedback	(Wilcox	&	Welch	2000)	and	the	response	of	vasa	 recta	 to	 ischemia	 (Z.	 Zhang	 et	 al.	 2004;	 Cowley	 et	 al.	 2015a).	 Importantly,	pericytes	 have	 been	 shown	 to	 constrict	 vasa	 recta	 in	 response	 to	 ROS	 but	 also	pericyte-mediated	constriction	was	inhibited	via	SOD	or	ROS	scavengers	(Z.	Zhang	et	
al.	2004;	Cowley,	M.	Abe,	Mori,	O'Connor,	Ohsaki	&	Zheleznova	2015a;	Crawford	et	al.	2012).	Taken	together,	evidence	suggests	renal	pericyte	are	able	react	to	surrounding	NO	and	ROS	levels	and	modulate	medullary	blood	vessels	in	response	to	ischemia	and	toxic	insult.	With	CNIs	able	to	produce	superoxide	within	the	medulla,	it	is	reasonable	to	 suggest	 that	 CNI-mediated	 vasoconstriction	 of	 vasa	 recta	 could	 be	 mediated	through	ROS	signalling	and	decreased	bioavailability	of	NO.			Interestingly,	new	research	has	demonstrated	the	beneficial	effects	of	inhibiting	ROS	production	 induced	 by	 CNIs.	One	 particular	 study	 by	 Ciarcia	 et	al	 used	 the	 specific	NADPH	oxidase	 inhibitor,	apocynin,	 to	reduce	all	haemodynamic	changes	seen	with	CsA	 administration	 along	 with	 a	 reduction	 of	 ROS	 production	 and	 increase	 in	 NO	bioavailability	 (Ciarcia	 et	 al.	 2015).	 Importantly,	 this	 was	 carried	 out	 in	 vivo	using	animal	models,	highlighting	 the	physiological	 relevance	ROS	 inhibition	may	have	 in	the	human	setting.	Despite	 the	 fact	NADPH	oxidase	 is	 thought	 to	be	responsible	 for	over	 50%	 of	 renal	 ROS	 production	 (Gill	 &	Wilcox	 2006;	 Cowley	 et	 al	 2015a),	 this	approach	 to	 attenuate	 ROS	 has	 been	 poorly	 investigated,	 with	 the	 majority	 of	
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research	 focusing	 on	 reduction	 of	 ROS	 rather	 than	 preventing	 its	 production.	Damiano	et	al	used	a	recombinant	manganese	SOD	in	CsA	treated	rats	to	significantly	reduce	 the	 ROS-mediated	 haemodynamic	 alterations	 induced	 via	 CsA	 and	 also	demonstrate	the	attenuated	renal	morphological	 lesions	seen	with	CsA	(Damiano	et	
al.	 2013).	 Their	 data	 suggests	 that	 ROS	 is	 somewhat	 responsible	 for	 both	 the	reduction	 of	 renal	 blood	 flow	 (acute	 nephrotoxicity)	 but	 also	 the	 morphological	changes	downstream	of	altered	RBF	seen	after	CNI	therapy	(chronic	nephrotoxicity).		Wang	et	al	highlighted	 the	 role	of	 lipid	peroxidation	 in	 response	 to	ROS	generation	after	CNI	 administration	 (Wang	&	 Salahudeen	1995).	 The	data	 suggested	 that	 CNIs	are	able	 to	 increase	significant	 levels	of	atherosclerosis	 in	 transplant	recipients	and	the	source	of	ROS	could	stem	from	cytochrome	P-450	(CYP	450)	metabolism	of	CNIs	producing	 the	 hydroxyl	 radical.	 CYP	 450	 activation	 induces	 superoxide	 production	(Freeman	 &	 Crapo	 1982),	 therefore	 metabolism	 of	 CNIs	 would	 result	 an	 excess	production	of	ROS	 through	direct	 (eNOS	and	mitochondrial	ROS)	and	 indirect	 (CYP	450	metabolism	and	 increased	ANG	 II)	mechanisms.	 Importantly,	 the	 author’s	 data	also	demonstrated	the	significant	attenuation	of	ROS	and	associated	renal	injury	after	the	use	of	vitamin	E	for	ROS	scavenging,	again	suggesting	a	role	of	ROS	production	in	CNI	nephrotoxicity.		The	results	produced	 in	this	chapter	have	highlighted	the	use	of	an	NADPH	oxidase	inhibitor	 for	 prevention	 of	 CNI	 renal	 damage.	 Apocynin	 was	 able	 to	 significantly	attenuate	 the	 CNI-induced	 production	 of	 ROS,	more	 specifically,	 superoxide,	 which	has	 been	 shown	 to	 effect	 the	 renal	 medullary	 microcirculation	 (Zou	 et	 al.	 2001;	Taylor	 et	 al.	 2006;	 Cowley	 et	 al	 2015a)	 and	 constrict	 vasa	 recta	 via	 pericytes	 (Z.	Zhang	 et	 al.	 2004),	 which	 is	 in	 fitting	with	 data	 presented	 in	 this	 chapter.	 NADPH	oxidase	has	been	shown	to	be	expressed	on	retinal	pericytes	(Mustapha	et	al.	2010)	and	NADPH	oxidase	derived	ROS	is	responsible	for	increased	pericyte	apoptosis	and	can	 be	 attenuated	 using	 apocynin	 in	 diabetic	 retinopathy	 (Mustapha	 et	 al.	 2010),	evidence	 that	 further	emphasises	a	 link	between	ROS	and	pericyte-mediated	vessel	constriction.		As	 mentioned	 in	 the	 results	 section	 of	 this	 chapter,	 changes	 in	 DHE	 fluorescence	occurred	 initially	 in	 the	 vascular	 compartment	 and	were	 significantly	 greater	 than	changes	measured	 in	 the	 tubules.	This	 indicates	 the	 vascular	 compartment	 is	more	sensitive	to	changes	in	local	ROS	and	is	in	fitting	with	observations	in	which	CsA	and	FK506	resulted	in	changes	in	vessel	diameter.	Localised	changes	in	blood	flow	would	
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thus	 impact	 upon	 tubular	 function,	 which	 is	 in	 fitting	with	 clinical	 observations	 of	altered	GFR	before	alterations	in	tubular	function.		Taken	 together,	along	with	results	produced	 in	 this	chapter,	 it	 is	clear	 that	ROS	are	involved	 in	 CNI	 nephrotoxicity.	 Given	 that	 ROS	 are	 capable	 of	 inducing	 pericyte-mediated	 vasoconstriction	 and	 prevention	 of	 ROS	 via	 apocynin,	 an	NADPH	 oxidase	inhibitor,	 attenuates	 the	 haemodynamic	 changes	 induced	 by	 CNIs,	 it	 is	 not	unreasonable	 to	 suggests	 targeting	 NADPH	 inhibition	 therapeutically	 would	 be	 an	excellent	strategy	for	the	reduction	of	pericyte-mediated	vasoconstriction	of	ensuing	CNI	nephrotoxicity.							 	
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7.	 General	discussion,	conclusions,	and	future	work			The	calcineurin	inhibitors	cyclosporine	A	and	tacrolimus	have	been	at	the	forefront	of	solid	organ	 transplantation	 for	 the	past	 thirty	 years.	Their	 introduction	 at	 the	 time	revolutionised	allograft	function	and	1-year	graft	survival	post-transplantation	rates	are	now	at	over	90%	(Haynes	et	al.	2013).	Their	use	however	has	been	hampered	by	their	 unwanted	 side	 effects	 including	 hypertension,	 glucose	 intolerance	 and	nephrotoxicity.	 The	 incidence	 of	 CNI-induced	 nephrotoxicity	 is	 30%	 (1	 year	 after	renal	 transplant)	 following	onset	of	 treatment	 (Nankivell	et	al.	 2003)	and	has	been	shown	 in	 100%	 of	 patients	 10	 years	 post	 transplant	 (Nankivell	 et	 al.	 2004).	Interestingly,	the	mechanisms	underlying	CNI-induced	nephrotoxicity	are	still	poorly	defined,	with	a	combination	of	factors	including	increased	vasoconstriction,	reduced	vasodilation	 and	 sympathetic	 nerve	 activation	 all	 thought	 to	 play	 a	 part	 in	 renal	decline.		This	 study	 set	 out	 to	 investigate	 the	 effects	 of	 CNIs	 on	 the	 renal	 medullary	microcirculation,	of	which	there	is	little	research,	and	primarily	their	effects	on	renal	pericytes.	Given	 that	CNIs	are	already	known	to	reduce	renal	cortical	blood	 flow	as	measured	by	changes	in	GFR	and	this	evidence	together	with	an	established	role	for	pericytes	as	renal	medullary	blood	flow	regulators,	the	effect	CNIs	have	on	medullary	blood	 flow	 is	 yet	 to	 be	 investigated	 and	 may	 enhance	 our	 understanding	 of	 the	cellular	mechanism	underlying	the	pathogenesis	of	CNI-induced	nephrotoxicity.			In	 this	 thesis,	 data	 presented	 in	 chapter	 3	 shows	 for	 the	 first	 time	 the	 contractile	effect	CNIs	have	on	renal	medullary	pericytes.	The	reduction	in	diameter	of	vasa	recta	
via	 pericytes	 is	 most	 likely	 to	 impede	 medullary	 blood	 flow,	 given	 that	 using	Poiseuille's	law	as	an	estimate	of	changes	in	blood	flow	(BF)	assumes	laminar	flow,	a	10%	decrease	 in	 diameter	would	 result	 in	 an	 1.5	 fold	 increase	 in	 vessel	 resistance	(Crawford	et	al.	2012).	Furthermore,	the	mTOR	inhibitor,	rapamycin,	failed	to	induce	any	 significant	 changes	 in	 vasa	 recta	 diameter,	 which	 is	 in	 fitting	 with	 clinical	observations	that	suggest	a	reduction	in	the	extent	and	manifestations	of	rapamycin	associated	nephrotoxicity.	The	 majority	 of	 research	 that	 has	 been	 conducted	 on	 CNI-induced	 nephrotoxicity,	with	respect	to	renal	blood	flow,	has	concentrated	on	the	larger	afferent	and	efferent	arterioles	of	 the	glomerulus	 (Naesens	et	al.	2009).	Very	 little	 information	regarding	any	 renal	 microvasculature	 modifications	 is	 available.	 Not	 surprisingly,	 this	 might	
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reflect	 the	 previous	 understanding	 of	 how	 medullary	 flow	 was	 thought	 to	 be	regulated.	Upstream	regulation	via	afferent	and/or	efferent	vasoconstriction/dilation	was	 recognised	 as	 the	main	 pathway	 for	medullary	 blood	 flow	 alterations	 (R.	 G.	 R.	Evans	et	al.	 2004),	 all	 changes	 in	capillary	blood	 flow	being	assumed	 to	be	passive.	However,	 in	recent	years,	 the	role	of	pericyte	cells	 in	regulation	of	medullary	blood	flow	has	received	a	significant	amount	of	attention.	Pallone	and	colleges	carried	out	much	 of	 the	 early	 research,	 which	 suggested	 pericytes	 were	 able	 to	 adapt	 to	surrounding	 conditions	 and/or	 endogenous	 stimuli	 to	 regulate	 vasa	 recta	 diameter	independent	of	arteriole	flow	(Pallone	&	Silldorff	2001).	In	addition,	given	that	MBF	accounts	for	less	than	1%	of	total	renal	blood	flow	and	yet	its	regulation	is	essential	for	 maintenance	 of	 the	 cortico-meduallry	 gradients	 and	 delivery	 of	 oxygen	 and	nutrients	(Kennedy-Lydon	et	al.	2012),	it	is	not	perhaps	surprising	that	regulation	of	this	highly	specialized	region	would	not	be	passive	and	is	tightly	regulated.		It	 is	 well	 known	 that	 CNIs	 induce	 increased	 vasoconstriction	 and	 reduced	vasodilation	 of	 the	 renal	 vasculature	 through	 alteration	 in	 the	 bioavailability	 of	 a	variety	 of	 endogenous	 compounds.	 These	 include	 an	 increase	 of	 ANG	 II,	 ET	 and	thromboxane,	 and	 a	 decrease	 of	 NO,	 PGE2	 and	 COX-2	 expression	 (Naesens	 et	 al.	2009).	 Interestingly,	 all	 the	 aforementioned	 compounds	 have	 also	 been	 shown	 to	constrict	or	dilate	vasa	recta	via	pericytes	(Crawford	et	al.	2012;	Crawford	et	al.	2013;	Rhinehart	 &	 Pallone	 2001b;	 Pallone	 1994;	 Silldorff	 et	 al.	 2002).	 In	 addition,	 it	 has	been	 shown	 that	 dysregulation	 of	 medullary	 blood	 flow	 can	 actually	 precede	 any	changes	seen	in	cortical	flow	(Mattson	et	al.	1992).	Yagil	was	able	to	demonstrate	the	detrimental	effects	CsA	has	on	post-transplant	kidneys,	concentrating	on	total	renal	blood	 flow.	 The	 author	 used	 post-ischemic	 kidneys	 injected	 with	 FITC-labelled	 Υ-globulin	 in	 rats	 and	 fluorescence	 microscopy	 readings	 at	 papilla	 to	 estimate	erythrocyte	 velocity	 as	 a	 readout	 of	 vasa	 recta	 blood	 flow	 and	 highlighted	 the	significant	 reduction	 of	 both	 renal	 cortical	 and	 medullary	 flow	 after	 CsA	administration	(Yagil	1990).	Taken	 as	 a	whole,	 evidence	 presented	 here	 in	 combination	with	 data	 yielded	 from	previous	studies	indicate	CNIs	may	have	a	more	profound	effect	on	medullary	blood	flow	 than	previously	 thought	 and	may	even	be	 an	 initial	 step	 in	 the	progression	of	nephrotoxicity.			Data	 presented	 in	 chapter	 4	 concentrated	 on	 investigating	 the	 effect	 of	 combining	antihypertensives	 with	 CNIs	 on	 CNI-mediated	 contraction	 of	 vasa	 recta	 based	 on	
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clinical	evidence	showing	 that	over	90%	of	post	operative	renal	 transplant	patients	will	develop	some	form	of	hypertension	(First	et	al.	1994;	Textor	et	al.	1994).		The	 data	 regarding	 the	 specific	 mechanism	 underlying	 the	 pathogenesis	 of	 CNI-induced	 hypertension	 varies,	 some	 clinicians	 will	 suggest	 only	 the	 vasculature	 is	involved	 will	 others	 only	 identify	 sympathetic	 nerve	 activation	 as	 responsible,	 as	being	compliant	due	to	its	action	on	vessels	(Hoorn	et	al.	2012).	Interestingly,	Hoorn	
et	al	 have	 identified	 a	 form	 of	 salt-sensitive	 hypertension	 after	 CNI	 treatment	 that	was	 mediated	 through	 NCC	 in	 the	 distal	 convoluted	 tubule	 (Hoorn	 et	 al.	 2011),	indicating	a	tubular	contribution	to	CNI-mediated	hypertension.	Since	the	risk	factors	for	 hypertension	 after	 renal	 transplantation	 include	 both	 donor	 and	 recipient	elements	 it	 is	 almost	 impossible	 to	 identify	 a	 single	 cause	 and	 thus	 the	 precise	pathogenesis	is	highly	complex.			Regardless	of	the	causal	mechanisms,	it	is	now	known	CNI-induced	hypertension	can	be	 controlled	 pharmacologically	 with	 a	 wide	 variety	 of	 antihypertensive	 agents.	Angiotensin	 II	 receptor	 inhibitors	 (ARIs)	 have	 been	 used	 to	 treat	 CNI-induced	hypertension	since	it	was	first	discovered	that	CsA	is	able	to	increase	circulating	ANG	II	 concentrations.	 Although	 many	 trials	 have	 investigated	 ARIs	 for	 their	 ability	 to	prevent	CNI-induced	hypertension,	their	relative	efficiency	in	doing	so	is	still	unclear.	Inigo	 et	 al	 demonstrated	 the	 insignificant	 effect	 losartan	 had	 on	 improving	 GFR	 in	transplant	 patients,	 although	 slightly	 reducing	 blood	 pressure	 (Iñigo	 et	 al.	 2001)	while	Rastghalam	et	al	postulated	that	complete	blockade	of	ANG	II	was	of	no	use	at	all	 for	prevention	of	hypertension	and	CNI-mediated	nephrotoxicity	 (Rastghalam	et	
al.	 2014).	 The	 results	 in	 this	 chapter	 suggest	 CNI-induced	 vasoconstriction	 of	 vasa	recta	in	not	mediated	through	ANG	II	acting	at	AT-1	receptors	since	losartan	failed	to	inhibit	 pericyte	 constriction	 of	 either	 CsA	 or	 FK506.	 Interestingly,	 ANG	 II	 has	 been	shown	 to	 significantly	 induce	pericyte	vasoconstriction	of	 vasa	 recta	 in	vitro	 and	 in	
situ	(Pallone	1994;	Crawford	et	al.	2012)	and	losartan	has	been	shown	to	successfully	inhibit	 in	 vitro	 and	 in	 situ	 pericyte	 vasoconstriction	 mediated	 via	 ANG	 II	 in	 these	studies	 (Rhinehart	 et	 al.	 2003;	 Crawford	 et	 al.	 2012).	 As	 seen	 in	 figure	 1.8	 of	 the	general	 introduction,	ANG	II	has	direct	and	indirect	mechanisms	of	vasoconstriction	within	the	kidney	and	taken	together,	it	can	be	postulated	that	although	production	of	ANG	II	is	increased	after	CNI	treatment,	its	effects	on	medullary	blood	flow	may	not	be	 direct	 and	 pericyte	 mediated	 vasoconstriction	 could	 be	 through	 an	 alternative	pathway,	 ANG	 II	 mediated	 ROS	 production,	 endothelin	 production	 or	 decreased	bioavailability	of	NO	for	example.		
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	Although	ANG	II	receptor	inhibition	failed	to	prevent	CNI-induced	vasoconstriction	in	this	 study,	 a	 variety	 of	 other	 antihypertensive	 agents	 were	 more	 successful.	Hydrochlorothiazide	 (HCT)	was	 able	 to	 significantly	 reduce	 CNI-mediated	pericyte-evoked	 constriction	 of	 vasa	 recta.	 Typically	 used	 for	 oedema	 treatment	 and	hypertension,	 HCT	 has	 now	 been	 suggested	 to	 prevent	 CNI-induced	 hypertension.	The	initial	data	for	this	hypothesis	was	adapted	from	Hoorn	et	al	who	demonstrated	a	direct	upregulation	of	NCC	in	the	distal	tubule	of	animals	after	treatment	with	FK506	(Hoorn	 et	 al.	 2011).	 Subsequently	 the	 induced	 salt-sensitive	 hypertension	 in	 mice	was	attenuated	by	NCC	inhibition.	HCT	is	a	NCC	inhibitor;	therefore	using	HCT	would	prevent	 NCC	 activation	 and	 result	 in	 an	 attenuated	 salt-	 sensitive	 hypertensive	response	after	CNI	administration.	How	HCT	is	able	to	directly	attenuate	CNI-induced	vasoconstriction	via	pericytes	 in	the	medulla	 is	still	unclear,	however	HCT	has	been	shown	 to	 have	 direct	 vasodilatory	 effects	 on	 a	 variety	 of	 blood	 vessels	 (A.	 D.	 A.	Hughes	2004;	Pickkers	et	al.	1998)	and	even	inhibit	intracellular	calcium	signalling	in	isolated	 cells	which	 is	 essential	 for	 contraction	 (SandstrÃ	m	1993).	Together,	 these	results	 suggest	HCT	acts	 to	 relax	VSMC’s	 leading	 to	vasodilation.	Although	not	SMC	themselves,	pericytes	have	similar	contractile	properties	to	SMC	and	express	similar	components	 of	 the	 contractile	machinery	 (Shepro	&	Morel	 1993)	 and	 even	 similar	levels	of	 cyclic	GMP	(an	enzyme	 in	high	concentrations	of	VSMCs	used	 for	dilation)	(Joyce	et	al.	1984).	Intriguingly,	 it	 has	 been	 shown	 that	 increased	 sodium	 and	 water	 uptake	 in	 the	medullary	thick	ascending	limbs	of	Henle	increases	the	production	of	medullary	ROS	(Cowley	et	al	2015a)	therefore	HCT-mediated	inhibition	of	this	excess	reabsorption,	through	 the	NCC,	 could	 prevent	 the	 production	 of	 ROS	 and	 attenuate	 the	 potential	ROS-mediated	 vasoconstriction	 of	 vasa	 recta	 by	 pericytes	 in	 the	 presence	 of	 CNIs.	Crawford	 et	 al	 were	 able	 to	 use	 a	 hypotonic	 insult	 within	 the	 live	 kidney	 slice	 to	produce	 an	 ATP-mediated	 vasodilation	 of	 vasa	 recta	 (Crawford	 et	 al.	 2012).	 Using	HCT	at	high	concentrations	(500	μM)	has	been	shown	to	 induce	hypotonic	shock	 in	isolated	 tubules	 (Lajeunesse	 &	 Brunette	 1991)	 therefore	 possibly	 result	 in	 a	hypotonic	shock	of	tubular	epithelial	cells	and	subsequently	release	ATP,	thus	further	highlights	the	role	of	tubulovascular crosstalk and how signaling molecules, NO and 
ATP from the above examples, from nearby structures could mediate local 
adaptions of blood flow in response to particular stress stimuli.  
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The results from chapter 4 also suggest a role of calcium signaling in CNI-mediated 
vasoconstriction. Diltiazem and isradipine are both calcium channel antagonists and 
although different in molecular structures and channel efficacy, they both primarily 
inhibit voltage-dependent calcium channel activation. Both diltiazem and isradipine 
were able to inhibit CNI-induced vasoconstriction of vasa recta and further helps 
identify a molecular mechanism underlying CNI-mediated constriction and suggest 
for their use against the prevention of CNI-induced hypertension. However, this 
observation is not new, calcium channel blockers (CCBs) have been used to treat 
CNI-induced hypertension (Rahn et	 al. 1999) and confirmed via the major 
randomized study by Midtvedt et	al who revealed their superior antihypertensive 
property compared to ACE inhibitors (Midtvedt et	al. 2001) and interestingly, the 
beneficial use of specifically diltiazem and isradipine for CNI-induced hypertension 
has also been confirmed by other studies (Ingsathit et	 al. 2006; Xue et	 al. 2010; 
Bursztyn et	al. 1997; van den Dorpel et	al. 1994; Becker et	al. 1996; van Riemsdijk 
et	al. 2000).  
Further highlighting the role of calcium inhibition for prevention of hypertension, 
vasa recta constriction has been show to be mediated through voltage gated calcium 
entry. Using fluorescence and electrophysiological techniques, Zhang et	 al were 
able to demonstrate that pericyte contractility is controlled through variations of 
membrane potential and voltage-gated calcium entry into pericytes (Z. Zhang et	al. 
2002). In addition, the authors were also able to show the inhibitory and 
vasodilatory effects diltiazem had on agonist-induced vasoconstriction and 
preconstricted vasa recta, respectively. This undoubtedly emphasizes the role of 
calcium signaling in pericyte constriction but also strongly suggests a mechanism 
for CCB inhibition of CNI-mediated vasoconstriction. This hypothesis is further 
supported by the notion of increased calcium signaling in VSMCs after treatment 
with CsA (Avdonin et	 al. 1999; Grzesk et	 al. 2012; Meyer-Lehnert et	 al. 1993). 
Although calcium channel inhibition did not completely abolish the 
vasoconstrictive effects of CNIs, CCBs do not inhibit the regulation of intracellular 
calcium signaling. Rises in intracellular calcium have been shown to constrict 
pericytes independent of extracellular calcium entry (Borysova et	al. 2013; Shepro 
& Morel 1993; Q. Zhang et	 al. 2006; Z. Zhang et	 al. 2002) therefore offers a 
possible mechanism for contraction independent of calcium entry.  
	 228	
The combined results of chapter 4 therefore parallel clinical observations regarding 
CNIs and antihypertensives. Although the exact mechanisms for protective 
pathways are unclear, specifically the contribution of NCC-mediated inhibition of 
pericyte contraction, data here further highlights that a better understanding of the 
medulla microcirculation and future studies to this end can only enhance our 
knowledge of all possible mechanisms involved in CNI-mediated nephrotoxicity 
and can help identify novel inform strategies for the prevention of CNI 
nephrotoxicity.  
 
One of the intentions of this thesis was to develop an in situ perfusion model for the 
use within the live kidney slice to better simulate the blood perfused mode of drug 
delivery to the inner medulla. Data presented in chapter 5 includes data yielded 
following setup and validation of this model and further investigates the effects of 
perfusing vasa recta with CNIs to offer a potentially enhanced understanding of 
CNIs and MBF. The results indicate that when perfused, CNIs have an enhanced 
contractile effect, their role in regulation of vasa recta via their action at pericytes is 
enhanced compared to superfusion, and as such are likely to contribute to CNI-
mediated medullary ischemia and nephrotoxicity. The results from this chapter 
suggest an endothelial cell to pericyte signal transduction pathway is involved in 
mediating the contractile effects seen in response to both perfusion of CsA and 
FK506. Interestingly, the communication between endothelial cells and pericytes 
has already been explored. Recently, Zhang et	 al suggested a role of DVR 
endothelium as an electrical syncytium (Q. Zhang et	al. 2006). Their results suggest 
that depolarizing or hyperpolarising waves are spread between cells to regulate 
vasomotin in vivo and that DVR gap junctions facilitate passage of signaling 
molecules (cAMP, Ca2+ and NO for example) between endothelial cells and 
pericytes to alter vessel diameter by their action as endothelium-dependent (hyper) 
depolarising agents. Furthermore, superoxide is produced by pericytes and therefore 
may be directed across myoendothelial junctions to limit the bioavailability of NO 
(Z. Zhang et	 al. 2004) further highlighting a role of ROS for pericyte mediated 
vasoconstriction.  
Several studies have already identified the expression of tight, gap and adherence 
junctions between pericytes and endothelial cells (Cuevas et	al. 1984; Tilton et	al. 
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1979; Gerhardt et	al. 2000; Gerhardt & Betsholtz 2003). This evidence, coupled to 
the fact calcium signaling has already been established between pericytes and 
endothelial cells (Z. Zhang et	al. 2002; Borysova et	al. 2013; Rhinehart et	al. 2003), 
strongly suggests that communication between these two linking cells is through a 
variety of complex pathways. Furthermore, it has also been demonstrated that 
communication between these cells can be independent of each other but 
interestingly, also communicate under certain stimuli to affect the regulation of 
other cells. This was highlighted by Zhang et	al who were able to stimulate vasa 
recta pericytes to induce an escalation of NO production from endothelial cells that 
were down stream from the pericyte itself and not necessarily in contact with the 
pericyte cell body or processes (Q. Zhang et	al. 2006). In addition, Peppiatt et	al 
were able to demonstrate pericyte to pericyte communication in retina (Peppiatt et	
al. 2006) highlighting the complex signaling mechanisms that pericytes have 
developed. Whilst it is known that CNIs are known to constrict the larger afferent 
arterioles of the glomerulus (although no specific mechanism has been defined), the 
data presented here demonstrates for the first time the ability of CNIs to induce 
vasoconstriction of vasa recta via pericytes when luminally perfused. This could 
have detrimental effects with regards to allograft dysfunction since pericytes have 
an essential role in the regulation of MBF (Pallone, Z. Zhang, et	 al. 2003) and 
pericyte-mediated contraction may play a role in medullary ischemia. With a 
transplanted kidney already being subjected to possible hours of ischemia, then 
subsequently exposed to ischemia reperfusion, an already established mechanism 
known to underlie transplant dysfunction (Regner & Roman 2012; Mittal & Kohli 
2014), the further CNI-mediated contraction of vasa recta may lead to chronic 
medullary ischemia in an already borderline hypoxic region of the kidney. Thus the 
importance of correct regulation of blood flow in the medulla is fundamental in 
maintaining function in transplanted kidneys. 
Interestingly, during allograft transplant, ROS are known to increase during both 
ischemia and reperfusion and play a central role on the pathophysiology of allograft 
dysfunction (Raedschelders et	 al. 2012). Given the fact CNIs are also known to 
produce ROS during allograft transplant (A. Y. Zhou & Ryeom 2014; Nishiyama, et	
al. 1998) and that the medullary microcirculation is particularly susceptible to 
changes in ROS production (Cowley et al 2015a; Wilcox 2002), investigating this 
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pathway for a possible mechanism underlying CNI-induced vasoconstriction would 
highlight a significant area in which the attenuation or prevention of CNI-induced 
vasoconstriction and nephrotoxicity might be further explored. 
 
Chapter 5 of this thesis investigates specific molecular mechanisms of CNI-induced 
vasoconstriction. Using multiphoton microscopy to delineate changes in molecular 
events highlighted the importance of NADPH oxidase in the generation of 
medullary ROS following treatment of live tissue with CNIs. Furthermore, data 
here suggests the use of specific NADPH inhibitors could potentially offer a 
defensive role against CNI-mediated oxidative damage and chronic nephrotoxicity.  
It is now known in the literature that CNIs are able to induce cellular and 
morphological changes of mitochondria to bring about larger upscale organelle and 
tissue damage. De Arribia et	 al have suggested a central role for mitochondria 
damage in CsA-mediated nephrotoxicity. Their hypothesis includes an increase of 
mitochondrial ROS production leading to cytochrome C release and cellular 
apoptosis, formation of pores in the outer mitochondrial membrane, again, leading 
to cytochrome C release and altered mitochondrial energy dynamics which could 
possibly lead to mitochondrial fission and apoptosis (de Arriba et	al. 2013). Their 
hypothesis has been some what confirmed by other groups who have similarly 
demonstrated mitochondrial ROS production via CsA (Perez de Hornedo et	 al. 
2007; van der Toorn et	al. 2007) and also pore formation (Brustovetsky & Dubinsky 
2000; Friberg et	 al. 1998) but both so far fail to determine CsA-induced 
mitochondrial fission leading to apoptosis thus the precise mechanisms remain 
unclear. The results of this chapter have also unfortunately failed to confirm any of 
these findings. The live kidney slice was unable to be loaded with the mitochondrial 
specific ROS dye MitoSOX therefore, although CNI’s may have increased 
mitochondrial ROS, it could not be detected. In addition, CNIs failed to (hyper) 
depolarize the mitochondrial membrane, which has been previously highlighted as a 
preceding requirement before an increase in ROS production (McBride et	al. 2006; 
Murphy 2009). Interestingly, depolarization has also been indicated as an after 
effect of ROS production in isolated cells rather than a precursor event (de Arriba et	
al. 2013; Perez de Hornedo et	al. 2007), therefore it is somewhat unclear to what 
extent mitochondria membrane potential plays in mitochondrial ROS production in 
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CsA-mediated toxicity. Intriguingly, this chapter has emphasized the role of 
cyclophiln D in the formation of the mitochondrial permeability transition pore 
required for mitochondrial transition upon insult. CsA was able to inhibit pore 
formation induced by chenodeoxycholate and thus preventing mitochondrial 
membrane depolarisation, hypothetically through CsA-Cyp-D binding, while 
tacrolimus and rapamycin failed to inhibit pore formation. This suggests a 
conceivable role for CsA in the protection of mitochondria damage by preventing 
mitochondria transition to apoptosis after insult. This theory has already been 
confirmed in multiple studies for myocardial ischemia reperfusion injury (Piot et	al. 
2008; Raedschelders et	al. 2012; Abdallah et	al. 2011; Halestrap et	al. 2004) and 
demonstrates the protective role CsA can have under certain conditions.  
Nonetheless, CsA and FK506 are known to induce ROS production and based on 
the results of this chapter, it is feasible to suggest they are able to induce an increase 
of medullary ROS via other non-mitochondrial pathways. Medullary ROS have 
been suggested to partake in a variety of roles including regulation of MBF, sodium 
homeostasis and hypertension (Cowley et al 2015a). In addition, it has also been 
demonstrated that DVR pericytes are able to induce ROS as well as constrict in 
response to ROS (Rhinehart & Pallone 2001b; Edwards et	al. 2011; O'Connor & 
Cowley 2012; Cowley et al 2015a). Taken together, for the first time, it is feasible 
to suggest that CNI therapy could cause medullary ROS production, as well as 
cortical ROS, which acts to constrict vasa recta via pericytes and contribute towards 
hypertension and nephrotoxicity. This offers a novel possible mechanism 
contributing towards CNI nephrotoxicity and sheds a new light in understanding the 
role dysregulation of MBF may have in this destructive condition.  
This chapter also demonstrates the potential protective effect NADPH oxidase 
inhibition has on attenuation of CNI-mediated production of ROS and associated 
nephrotoxicity. Currently, the majority of the literature regarding CNI-induced ROS 
involves its production in the cortical region of the kidney and focuses on ROS 
scavenging. Very little, if any, focuses on the role of medullary ROS and preventing 
its production rather than post-hoc scavenging. Given that NADPH oxidase 
accounts for over 50% of ROS production in the kidney (Cowley et al 2015b) and 
typically, prevention of production may be more efficient that scavenging, it seems 
logical to target the site of production of the biggest source of ROS with the hope of 
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attenuating its production and reducing the onset of oxidative damage. Interestingly, 
it has been shown that CNIs increase NADPH expression and activity within the 
kidney after renal transplant (Khanna & Pieper 2007) inevitably increasing ROS 
production. Furthermore, Ciarcia et	al used a specific NADPH inhibitor, apocynin, 
to completely ameliorate the acute hemodynamic and chronic morphological 
changes seen with CsA in rats which is in fitting with data provide here (Ciarcia et	
al. 2015). Moreover, this chapter has also highlighted medullary blood vessels as 
the initial sources of ROS suggesting vasa have a more influential role in the 
progression of nephrotoxicity than first perceived. For example, Buffoli et	al have 
used a polyphenol to restore morphological fibrotic changes in the cortex induced 
by CsA, however medullary fibrosis, especially around vasa recta, was still evident 
suggesting prolonged irreversible damage (Buffoli et	 al. 2005). The results from 
this chapter further demonstrates the ability of apocynin to inhibit CNI-induced 
ROS production within the medulla, and highlights its potential role n the 
attenuation of medullary ROS production and reduced risk for the development of 
CNI-induced nephrotoxicity. A schematic diagram for possible mechanisms 






Figure 7.0 Schematic diagram highlighting possible pathways involved in 
CNI-mediated pericyte-evoked constriction of vasa recta. Summary of possible 
pathways involved in CNI-mediated constriction of vasa recta via pericytes. CNIs, 
calcineurin inhibitors; ROS, reactive oxygen species; TGF-β, transforming growth 
factor; ET-1, endothelin 1; NO, nitric oxide; ΔΨM, mitochondrial membrane 
potential.  
  














Secondly,	perfusion	of	 in	situ	 single	vasa	recta	has	 increased	our	understanding	 the	role	tubulovascular	crosstalk	has	 in	regulation	of	MBF	and	communication	between	structures.	However,	the	perfusion	in	this	thesis	did	not	allow	perfusate	exchange	and	therefore	 does	 not	 directly	 replicate	 in	 vivo	 physiological	 conditions.	 Future	 work	would	enable	a	perfusate	exchange	system	to	be	established,	although	this	 is	highly	dependent	on	equipment	and	technical	expertise	but	would	support	a	similar	system	seen	 with	 isolated	 perfusion	 that	 enables	 researchers	 to	 carry	 out	 perfusate	exchange.	Excitingly,	the	technical	equipment	required	could	possibly	investigate	the	decreased	 flow	 measurement	 as	 mentioned	 above	 through	 similar	 analytical	techniques	 used	 for	 isolated	 perfused	 tubule	 experiments.	 Particular	 isolated	perfusion	 experiments	 allow	 the	 perfusate	 to	 be	 collected	 after	 perfusion	 through	hollow	 structures.	 If	 the	 same	 technique	were	 carried	 over	 to	 the	 live	 slice	model,	collection	of	perfusate	could	be	analysed	to	identify	alterations	in	sodium	or	other	ion	concentrations	 to	 identify	 possible	 endothelial	 cell	 to	 pericyte	 interactions	 under	normal	physiological	 conditions.	However,	 under	pericyte	 vasoconstriction	 from	an	exogenous	 bath	 application	 of	 vasoconstrictor	 for	 example,	 the	 collected	 perfusate	could	be	compared	 to	 the	control	 conditions	 to	help	 identify	possible	alterations	of	salt	 concentrations	 or	 even	 signalling	 molecules	 that	 could	 be	 important	 in	endothelial	cell	and	pericyte	communication.				As	highlighted	in	the	discussion	section	of	chapter	4,	it	was	suggested	that	a	high	K+	membrane	depolarisation	experiment,	 following	application	of	CNI	and	CCB,	 should	be	carried	out	to	assess	reversibility	of	Ca2+	inhabitation	and	ability	of	isradipine	and	diltiazem	to	be	washed	out	of	the	experimental	setup.	The	membrane	depolarisation	of	 K+	 after	 CCB	wash	would	 highlight	 a	 possible	mechanism	 for	 pericyte-mediated	vasoconstriction	of	DVR	 in	 response	 to	CNI’s,	 and	suggest	CNI’s	are	able	 to	directly	affect	either	pericyte	membrane	potential	or	through	EC	membrane	potential	which	could	 hypothetically	 induce	 pericyte	 depolarisation	 through	 gap	 and	 hetrocellular	gap	 junctions.	 Previously,	 Zhang	 et	 al	 have	 highlighted	 the	 use	 of	 a	 high	 K+	 bath	solution	 to	 induce	membrane	 depolarisation	 of	 pericytes	 in	 their	 isolated	 perfused	DVR	 technique	 (Z.	 Zhang	 et	 al.	 2002)	 however	 due	 to	 the	 nature	 of	 the	 isolated	technique,	 it	 is	 unclear	 to	 which	 site	 depolarisation	 commences,	 either	 EC’s	 or	pericytes.	 Nonetheless,	 the	 authors	 where	 able	 to	 demonstrate	 the	 inhabitation	 of	depolarisation	through	use	of	diltiazem	(Z.	Zhang	et	al.	2002).	Although	not	presented	in	the	author’s	manuscript,	personal	correspondence	with	the	authors	have	stated	the	
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inhibition	 was	 reversible	 with	 CCB’s	 and	 could	 be	 washed	 out	 after	 several	experiments.	This	was	highlighted	due	to	the	fact	isolated	perfused	DVR	can	be	used	for	more	 than	 one	 experiment	 due	 to	 the	washable	 nature	 of	 the	 setup	 and	 timely	manor	these	types	of	experiments	take.		Future	experiments	in	the	live	slice	model	with	a	high	K+	solution	after	CNI	and	CCB	exposure	would	highlight	a	possible	mechanism	for	CNI-induced	vasoconstriction	via	pericytes	and	could	be	further	investigated	with	perfusion	in	combination	with	Ca2+	fluorescent	 probes	 and	 imaging	 techniques	 to	 establish	 the	 site	 of	 membrane	depolarisation.	Identifying	the	initial	site	of	depolarisation,	most	likely	through	EC’s	if	perfusion	 was	 used,	 could	 help	 pinpoint	 a	 possible	 mechanism	 for	 CNI-mediated	pericyte	 vasoconstriction	 and	 novel	 therapeutic	 strategies	 for	 the	 prevention	 of	reduced	RMBF	and	acute	nephrotoxicity	after	CNI	therapy.		The	multiphoton	data	presented	here	highlights	the	role	ROS	may	potentially	have	in	regulation	 of	 MBF	 during	 CNI	 therapy.	 	 Although	 not	 directly	 measurable,	 the	increased	 production	 of	 ethidium	 fluorescence	 suggests	 that	 an	 increase	 of	superoxide	may	 be	 responsible	 for	 pericyte	 vasoconstriction.	 This	 could	 be	 further	investigated	using	functional	DIC	experiments	with	apocynin	to	ascertain	the	degree	ROS	play	in	pericyte	vasoconstriction.		Additionally,	using	MPM	with	 in	situ	perfusion	of	vasa	recta	opens	a	wide	variety	of	experiments	 to	 investigate	 the	 molecular	 mechanism	 involved	 in	 CNI-induced	vasoconstriction.	For	example,	experiments	using	calcium	imaging,	researchers	could	confirm	 the	 role	 of	 pericyte/endothelium	 interactions	 after	 CNI	 perfusion	 to	 help	identify	 temporal	 calcium	 signalling	 and	 how	 this	 correlates	 to	 changes	 in	 vessel	diameter.	Moreover,	 to	what	degree	calcium	signal	propagations	affect	 surrounding	tissues	like	collecting	ducts	and	ascending	limbs	could	be	investigated	to	include	CNI-mediated	 tubulovascular	 cross	 talk.	 This	 would	 offer	 further	 insight	 and	may	 help	identify	potential	novel	mechanisms	for	combating	progression	of	CNI	nephrotoxicity.			Although	 the	 use	 of	 the	 SD	 rat	model	 for	 investigations	 into	 acute	 renal	 injury	 has	been	well	documented	and	even	used	to	this	day	(Bach	2013),	the	effects	of	CNI’s	on	small	animal	renal	function	are	less	well	understood.	For	example,	administration	of	CNI’s	 to	 animal	 models	 in	 similar	 doses	 received	 by	 patients,	 on	 a	 weight	 basis,	produces	significantly	lower	incidences	of	acute	or	chronic	renal	dysfunction	(Yang	et	
al	2010)	and	can	only	be	enhanced	with	extremely	high	concentrations	of	CNIs	or	a	
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